Evaluation of the stimulatory effects of

EBC-46 on dermal fibroblast and keratinocyte

wound healing responses in vitro and correlation

to preferential healing in vivo by Moses, Rachael Louise
 
 
 
 
 
 
 
 
Evaluation of the Stimulatory Effects of  
EBC-46 on Dermal Fibroblast and Keratinocyte 
Wound Healing Responses in Vitro and Correlation 
to Preferential Healing in Vivo 
 
 
Rachael Louise Moses BSc, MSc 
Thesis presented for the degree of  
Doctor of Philosophy 
 
 
 
Stem Cells, Wound Repair & Regeneration, 
Oral and Biomedical Sciences, 
Cardiff Institute of Tissue Engineering & Repair (CITER), 
School of Dentistry, 
College of Biomedical and Life Sciences, 
Cardiff University, 
Cardiff, UK 
 
August, 2016 

ii 
 
Dedication 
 
I would like to dedicate this thesis to my Mum, you have been an inspiration to me 
and given me every opportunity. I am truly thankful for your unconditional love and 
support, making this PhD possible. Thank you for always being there; I love you.   
iii 
 
Acknowledgements 
 
Firstly, I would like to give utmost thanks and appreciation to my two supervisors, 
Dr Ryan Moseley and Dr Robert Steadman. You have provided invaluable expertise, 
support, encouragement and enthusiasm throughout my project; I have thoroughly 
enjoyed this project. I have greatly appreciated your guidance and encouragement of 
my future career in research. 
 
In addition, I am hugely grateful to all who have assisted me and provided support 
from the School of Dentistry, Institute of Nephrology and Tenovus Building. 
Particular thanks go to Dr Adam Midgeley, who has provided vital support and 
advice on experimental procedures and subsequent analysis. I would like to thank 
Professor Rachel Errington, Dr Rachel Howard-Jones and Marie Wiltshire, their 
assistance and knowledge on flow cytometry procedures and the specialised analysis 
software was greatly appreciated. I would also like to thank the technical team at the 
School of Dentistry; who have all contributed to the successful running of the 
department, along with providing equipment expertise and knowledge. 
 
Additionally, I would like to express huge thanks to Dr Glen Boyle and Professor 
Peter Parsons, for allowing me the opportunity to perform Microarray analysis at 
Queensland Institute of Medical Research (QIMR), along with crucial training on 
undertaking these studies, and access and training on the specialised analysis 
software. I would like to thank the rest of the department at QIMR for graciously 
welcoming me and providing support and friendship, in particular Carly, Pei, Tash, 
Jacinta, Jenny and Vaish. 
 
I have been lucky to work with a number of great colleagues and friends in the 
School of Dentistry, who have provided scientific support, brilliant friendships, great 
humour; and personal support and encouragement, especially on those night shifts 
with cell cycle analysis! I would like to thank my friends, Nic, Rhi, Châni, Jen, Liv, 
Karina and Shannon, who have been there for me throughout this project, providing 
fantastic friendships and unlimited support.  
 
This project was funded by QBiotics Ltd., and I would like to take this moment to 
thank Dr Paul Reddell and Dr Victoria Gordon for giving me this wonderful 
opportunity to undertake a research project that I have thoroughly loved. I am also 
grateful for the funding received by CITER, enabling my research travel to QIMR, 
giving me an amazing experience and obtaining essential data.  
 
Finally, I would like to express heartfelt thanks to my wonderful family, in particular 
my Mum, Steve and grandparents; you have provided unlimited and unwavering 
support, encouragement and love throughout my project, keeping me somewhat 
sane! You have been there for me at every stage; I love you all very much and 
greatly appreciate all that you have done for me.  
  
iv 
 
Abstract 
 
The novel epoxy-tiglianes, EBC-46 and ‘lesser activity’ EBC-211, are sourced from 
seeds of the Fountain’s Blushwood Tree (Fontainea picrosperma), indigenous to 
Queensland Tropical Rainforest. Australian biotechnology company, QBiotics Ltd., 
has demonstrated that EBC-46 stimulates exceptional dermal wound healing 
responses in vivo, following cancer treatment and tumour destruction in domesticated 
animals.  Consequently, QBiotics is developing EBC-46 as a veterinary anti-cancer 
pharmaceutical and performing human clinical trials.  However, little is known on 
how EBC-46 induces its exceptional healing effects, manifested as accelerated 
wound re-epithelialisation, closure and reduced scarring. 
 
This study aimed to elucidate how EBC-46 and EBC-211 mediates these exceptional 
wound healing effects in vitro, through analysis of HaCaT keratinocyte and dermal 
fibroblast/myofibroblast genotypic and phenotypic responses, following epoxy-
tigliane treatment (0.001-100µg/ml).  A number of key wound healing responses 
were assessed, including proliferation, cell cycle progression, scratch wound 
repopulation; and transforming growth factor-β1 (TGF-β1)-driven, fibroblast-
myofibroblast differentiation. 
 
Studies demonstrated that both EBC-46 and EBC-211 induced fibroblast and HaCaT 
cytotoxicity at 100µg/ml.  EBC-46 and EBC-211 (0.001-10µg/ml) significantly 
retarded fibroblast proliferation and delayed S/G2 cell cycle transition, but exerted 
no significant effects on fibroblast migratory responses.  Although EBC-46 had no 
effects on α-smooth muscle actin (α-SMA) expression, stress fibre organization and 
myofibroblast formation (0.001-0.01µg/ml and 1-10µg/ml), EBC-46 significantly 
inhibited α-SMA expression and stress fibre formation at 0.1µg/ml, with cells 
retaining normal fibroblast morphologies.  EBC-211 induced similar effects at 
10µg/ml. 
 
Both EBC-46 and EBC-211 (0.001-10µg/ml) stimulated significant HaCaT 
proliferation, G1/S and S/G2 cell cycle transitions; and accelerated scratch wound 
repopulation, even with mitomycin C.  Microarray analysis and protein level 
validation, identified numerous differentially expressed genes in epoxy-tigliane-
treated, HaCaTs.  Up-regulated genes included certain keratins and others associated 
with promoting cell cycle progression, proliferation and migration.  Down-regulated 
genes included other keratins and genes associated with inhibiting cell cycle 
progression and proliferation, including certain cytokines and chemokines. 
 
This study has provided evidence to explain the enhanced re-epithelialisation and 
reduced scarring responses observed in epoxy-tigliane-treated skin.  Furthermore, it 
highlights the potential of epoxy-tiglianes as novel therapeutics for impaired dermal 
wound healing and excessive scarring situations. 
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Chapter 1 – Introduction 
 
1.1 Overview 
 
EBC-46 was found in the seeds of the Fountain’s Blushwood Tree (Fontainea 
picrosperma), indigenous to the Queensland Tropical Rainforest. EBC-46 was sourced 
due to its’ potential to have potent bioactivity and was developed by QBiotics Ltd. 
(Queensland, Australia). EBC-46 was discovered to have an anti-cancer effect through 
the palliative treatment of solid tumours on cats, dogs and horses. This treatment was 
shown to have remarkable success in the ablation of the tumours and sarcoids, without 
evidence of any long term side effects (QBiotics Ltd.). An exceptional wound healing 
response at treatment sites was observed, following tumour ablation; producing good 
cosmetic outcomes in affected areas. In light of these obvious beneficial anti-tumour 
and pro-healing effects, QBiotics Ltd. are developing EBC-46 as a veterinary 
pharmaceutical for the treatment of solid tumours in these animals (QBiotics Ltd.).  
Furthermore, as QBiotics Ltd. has compelling proof-of-concept data of the drug's 
efficacy and safety both in cancer models in mice and in other domesticated animals, 
QBiotics Ltd. is rapidly advancing the drug towards the necessary regulatory approvals 
for conducting human clinical phase I/II trials (QBiotics Ltd.). 
 
As a result of this observed exceptional wound healing effect and with little 
information regarding how EBC-46 induces this effect, this PhD study has focused on 
elucidating how it affects two cell types strongly involved in the acute skin wound 
healing response, i.e. dermal fibroblasts and epidermal keratinocytes (Singer & Clark 
1999; Guo & DiPietro 2010). Dermal fibroblasts were used throughout this project 
from normal skin; and a keratinocytes cell line, human adult, spontaneously 
immortalized, epidermal keratinocytes (HaCaTs), were also used (Boukamp et al. 
1988). A number of in vitro studies were performed to determine the effect of EBC-
46 on various aspects of the wound healing process. These included assays to assess 
cell proliferation, viability, cell cycle progression, migration, differentiation, global 
gene expression; and finally protein expression and activity. This is the first time the 
effects of these novel epoxy-tiglianes on wound healing cells have been analysed. 
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These cells were chosen as they will hopefully replicate the in vivo effects seen in the 
animal palliative studies (Reddell et al. 2014). Comparisons were also made between 
EBC-46 and a ‘lesser activity’ analogue, EBC-211, across a range of concentrations 
(0-100µg/ml). This aimed to determine the optimal dose range in vitro, while 
observing the effects of these novel epoxy-tiglianes on the normal genotypic and 
phenotypic responses of both fibroblasts and keratinocytes. It had been previously 
shown through preliminary studies that EBC-46 may act as a protein kinase C (PKC) 
regulator. The global gene expression analysis may confirm this through differentially 
expressed genes downstream of this pathway (Boyle et al. 2014; Reddell et al. 2014).  
 
1.2 Skin Structure and Function 
 
The skin is the largest organ of the body performing various vital functions, such as 
providing a protective barrier from the external environment. The level of protection 
provided by the skin is multi-factorial, encompassing protection against pathogens and 
preventing ultraviolet (UV) damage, along with protection against chemical, physical 
and immune damage (Menon 2002; Walters & Roberts 2002; Denning 2004; Candi et 
al. 2005; Ovaere et al. 2009; Darlenski et al. 2011; D’Orazio et al. 2013). It also acts 
as a protection against free radical molecules, reducing the chance of oxidative damage 
occurring (Menon 2002; Baumann 2007). The skin is predominantly responsible for 
maintaining homeostasis of a number of key functions, such as thermoregulation and 
preventing the loss of water (Kalinin et al. 2002; Menon 2002; Walters & Roberts 
2002; Candi et al. 2005; Darlenski et al. 2011). It is also one of the major sensory 
organs providing great detail about the surroundings (Menon 2002; Walters & Roberts 
2002; Boulais & Misery 2008; Darlenski et al. 2011).  
 
There are a large number of cells associated with these functions, which are constantly 
regenerated to maintain their actions; keeping the balance between proliferation, 
differentiation and apoptosis of the cells to maintain the functionality of the skin 
(Haake et al. 2001; Walters & Roberts 2002; Moll et al. 2005; Gurtner et al. 2008; 
Merad et al. 2008; Pastar et al. 2014; Ghatak et al. 2015). There are three layers 
separating the muscle layer from the environment: the epidermis, dermis and 
hypodermis, depicted in Figure 1.1 (Song et al. 1997; Braiman-Wiksman et al. 2007; 
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Stephens & Genever 2007; Bottcher-Haberzeth et al. 2010). The hypodermis is present 
directly above the muscle layer and is also termed the subcutaneous layer. It contains 
adipocytes providing protection and insulation (Song et al. 1997; Stephens & Genever 
2007). The epidermis and dermis comprise the skin, each comprising of a number of 
cells, although the level of organisation of the cells varies considerably. The epidermis 
is more cellular and the dermis consists mainly of ECM proteins (Song et al. 1997; 
Haake et al. 2001; Moll et al. 2005; Boulais & Misery 2008; Merad et al. 2008; Eckes 
et al. 2010; Tracy et al. 2016). The epidermis has a structured appearance with layers 
of each cell type as they differentiate along the pathway (Song et al. 1997; Menon 
2002; Stephens & Genever 2007; Bragulla & Homberger 2009). In contrast, the dermis 
is less regimentally organised, it is divided into two main sections: the papillary region 
and the reticular region (Song et al. 1997; Sorrell & Caplan 2004; Stephens & Genever 
2007).  
 
Preserving or re-establishing the integrity of the skin is vital, as loss of the protective 
barrier can allow contamination of the injury site and affect the normal functionality 
of the skin (Singer & Clark 1999; Fuchs 2007; Ovaere et al. 2009; Darlenski et al. 
2011). Millions of people are affected worldwide each year as a result of a loss of the 
protective barrier, this is primarily a result of burns and chronic wounds, but can 
significantly affect the lives of those affected (Singer & Clark 1999; Menke et al. 2007; 
Pastar et al. 2014; Dreifke et al. 2015). Due to the major importance of the skin and all 
the functions it performs, it is vital for the continual regeneration and rapid repair of 
any injuries to prevent loss of integrity and prevent any subsequent disability resulting 
from this loss of integrity (Walters & Roberts 2002; Kondo & Ishida 2010; Pastar et 
al. 2014). There is a degree of elasticity present in the skin allowing for more flexibility 
with movement and to prevent tearing of the skin with the slightest alteration. This is 
essential, as the skin has to extend and retract as muscles contract and relax, without 
causing damage to the skin (Kielty et al. 2002; Sherratt 2009; McGrath & Uitto 2010). 
This flexibility is enabled through the presence of elastic fibres within the connective 
tissue of the dermis. However, this elasticity decreases with age, reducing the tensile 
strength of the skin (Kielty et al. 2002; Baumann 2007; Sherratt 2009; Cheng et al. 
2011; Tobin 2016). This elasticity increases the durability of the skin allowing it to 
withstand a large amount of forces that are exerted against it, including shear force and  
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Figure 1.1: Section through the skin showing epidermis, dermis and hypodermis. 
The epidermal layers are depicted with desmosomes and hemidesmosomes, 
providing an adhesion role within the epidermis (McGrath & Uitto 2010).  
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friction (McGrath & Uitto 2010). 
 
1.2.1 Epidermis 
The cells in the epidermis are organised in a way that as they differentiate; they move 
progressively further away from the basement membrane, until the uppermost layer of 
dead cells is removed (Kalinin et al. 2002; Walters & Roberts 2002; Candi et al. 2005; 
Bragulla & Homberger 2009; Eckhart et al. 2013). The epidermis consists of stratified 
squamous epithelial cells, with keratinocytes forming the majority of cells present, 
approximately 95%; with the other 5% consisting of melanocytes, Merkel cells and 
Langerhan’s cells (Menon 2002; Romani et al. 2003; Moll et al. 2005; Boulais & 
Misery 2008; Bragulla & Homberger 2009; Sprenger et al. 2013). Keratinocytes are 
present at different points of differentiation, starting from the layer above the basement 
membrane going to the uppermost layer of the skin, forming a 100-150µm thickness: 
the stratum basale, the stratum spinosum, stratum granulosum and the stratum 
corneum, as depicted in Figure 1.1 (Menon 2002; Walters & Roberts 2002; Fuchs 
2007; D’Orazio et al. 2013; Pastar et al. 2014). The columnar cells in the stratum 
basale are the only dividing cells within the four sections, with terminal differentiation 
occurring across the others, committing the cells to differentiate through the four layers 
until reaching the skin surface forming the dead, but functional, cell layer (Fuchs 1995; 
Haake et al. 2001; Menon 2002; Blanpain et al. 2004; D’Orazio et al. 2013; Eckhart et 
al. 2013; Pastar et al. 2014). As the cells differentiate, they migrate towards the skin 
surface and adapt to perform the functions specific to that layer. The cells also change 
morphology as they progress along the differentiation pathway, increasing in size and 
flattening (Eckert & Rorke 1989; Fuchs 1995; Haake et al. 2001; Lian & Yang 2004; 
Lippens et al. 2005; Eckhart et al. 2013).  
 
Cells in the stratum basale are involved in the process for the protection of cells from 
UV damage. This involves melanocytes present both in the basal layer and the 
suprabasal layer (Yamashita et al. 2005; Katagiri et al. 2006; D’Orazio et al. 2013; 
Natarajan et al. 2014). These cells are pigment producing cells that synthesise melanin 
from tyrosine; the melanin is then used to ‘cap’ the basal cells (Tsatmali et al. 2002; 
Yamashita et al. 2005; Katagiri et al. 2006; Cichorek et al. 2013). This protects the 
cells at the earliest point in the differentiation process, preventing the mutation of cells 
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at the stratum basale and the subsequent differentiation of these mutated cells to the 
skin surface (Walters & Roberts 2002; Yel et al. 2014). Melanocytes form attachments 
with keratinocytes through the use of the transmembrane protein, epithelial cadherin 
(E-cadherin), forming an adherent junction between the two cells allowing the transfer 
of melanin to the keratinocytes (Haake et al. 2001; Tsatmali et al. 2002; Boissy 2003; 
Natarajan et al. 2014; Tarafder et al. 2014). Also present in the stratum basale are slow 
cycling stem cells, which also need to be protected from sun exposure (Menon 2002; 
Fuchs 2007; D’Orazio et al. 2013; Panich et al. 2016). As one daughter stem cell 
remains a stem cell and the other differentiates along the pathway, it is important to 
prevent the mutation of these cells (Watt 1998; Haake et al. 2001; Panich et al. 2016).  
 
Other epidermal cells are Merkel cells, mechanoreceptors which are involved in 
sensation of touch (Ogawa 1996; Moll et al. 2005; Boulais & Misery 2007; Boulais & 
Misery 2008; Woo et al. 2015). Merkel cells are closely associated with the nerves. 
Epidermal Merkel cells produce nerve growth factor (NGF) and the dermal Merkel 
cells produce the receptor for this growth factor providing the connection to the nerves 
(Haake et al. 2001; Boulais & Misery 2007; Woo et al. 2015). Langerhan’s cells are 
also present in the epidermis and are part of immune system in the skin through the 
role of antigen presenting cells (APCs; Boulais & Misery 2008; Merad et al. 2008; 
Igyarto & Kaplan 2013). Langerhan’s cells are the skin specific form of dendritic cells 
and like other dendritic cells; these interact with T cells to perform the function of 
presenting foreign antigens (Haake et al. 2001; Romani et al. 2003; Merad et al. 2008; 
Igyarto & Kaplan 2013). The cells within layers and between layers are connected 
through desmosomes, while cells in the stratum basale are connected to the basement 
membrane by hemidesmosomes; as shown in Figure 1.1 (Garrod 1993; Burdett 1998; 
Nievers et al. 1999; Menon 2002; Walters & Roberts 2002; Calkins & Setzer 2007; 
Fuchs 2007; Suter et al. 2009). 
 
 
1.2.1.1     Keratinocytes 
Keratinocytes are a form of squamous epithelial cells and account for approximately 
95% of the epidermis (Kalinin et al. 2002; Menon 2002; Denning 2004; Sprenger et 
al. 2013). These cells are, therefore, a vital cell to focus on in regards to epidermal 
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wounding and the subsequent re-epithelialisation (Varani 1998; Menon 2002; Patel et 
al. 2006; Koivisto et al. 2012; Pastar et al. 2014). Keratinocytes are present across the 
four layers of the epidermis, with slightly altered cell morphology in each layer; with 
the different morphologies corresponding to their functions at each epidermal depth 
(Eckert & Rorke 1989; Fuchs 1995; Menon 2002; McGrath & Uitto 2010).  
 
During wound healing, an increased presence of keratinocytes is required to allow for 
successful re-epithelialisation. Keratinocytes are already present at the wound site, 
although terminal differentiation is halted in those required in the healing process 
(Braiman-Wiksman et al. 2007; Bader & Kao 2009; Koivisto et al. 2012; Pastar et al. 
2014). This prevents the basal keratinocytes from differentiating through the epidermal 
layers before becoming part of the cornified layer and eventually ‘shed’ from the skin 
(Eckert & Rorke 1989; Kalinin et al. 2002; Candi et al. 2005; Eckhart et al. 2013). 
Keratinocytes can sense their environment, due to the presence of sensory proteins and 
a close connection to sensory neurons. This allows them to convey information about 
their surroundings and can cause the keratinocytes to change their shape or action. It 
may also play a part in the detection of injury to the epidermal layers (O’Toole 2001; 
Haase et al. 2003; Gilcrease 2007; Boulais & Misery 2008). Keratinocytes are also 
able to sense the surrounding ECM and use this ability when they are migrating across 
a wound edge. Migration occurs via the extension of the cell edge forming 
lamellipodia-like structures and form focal adhesions with the extracellular matrix 
(ECM) through the use of integrin receptors (O’Toole 2001; Fuchs 2007; Li et al. 
2007; Suter et al. 2009; Pastar et al. 2014). Through this signalling mechanism, 
keratinocytes are able to sense the presence of fibronectin in the epithelial layers 
through the integrins, α5β1 and α3β1 (Grinnell 1992; Kim et al. 1992; O’Toole 2001; 
Grose et al. 2002; Gilcrease 2007; Li et al. 2007; Pastar et al. 2014).  
 
Keratinocytes possess integrin attachments, which need to be disassembled to allow 
the leading edge of the cell to protrude and release the traction tension at the trailing 
edge of the cell. This is achieved by a cyclical process of protrusion, adhesion and 
retraction (Cooper 2000; Van Haastert & Devreotes 2004; Gilcrease 2007; Vicente-
Manzanares & Horwitz 2011; Petrie & Yamada 2012). Focal adhesions between the 
cell and the ECM provide a degree of stability to the cell. However, a balance is 
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required, as the strength of adhesion and speed of migration operate in opposite ways, 
with strong focal adhesions slowing the migratory speed of cells (Palecek et al. 1997; 
Maheshwari et al. 2000; Chan et al. 2011; Velnar et al. 2009; Vicente-Manzanares & 
Horwitz 2011; Kim & Wirtz 2013). In order to stabilise the attachment of the epidermis 
to the dermis, there are anchoring filaments that can connect the basement membrane 
to the dermis. This is performed by type VII collagen, part of the anchoring fibrils 
group of collagens (Borradori & Sonnenberg 1996; Aumailley & Rousselle 1999; 
O’Toole 2001; Li et al. 2007; Suter et al. 2009; Gordon & Hahn 2011; Mouw et al. 
2014). However, this appears to be slow to develop at wound sites, affecting the 
integrity of the epidermal to dermal connection and resulting in a less stable structure, 
compared to unwounded areas (Gras et al. 2001; O’Toole 2001; Nyström et al. 2013).   
 
The majority of integrin receptors recognise a specific amino acid sequence, RGD 
(arginine, glycine and aspartic acid; Kim et al. 1992; Ruoslahti 1996; O’Toole 2001; 
Li et al. 2007). This sequence is present in the cell attachment region of the integrin 
and binds to ECM proteins, such as fibronectin and vitronectin (Ruoslahti 1996; 
O’Toole 2001; Humphries et al. 2006; Li et al. 2007). The integrins that recognise and 
attach to RGD sequences are the αv integrins, α5β1, α8β1 and αIIbβ. Other integrin 
binding sequences are used for the attachment to other ECM proteins, such as to 
collagen and laminin (O’Toole 2001; Humphries et al. 2006; Li et al. 2007; Reynolds 
et al. 2008; Parsons et al. 2010). Some of these integrins are vital for the migration of 
keratinocytes to occur, such as α2β1 integrin that binds to a specific binding sequence 
on type 1 collagen and enables the cell to traverse across the collagen matrix (Kim et 
al. 1992; O’Toole 2001; Grose et al. 2002; Fuchs 2007). This assistance in cell motility 
is by the integrins present on the keratinocytes binding to the specific ligand present 
on the ECM proteins and forming cell adhesions. This connects the actin cytoskeleton 
of the cell to the ECM and can be used to pull the cell along the surface of the matrix 
(Revenu et al. 2004; Fuchs 2007; Gilcrease 2007; Parsons et al. 2010). After injury, 
there is an up-regulation of integrins present in the epidermis, including those that act 
as a receptor for fibronectin, vitronectin and laminin; some of which have a low 
presence in the unwounded epidermis but play a part in the migration of cells to the 
injury site (Gilcrease 2007; Koivisto et al. 2012; Longmate & DiPersio 2014).  
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Keratinocytes produce matrix metalloproteinases (MMPs) at the wound site, in 
particular MMP-1, -2 and -9 (Martin 1997; Pilcher et al. 1997; Varani 1998; Li et al. 
2007; Philips et al. 2011). These allow the breakdown of the fibrin clot and sever the 
anchoring structures connecting the basal keratinocytes to the basement membrane; 
and allows their migration to the surface for re-epithelialisation (Martin 1997; O’Toole 
2001; Philips et al. 2011; Graves et al. 2014). This expression is normally present, but 
there is a noticeable increase in the expression of these MMPs during cell migration. 
This allows for the movement of keratinocytes from both the wound edge and those 
anchored at the basement membrane (Martin 1997; O’Toole 2001; Joo & Seomun 
2008; Stevens & Page-McCaw 2012; Pastar et al. 2014; Caley et al. 2015). The 
migrating keratinocytes are responsible for the production of the MMPs involved in 
degrading collagen type I and III, which aids their migration through the breakdown 
of the ECM (O’Toole 2001; Bigg et al. 2007; Hattori et al. 2009; Caley et al. 2015; 
Rohani & Parks 2015; Van Doren 2015).  
 
Keratinocytes are recruited and activated through the actions of specific growth 
factors. This is apparent during the different phases of acute skin wound healing, where 
certain factors are responsible for the stimulation of keratinocyte migration to wound 
site and other factors stimulating their subsequent proliferation at the site (Broughton 
et al. 2006a; Koivisto et al. 2012; Peplow & Chatterjee 2013; Longmate & DiPersio 
2014; Seeger & Paller 2015). During the initial haemostasis stage of wound healing, it 
is the release of interleukin (IL)-1 and tumour necrosis factor-α (TNF-α) from 
macrophages present at the wound site, that attracts keratinocytes to the area and their 
presence is required for successful and rapid re-epithelialisation (Chen et al. 1995; 
Banno et al. 2004; Broughton et al. 2006b; Brancato & Albina 2011; Koh & DiPietro 
2011). As the wound healing process develops, other components are responsible for 
producing the growth factors and cytokines necessary for stimulating the migration 
and proliferation of keratinocytes to the injured site (Bennett & Schultz 1993; Gillitzer 
& Goebeler 2001; Barrientos et al. 2008; Peplow & Chatterjee 2013; Seeger & Paller 
2015).  
 
The epidermal growth factor (EGF) family have been shown to play a role in this 
activation, along with keratinocyte growth factor (KGF), which has been shown to also 
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possess a potent proliferative stimulation of keratinocytes (Guo et al. 1993; Martin 
1997; Maas-Szabowski et al. 2000; auf demKeller et al. 2004; Barrientos et al. 2008; 
Reinke & Sorg 2012). Within the EGF family of growth factors, there are a number 
that are associated with this regulatory function acting on keratinocytes, stimulating 
their proliferation and migration. These include EGF, heparin binding epidermal 
growth factor (HB-EGF) and transforming growth factor-α (TGF-α), all of which use 
the EGF receptor for the keratinocyte activation and proliferation at the wound edge 
(Gailit & Clark 1994; Martin 1997; Haase et al. 2003; Hernández-Quintero et al. 2006; 
Barrientos et al. 2008; Gurtner et al. 2008; Peplow & Chatterjee 2013). The EGF 
receptor is located throughout the epidermal layers, but is more concentrated at the 
basal layer and is partly responsible for successful re-epithelialisation, as its presence 
allows the growth factors to stimulate keratinocyte proliferation and migration to the 
wound site (Nanney et al. 1984; Martin 1997; Barrientos et al. 2008; Pastore et al. 
2008).  
 
Some of these growth factors have a dual function, such as IL-1 and TNF-α, which 
have been shown to have a chemotactic and stimulative effect on keratinocytes, 
directly and indirectly, respectively (Tang & Gilchrest 1996; Maas-Szabowski et al. 
1999; Werner & Grose 2003; Banno et al. 2004; Barrientos et al. 2008). These factors 
also increase the expression of KGF, through a paracrine mechanism depicted in 
Figure 1.2. KGF is released by fibroblasts and induces a proliferative action on 
keratinocytes (Guo et al. 1993; Tang & Gilchrest 1996; Maas-Szabowski et al. 1999; 
auf demKeller et al. 2004; Witte & Kao 2005; Broughton et al. 2006a; Barrientos et 
al. 2008; Menon et al. 2012). Another dual function example is with EGF, which has 
been shown to have a stimulatory effect on keratinocyte migration (Uchi et al. 2000; 
Peplow & Chatterjee 2013; Seeger & Paller 2015). It has a mitogenic effect on 
keratinocytes through the activation of GTPase Rac proteins, involved in the cell 
crawling process through the facilitation of focal adhesion formation and the 
movement of the lamellipodia across the substrate (Martin 1997; Li et al. 2007; 
Barrientos et al. 2008; Seeger & Paller 2015).  
 
Keratinocytes themselves also express a number of growth factors, both for their own 
benefit acting in an autocrine manner, but also in a paracrine way, producing growth 
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Figure 1.2: The autocrine and paracrine relationship between fibroblasts and 
keratinocytes, depicting the growth factors and cytokines released from each cell 
type. The factors in bold are involved in stimulating KGF release by fibroblasts, 
through direct stimulation of KGF release (IL-1α and IL-1β), along with 
regulating KGF expression (IL-6, PTHrP and PDGF-BB) acting through 
paracrine mechanisms; and stimulation of keratinocyte proliferation (TGF-α) 
through autocrine mechanisms (Bader & Kao 2009).  
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factors that will activate other cells (Maas-Szabowski et al. 1999; Witte & Kao 2005; 
Barrientos et al. 2008; Bader & Kao 2009). The main example of this autocrine and 
paracrine relationship occurring is with the mutualistic relationship between 
fibroblasts and keratinocytes during wound healing (Martin 1997; Maas-Szabowski et 
al. 1999; Witte & Kao 2005; Werner et al. 2007; Barrientos et al. 2008; Bader & Kao 
2009; Menon et al. 2012). IL-6 is one of the growth factors that both fibroblasts and 
keratinocytes express in an autocrine and paracrine manner, as shown in Figure 1.2 
(Uchi et al. 2000; Werner et al. 2007; Bader & Kao 2009). Fibroblasts secrete KGF-1 
and KGF-2, which along with IL-6 have a proliferative and migratory effect on 
keratinocytes, directing them towards the wound site (Broughton et al. 2006a; 
Hernández-Quintero et al. 2006; Barrientos et al. 2008; Turabelidze & DiPietro 2012).  
 
Keratinocytes also have a role in angiogenesis at the wound site through the production 
of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF; Broughton et al. 2006a; Werner et al. 2007; Barrientos et al. 2008; Velnar et 
al. 2009; Johnson & Wilgus 2014). VEGF is produced by other cells present in both 
the dermis and epidermis, although it appears that keratinocytes are the main 
contributor to the release of this growth factor (Werner & Grose 2003; Broughton et 
al. 2006a; Werner et al. 2007; Barrientos et al. 2008; Seeger & Paller 2015). This 
stimulates the growth of new capillaries and the production of endothelial cells 
(Tonnesen et al. 2000; Broughton et al. 2006a; Barrientos et al. 2008; Johnson & 
Wilgus 2014). Expression of VEGF by keratinocytes is stimulated by a number of 
other growth factors and at different stages in the wound healing process (Werner & 
Grose 2003; Barrientos et al. 2008; Velnar et al. 2009; Johnson & Wilgus 2014). 
Initially VEGF expression is stimulated by the release of IL-1 and TNF-α from 
macrophages, followed by the release of KGF-2 and transforming growth factor-β1 
(TGF-β1), the latter of which is involved in the differentiation of fibroblasts to 
contractile myofibroblasts (Frank et al. 1995; Koyama et al. 2002; Broughton et al. 
2006a; Barrientos et al. 2008; Bao et al. 2009; Pakyari et al. 2013). Keratinocytes also 
express nitric oxide (ṄO), and the combined presence of ṄO and VEGF increases the 
expression of VEGF at the wound site (Broughton et al. 2006a; Bao et al. 2009). ṄO 
has been demonstrated to stimulate keratinocyte migration, acting through a 
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cGMP/PKG-Rho-GTPase pathway. This is believed to impact on the cytoskeleton, 
inducing this migratory response (Zhan et al. 2015).  
 
KGF, also referred to as fibroblast growth factor-7 (FGF-7), has a highly proliferative 
effect on keratinocytes and is released by fibroblasts (Ruehl et al. 2002; auf demKeller 
et al. 2004; Barrientos et al. 2008; Bader & Kao 2009). The expression of KGF by 
fibroblasts is stimulated by the release of factors from keratinocytes, such as IL-1α and 
IL-1β, again showing the close association between the two cells types and the 
autocrine and paracrine relationship, depicted in Figure 1.2 (Tang & Gilchrest 1996; 
Maas-Szabowski et al. 1999; Werner et al. 2007; Bader & Kao 2009; Menon et al. 
2012; Seeger & Paller 2015). KGF has another angiogenic affect, besides increasing 
VEGF expression; it induces a mitogenic effect on vascular endothelial cells required 
for the production of new capillaries (Frank et al. 1995; Barrientos et al. 2008; Bao et 
al. 2009).  In an effort to maintain high levels of keratinocytes at the wound site, KGF 
expression decreases the apoptosis of keratinocytes by decreasing the action of 
reactive oxygen species (ROS), responsible for causing cellular damage and the 
subsequent cell apoptosis. KGF increases the detoxification of ROS through the 
transcription of enzymes involved in the detoxifying ROS (Werner 1998; Beer et al. 
2000; Kovacs et al. 2009).  
 
The proliferation of keratinocytes is also increased by the presence of fibrin, an integral 
component of the fibrin clot necessary to provide a temporary protective barrier before 
re-epithelialisation occurs. This proliferation of keratinocytes drives the re-
epithelialisation process (Yamamoto et al. 2005; Broughton et al. 2006a; Menon et al. 
2012). This stimulation of keratinocytes occurs through fibrin increasing the release 
of TGF-α from keratinocytes (Yamamoto et al. 2005). TGF-α has been shown to 
increase the proliferation activity of both keratinocytes and fibroblasts, acting in an 
autocrine and paracrine manner, respectively. It also indirectly increases the 
proliferation and migration of keratinocytes by increasing the binding capacity of the 
EGF receptor (Miller et al. 2005; Yamamoto et al. 2005; Bader & Kao 2009; Seeger 
& Paller 2015).   
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There have been conflicting opinions on the effect of TGF-β1 on keratinocyte 
proliferative ability, some indicate inhibition and others that increased expression 
stimulates proliferation. Furthermore, it is has been shown that increased TGF-β1 
expression stimulated keratinocyte migration, through upregulation of the integrins 
involved in keratinocyte migration (Koivisto et al. 2012; Peplow & Chatterjee 2013; 
Hameedaldeen et al. 2014; Longmate & DiPersio 2014). Less information is known 
regarding the effects of TGF-β2 and TGF-β3 on keratinocyte migration, although TGF-
β3 has been described as contributing to keratinocyte migration, through TGF-β 
receptor II (Bandyopadhyay et al. 2006; Barrientos et al. 2008; Le et al. 2012; Rad et 
al. 2015).  
 
1.2.1.2     Keratins 
Keratinocytes contain keratin intermediate filaments forming bundles within the cells 
(Fuchs 1995; Magin et al. 2007; Moll et al. 2008; Bragulla & Homberger 2009; Ramms 
et al. 2013). There are specific pairs associated with each of the four levels of the 
epidermis, with an overlap across the layers as differentiation of each cell type occurs 
(Fuchs 1995; Haake et al. 2001; Menon 2002; Gu & Coulombe 2007; Moll et al. 2008; 
Bragulla & Homberger 2009). In the stratum basale, the keratin (Krt) pair is 5 and 14. 
The stratum spinosum contain the pair 1 and 10. This pair converts from 1 to 2 and 
from 10 to 11 in the stratum granulosum layer, with Krt pair 1 and 10 being present 
again in the stratum corneum, along with disulphide bonds to increase the structural 
support (Fuchs 1995; Freedberg 2001; Haake et al. 2001; Menon 2002; Vaidya & 
Kanojia 2007; Moll et al. 2008; Bragulla & Homberger 2009). The presence of these 
pairs alters during wound healing with a decreased expression of Krt1 and Krt10 and 
an increased presence of Krt6 and Krt16, due to their roles in differentiation and 
proliferation, respectively (Fuchs 1995; Haake et al. 2001; Magin et al. 2007; Vaidya 
& Kanojia 2007; Bragulla & Homberger 2009).  
 
Each keratin present has a specific function in maintaining a functional epidermal layer 
to provide the strong protective barrier of the skin (Menon 2002; Gu & Coulombe 
2007; Magin et al. 2007; Bragulla & Homberger 2009). Due to the functionality of 
these proteins being reliant on interactions with other keratin filaments, in most cases 
both keratin types are required to be present for normal function to occur (Magin et al. 
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2007; Moll et al. 2008; Arin 2009; Bragulla & Homberger 2009; Ramms et al. 2013). 
However in other cases, another keratin type can be used as a replacement if the 
original form is absent or mutated. An example of this is evident in epidermis bullosa 
simplex, which affects the spinous layer of the epidermis (Bragulla & Homberger 
2009). This is a result of a mutation occurring in the gene for Krt5 or Krt14. In the 
case of Krt14, the substitute Krt15 may be used; however, it still produces some 
symptoms, but in a less severe form (Fuchs 1995; Lloyd et al. 1995; Moll et al. 2008; 
Arin 2009; McLean & Moore 2011; Ramms et al. 2013). In contrast, if the gene for 
Krt5 is affected, there is no substitute suitable so a more severe form of epidermis 
bullosa simplex is evident (Steinert 2001; Bragulla & Homberger 2009). There are 
other types of keratin present in the other components of the skin, with specific 
functions, such as the hair follicles. A number of keratins are present in the hair follicle 
which are specific to this site and used to be named reflecting this; Krt6hf (hair follicle 
expression), Krt6irs1-4 (inner root sheath) and Krt25irs1-4, now termed Krt75, Krt71-
74 and Krt25-28, respectively (Fuchs 1995; Vaidya & Kanojia 2007; Moll et al. 2008; 
Bragulla & Homberger 2009; McLean & Moore 2011). The outer root sheath and 
companion layer also contain Krt5 and Krt14; and Krt6 and Krt16, respectively 
(Waseem et al. 1999; Fuchs 2007; Vaidya & Kanojia 2007; Bragulla & Homberger 
2009). The hair follicle bulge has also been shown to contain a reservoir of epithelial 
stem cells, with Krt15 considered a biomarker for these stem cells (Whitbread & 
Powell 1998; Liu et al. 2003; Ohyama 2007; Bose et al. 2013). 
 
Krt6 and Krt16, along with Krt17, have been shown to be upregulated in response to 
injury and are thought to play a part in the re-epithelialisation process, although the 
mechanism behind their actions is not yet fully understood (Fuchs 1995; Santos et al. 
2002; Mazzalupo et al. 2003; Sivamani et al. 2007; Bragulla & Homberger 2009). The 
upregulation of Krt6 and Krt16 during wound healing has been shown to be induced 
by both EGF and TGF-α (Jiang et al. 1993; Fuchs 1995; Freedberg et al. 2001; Komine 
et al. 2000; Barrientos et al. 2008; Bragulla & Homberger 2009). These two keratin 
types, along with Krt17, are considered to be a keratinocyte marker for when the cells 
are in an activated state, such as in the wound healing response or the 
hyperproliferation observed in cancer. During this state, the keratinocytes proliferate, 
migrate and change their cell structure as a result of cell crawling (Paladini & 
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Coulombe 1998; Freedberg et al. 2001; Bragulla & Homberger 2009). IL-1 is strongly 
involved in this activation process and has been shown to increase the expression of 
Krt6 (Freedberg et al. 2001). Receptors to IL-1 are present on the keratinocyte surface, 
allowing the activation of keratinocytes to be initiated (Freedberg et al. 2001; Komine 
et al. 2001). TNF-α and TGF-α, both associated with keratinocyte functions, have been 
shown to behave in a regulatory manner towards Krt6, resulting in a specific response 
to the stimulus depending on whether an inflammatory or proliferative response is 
required, respectively (Jiang et al. 1993; Fuchs 1995; Freedberg et al. 2001; Komine 
et al. 2001). However, this increased proliferative response of the keratinocytes can be 
detrimental, as increased expression of Krt17 has been shown to correlate to an 
increased severity of the skin disorder, psoriasis (Bonnekoh et al. 1995; Leigh et al. 
1995; Gudmundsdottir et al. 1999; Zhang et al. 2012; Jin & Wang 2014). 
 
1.2.2     Dermis  
There are a number of different components in the dermis, including the connective 
tissue layer of the skin involved in producing elastic force and tensile strength to the 
tissue (Haake et al. 2001; Kielty et al. 2002; McGrath et al. 2004; Sherratt 2009). The 
dermis performs many functions, some of which are required to maintain the strength 
and flexibility of the skin. The main functions are: protection from injury, 
thermoregulation and sensory receptors to detect pressure (Haake et al. 2001; Menon 
2002; McGrath et al. 2004; Darlenski et al. 2011; Hubmacher & Apte 2013).  
 
There are numerous proteins present in the ECM, which are involved in maintaining 
dermal functions; including collagens, proteoglycans and glycoproteins. The ECM is 
synthesised by fibroblasts, which are a major cell type present in the dermis (Agren & 
Werthén 2007; Schultz & Wysocki 2009; Frantz et al. 2010; Guo & DiPietro 2010; 
Reinke & Sorg 2012; Hubmacher & Apte 2013). Fibroblasts are especially important 
in injury and healing due to their ability to produce ECM components in order to repair 
the defect site and reinstating the damaged protective barrier functions (Agren & 
Werthén 2007; Schultz & Wysocki 2009; Frantz et al. 2010; Reinke & Sorg 2012; 
Bainbridge 2013; Tracy et al. 2016). There are other components present which are 
also essential for the synthesis of the ECM, such as cytokines and growth factors 
(Barrientos et al. 2008; Schultz & Wysocki 2009; Kim et al. 2011; Behm et al. 2012).   
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There are 28 types of collagen that are known, several of which are involved in various 
roles in skin. The majority present are two of the fibrillar collagens, type I 
(approximately 80%) and type III collagen (10%; O’Toole 2001; Gelse et al. 2003; 
Ricard-Blum & Ruggiero 2005; Heino 2007; Schultz & Wysocki 2009; Gordon & 
Hahn 2011; Xue & Jackson 2015; Tracy et al. 2016). In type I collagen, three collagen 
α-chains are joined together in a proline rich triple helical structure, consisting of a 
(glycine-X-Y) formation. This comprises a procollagen molecule, before it is 
transported out of the cell and undergoes a number of post-translational modifications; 
the most common modification is with prolyl hydroxylase, which induces the 
hydroxylation of prolines and forming 4-hydroxyproline, required for collagen triple 
helix formation (O’Toole 2001; Gelse et al. 2003; Myllyharju 2003; Ricard-Blum & 
Ruggiero 2005; Gorres & Raines 2010; Gordon & Hahn 2011; Krieg & Aumailley 
2011; Mouw et al. 2014). Procollagen peptidases are involved in removing the C- and 
N-terminals of procollagen, producing tropocollagen. Numerous tropocollagen 
proteins form collagen fibrils (Stadelmann et al. 1998; Ricard-Blum & Ruggiero 2005; 
Mouw et al. 2014). These fibrils then undergo covalent cross-links with other collagen 
fibrils, forming collagen fibres which increase the tensile strength and stability of the 
structure through the use of the enzyme, lysyl oxidase (Gelse et al. 2003; Diegelmann 
& Evans 2004; Krieg & Aumailley 2011; Hubmacher & Apte 2013; Mouw et al. 2014; 
Xue & Jackson 2015; Tracy et al. 2016). Collagens are able to interact with cells 
through the presence of collagen specific receptors on cell surfaces. The largest family 
of receptors involved are the integrins. In the dermis, fibroblasts connect to collagens 
through multiple integrins, specifically α1β1, α2β1 and α3β1 (O’Toole 2001; Moulin 
& Plamondon 2002; Ricard-Blum & Ruggiero 2005; Agren & Werthén 2007; Heino 
2007; Schultz & Wysocki 2009; Xue & Jackson 2015; Tracy et al. 2016).  
 
1.2.2.1     Fibroblasts 
Fibroblasts possess a spindle-shape morphology and are one of the major cell types 
involved in acute skin wound healing (Moulin & Plamondon 2002; Wozniak et al. 
2004; Birch et al. 2005; Agren & Werthén 2007; Schultz & Wysocki 2009; Li & Wang 
2011; Bainbridge 2013; Tracy et al. 2016). Fibroblasts have a number of functions in 
the dermis, including the production of ECM components, contraction of the wound 
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through differentiation to myofibroblasts, supporting re-epithelialisation through the 
autocrine and paracrine interaction with keratinocytes at the wound site; and the 
production of granulation tissue and new capillaries (Maas-Szabowski et al. 1999; 
Agren & Werthén 2007; Werner et al. 2007; Barrientos et al. 2008; Schultz & Wysocki 
2009; Guo & DiPietro 2010; Bainbridge 2013; Tracy et al. 2016). Fibroblasts also 
provide the contractile force required to pull the wound edges together, as a result of 
the differentiation of dermal fibroblasts to contractile myofibroblasts (Gabbiani 2003; 
Desmouliere et al. 2005; Broughton et al. 2006a; Li & Wang 2011; Micallef et al. 
2012; Darby et al. 2014). There are two sub-populations of fibroblasts in the dermis, 
present in the upper papillary dermis and the lower reticular dermis. There are 
differences in fibroblast functions between these sub-population, with papillary 
fibroblasts releasing less KGF and greater granulocyte macrophage colony-stimulating 
factor (GM-CSF) than reticular fibroblasts. These differences impact on keratinocyte 
proliferation and differentiation responses (Schafer et al. 1985; Sorrell & Caplan 2004; 
Sorrell et al. 2004; Sorrell et al. 2008). Due to the variation between the fibroblasts 
present in these two sub-populations, there are differences between the ECM present 
in each layer, including the type of collagen fibres present (Sorrell & Caplan 2004; 
Sorrell et al. 2004). In the papillary dermis, the collagen fibres synthesised are thin 
structures. In contrast, the collagen fibres produced in the reticular dermis are more 
densely comprised (Sorrell & Caplan 2004; Sorrell et al. 2004; Watt & Fujiwara 2011). 
Some of the fibroblasts present at the wound site migrate to the area in response to 
chemotactic signals, such as TNF-α, platelet-derived growth factor (PDGF), EGF and 
insulin-like growth factor-1 (IGF-1; Seppa et al. 1982; Bennett & Schultz 1993; 
Barrientos et al. 2008; Bainbridge 2013; Olczyk et al. 2014). However, some 
fibroblasts at the wound site are derived from multipotent cells present in the 
undamaged dermis and have the ability to differentiate into dermal fibroblasts (Toma 
et al. 2001; Fernandes et al. 2004; Shaw & Martin 2009; Reilkoff et al. 2011).  These 
cells are circulating fibrocytes, which are a distinct population from fibroblasts, but 
also possess a number of fibroblastic features. These include the synthesis of ECM 
components, release of cytokines and growth factors required for wound healing, 
inducing contraction required for wound closure; and stimulating angiogenesis (Metz 
2003; Quan et al. 2004; Kao et al. 2011; Bianchetti et al. 2012; Blakaj & Bucala 2012; 
Suga et al. 2014). Due to this variety of functions, they are capable of contributing to 
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the wound healing process directly and through their ability to differentiate into dermal 
fibroblasts and contractile myofibroblasts (Metz 2003; Bellini & Mattoli 2007; Strieter 
et al. 2009; Blakaj & Bucala 2012; Van Linthout et al. 2014).  
 
In addition to new ECM synthesis, fibroblasts are responsible for the organisation and 
remodelling of the newly-deposited ECM (Agren & Werthén 2007; Schultz & 
Wysocki 2009; Eckes et al. 2010; Olczyk et al. 2014; Tracy et al. 2016). Therefore, a 
dysfunction in dermal fibroblasts or conversion to senescent fibroblasts will have a 
resulting impact on ECM architecture, potentially leading to impaired healing (Cook 
et al. 2000; Sorrell & Caplan 2004; Wall et al. 2008; Schultz & Wysocki 2009; Wells 
et al. 2015). Fibroblasts regulate the turnover of the ECM by controlling the expression 
of the MMPs responsible for the breakdown of the ECM, along with the inhibitors of 
these proteases, tissue inhibitors of metalloproteinases (TIMPs; Nagase et al. 2006; 
Gill & Parks 2008; Schultz & Wysocki 2009; Li & Wang 2011; Watt & Fujiwara 2011; 
Behm et al. 2012; Caley et al. 2015; Rohani & Parks 2015). The presence of TGF-β1 
decreases the turnover of the ECM by decreasing the expression of MMPs and 
increasing the expression of TIMPs (Overall et al. 1989; Zeng et al. 1996; Barrientos 
et al. 2008; Schultz & Wysocki 2009; Watt & Fujiwara 2011). If ECM synthesis is 
higher than degradation, this can lead to an unorganised ECM structure and the 
formation of fibrotic tissue. This is as a result of the new ECM being continually 
deposited without a regulated degradation occurring (Li et al. 2007; Kisseleva & 
Brenner 2008; Schultz & Wysocki 2009; Watt & Fujiwara 2011). If a high presence 
of activated fibroblasts remain at the wound site, this results in ECM synthesis 
continuing without adequate degradation, leading to excessive ECM deposition and 
scar tissue formation (Li et al. 2007; Eckes et al. 2010; Watt & Fujiwara 2011; Jumper 
et al. 2015; Xue & Jackson 2015). Dysfunctional ECM turnover is also present in 
chronic wounds; although in this situation, there is increased degradation of the ECM, 
believed to be a result of increased expression of proteases at the wound site 
(Trengrove et al. 1999; Cook et al. 2000; Agren & Werthén 2007; McCarty & Percival 
2013). 
 
The migration of fibroblasts into the wound site is modulated by chemotactic signals. 
The source of the growth factors responsible for chemotaxis varies throughout the 
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wound healing process (Seppa et al. 1982; Pierce et al. 1989; Werner & Grose 2003; 
Li et al. 2004; Broughton et al. 2006a; Andrae et al. 2008; Schultz & Wysocki 2009; 
Schneider et al. 2010; Bainbridge 2013; Olczyk et al. 2014; Balaji et al. 2015). 
Initially, platelets and macrophages produce PDGF, which activates the fibroblasts and 
stimulates them to produce ECM components, including collagens, 
glycosaminoglycans and fibronectin; re-establishing the dermal matrix (Broughton et 
al. 2006a; Agren & Werthén 2007; Barrientos et al. 2008; Pakyari et al. 2013; Olczyk 
et al. 2014). Increased expression of PDGF stimulates fibroblast proliferation and 
subsequent ECM synthesis. This increase is also beneficial for the production of new 
capillaries in the granulation tissue (Sato et al. 1993; Battegay et al. 1994; Barrientos 
et al. 2008; Raica & Cimpean 2010; Watt & Fujiwara 2011; Reinke & Sorg 2012). 
PDGF has also been shown to upregulate MMPs during the remodelling stage of 
wound healing, allowing for the removal of damaged ECM. This is necessary for the 
successful remodelling of the ECM and allowing for an organised deposition of the 
new ECM to be assembled (Jinnin et al. 2005; Risinger et al. 2006; Barrientos et al. 
2008; Gill & Parks 2008; Schultz & Wysocki 2009; Risinger et al. 2010; Reinke & 
Sorg 2012). FGF, also produced by fibroblasts has also been shown to increase ECM 
synthesis. Additionally, it increases the migration of more fibroblasts to the wound 
site, allowing for further production of ECM components (Wilkie et al. 1995; 
Barrientos et al. 2008; Xie et al. 2008; Schultz & Wysocki 2009).  
 
A positive feedback system exists between fibroblasts and keratinocytes, with the 
dermal fibroblasts producing a number of growth factors and cytokines, which 
stimulate the proliferation of keratinocytes and induce release of factors shown to 
subsequently increase fibroblast proliferation (Maas-Szabowski et al. 1999; Maas-
Szabowski et al. 2000; Werner & Smola 2001; Werner & Grose 2003; Bader & Kao 
2009). Both cells exert autocrine and paracrine actions, through the release of such 
factors which stimulate their own proliferation and the release of soluble factors to 
increase the proliferation of the other cell type (Witte & Kao 2005; Werner et al. 2007; 
Bader & Kao 2009). This autocrine and paracrine interaction between the fibroblasts 
and keratinocytes is shown in Figure 1.2 (Bader & Kao 2009). TGF-β1 also increases 
the expression of connective tissue growth factor (CTGF) from fibroblasts and acts in 
an autocrine manner by increasing the proliferation of fibroblasts; and it has been 
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shown to produce some of the components required for ECM synthesis (Igarashi et al. 
1993; Frazier et al. 1996; Sorrell & Caplan 2004; Daniels et al. 2003; Barrientos et al. 
2008). During wound healing, TGF-β1 and TGF-β2 from the TGF-β superfamily 
exhibit the highest presence; TGF–β3 is also present, although at a lower level (Frank 
et al. 1996; Yang et al. 1999; Barrientos et al. 2008; Reinke & Sorg 2012). TGF-β2 has 
been shown to have a potent attractant for fibroblasts to the wound site, whilst TGF-
β3 has been shown to have a positive effect on the migration of fibroblasts. TGF-β3 has 
also been shown to possess potent anti-scarring properties (Shah et al. 1995; Frank et 
al. 1996; Barrientos et al. 2008; Kishi et al. 2012; Lichtman et al. 2016).   
 
Before the conversion of fibroblasts to contractile myofibroblasts, there is a weak 
contractile force produced by the fibroblasts, forming stress fibres consisting of 
bundles of actin fibres; these ‘active’ fibroblasts have been referred to as proto-
fibroblasts (Hinz et al. 2001; Tomasek et al. 2002; Hinz 2007; Shaw & Martin 2009). 
The main contractile force is generated once myofibroblasts are activated by the 
presence of TGF-β1 (Desmoulière et al. 1993; Grinnell 1994; Serini & Gabbiani 1999; 
Gabbiani 2003; Desmouliere et al. 2005; Shaw & Martin 2009). Fibroblasts produce a 
tensile force as a result of the interaction between actin and myosin. These are involved 
in the cell crawling process as the cytoskeleton changes conformation and form 
adhesions to the ECM, as the cell migrates across the ECM (Kolega et al. 1991; Conrad 
et al. 1993; Lauffenburger & Horwitz 1996; Ananthakrishnan & Ehrlicher 2007; Li & 
Wang 2011; Reinke & Sorg 2012). In addition to involvement in wound contraction, 
TGF-β1 has been shown to increase the expression of a number of integrins for 
collagen, fibronectin and vitronectin (Gailit et al. 1994; Thannickal et al. 2003; Schultz 
& Wysocki 2009; Watt & Fujiwara 2011; Hameedaldeen et al. 2014).  
 
Other soluble factors in this process, such as IL-1α and IL-1β, are involved with 
stimulating the release of other factors, such as IL-6 and IL-8 from keratinocytes and 
fibroblasts, respectively (Uchi et al. 2000; Werner et al. 2007; Bader & Kao 2009). 
The benefit of the close association between fibroblasts and keratinocytes is seen in 
successful wound healing, as both cells are vital to this mechanism (Werner et al. 2007; 
Bader & Kao 2009; Guo & DiPietro 2010; Schreml et al. 2010; Menon et al. 2012; 
Bainbridge 2013; Pastar et al. 2014). This mutually beneficial interaction between 
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fibroblasts and keratinocytes is important for the regulation of the ECM, ensuring that 
re-epithelialisation occurs successfully and the synthesis and degradation of the ECM 
is tightly regulated (Sawicki et al. 2005; Witte & Kao 2005; Werner et al. 2007; Menon 
et al. 2012). It is thought that the connection between the fibroblasts and keratinocytes 
is mediated through the AP-1 family of transcription factors present in fibroblasts and 
therefore, fibroblasts are believed to oversee the regulation of ECM synthesis and re-
epithelialisation (Angel et al. 2001; Florin et al. 2004; Sorrell & Caplan 2004; Schultz 
& Wysocki 2009).  
 
1.2.2.2     Myofibroblasts 
When tissue injury occurs, some fibroblasts present at the injury site are activated to 
differentiate into myofibroblasts. This is due to a combination of mechanical stress on 
the tissue, along with activation by TGF-β1 (Desmouliere et al. 2005; Hinz 2007; 
Meran et al. 2008; Li & Wang 2011; Leung et al. 2012). In addition, the splice variant 
of the glycoprotein, fibronectin (ED-A), is also involved in activating this 
differentiation to a myofibroblast phenotype (Gabbiani 2003; Desmouliere et al. 2005; 
Hinz 2007; Li & Wang 2011). The activation of fibroblasts to myofibroblasts occurs 
in a two-step process, with the production of a proto-myofibroblast as an intermediate 
step, as shown in Figure 1.3 (Tomasek et al. 2002; Daniels et al. 2003; Gabbiani 2003; 
Desmouliere et al. 2005; Li & Wang 2011; Darby et al. 2014). The function of 
myofibroblasts is essential for the closure of the wound, as they impart a contraction 
on the wound edges to bring them together (Tomasek et al. 2002; Gabbiani 2003; Hinz 
2007; Li & Wang 2011; Sarrazy et al. 2011).  
 
This contractile force is generated from α-smooth muscle actin (α-SMA), which are 
expressed by the myofibroblasts and deemed as a characteristic marker of true 
myofibroblasts (Serini & Gabbiani 1999; Tomasek et al. 2002; Gabbiani 2003; Hinz 
2007; Hinz et al. 2007; Eckes et al. 2010; Darby et al. 2014). There are different forms 
of smooth muscle actin present at the intermediate step where proto-myofibroblasts 
are present; α-actin is not present at this stage, but β- and γ-actin isoforms are present 
instead (Tomasek et al. 2002; Gabbiani 2003; Desmouliere et al. 2005). This  
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Figure 1.3: Process of differentiation from fibroblast to proto-myofibroblast to 
myofibroblasts; and the factors involved in the conversion, TGF-β1 and ED-A 
splice variant fibronectin (Tomasek et al. 2002). 
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conversion of actin types present between the intermediate and fully activated 
myofibroblast confirms that α-SMA is a reliable marker for the active form of 
myofibroblasts (Gabbiani 2003; Desmouliere et al. 2005; Li & Wang 2011). Other 
filament types that are used as a positive marker for myofibroblasts are the 
intermediate filament, vimentin and in some tissues desmin. These cells can be 
distinguished from fibroblasts by the absence of desmin and α-SMA, although 
fibroblasts also test positive for the presence of vimentin (Eyden 2008; Gabbiani 1992; 
Li & Wang 2011; Darby et al. 2014). Myofibroblasts contain a network of 
microfilaments that are arranged in bundles, these microfilaments need a connection 
to the surrounding ECM, so that the contractile force generated can be exerted onto 
the matrix (Tomasek et al. 2002; Gabbiani 2003; Hinz 2007; Micallef et al. 2012; 
Darby et al. 2014). These connections are termed focal adhesion sites, which connect 
the intracellular actin with the ECM for both the proto-myofibroblast and the activated 
myofibroblast (Tomasek et al. 2002; Gabbiani 2003; Hinz 2007; Eckes et al. 2010; Li 
& Wang 2011; Darby et al. 2014). 
 
The benefit of closing the wound space at the dermal level is the provision of a 
protective barrier for the underlying connective tissue (Li & Wang 2011; Eming et al. 
2014). Contraction takes place during the proliferative stage of the wound healing 
process, when high numbers of fibroblasts are present at the wound site, with the 
potential to differentiate into myofibroblasts (Desmouliere et al. 2005; Hinz 2007; Li 
& Wang 2011; Darby et al. 2014). This contraction and subsequent closure of the 
wound needs to be tightly regulated, as too much or too little contraction can have 
implications on the healing mechanism (Tomasek et al. 2002; Gabbiani 2003; Eckes 
et al. 2010; Li & Wang 2011; Hinz et al. 2012; Van De Water et al. 2013; Darby et al. 
2014; Darby et al. 2016). Too little contraction may prevent successful closure of the 
wound, whilst excess contraction can affect the appearance of the scar, but more 
importantly may cause a loss of function in that area (Gabbiani 2003; Moulin et al. 
2004; Eckes et al. 2010; Li & Wang 2011; Micallef et al. 2012; Eming et al. 2014; 
Rabello et al. 2014). Furthermore, as the dermal layers close, this allows successful re-
epithelialisation to occur due to the closer proximity of the two edges (Martin 1997; 
Häkkinen et al. 2011; K J Rolfe & Grobbelaar 2012; Rittié 2016). Another function of 
myofibroblasts is their ability to produce large quantities of ECM proteins at the injury 
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site, in particular type I-VI collagens, type XVIII collagen, glycoproteins, 
glycosaminoglycans and proteoglycans. All of these ECM components are vital for the 
effective synthesis of new dermal tissue (Tomasek et al. 2002; Hinz 2007; Li & Wang 
2011; Darby et al. 2014). In addition, myofibroblasts produce components that are 
necessary for the remodelling of the ECM, such as MMPs and TIMPs (Powell et al. 
1999; Li & Wang 2011).  
 
TGF-β1 induces its response on fibroblasts through binding to TGF-β receptors (TβRs) 
and activating downstream intracellular signalling molecules. These transcription 
regulators are part of the SMAD family, as depicted in Figure 1.4 (Kretzschmar & 
Massague 1998; Schiller et al. 2004; ten Dijke & Hill 2004; Verrecchia et al. 2006; 
Ross & Hill 2008; Xu et al. 2012). The ligand binds to TβRII, which subsequently 
binds to TβRI, forming a complex; this complex phosphorylates and activates SMAD 
regulators (Heldin et al. 1997; Kretzschmar & Massague 1998; Schiller et al. 2004; ten 
Dijke & Hill 2004; Verrecchia et al. 2006; Ross & Hill 2008; Xu et al. 2012). There 
are multiple type I and II receptors, these are referred to as Activin-receptor-like 
kinases (ALKs); ALK4, ALK5 and ALK7 are involved in SMAD2 and SMAD3 
phosphorylation (Miyazono 2000; ten Dijke & Hill 2004; Moustakas & Heldin 2008). 
Receptor-associated SMADs (R-SMADs), SMAD2 and SMAD3, are phosphorylated 
by the TβRs; the recruitment of R-SMADs to the TβR complex is aided by a SMAD 
anchor for receptor activation (SARA). Once the R-SMAD has been phosphorylated, 
co-SMAD4 forms a complex with this phosphorylated R-SMAD. This complex is 
subsequently internalised into the nucleus and gene transcription initiated (Heldin et 
al. 1997; Inman et al. 2002; Javelaud & Mauviel 2004; Schiller et al. 2004; ten Dijke 
& Hill 2004; Verrecchia et al. 2006; Ross & Hill 2008; Xu et al. 2012). R-SMAD2, R-
SMAD3 and co-SMAD4 are the SMADs present in vertebrates and involved in TGF-
β signalling (Attisano & Wrana 1998; Kretzschmar & Massague 1998).  
 
TGF-β exerts its response through this SMAD signalling pathway and induces the 
differentiation of fibroblasts to myofibroblasts. SMAD3 has been demonstrated to play 
a key role in producing a fibrotic response and SMAD2 overexpression induced 
increased α-SMA expression (Evans et al. 2003; Javelaud & Mauviel 2004; Schiller et 
al. 2004; Verrecchia et al. 2006; Darby et al. 2014). However, there are inhibitory  
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Figure 1.4: TGF-β/SMAD signalling pathway, showing binding of TGF-β to 
TβRs, initiating activation of downstream signalling through SMADs and 
initiating gene transcription (Schiller et al. 2004).  
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SMADS, SMAD6 and SMAD7, which are involved in opposing this fibrotic response. 
SMAD7 has been shown to inhibit TGF-β signalling, through inhibiting SMAD3 
phosphorylation and preventing the formation of R-SMAD and co-SMAD complexes; 
and the subsequent downstream signalling (Kretzschmar & Massague 1998; Miyazono 
2000; Javelaud & Mauviel 2004; Schiller et al. 2004; Moustakas & Heldin 2008). 
 
Hyaluronan, a glycosaminoglycan found in the ECM, has been demonstrated to be 
involved in TGF-β1-mediated, fibroblast to myofibroblast differentiation (Jenkins et 
al. 2004; Meran et al. 2007; Webber et al. 2009a). It has been shown to be a vital part 
of inducing differentiation, although inhibition of hyaluronan synthesis does not affect 
phosphorylation of SMAD3. However, SMAD3 is involved in TGF-β1-mediated, 
fibroblast proliferation (Webber et al. 2009a). Formation of a hyaluronan pericellular 
coat is involved in fibroblast to myofibroblast differentiation; as production of the 
pericellular coat was absent with inhibited hyaluronan synthesis, which resulted in 
inhibition of differentiation to myofibroblasts (Webber et al. 2009a, 2009b). This 
involvement of hyaluronan in TGF-β1-mediated, differentiation is evident in dermal 
fibroblasts, but not oral fibroblasts (Meran et al. 2007). Oral mucosal fibroblasts resist 
TGF-β1-mediated differentiation, this is thought to be partly due to a decreased 
expression of hyaluronan compared to dermal fibroblasts. This is potentially due to the 
decreased expression of hyaluronan synthase 2 enzyme (HAS2) by oral mucosal 
fibroblasts (Meran et al. 2007, 2008). Additionally, high expression of HAS3 was 
evident in oral fibroblasts, compared to a much lower expression in dermal fibroblasts; 
whereas HAS1 was not expressed by oral fibroblasts, but was by dermal fibroblasts. 
However, alteration of HAS1 expression levels in oral mucosal or dermal fibroblasts 
did not impact on TGF-β1-mediated, differentiation (Meran et al. 2007; Glim et al. 
2014). TGF-β1 is also involved in synthesis of tumour necrosis factor-stimulating 
gene-6 (TSG-6), which is a hyaluronan binding protein and involved in pericellular 
coat formation. CD44 and EGF receptor (EGFR) are cell surface receptors, which are 
involved in the downstream actions of hyaluronan. Hyaluronan associates with CD44, 
inducing its co-localisation to EGFR, initiating the downstream pathways and resulting 
in myofibroblast formation (Midgley et al. 2013; Midgley et al. 2015).  
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When myofibroblasts are no longer required within the wound once closure is 
achieved, it is believed that myofibroblasts undergo apoptosis preventing further 
contractile forces acting on the wound site (Desmoulière et al. 1995; Desmoulière et 
al. 1997; Martin 1997; Hinz 2007; Häkkinen et al. 2011; Li & Wang 2011; Darby et 
al. 2014). Another mechanism for the cessation of contraction at the wound site are 
thought to be ‘stop signals’ released as the mechanical tension at the wound site is 
eased, due to closure of the injured tissue. Decreased α-SMA is also evident when 
tension decreases (Martin 1997; Hinz et al. 2001; Tomasek et al. 2002; Gabbiani 2003; 
Hinz 2007). Although programmed cell death is the most accepted fate for redundant 
myofibroblasts, there is also a theory that they may revert their phenotype back into a 
fibroblast (Gabbiani 2003; Desmouliere et al. 2005; Li & Wang 2011). However, it is 
not yet known how this dedifferentiation would occur and which factors may support 
this conversion (Gabbiani 2003; Li & Wang 2011).  
 
1.2.3     Extracellular Matrix 
The ECM is a vital component of skin, amongst other tissues; and represents the non-
cellular aspect of tissues. One of its main functions is providing strength and structure 
to the tissue, through a variety of ECM components (Frantz et al. 2010; Lu et al. 2011; 
Hubmacher & Apte 2013; Mouw et al. 2014; Naba et al. 2016). It is often referred to 
as being the ‘gel-like’ component surrounding the cells, being comprised of water, 
proteins and polysaccharides (Schultz & Wysocki 2009; Eckes et al. 2010; Frantz et 
al. 2010). The different components of the ECM have specific functions. For instance, 
collagens are the predominate protein component of the ECM and involved in the 
scaffold structure, providing integrity to the tissue (Gelse et al. 2003; Eckes et al. 2010; 
Frantz et al. 2010; Gordon & Hahn 2011; Mouw et al. 2014). There are a number of 
collagen types present in the skin, but type I and III collagen are the main forms 
secreted by fibroblasts in the newly formed granulation tissue (Bazin et al. 1976; 
Haukipuro et al. 1991; Gelse et al. 2003; Schultz & Wysocki 2009; Olczyk et al. 2014). 
Collagen type I is the predominate form, but there is a higher presence of type III 
collagen in foetal wounds compared to adult, dermal wounds (Gelse et al. 2003; Cuttle 
et al. 2005; Schultz & Wysocki 2009; Cheng et al. 2011; Leung et al. 2012; Olczyk et 
al. 2014). The intrinsic differences between the two fibrillar collagens may account for 
the difference in scar formation following wounding. Type III collagen is associated 
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with more elastic tissues. Therefore, the higher presence of this type may result in a 
less rigid wound site and produce a scarless healing response (Gelse et al. 2003; Cuttle 
et al. 2005; Leung et al. 2012; Muiznieks & Keeley 2013; Olczyk et al. 2014).  
 
Other proteins present in the ECM include elastin, laminin and fibronectin (Schultz & 
Wysocki 2009; Eckes et al. 2010; Mouw et al. 2014; Olczyk et al. 2014). Elastin is 
comprised of cross-linked tropoelastin subunits and is also associated with providing 
elasticity to the tissue (Debelle & Tamburro 1999; Midwood & Schwarzbauer 2002; 
Tamburro et al. 2005; Frantz et al. 2010; Singh et al. 2010; Kim et al. 2011; Tracy et 
al. 2016). Additionally, along with collagen, elastin provides structural support to the 
tissues allowing tissues to withstand tensile stress (Frantz et al. 2010; Muiznieks & 
Keeley 2013; Mouw et al. 2014). Elastin is closely linked to collagen fibres to provide 
the degree of flexibility, with the collagen fibres reducing the degree that the fibres 
can extend. The combination of these two predominant ECM proteins results in a 
strong tissue that is able to withstand stresses (Frantz et al. 2010; Van Doren 2015). 
An important observation is the lack of elastin in the newly-deposited granulation 
tissue following injury. This could contribute to the more rigid matrix observed in scar 
tissue (Schultz & Wysocki 2009; Eckes et al. 2010). Another glycoprotein contributing 
to the tensile strength of the skin is laminin. It is referred to as an adhesive protein and 
is a major component of the basement membrane (Nishiyama et al. 2000; Bosman & 
Stamenkovic 2003; Eckes et al. 2010; Kim et al. 2011; Mouw et al. 2014). Laminins 
have a variety of functions, in addition to providing the structural integrity of the 
basement membrane. They are strongly involved in cell-matrix interaction, through 
the basement membrane (Korang et al. 1995; Bosman & Stamenkovic 2003; Schneider 
et al. 2007; Mouw et al. 2014). Other functions include an involvement in cell 
proliferation, migration and differentiation. Laminin-332, after cleavage by MMPs 
present, is thought to be involved in keratinocyte migration at the wound edge through 
the provision of pro-migratory tracks for the keratinocytes to migrate across 
(Schneider et al. 2007; Schultz & Wysocki 2009; Eckes et al. 2010; Schlage et al. 
2015). Fibronectin, is another adhesive protein present in the ECM, in particular in the 
basement membrane zone (Ruoslahti 1984, 1988a; Schultz & Wysocki 2009; Eckes et 
al. 2010; Singh et al. 2010; Mouw et al. 2014; Tracy et al. 2016). This glycoprotein 
also possesses many functions, including structural support, cell adhesion and 
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regulating cell-matrix interactions (Corbett et al. 1997; Schultz & Wysocki 2009; 
Eckes et al. 2010; Singh et al. 2010; Tracy et al. 2016). It has a vital role in the acute 
wound healing response, through the formation of a provisional matrix with fibrin. 
This matrix allows the infiltration of fibroblasts and other cells required to synthesise 
a new ECM, along with providing a structure for keratinocytes to migrate across during 
re-epithelialisation (Clark et al. 1982; Greiling & Clark 1997; Agren & Werthén 2007; 
Schultz & Wysocki 2009; Eckes et al. 2010; Olczyk et al. 2014; Reinke & Sorg 2012).  
 
In addition to the structural proteins and adhesive glycoproteins, the ECM is also 
comprised of various proteoglycans and glycosoaminoglycans. These surround the 
ECM proteins and help organise the arrangement of collagen fibrils to increase tissue 
strength (Ruoslahti 1988b; Agren & Werthén 2007; Schultz & Wysocki 2009; Eckes 
et al. 2010; Mouw et al. 2014; Tracy et al. 2016). Proteoglycans are negatively charged 
molecules comprised of a protein backbone, with polysaccharide 
(glycosoaminoglycan) chains attached. These are present in the ECM and in the 
basement membrane (Ruoslahti 1988b; Kjeuin & Lindahl 1991; Schultz & Wysocki 
2009; Eckes et al. 2010; Ghatak et al. 2015; Smith & Melrose 2015; Tracy et al. 2016). 
They are hydrophilic molecules and capable of holding large volumes of water, 
approximately 1000-times their volume. This provides hydration to the tissue and 
contributes to the gel-like composition of the ECM (Ruoslahti 1988b; Schultz & 
Wysocki 2009; Culav et al. 1999; Eckes et al. 2010; Schaefer & Schaefer 2010; Smith 
& Melrose 2015; Tracy et al. 2016). There are two main categories of proteoglycans, 
heparan sulphate proteoglycans and chondroitin sulphate proteoglycans (Ruoslahti 
1988b; Kjeuin & Lindahl 1991; Kim et al. 2011; Mouw et al. 2014; Ghatak et al. 2015; 
Smith & Melrose 2015). Heparan sulphate proteoglycans include perlecan and 
syndecan, present in the early stages of wound healing (Gallagher et al. 1986; Oksala 
et al. 1995; Bishop et al. 2007; Kim et al. 2011; Sarrazin et al. 2011; Olczyk et al. 
2014). Perlecan has a role in regulating VEGF, PDGF and FGF2; and their subsequent 
wound healing functions, such as angiogenesis, cell proliferation, migration and 
adhesion (Iozzo 1998; Guimond & Turnbull 1999; Bosman & Stamenkovic 2003; 
Bishop et al. 2007; Eckes et al. 2010; Kim et al. 2011). Chondroitin sulphate 
proteoglycans include versican and the small leucine-rich proteoglycans, decorin and 
biglycan. These occur later in the wound healing process, approximately 2 weeks after 
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injury (Kjeuin & Lindahl 1991; Iozzo 1998; Iozzo & Proteoglycans 1999; Agren & 
Werthén 2007; Schaefer & Iozzo 2008; Kim et al. 2011; Olczyk et al. 2014). Versican 
has been shown to have a role in the stimulation of fibroblast and keratinocyte 
proliferation. However, for fibroblast proliferation, this appears to be true for versican 
V1 isoform, with V2 isoform showing an inhibitory response on proliferation 
(Zimmermann et al. 1994; Zhang et al. 1998; Bosman & Stamenkovic 2003; Sheng et 
al. 2005; Wight et al. 2014). Other functions of the chondroitin sulphate proteoglycans 
include the provision of strength to the tissue, through resisting compressive force 
(Iozzo 1998; Bosman & Stamenkovic 2003; Eckes et al. 2010). Decorin plays a role 
in collagen fibril formation, which contributes to skin integrity. This response has been 
demonstrated through knockout animal studies, displaying abnormal collagen fibril 
organisation and a large variety in the diameter of these fibrils, leading to a decreased 
level of tensile strength (Iozzo 1998; Reed & Iozzo 2002; Muiznieks & Keeley 2013; 
Smith & Melrose 2015).   
 
The most prevalent glycosaminoglycan in the skin is hyaluronan, which is involved in 
fibroblast proliferation, migration, differentiation to myofibroblasts; and in collagen 
production (Agren & Werthén 2007; Meran et al. 2007; Huang et al. 2008; Meran et 
al. 2008; Tracy et al. 2016). However, there appears to be a difference in wound 
healing responses depending on the size of hyaluronan present, impacting on 
inflammation, proliferation, ECM synthesis and myofibroblast differentiation (Tolg et 
al. 2014a; Ghatak et al. 2015; Tracy et al. 2016). Native, larger molecule-weight 
hyaluronan (>500 kDa) decreased inflammation, increased synthesis of type III 
collagen, and increased expression of TGF-β3 from dermal fibroblasts; all these actions 
contribute to preferential healing responses (David-Raoudi et al. 2008; Tolg et al. 
2014b; Tracy et al. 2016). Whereas, smaller molecular-weight hyaluronan (<400 kDa) 
has a contrasting response, with increased inflammation, increased synthesis of type I 
collagen, enhanced proliferation of fibroblasts; and increased expression of TGF-β1 
from dermal fibroblasts and resultant differentiation to myofibroblasts (David-Raoudi 
et al. 2008; Tolg et al. 2012; Tolg et al. 2014b; Tracy et al. 2016). As previously 
mentioned, hyaluronan has been shown to influence the TGF-β1 signalling pathway, 
mediating the differentiation to myofibroblasts (Jenkins et al. 2004; Meran et al. 2007; 
Webber et al. 2009a). Increased presence of these smaller molecular-weight 
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hyaluronan fragments leads to fibrosis. These fragments are produced through 
degradation of native hyaluronan by hyaluronidases and reactive oxygen species 
present in adult skin (David-Raoudi et al. 2008; Tolg et al. 2014b; Ghatak et al. 2015; 
Tracy et al. 2016). However, in contrast, a high level of intact, native hyaluronan is 
seen in foetal wounds. This decreased fibrotic response is characteristic of the scarless 
healing observed in early-gestational, foetal healing (David-Raoudi et al. 2008; 
Schultz & Wysocki 2009b; Tolg et al. 2014b; Tracy et al. 2016).  
 
The ECM is essential for cells to exert a number of functions. This is also true for the 
re-epithelialisation process, through the provision of the scaffold matrix and basement 
membrane, allowing the migration of keratinocytes across the wound site (Clark et al. 
1982; O’Toole 2001; Schultz & Wysocki 2009; Hubmacher & Apte 2013). The 
supportive ECM and basement membrane also provide a structure for the 
differentiation of keratinocytes, from the basal layer to the formation of corneocytes 
(Watt 1989; Menon 2002; Hubmacher & Apte 2013). In addition, the interaction 
between the cells and the ECM, along with direct ECM-growth factor interactions, are 
vital for the normal function of the skin. Such events mediate cell responses and the 
remodelling of the ECM itself (Agren & Werthén 2007; Schultz & Wysocki 2009; 
Eckes et al. 2010; Tracy et al. 2016). There is a continual turnover of the ECM, through 
synthesis and degradation, involving MMPs and TIMPs. This turnover process is 
especially important during wound healing and the ECM remodelling phase, this is 
discussed further in Section 1.3.4 (Parks 1999; Schultz & Wysocki 2009; Kim et al. 
2011; Olczyk et al. 2014; Arpino et al. 2015; Caley et al. 2015; Xue & Jackson 2015). 
Variations in these interactions can result in detrimental effects; such examples of 
dysfunctional ECM turnover are demonstrated in fibrosis and chronic wounds. In 
chronic wounds the ECM does not remodel successfully, due to excessive degradation 
and insufficient ECM synthesis. In contrast, excessive ECM synthesis and reduced 
degradation contributes to fibrotic tissue formation (Trengrove et al. 1999; Agren & 
Werthén 2007; Wynn 2008; Schultz & Wysocki 2009; Eckes et al. 2010; Watt & 
Fujiwara 2011; McCarty & Percival 2013; Xue & Jackson 2015; Tracy et al. 2016).  
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1.3     Acute Skin Wound Healing 
 
The skin is capable of self-repair through a set of overlapping phases of acute skin 
wound healing. These are performed in a particular order to ensure successful repair. 
The main stages involved are haemostasis, inflammation, migration and proliferation 
of cells to form the new epithelium and dermal ECM; and finally, the remodelling of 
the affected tissue, as depicted in Figure 1.5 (Beanes et al. 2003; Braiman-Wiksman 
et al. 2007; Li et al. 2007; Velnar et al. 2009; Guo & DiPietro 2010; Kondo & Ishida 
2010; Reinke & Sorg 2012; Portou et al. 2015). Rapid contraction and closure of the 
wound occurs to re-instate the protective barrier (Gabbiani 2003; Desmouliere et al. 
2005; Li et al. 2007; Velnar et al. 2009; Eckes et al. 2010; Bainbridge 2013). There is 
also a rapid synthesis of the newly formed ECM. However, the new ECM is deposited 
in a disorganised manner below the newly-formed epidermis (Shah et al. 1995; 
Traversa & Sussman 2001; Beanes et al. 2003; Velnar et al. 2009; Xue & Jackson 
2015). The combination of these two processes results in the production of fibrotic 
scar tissue (Velnar et al. 2009; Li & Wang 2011; Watt & Fujiwara 2011; Reinke & 
Sorg 2012; Xue & Jackson 2015). In normal acute skin wound healing, this is a very 
tightly regulated mechanism, with all aspects of the process carefully balanced to 
produce the successful healing of the injury. This requires an optimal amount of ECM 
components deposited to allow healing without the formation of excess scar tissue. 
Conversely, ECM degradation needs to be regulated, as excess degradation is shown 
to occur in chronic wounds (Bullen et al. 1995; Stadelmann et al. 1998; Menke et al. 
2007; Muller et al. 2008; Xie et al. 2008; Velnar et al. 2009; Cox & Erler 2011; Reinke 
& Sorg 2012).  
 
As mentioned previously, it is the interaction between different cells and between cells 
and the ECM that results in successful wound healing (Werner et al. 2007; Barrientos 
et al. 2008; Eckes et al. 2010; Watt & Fujiwara 2011; Reinke & Sorg 2012). These 
interactions control a number of functions during the overlapping wound healing 
phases, including cell proliferation, migration, differentiation; and synthesis of new 
ECM components. There is an overlap of functions for these mediators, with many 
belonging to several categories or families, depending on the effects they exert  
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Figure 1.5: Overlapping phases of the wound healing process, depicting the four 
main stages, haemostasis, inflammation, proliferation and remodelling (Beanes 
et al. 2003). 
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(Gillitzer & Goebeler 2001; Diegelmann & Evans 2004; Birch et al. 2005; Li et al. 
2007; Barrientos et al. 2008; Guo & DiPietro 2010; Behm et al. 2012; Reinke & Sorg 
2012). A number of pro-inflammatory cytokines are released following wounding, 
including TNF-α, IL-1 and IL-6. An overview of their functions is described in Table 
1.1 (Hübner et al. 1996; Gillitzer & Goebeler 2001; Lin et al. 2003; Broughton et al. 
2006a; Barrientos et al. 2008; Behm et al. 2012; Reinke & Sorg 2012). There are 
several growth factors involved in acute skin wound healing; some of the main factors 
are described in Table 1.2 (Hashimoto 2000; Broughton et al. 2006a; Barrientos et al. 
2008; Schultz & Wysocki 2009; Toriseva & Kähäri 2009; Behm et al. 2012; 
Turabelidze & DiPietro 2012; Pastar et al. 2014). 
 
1.3.1     Haemostasis 
Haemostasis is a very rapid process, occurring instantaneously after injury with the 
aim to minimise blood loss from the injury site (Gurtner et al. 2008; Li et al. 2007; 
Velnar et al. 2009; Guo & DiPietro 2010; Reinke & Sorg 2012; Bielefeld et al. 2013). 
Vasoconstriction of nearby capillaries occurs as a reflex reaction to injury in an effort 
to halt or reduce bleeding (Rendell et al. 2002; Monaco & Lawrence 2003; Velnar et 
al. 2009; Beldon 2010; Reinke & Sorg 2012). However, it has been shown that a 
difference in blood flow through a wound is determined at a microvascular level and 
may be the cause behind abnormal scarring in some instances (Clark & Leung 1996; 
Rendell et al. 1997; Amadeu et al. 2003). The formation of a fibrin clot forms an 
alternative protective barrier from the environment to minimise infection of the wound 
(Martin 1997; Clark 2001; Monaco & Lawrence 2003; Li et al. 2007; Schäfer & 
Werner 2008; Velnar et al. 2009). The fibrin clot also provides a provisional matrix 
necessary in the later stages of acute skin wound healing (Corbett et al. 1997; Greiling 
& Clark 1997; Clark 2001; Broughton et al. 2006a; Li et al. 2007; Velnar et al. 2009; 
Reinke & Sorg 2012; Olczyk et al. 2014). Incoming cells that are required for the 
remodelling of the ECM, along with immune cells required for the clearance of debris 
from the wound site, bind to this temporary scaffold to enable them to carry out their 
vital function in this process (Traversa & Sussman 2001; Li et al. 2007; Gurtner et al. 
2008; Velnar et al. 2009; Reinke & Sorg 2012; Portou et al. 2015; Xue & Jackson 
2015). 
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Table 1.1: Predominant cytokines and chemokines involved in acute skin wound 
healing (Gillitzer & Goebeler 2001; Werner & Grose 2003; Broughton et al. 
2006a; Broughton et al. 2006b; Behm et al. 2012; Turabelidze & DiPietro 2012; 
Balaji et al. 2015). 
 
Mediator 
 
Source 
 
Function 
 
TNF-α Neutrophils 
Macrophages 
Inflammation 
Re-epithelialisation 
 
IFN-γ 
T-helper lymphocytes 
Cytotoxic T cells 
Natural killer cells 
Antigen presentation 
Antiviral activity 
Cytokine production 
 
IL-1 
Neutrophils 
Monocytes 
Macrophages 
Keratinocytes 
 
Inflammation 
Re-epithelialisation 
 
IL-6 
Neutrophils 
Macrophages 
Keratinocytes 
Inflammation 
Re-epithelialisation 
 
IL-8 
Macrophages 
Keratinocytes 
Re-epithelialisation 
ECM turnover 
Inflammation 
 
IL-10 
T-helper lymphocytes 
Keratinocytes 
Inhibition of angiogenesis 
Inhibition of fibroblast 
motility 
CCL2 
(MCP-1) 
 
Keratinocytes 
Inflammation 
Monocyte chemotaxis 
Mast cell chemotaxis 
CCL5 
(RANTES) 
 
Keratinocytes 
Inflammation 
Monocyte chemotaxis 
Lymphocyte chemotaxis 
 
CXCL10 
(IP-10) 
 
Keratinocytes 
Inflammation 
Lymphocyte chemotaxis 
Monocyte chemotaxis 
Delays re-epithelialisation 
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Table 1.2: Predominant growth factors involved in acute skin wound healing 
(Werner & Grose 2003; Broughton et al. 2006a; Broughton et al. 2006b; 
Barrientos et al. 2008; Toriseva & Kähäri 2009; Behm et al. 2012; Turabelidze & 
DiPietro 2012). 
 
Mediator 
 
Source 
 
Function 
 
 
 
PDGF 
Platelets 
Macrophages 
Fibroblasts 
Keratinocytes 
Endothelial cells 
Inflammation 
Granulation tissue formation 
ECM synthesis/degradation 
Re-epithelialisation 
 
CTGF 
Fibroblasts 
Platelets 
Re-epithelialisation 
Granulation tissue formation 
ECM synthesis/degradation 
 
IGF 
Platelets 
Keratinocytes 
Fibroblasts 
Re-epithelialisation 
ECM synthesis 
FGF-7 
(KGF) 
Fibroblasts Re-epithelialisation 
Neovascularisation 
 
FGF-2 
(bFGF) 
Keratinocytes 
Fibroblasts 
Macrophages 
Angiogenesis 
Granulation tissue formation 
ECM synthesis/degradation 
Re-epithelialisation 
 
 
TGF-β1 
Platelets 
Keratinocytes 
Fibroblasts 
Macrophages 
Contraction 
Inflammation 
Re-epithelialisation 
Angiogenesis 
ECM synthesis 
 
 
VEGF 
Platelets 
Macrophages 
Keratinocytes 
Endothelial cells 
Fibroblasts 
Neutrophils 
 
Angiogenesis 
Vascular permeability 
Granulation tissue formation 
 
EGF 
Platelets 
Macrophages 
Fibroblasts 
Re-epithelialisation 
ECM synthesis/degradation 
 
TGF-α 
Platelets 
Neutrophils 
Macrophages 
Keratinocytes 
  
Re-epithelialisation 
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Immediately after injury occurs, the coagulation cascade is initiated; the extrinsic 
pathway is activated following disruption to the blood vessels (Hoffman et al. 1995; 
Monaco & Lawrence 2003; Mackman 2004; Li et al. 2007; Reinke & Sorg 2012; Palta 
et al. 2014). This disruption exposes the subendothelial cell-surface glycoprotein, 
tissue thromboplastin (Factor III), also known as tissue factor (TF), to calcium-
activated, factor VIIa, which circulates in the blood stream. The activated complex 
formed is TF:FVIIa, which further activates factors in the extrinsic pathway and 
initiates a coagulation response (Hoffman et al. 1995; Walsh 2003; Mackman 2004; 
Palta et al. 2014). Aggregated platelets at the wound also stimulate the chemotaxis of 
necessary cells to the injured site and the subsequent activation of downstream 
processes. This allows successful dermal wound repair to occur (Monaco & Lawrence 
2003; Broughton et al. 2006a; Reinke & Sorg 2012; Portou et al. 2015). The insoluble 
fibrin clot is a combination of fibrin fibres with platelets interspersed within the fibrin 
scaffold. It also contains a number of growth factors and cytokines, including PDGF, 
TGF-β1, EGF and IGFs; contained within the α-granules of platelets (Martin 1997; 
Monaco & Lawrence 2003; Li et al. 2007; Velnar et al. 2009; Portou et al. 2015). The 
high concentrations of growth factors and cytokines act as a chemotactic stimulus to 
inflammatory cells, together with the cells required to re-establish the epidermal and 
dermal layers (Deuel et al. 1982; Martin 1997; Heldin & Westermark 1999; Monaco 
& Lawrence 2003; Li et al. 2007; Velnar et al. 2009).  
 
Fibrin fibres are produced through the cleavage of fibrinogen by thrombin (Martin 
1997; Monaco & Lawrence 2003; Mackman 2004; Li et al. 2007; Olczyk et al. 2014; 
Palta et al. 2014). Other glycoproteins present in this matrix include, plasma 
fibronectin, vitronectin and thrombospondin, which are released from platelet α-
granules. These glycoproteins also have a role in haemostasis through platelet 
aggregation and formation of the blood clot (Ruoslahti 1988a; Greiling & Clark 1997; 
Monaco & Lawrence 2003; Li et al. 2007; Velnar et al. 2009; Reinke & Sorg 2012; 
Olczyk et al. 2014; Palta et al. 2014). Additionally, these glycoproteins are involved 
in cell-matrix interactions, matrix-matrix interactions, cell migration and cell 
proliferation (Ruoslahti 1984; Ruoslahti 1988a; Mutsaers et al. 1997; Monaco & 
Lawrence 2003; Schultz & Wysocki 2009; Eckes et al. 2010). Fibronectin, vitronectin 
and thrombospondin are part of a group of ECM ligands for integrins, which are 
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strongly involved in cell adhesion (Ruoslahti 1996; Mutsaers et al. 1997; Preissner & 
Seiffert 1998; Santoro & Gaudino 2005; Li et al. 2007; Kim et al. 2011; Longmate & 
DiPersio 2014; Olczyk et al. 2014). One member of the integrin family, glycoprotein 
IIb/IIIa, is present on the cell membranes of platelets and play a role in the aggregation 
to each other forming a clot (Ruoslahti 1996; Mutsaers et al. 1997; Yang et al. 1999; 
Beanes et al. 2003; Gilcrease 2007; Palta et al. 2014). It is through the contact between 
platelets or other blood components with the exposed collagen as a result of tissue 
injury, that the release of factors from platelets is triggered. These released factors 
include growth factors, clotting factors and ECM proteins (Diegelmann & Evans 2004; 
Li et al. 2007; Velnar et al. 2009; Olczyk et al. 2014; Palta et al. 2014). Pro-
inflammatory factors, such as serotonin, prostaglandins and thromboxane A2, are also 
released from the platelets present in the fibrin clot. It is the high concentrations of 
these factors that act as a cue to initiate the inflammatory phase, due to the 
chemoattractant signals towards immune cells (Martin 1997; Stadelmann et al. 1998; 
Traversa & Sussman 2001; Li et al. 2007; Velnar et al. 2009; Palta et al. 2014).  
 
1.3.2     Inflammatory Phase 
Overlapping with the late stage of haemostasis, the inflammatory phase commences 
responding to chemoattractant cues signalling to inflammatory cells, such as 
neutrophils and monocytes. However, the inflammatory stage can be divided into an 
early and late stage, where the neutrophils are most active at the earlier stages, with 
macrophages taking over in the late stages (Diegelmann & Evans 2004; Martin & 
Leibovich 2005; Li et al. 2007; Velnar et al. 2009; Koh & DiPietro 2011; Reinke & 
Sorg 2012; Olczyk et al. 2014). During the early stage, the complement cascade is 
activated, a process known to play a part in the immune response at the wound site 
(Stadelmann et al. 1998; Beanes et al. 2003; Velnar et al. 2009; Koh & DiPietro 2011). 
One aspect of this process is the production of complement components, C3a and C5a, 
which along with TGF-β1, have been shown to behave as chemoattractants towards 
neutrophils. Bacterial and platelet peptides produced by fibrinolysis at the wound site 
also exert a chemoattractant signal towards neutrophils (Beanes et al. 2003; Monaco 
& Lawrence 2003; Chin et al. 2004; Velnar et al. 2009; Reinke & Sorg 2012; Olczyk 
et al. 2014). This process is very rapid, allowing neutrophils to migrate to the wound 
site within minutes of injury occurring. These remain at the injured site for a few days, 
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or until they have succeeded in clearing the cell debris and bacteria (Martin 1997; Dovi 
et al. 2004; Li et al. 2007; Velnar et al. 2009; Reinke & Sorg 2012; Wilgus et al. 2013).  
 
Neutrophils are initially present in high numbers as their main function is to remove 
any contaminants, such as bacteria present in the wound and damaged tissue. This is 
achieved through phagocytosis and the production of ROS (Monaco & Lawrence 
2003; Dovi et al. 2004; Schäfer & Werner 2008; Velnar et al. 2009; Guo & DiPietro 
2010; Reinke & Sorg 2012; Wilgus et al. 2013; Olczyk et al. 2014). Neutrophils digest 
the bacteria present at the wound site through the use of proteases, with different 
enzymes being required depending on the digestion target (Yager & Nwomeh 1999; 
Broughton et al. 2006a; Toriseva & Kähäri 2009; Velnar et al. 2009; Lu et al. 2011; 
Reinke & Sorg 2012; Wilgus et al. 2013). The unwounded area adjacent to the injury 
site is protected from these highly active enzymes by the high presence of protease 
inhibitors. This is sufficient as a protection mechanism unless there is an excessive 
inflammatory response overwhelming the inhibitory proteases (Yager & Nwomeh 
1999; Broughton et al. 2006a; Koh & DiPietro 2011; McCarty & Percival 2013; 
Wilgus et al. 2013). Although the phagocytosis of bacteria and cell debris is thought 
to be the main function of neutrophils at a wound site, they have also been shown to 
be a reservoir of pro-inflammatory cytokines and chemokines (Martin 1997; Scapini 
et al. 2000; Reinke & Sorg 2012; Wilgus et al. 2013; Olczyk et al. 2014; Tecchio et al. 
2014; Tecchio & Cassatella 2016).  
 
Neutrophils migrate to the wound site through a series of cell adhesion processes. 
Firstly, there are changes to the cell surface adhesion molecules on the neutrophils 
causing them to become ‘sticky’ and along with a selectin-dependent cell adhesions, a 
weak attachment to the endothelial cell layer occurs (Springer 1994; Martin 1997; 
Monaco & Lawrence 2003; Broughton et al. 2006a; Petri & Bixel 2006; Velnar et al. 
2009). This weak bond causes the neutrophils to roll along the endothelium at a slower 
pace allowing a stronger β2 integrin-mediated adhesion to occur. The subsequent 
strong bond results in diapedesis occurring, where neutrophils and other leukocytes 
migrate through the blood vessel walls to the wound site (Butcher et al. 1991; Ager 
1994; Springer 1994; Martin 1997; Monaco & Lawrence 2003; Petri & Bixel 2006; 
Velnar et al. 2009). The gaps within the endothelial cell layer occur as a result of the 
42 
 
synthesis of leukotrienes and prostaglandins, both of which cause an inflammatory 
reaction. This leads to the vasodilation of blood vessels (Hedqvist et al. 2000; 
Broughton et al. 2006a; Pober & Sessa 2007; DiStasi & Ley 2009). The initial 
synthesis of these two inflammatory molecules is through the activation of the 
cyclooxygenase-2 enzyme (COX-2), which causes the downstream synthesis of 
prostaglandins and leukotrienes, resulting in vasodilation and inflammation, 
respectively (Broughton et al. 2006a; Li et al. 2007; Pober & Sessa 2007; DiStasi & 
Ley 2009). This inflammatory effect causes gaps to form within the endothelial cell 
layer, also known as a leaky capillary wall; and allows the migration of neutrophils 
out of the blood vessel. Proteins have also been shown to migrate through these gaps 
and cause a local swelling reaction (Hedqvist et al. 2000; Broughton et al. 2006a; Pober 
& Sessa 2007; DiStasi & Ley 2009; Velnar et al. 2009). A beneficial effect of the 
action of COX-2 is that the vasodilation and leaky blood vessels allows for the 
translocation of leukocytes from the circulating blood to the wound site (Broughton et 
al. 2006a; Pober & Sessa 2007; DiStasi & Ley 2009).  
 
Monocytes are initially attracted to the wound site before undergoing differentiation 
to macrophages. Monocytes circulate in the blood allowing a ready supply to be 
converted to macrophages and activated at sites of injury (Martin 1997; Monaco & 
Lawrence 2003; Li et al. 2007; Velnar et al. 2009; Guo & DiPietro 2010; Brancato & 
Albina 2011; Olczyk et al. 2014). Macrophages also produce signalling factors initially 
released from the both neutrophils and degranulating platelets (Monaco & Lawrence 
2003; Diegelmann & Evans 2004; Velnar et al. 2009). Once the neutrophils have 
cleared the bacteria and contaminants, macrophages activated at the wound site clear 
the apoptotic neutrophils that have fulfilled their job of clearing the wound debris. 
They have also been shown to induce apoptosis of neutrophils and other immune cells 
(Monaco & Lawrence 2003; Martin & Leibovich 2005; Li et al. 2007; Velnar et al. 
2009; Guo & DiPietro 2010; Brancato & Albina 2011; Koh & DiPietro 2011; Wilgus 
et al. 2013). Neutrophils need to be cleared from the wound site without causing a new 
inflammatory reaction, performed by two main mechanisms. Neutrophils can undergo 
apoptosis and then rely on macrophages to remove them from the site. Alternatively, 
neutrophils can migrate to the wound surface and be shed from the skin surface 
(Monaco & Lawrence 2003; Li et al. 2007; Velnar et al. 2009; Guo & DiPietro 2010; 
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Koh & DiPietro 2011; Wilgus et al. 2013). As macrophages have a longer lifespan, 
these remain for a longer time-period at the wound site than the neutrophils and 
continue the work of the neutrophils. Macrophages are further capable of working in 
lower pH conditions (Martin 1997; Mosser & Edwards 2008; Velnar et al. 2009; Guo 
& DiPietro 2010; Parihar et al. 2010; Reinke & Sorg 2012; Olczyk et al. 2014).  
 
Macrophages need to undergo activation so they can carry out a number of functions. 
The main function is inducing the transition from the inflammatory phase to the 
proliferative phase. This is achieved through stimulation of fibroblasts and 
keratinocytes to the wound site; these cells are required in the proliferative phase. 
Another function is stimulating angiogenesis to ensure sufficient blood supply to the 
repaired area (Martin & Leibovich 2005; Li et al. 2007; Velnar et al. 2009; Guo & 
DiPietro 2010; Koh & DiPietro 2011; Reinke & Sorg 2012; Lech & Anders 2013; 
Lucas et al. 2010; Portou et al. 2015; Snyder et al. 2016). Macrophages stimulate these 
cells through the production of growth factors and other mediators, such as TGF-β1, 
TGF-α, FGF, HB-EGF and collagenase (Monaco & Lawrence 2003; Diegelmann & 
Evans 2004; Li et al. 2007; Velnar et al. 2009; Brancato & Albina 2011; Koh & 
DiPietro 2011; Reinke & Sorg 2012). There are two categories of macrophages, M1 
and M2, referred to as the classically activated and the alternatively activated, 
respectively. These two subtypes of macrophages induce different responses during 
wound healing (Mosser & Edwards 2008; Lucas et al. 2010; Koh & DiPietro 2011; 
Snyder et al. 2016). M1 macrophages are developed from resting macrophages, the 
transition is induced by pro-inflammatory cytokines or microbial components. These 
activated macrophages are then capable of expressing pro-inflammatory cytokines, 
along with chemokines to attract further immune cells to the wound site (Mosser & 
Edwards 2008; Koh & DiPietro 2011; Ashcroft et al. 2012; Lech & Anders 2013; 
Snyder et al. 2016). M2 macrophages are also referred to as the resolution 
macrophages, due to their contrasting role to M1 macrophages. They induce anti-
proliferative cytokines and reduce the expression of pro-inflammatory cytokines 
(Lucas et al. 2010; Parihar et al. 2010; Snyder et al. 2016). In addition, their functions 
include angiogenesis, ECM remodelling and MMP production, all of which contribute 
to a reparative response (Lucas et al. 2010; Lech & Anders 2013; Snyder et al. 2016).  
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Neutrophils and macrophages release cytokines, which act as a chemoattractant to T-
lymphocytes. These cells migrate to the wound site after the inflammation stage has 
concluded and are necessary for the next process to take place. The chemoattractant 
agents towards T-lymphocytes are IL-1, complement components and the degradation 
products of IgG. Lymphocytes also require activation at the wound site to perform 
their actions (Scapini et al. 2000; Velnar et al. 2009; Guo & DiPietro 2010; Olczyk et 
al. 2014). Approximately 2-3 days after injury, macrophages continue to clear the 
wound of any contaminants, then along with lymphocytes, these produce enzymes in 
response to IL-1 and TNF-α to degrade wound components before the ECM 
remodelling process occurs (Monaco & Lawrence 2003; Velnar et al. 2009; Reinke & 
Sorg 2012; Olczyk et al. 2014). MMPs are mainly involved in this degradation of the 
damaged ECM. They are expressed by a number of cells involved in wound healing, 
allowing this process to occur across the various phases (Monaco & Lawrence 2003; 
Broughton et al. 2006a; Velnar et al. 2009; McCarty & Percival 2013; Rohani & Parks 
2015). Initially, monocytes and macrophages are responsible for the MMP production, 
with this role later undertaken by fibroblasts and keratinocytes (Broughton et al. 
2006a; Velnar et al. 2009; McCarty & Percival 2013; Olczyk et al. 2014; Caley et al. 
2015).  
 
1.3.3     Proliferative Phase 
The proliferative phase lasts for approximately 2 weeks and commences within a few 
days of injury. It is necessary to produce the large numbers of fibroblasts and 
keratinocytes required for the production of the ECM and epidermis, respectively 
(Stadelmann et al. 1998; Beanes et al. 2003; Li et al. 2007; Gurtner et al. 2008; Velnar 
et al. 2009; Reinke & Sorg 2012; Bainbridge 2013; Olczyk et al. 2014; Xue & Jackson 
2015). The proliferative phase is focused mainly on the reparative process; the initial 
phases could be considered as damage control with the cessation of blood flow and 
formation of a temporary barrier. The inflammation phase ensures that the wound site 
is free from contaminants before restoration of the epidermis and underlying dermis 
(Stadelmann et al. 1998; Li et al. 2007; Velnar et al. 2009; Kondo & Ishida 2010; 
Reinke & Sorg 2012; Olczyk et al. 2014). The two main aspects of the proliferative 
phase are re-epithelisation, to establish a more permanent barrier replacing the 
temporary fibrin clot; and the synthesis of new ECM by the fibroblasts that have 
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migrated to the wound site (Stadelmann et al. 1998; Velnar et al. 2009; Kondo & Ishida 
2010; Reinke & Sorg 2012; Bainbridge 2013; Olczyk et al. 2014; Pastar et al. 2014). 
 
1.3.3.1     Re-epithelialisation 
For the re-epithelialisation aspect of this phase, undamaged keratinocytes migrate from 
the wound edge. Additionally, epidermal stem cells migrate from the stem cell bulge 
in the hair follicles, along with from sebaceous glands and sweat glands (Watt 1998; 
Li et al. 2007; Guo & DiPietro 2010; Koivisto et al. 2012; Reinke & Sorg 2012; Olczyk 
et al. 2014; Pastar et al. 2014; Ojeh et al. 2015). The migration of keratinocytes from 
both the basement membrane and the undamaged areas adjacent to the wound site 
allows re-epithelialisation, creating a more permanent barrier than the temporary fibrin 
clot (Broughton et al. 2006b; Li et al. 2007; Koivisto et al. 2012; Pastar et al. 2014; 
Seeger & Paller 2015). Initially, the focus of migrating keratinocytes is to re-establish 
the uppermost layers of the epidermis to seal the wound, before re-constructing the 
basement membrane and allowing terminal differentiation of keratinocytes to continue 
and re-build each epidermal layer in an ascending manner (Broughton et al. 2006b; 
Patel et al. 2006; Li et al. 2007; Velnar et al. 2009; Koivisto et al. 2012; Kroeze et al. 
2012; Reinke & Sorg 2012; Olczyk et al. 2014; Pastar et al. 2014). As the epidermal 
layers are re-established, there are various changes in keratin expression at the wound 
site, as previously described (Section 1.2.1.2, Fuchs 1995; Haake et al. 2001; Santos 
et al. 2002; Magin et al. 2007; Bragulla & Homberger 2009). Keratins appear to be 
less segmented between the layers of the epidermis, with keratin pairs expressed in 
additional layers to their normal expression site in unwounded skin (Martin 1997; 
Haake et al. 2001; Magin et al. 2007; Bragulla & Homberger 2009). Additional 
keratins are also expressed at the wound sites that are not present in unwounded skin. 
These include Krt6, Krt16 and Krt17, which are upregulated following epidermal 
injury (Fuchs 1995; Martin 1997; Santos et al. 2002; Mazzucchelli 2002; Sivamani et 
al. 2007; Bragulla & Homberger 2009; Moll et al. 2008).  
 
In order for the keratinocytes to migrate across the fibrin clot from the unwounded 
epidermis, the fibrin clot needs to be removed. In addition, hemidesmosomes, the 
connections between the keratinocytes and the ECM, need to be disrupted to allow the 
migration of keratinocytes through the epidermal levels to replace those lost during 
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injury (Martin 1997; Li et al. 2007; Reinke & Sorg 2012; Longmate & DiPersio 2014; 
Pastar et al. 2014; Rohani & Parks 2015; Seeger & Paller 2015). Hemidesmosomes 
hold keratinocytes in place to the ECM, along the basal lamina. The keratinocytes 
themselves produce the enzymes required to dissociate from their tethered positions 
and migrate to the wound site (Martin 1997; Li et al. 2007; Koivisto et al. 2012; 
Longmate & DiPersio 2014; Pastar et al. 2014; Rohani & Parks 2015). Plasmin is 
responsible for dissolving the fibrin clot and breaking the hemidesmosomes 
connection to keratinocytes. Plasminogen is the precursor to plasmin and is present as 
part of the fibrin clot (Jensen & Lavker 1996; Martin 1997; Cesarman-maus & Hajjar 
2005; Koivisto et al. 2012). Cleavage and activation of plasminogen to form the 
reactive plasmin is achieved through the action of tissue-type plasminogen activator 
(tPA) or urokinase-type plasminogen activator (uPA). Plasmin can act in a positive 
feedback mechanism, by cleaving both tPA and uPA, which in turn can cleave and 
activate plasminogen (Blasi 1988; Novokhatny et al. 1995; Bugge et al. 1996; Martin 
1997; Cesarman-maus & Hajjar 2005; Koivisto et al. 2012). The actions of tPA and 
uPA are fibrin specific, with these activators specifically targeting plasminogen bound 
to fibrin. The activity of tPA is greatly increased in the presence of fibrin, allowing for 
the cleavage and activation of plasminogen (Blasi 1988; Collen & Lijnen 2005, 2009). 
The presence of tPA and uPA are increased by keratinocytes that have migrated to the 
wound site. These keratinocytes also provide a complementary receptor for uPA. The 
combination of these components present allows plasmin to be activated and achieve 
the desired result of dissolving the temporary fibrin clot (Grøndahl-Hansen et al. 1988; 
Rømer et al. 1991, 1994; Martin 1997; Koivisto et al. 2012). The gene expression for 
both uPA and its respective receptor are upregulated by the enzymes associated with 
keratinocyte proliferation and migration, such as EGF and KGF (Tsuboi et al. 1993; 
Clark 1996; Ploug 2003).  
 
MMPs within the wound site are also responsible for dissolving the fibrin clot and the 
surrounding ECM, including MMP-1, -9 and -10. Each MMP has a different target for 
enzymatic breakdown. As with the action of plasmin, keratinocytes present at the 
wound site are responsible for the production of these proteinases (Martin 1997; Li et 
al. 2007; Behm et al. 2012; Koivisto et al. 2012; Hameedaldeen et al. 2014; Olczyk et 
al. 2014; Pastar et al. 2014; Rohani & Parks 2015). However, not all of the MMPs 
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present are produced by keratinocytes of the same origin. MMP-1 is produced by 
migrating keratinocytes from the basal and suprabasal layers and MMP-10 is produced 
by the undamaged keratinocytes that are present along the wound edge (Martin 1997; 
Pilcher et al. 1997; Krampert et al. 2004; Koivisto et al. 2012; Pastar et al. 2014; 
Rohani & Parks 2015). All three of these MMPs are classified into different groups 
within the MMP family of enzymes, according to their function. MMP-1 is part of the 
collagenase family, MMP-9 from the gelatinase family; and MMP-10 from the 
stromelysins (Martin 1997; Koivisto et al. 2012; Olczyk et al. 2014; Rohani & Parks 
2015).   
 
MMP-1 is responsible for the cleavage of interstitial collagens, typically types I and 
III collagen, allowing for the migration of keratinocytes into the wound space. Type I 
collagen is known to form a large part of the ECM prior to its repair (Martin 1997; 
Pilcher et al. 1997; Li et al. 2007; Gill & Parks 2008; Olczyk et al. 2014; Pastar et al. 
2014; Rohani & Parks 2015). Type IV and type VII collagen are cleaved by the action 
of MMP-9, due to their roles in the basal lamina and as an anchoring fibril collagen, 
respectively (Hudson et al. 1993; Martin 1997; Bigg et al. 2007; Abreu-Velez & 
Howard 2012; Olczyk et al. 2014). This is believed to allow the migration of 
keratinocytes from the basal layer to the wound site and basement membrane 
remodelling (Martin 1997; Falanga 2005; Li et al. 2007; Koivisto et al. 2012). MMP-
10 is upregulated in wound healing and expressed by migrating keratinocytes. It also 
has the least specificity out of the three MMPs involved (Martin 1997; Krampert et al. 
2004; Gill & Parks 2008; Koivisto et al. 2012; Rohani & Parks 2015). An excessive 
presence of proteinases will affect the normal healing process and may be one of the 
causes for impaired healing and wound closure in chronic wounds (Martin 1997; 
Schultz & Wysocki 2009; Toriseva & Kähäri 2009; Guo & DiPietro 2010; Koivisto et 
al. 2012; Pastar et al. 2014; Rohani & Parks 2015).  
 
During normal healing, ECM degradation is regulated to prevent excessive ECM 
breakdown; this is essential for normal tissue function (Li et al. 2007; Schultz & 
Wysocki 2009; Velnar et al. 2009; Cox & Erler 2011). Keratinocytes eventually 
downregulate MMP expression and return to their normal function of terminal 
differentiation throughout the epidermal layers, along with the formation of new 
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hemidesmosomes (Martin 1997; Li et al. 2007; Koivisto et al. 2012; Longmate & 
DiPersio 2014). It is through this tightly regulated production of cytokines and growth 
factors and their interaction with the ECM components that increases and decreases 
the production of MMPs. This affects the synthesis of newly formed ECM (Schultz & 
Wysocki 2009; Toriseva & Kähäri 2009; Velnar et al. 2009; Behm et al. 2012). One 
such example is TGF-β1, which has been shown to stimulate the production of various 
ECM components. It also regulates MMP and TIMP expression, involved in ECM 
degradation (Li et al. 2007; Schultz & Wysocki 2009; Toriseva & Kähäri 2009; Velnar 
et al. 2009; Watt & Fujiwara 2011). TGF-β1 has also been shown to upregulate the 
expression of MMP by keratinocytes, contributing to keratinocyte migration (Gill & 
Parks 2008; Philips et al. 2011; Pastar et al. 2014).   
 
During keratinocyte migration to the wound site, a process called cell crawling occurs. 
This involves the action of integrins and the keratinocyte actin cytoskeleton. This 
process involves a series of steps that are repeated until the cell has reached the 
required location (Cooper 2000; Haase et al. 2003; Li et al. 2007; Velnar et al. 2009; 
Reinke & Sorg 2012). The steps involved are the initial protrusion of the leading edge 
of the cell; cell focal adhesions are then formed between the leading edge and the 
substratum to increase stability. Finally, dissociation of focal adhesions at the rear of 
the cell occurs, allowing the retraction of the trailing edge of the cell to the cell body 
(Van Haastert & Devreotes 2004; Gilcrease 2007; Clainche & Carlier 2008; Velnar et 
al. 2009; Vicente-Manzanares & Horwitz 2011; Krause & Gautreau 2014; Seeger & 
Paller 2015). Actin filaments possess a natural polarity and when they undergo 
polymerisation in cell crawling. New actin monomers are added at the positive end 
and removed from the negative end in a process referred to as ‘actin treadmilling’. It 
is the repeated addition to the positive end that pushes the cell structure out at the 
leading edge and facilitates the movement of the cell (Clainche & Carlier 2008; Velnar 
et al. 2009; Parsons et al. 2010; Krause & Gautreau 2014).  
 
The focal adhesion complexes formed and activated between the cell and the 
substratum occur from the binding of integrins to specific proteins present in the ECM 
and the actin filaments present at the leading edge (Cooper 2000; Wozniak et al. 2004; 
Velnar et al. 2009; Vicente-Manzanares & Horwitz 2011; Kim & Wirtz 2013; 
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Longmate & DiPersio 2014). The proteins involved in connecting actin to integrin are 
α-actinin, vinculin and talin (Cooper 2000; Wozniak et al. 2004; Vicente-Manzanares 
& Horwitz 2011; Koivisto et al. 2012). The direction of movement of the cell is 
determined by a polarity effect and a chemoattractive substance, attracting the cells to 
the wound site (Van Haastert & Devreotes 2004; Clainche & Carlier 2008; Velnar et 
al. 2009; Vicente-Manzanares & Horwitz 2011; Kim & Wirtz 2013). The 
chemoattractant force directs the cell to a specific location, the injury site, in a positive 
chemotactic direction through the production of a chemical gradient. The new position 
is stabilised with the formation of focal adhesion complexes (Li et al. 2007; Velnar et 
al. 2009; Parsons et al. 2010; Reinke & Sorg 2012; Krause & Gautreau 2014). 
However, this provides a tension on the focal adhesion complexes still present at the 
trailing edge, requiring these to be dissociated to allow the retraction of the back of the 
cell (Clainche & Carlier 2008; Velnar et al. 2009; Parsons et al. 2010; Krause & 
Gautreau 2014). The contractile force that takes place within the cell uses the 
actomyosin filaments to allow the retraction of the trailing edge of the cell. Myosin 
motor proteins and their connection to the actin filaments are involved in producing 
this force and breaking the connections between the actin cytoskeleton and the 
integrins at the trailing edge (Gilcrease 2007; Clainche & Carlier 2008; Velnar et al. 
2009; Parsons et al. 2010; Kim & Wirtz 2013). 
 
Dependent on the cells desired at the site, there are specific chemotactic agents 
required to produce the signal. This is dependent on the stage of the wound healing 
process, as the attraction of inflammatory cells is stimulated by the products of the 
haemostasis process, degranulating platelets and growth factors specific to that stage 
(Scapini et al. 2000; Traversa & Sussman 2001; Monaco & Lawrence 2003; Velnar et 
al. 2009; Reinke & Sorg 2012; Olczyk et al. 2014). In the proliferation stage, products 
of the inflammation stage are used as chemoattractants, such as TGF-β1 and PDGF. 
These growth factors attract fibroblasts to the site, in order to produce the ECM 
components required for the synthesis of new ECM, replacing the temporary matrix 
present during the earlier stages (Seppa et al. 1982; McDougall et al. 2006; Li et al. 
2007; Velnar et al. 2009; Reinke & Sorg 2012; Olczyk et al. 2014). The migration of 
keratinocytes commences earlier in the healing process, approximately a few hours 
after wounding due to the importance of re-establishing the protective barrier. 
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Therefore, chemoattractant agents, such as TGF-α and EGF, provide the chemotactic 
signals for these cells along with enhancing the proliferative action of keratinocytes 
(Li et al. 2007; Velnar et al. 2009; Koivisto et al. 2012; Olczyk et al. 2014; Pastar et 
al. 2014; Seeger & Paller 2015). 
 
The production of new integrins at the leading edge and the dissolution of those at the 
trailing edge takes time, resulting in the delay seen before migration occurs. The type 
of integrin expressed depends on the ECM protein it will bind to (Grinnell 1992; 
Larjava et al. 1993; Martin 1997; Humphries et al. 2006; Velnar et al. 2009; Longmate 
& DiPersio 2014). These specificities are determined by receptors expressed on the 
surface of integrins. Some examples are α5β1 and αvβ6 expressing the receptors for 
fibronectin and tenascin respectively; and αvβ5 expressing the vitronectin receptor. 
Some integrins can express receptors for multiple targets, such as α2β1 integrin 
expressing the receptor for both collagen and laminin (Larjava et al. 1993; Martin 
1997; Humphries et al. 2006; Gilcrease 2007; Koivisto et al. 2012; Longmate & 
DiPersio 2014). In addition to expressing the appropriate receptors for each protein, 
integrins are also able to convey information between the cell and ECM, acting in a 
two-directional manner allowing for cell migration regulation (Humphries et al. 2006; 
Gilcrease 2007; Velnar et al. 2009; Koivisto et al. 2012; Longmate & DiPersio 2014). 
These integrins form a connection to the cytoskeleton. The keratinocyte cytoskeleton 
is comprised of a network of keratin intermediate fibres, providing structure to the cell 
whilst also allowing for a degree of flexibility in the cell, necessary for cell migration 
(Gu & Coulombe 2007; Windoffer et al. 2011; Hobbs et al. 2012). Different cells can 
migrate at different speeds. It is mainly dependent on the strength of adhesion to the 
ECM, as reduced adhesion strength can allow more rapid migration of the cells 
requiring a balance between migration and adhesion to be established (Maheshwari et 
al. 2000; Velnar et al. 2009; Nardini et al. 2016). Speed of cell motility is also 
dependent on the phase of wound healing and the resultant chemoattractive force. 
Initially, there is a high chemoattractive signal for migrating cells causing a rapid 
migration of cells to the wound site, but as the healing process occurs, there is less 
demand for more cells to migrate to the area. This results in a decreased 
chemoattractant signal and reduced cell migration speed (Van Haastert & Devreotes 
2004; Li et al. 2007; Velnar et al. 2009; Reinke & Sorg 2012).  
51 
 
 
There are a number of growth factors involved in the cell crawling process, along with 
general re-epithelisation, some of which are part of the positive feedback loop between 
the fibroblasts and keratinocytes, such as KGF; which has a vital role in keratinocyte 
proliferation (Finch et al. 1989; Werner 1998; Maas-Szabowski et al. 1999; auf 
demKeller et al. 2004; Barrientos et al. 2008; Bader & Kao 2009; Shirakata 2010; 
Koivisto et al. 2012; Seeger & Paller 2015). Rapid re-epithelisation is a beneficial 
property for restoring the protective barrier with the aim of preventing infection of the 
wound site. This is especially important in patients with burns or chronic wounds, 
where large areas of the epidermis may be affected (Martin 1997; Usui et al. 2008; 
Koivisto et al. 2012; Pastar et al. 2014; Rowan et al. 2015; Seeger & Paller 2015; Rose 
& Chan 2016). There are two systems in place for re-establishing the vasculature to 
the dermis and epidermis, through the repair of damaged vessels or through 
neovascularisation. The growth factors involved in promoting angiogenesis are FGF, 
VEGF, TGF-β1, TGF-α and angiogenin. A number of cells are responsible for the 
production of these angiogenic factors, including macrophages, fibroblasts and 
keratinocytes (Tonnesen et al. 2000; Uchi et al. 2000; Barrientos et al. 2008; Velnar et 
al. 2009; Reinke & Sorg 2012; Johnson & Wilgus 2014). Although multiple cell types 
are involved in the neovascularisation process, it is the keratinocytes that are mainly 
responsible for the production of new capillaries. Macrophages and fibroblasts release 
growth factors that act on the keratinocytes and stimulate them to release VEGF and 
produce the resultant capillary growth (Frank et al. 1995; Tonnesen et al. 2000; 
Broughton et al. 2006a; Li et al. 2007; Velnar et al. 2009; Johnson & Wilgus 2014). 
There is an angiogenic inhibitor also present at the wound site, angiostatin. This is to 
ensure that the new capillary growth does not go unregulated (Cesarman-maus & 
Hajjar 2005; Velnar et al. 2009; Johnson & Wilgus 2014; Olczyk et al. 2014). 
 
1.3.3.2     Dermal Extracellular Matrix Synthesis 
ECM synthesis is required to produce granulation tissue as a replacement for the 
temporary fibrin scaffold formed earlier in the wound healing process. However, a 
balance between ECM synthesis and degradation is necessary for sufficient 
organisation of the ECM to occur (McDougall et al. 2006; Velnar et al. 2009; Kim et 
al. 2011; Reinke & Sorg 2012; Olczyk et al. 2014; Xue & Jackson 2015). Granulation 
52 
 
tissue consists of a number of components, including macrophages, fibroblasts, 
fibronectin, fibrinogen, hyaluronan, collagen and the newly re-established vasculature 
(Schultz & Wysocki 2009; Velnar et al. 2009; Eckes et al. 2010; Mouw et al. 2014; 
Olczyk et al. 2014; Xue & Jackson 2015; Tracy et al. 2016).  
 
The synthesis of the ECM is dictated by the production of ECM components and 
proteases by fibroblasts. The ECM components produced include procollagen types I 
and III, fibronectin, hyaluronan and proteoglycans (Gelse et al. 2003; Agren & 
Werthén 2007; Schultz & Wysocki 2009; Velnar et al. 2009; Guo & DiPietro 2010; 
Olczyk et al. 2014; Tracy et al. 2016). The production of these ECM components by 
fibroblasts provides a degree of structure and stability to the matrix. The organisation 
of the matrix has high importance to allow the normal functions of the dermal matrix 
to occur and provide the scaffold for migrating cells (Schultz & Wysocki 2009; Velnar 
et al. 2009; Frantz et al. 2010; Hubmacher & Apte 2013; Tracy et al. 2016). The 
migration of fibroblasts to the wound site occurs a few days after injury and they 
initiate the formation of granulation tissue. There is an initial delay in fibroblast 
migration, due to there being in an inactive or quiescent state (Martin 1997; Monaco 
& Lawrence 2003; Li et al. 2004; Velnar et al. 2009; Bainbridge 2013; Olczyk et al. 
2014). The proliferation of fibroblasts at the wound site is mediated indirectly through 
an autocrine mechanism by the activation of TGF-β1. This growth factor has been 
shown to be involved in stimulating fibroblast proliferation (Cordeiro et al. 2000; 
Broughton et al. 2006a; Li et al. 2007; Meran et al. 2008; Olczyk et al. 2014; Tracy et 
al. 2016).  
 
Fibroblasts are attracted quite specifically to the wound site by the presence of growth 
factors sending out chemoattractant signals. The growth factors involved in this 
chemotaxis are TGF-β1 and PDGF (Pierce et al. 1989; Heldin & Westermark 1999; 
McDougall et al. 2006; Li et al. 2007; Velnar et al. 2009; Behm et al. 2012; Bainbridge 
2013; Olczyk et al. 2014). These growth factors are present at the wound site, due to 
their release from degranulating platelets and inflammatory cells. The expression of 
PDGF is further increased by fibroblasts at the wound site by autocrine stimulation 
from the fibroblasts, increasing the chemoattractant signal to other migrating 
fibroblasts (Pierce et al. 1989; Broughton et al. 2006a; Schultz & Wysocki 2009; 
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Velnar et al. 2009; Olczyk et al. 2014). Fibroblasts synthesise and deposit collagen, 
initially a high proportion of type III collagen is synthesised. Approximately 40% of 
the collagen present in granulation tissue is type III collagen, compared to only 25% 
type III collagen present in unwounded tissue (Li et al. 2007; Velnar et al. 2009; Cheng 
et al. 2011; Reinke & Sorg 2012; Bainbridge 2013; Olczyk et al. 2014; Xue & Jackson 
2015; Tracy et al. 2016). The benefit of type III collagen being laid down initially is 
the rapid speed with which it can be synthesised, providing a temporary structure for 
other matrix molecules to develop around (Mutsaers et al. 1997; Monaco & Lawrence 
2003; Li et al. 2007; Velnar et al. 2009; Bainbridge 2013). Some fibroblasts at the 
wound site undergo differentiation into myofibroblasts, which are strongly associated 
with the contraction of the wound site, enabling closure between the wound edges. 
This contraction at the wound site is required for wound closure, but also contributes 
to scar formation; therefore this process needs to be tightly regulated as previously 
mentioned (Gabbiani 2003; Desmouliere et al. 2005; Broughton et al. 2006a; Li et al. 
2007; Eckes et al. 2010; Reinke & Sorg 2012; Bainbridge 2013; Olczyk et al. 2014).  
 
An important aspect of re-establishing an ECM is the production of a blood supply to 
the newly synthesised matrix. There are multiple angiogenic factors that are released 
to promote both the formation of new capillaries and the repair of damaged vessels 
(Tonnesen et al. 2000; Li et al. 2007; Velnar et al. 2009; Reinke & Sorg 2012; DiPietro 
2013; Olczyk et al. 2014). In addition, migration of the cells responsible for these 
angiogenic functions to the wound site is necessary. There are a number of 
chemoattractants involved, including TGF-α, VEGF, angiopoietin, fibrin and lipid 
growth factors (Tonnesen et al. 2000; Szpaderska et al. 2005; Li et al. 2007; Velnar et 
al. 2009; Reinke & Sorg 2012; DiPietro 2013; Johnson & Wilgus 2014; Olczyk et al. 
2014). Presence of a blood supply to the matrix is necessary for providing oxygen to 
the cells required in cell metabolism. Degradation of existing structures, including the 
basal lamina, are required to allow formation of new vasculature to both the epithelial 
layers and the dermal matrix (Tonnesen et al. 2000; Li et al. 2007; Velnar et al. 2009; 
Reinke & Sorg 2012; DiPietro 2013; Johnson & Wilgus 2014).  
 
MMPs are involved in the degradation of the damaged ECM, allowing a new matrix 
to be synthesised without any damaged components being incorporated. There are 
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specific proteases depending on the target of degradation, for example damaged 
collagen fibres are degraded by the actions of collagenases (Martin 1997; Broughton 
et al. 2006a; Li et al. 2007; Kim et al. 2011; Bainbridge 2013; Rohani & Parks 2015; 
Xue & Jackson 2015). Another target of the MMPs is the remaining debris from the 
earlier wound healing stages, such as any remaining immune and inflammatory cells 
that have completed their job of clearing the bacteria and providing the chemotactic 
signals to the fibroblasts and other cells required later in the process (Monaco & 
Lawrence 2003; Broughton et al. 2006a; Olczyk et al. 2014). TGF-β1 has opposing 
responses on different MMPs, with MMP-1 inhibited and MMP-2 stimulated, along 
with increased TIMP activity in fibroblasts (Schultz & Wysocki 2009; Philips et al. 
2011; Watt & Fujiwara 2011; Xue & Jackson 2015). Additionally, the expression of 
MMP-1 is up-regulated through the actions of IL-1β and IL-6; whereas the expression 
of TIMPs is upregulated by the actions of TNF-α and TGF-β1 (Circolo et al. 1991; 
Dasu et al. 2003; Behm et al. 2012). 
 
1.3.4     Remodelling Phase 
Variations in the levels of MMPs and TIMPs occur during the remodelling phase, with 
the aim is to increase the tensile strength of the tissue by modulating the composition 
of the matrix (Monaco & Lawrence 2003; Li et al. 2007; Velnar et al. 2009; Philips et 
al. 2011; Bainbridge 2013; Xue & Jackson 2015). A careful balance between MMPs 
and their inhibitors, TIMPs, is required for optimal healing. If excessive production of 
MMPs is present, this may lead to failure to heal the wound site as degradation of the 
matrix will occur at a faster rate that ECM deposition (Trengrove et al. 1999; Mwaura 
et al. 2006; Li et al. 2007; Menke et al. 2007; Rayment et al. 2008; Schultz & Wysocki 
2009). Conversely, decreased expression of some MMPs, including MMP-1 and 
MMP-9, may lead to the decreased degradation of ECM causing an excess granulation 
tissue deposition (Lafuma et al. 1994; Broughton et al. 2006a; Li et al. 2007; Lee et al. 
2015; Rohani & Parks 2015). A balance between the actions of MMPs and TIMPs is 
normally reached approximately 3 weeks after the injury occurred. This remodelling 
period, where the ECM undergoes a turnover process, can last anywhere between a 
number of months up to a couple of years, depending on the size of the area undergoing 
remodelling (Li et al. 2007; Velnar et al. 2009; Reinke & Sorg 2012; Xue & Jackson 
2015). 
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One of the major changes seen between the ECM composition during the proliferative 
and remodelling stages is the percentages of type I and III collagen present (Monaco 
& Lawrence 2003; Li et al. 2007; Reinke & Sorg 2012; Bainbridge 2013; Olczyk et 
al. 2014; Xue & Jackson 2015). Type III collagen is initially laid down in the 
proliferative stage, resulting in a higher proportion of type III collagen present in 
granulation tissue, compared to unwounded tissue. It is during the remodelling stage 
that type III collagen is gradually replaced by type I collagen (Haukipuro et al. 1991; 
Broughton et al. 2006a; Li et al. 2007; Cheng et al. 2011; Olczyk et al. 2014). The 
proportion of type I and III collagen present in the remodelled ECM, after the 
maturation of the granulation tissue, alters to approximately the same proportion as in 
unwounded tissue; scar formation typically occurs at this point (Broughton et al. 
2006a; Li et al. 2007; Olczyk et al. 2014; Xue & Jackson 2015). The intrinsic 
differences between the two fibrillar collagens may account for the difference in scar 
formation following wounding. Type I collagen is associated with a higher tissue 
tensile strength, but also has a degree of stiffness (Gelse et al. 2003; Bainbridge 2013). 
In contrast, type III collagen is associated with more elastic tissues. Therefore, the 
higher presence of this type in early-gestational, foetal wound healing may result in a 
less rigid wound site and produce a scarless healing response (Gelse et al. 2003; Cuttle 
et al. 2005; Li et al. 2007; Leung et al. 2012; Olczyk et al. 2014). There is a 
proportionate relationship between the amount of type I collagen present and the 
strength of the granulation tissue. However, the remodelled tissue only reaches 
approximately 80% of the tensile strength found in unwounded tissue (Monaco & 
Lawrence 2003; Broughton et al. 2006a; Li et al. 2007; Velnar et al. 2009; Olczyk et 
al. 2014; Xue & Jackson 2015; Rose & Chan 2016). The increase in tensile strength is 
associated with the organised formation of the fibres and the cross-linking that occurs 
between fibres. The cross-linking is controlled by the enzymes lysyl and prolyl 
oxidases, increasing the tissue strength. These enzymes are released by the fibroblasts 
still present in the newly-synthesised matrix (Gelse et al. 2003; Gordon & Hahn 2011; 
Mouw et al. 2014; Olczyk et al. 2014; Xue & Jackson 2015; Tracy et al. 2016). 
 
Throughout the remodelling stage, there is a decreased turnover of the ECM, resulting 
in a decreased production of proteoglycans and other matrix components, due to 
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decreased chemoattraction to migrating cells (Monaco & Lawrence 2003; Velnar et al. 
2009; Reinke & Sorg 2012). This leads to an overall decrease in the metabolic demand 
of the wound site, due to a decreased action by the cells. In addition, there is a reduction 
in the number of cells present at the wound site, as cells no longer required undergo 
apoptosis (Desmoulière et al. 1995; Desmoulière et al. 1997; Greenhalgh 1998; Velnar 
et al. 2009; Reinke & Sorg 2012). Initially, during the proliferative stage, small vessels 
were formed in response to angiogenic factors, a microvasculature to provide the 
oxygenation of the tissues. During the remodelling stage, these capillaries combine 
together to form larger vessels. This is in response to the changing environment of the 
ECM as the granulated tissue matures and remodels, the resultant decreased cell 
metabolism lowers the overall oxygen demand (Baum & Arpey 2005; Li et al. 2007; 
Velnar et al. 2009; Reinke & Sorg 2012; Olczyk et al. 2014; Portou et al. 2015). 
 
A number of growth factors are also implicated in this remodelling phase, in particular 
PDGF, TGF-β1 and FGF. Their role at this point is the continual closure of the wound 
site, an action initially stimulated by the fibroblasts and their conversion to the 
contractile myofibroblast phenotype (Mutsaers et al. 1997; Traversa & Sussman 2001; 
Baum & Arpey 2005; Velnar et al. 2009; Bainbridge 2013). The role of TGF-β1 in the 
remodelling stage is to push the turnover balance more towards the deposition of the 
newly synthesised matrix. This is achieved through increasing the presence of TIMPs 
at the wound site, which subsequently decreases the action of MMPs (O’Kane & 
Ferguson 1997; Broughton et al. 2006a; Watt & Fujiwara 2011; Micallef et al. 2012; 
Xue & Jackson 2015).  
 
1.4     Preferential Healing Situations 
 
1.4.1     Foetal Wound Healing 
There is evidence of scarless healing occurring in early foetal wounds producing 
normal skin architecture at the wound site. This only appears to occur in foetal injuries 
before the end of the second trimester. In contrast, all foetal injuries that occur after 
this time-point heal in the same manner as adult wounds, with the production of fibrous 
tissue leading to scar formation (Lorenz et al. 1992; Mast et al. 1992; Lorenz & Adzick 
1993; Ferguson & Kane 2004; Lo et al. 2012; Rolfe & Grobbelaar 2012; Turabelidze 
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& DiPietro 2012; Malik et al. 2015). It was initially thought that the sterile 
environment of the uterus was involved in this scarless healing process. However, it 
was shown that it may be a result of intrinsic differences between foetal tissue and 
adult tissue (Adzick & Lorenz 1994; Dillon et al. 1994; Broker et al. 1999; Longaker 
et al. 2001; Bullard et al. 2003; Wagner & Wehrmann 2007; Rolfe & Grobbelaar 2012; 
Yagi et al. 2016). Foetal wound healing occurs more rapidly than the adult wound 
healing, despite the same stages of wound healing occurring. There are differences 
seen between the cell types present and the respective ratios of these cells, which may 
account for the variation in wound healing and skin architecture observed between the 
tissue types (Lorenz & Adzick 1993; Adzick & Lorenz 1994; Lee & Eun 1999; Bullard 
et al. 2003; Broughton et al. 2006b; Lo et al. 2012; Rolfe & Grobbelaar 2012; Yagi et 
al. 2016). Additionally, there are variations between the lengths of time that each stage 
lasts for, such as a reduced inflammation stage. This reduced response may account 
for the rapid healing observed in foetal tissue, compared to a longer healing period 
observed in adult dermal healing (Mast et al. 1992; Adzick & Lorenz 1994; Cass et al. 
1997; Broker et al. 1999; Ferguson & Kane 2004; Chen et al. 2007; Rajan & Murray 
2008; Nauta et al. 2011; Kishi et al. 2012; Malik et al. 2015; Yagi et al. 2016). It has 
been proposed that the difference in healing patterns between the two tissue types may 
be a result of foetal tissue undergoing regeneration, as opposed to the repair 
mechanism that occurs in adult dermal healing (Mast et al. 1992; Adzick & Lorenz 
1994; Longaker et al. 2001; Bullard et al. 2003; Kishi et al. 2012; Yagi et al. 2016).  
 
Correlating with the differences seen between adult and foetal wound healing, in 
regards to cell types present in the healing processes, there are also subtle variations 
seen between the stages of the wound healing process (Mast et al. 1992; Wagner & 
Wehrmann 2007; Rolfe & Grobbelaar 2012; Yagi et al. 2016). Initially, there is a 
reduced aggregation of platelets in foetal wounds; contact between the aggregated 
platelets and collagen is still required for the production of a number of growth factors, 
TGF-β1, TGF-β2 and PDGF. The level of growth factors produced by this contact is 
much reduced, compared to adult dermal healing (Adzick & Lorenz 1994; Cass et al. 
1997; Broker et al. 1999; Bullard et al. 2003; Larson et al. 2010; Kishi et al. 2012; 
Yagi et al. 2016). These three growth factors are associated with a profibrotic function, 
so their much reduced presence may contribute to the scarless healing observed in 
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foetal wounds. Although TGF-β1 and TGF-β2 are still present in foetal wounds, it has 
been shown that they are rapidly cleared from the wound site (Mast et al. 1992; Adzick 
& Lorenz 1994; Belford 1997; Cass et al. 1997; Broker et al. 1999; Bullard et al. 2003; 
Ferguson & Kane 2004; Larson et al. 2010; Rolfe & Grobbelaar 2012; Yagi et al. 
2016). A higher expression of TGF-β3 has been shown in foetal wounds TGF-β3 has 
been proposed as an anti-scarring therapy, due to its association with improved scar 
formation (Soo et al. 2003; Wagner & Wehrmann 2007; Rajan & Murray 2008; Larson 
et al. 2010; Kishi et al. 2012; Lo et al. 2012; Rolfe & Grobbelaar 2012; Malik et al. 
2015; Yagi et al. 2016).  
 
Foetal tissue appears to produce a greatly reduced inflammatory response, potentially 
resulting from the decreased inflammatory signals normally produced by platelets, 
through the release of TGF-β1 and PDGF. These growth factors are involved in the 
recruitment of inflammatory and immune cells to the wound site in adult dermal 
healing (Cass et al. 1997; Bullard et al. 2003; Larson et al. 2010; Kishi et al. 2012; 
Rolfe & Grobbelaar 2012). The reduced inflammation stage correlates with a much 
reduced presence of the immune and inflammatory cells, in particular neutrophils, 
macrophages and mast cells (Adzick & Lorenz 1994; Bullard et al. 2003; Larson et al. 
2010; Kishi et al. 2012; Lo et al. 2012; Rolfe & Grobbelaar 2012). These cells have 
been shown to be present at higher levels during adult wound healing, with mast cells 
associated with the production of fibrotic tissue resulting in scar formation (Mak et al. 
2009; Gauglitz et al. 2011; Leung et al. 2012). In addition to the reduced numbers of 
inflammatory cells present at the wound site, the length of time that they remain at the 
site for is also reduced, along with a lower activity. Expression levels of pro-
inflammatory cytokines, such as IL-6 and IL-8, are also lowered in foetal wounds. It 
is thought that the reduced presence of immune cells in foetal wound healing is due to 
the development of the immune system not being fully functional (Mast et al. 1992; 
Adzick & Lorenz 1994; Cowin et al. 1998; Liechty et al. 1998; Liechty et al. 2000; 
Rolfe & Grobbelaar 2012). At the end of the second trimester, it is thought that the 
immune system is more developed and as a result will produce a higher inflammatory 
response to injury and subsequent scarring. This leads to the theory that the level of 
inflammation has a marked effect on the production of fibrotic tissue (Cowin et al. 
1998; Rajan & Murray 2008; Larson et al. 2010; Kishi et al. 2012; Yagi et al. 2016). 
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In addition to a reduced production of fibrotic tissue at the dermal layer, there is an 
increased re-epithelialisation process of foetal wounds, compared to adult dermal 
wounds (Wagner & Wehrmann 2007; Coolen et al. 2010; Kishi et al. 2012; Lee et al. 
2012; Lo et al. 2012; Rolfe & Grobbelaar 2012). The cell crawling process of the 
keratinocytes does not occur in foetal wounds. Instead, a process referred to as ‘purse 
string closure’ occurs through the use of an actin cable. This is a much more rapid 
process, compared to the adult wound re-epithelialisation as the dissociation and 
forming of new integrins is not required, allowing wound closure to begin promptly 
after injury (Belford 1997; Martin 1997; Redd et al. 2004; Wagner & Wehrmann 2007; 
Lee et al. 2012; Rolfe & Grobbelaar 2012). There are different keratins present in 
early-gestational, foetal epithelia, compared to adult skin epithelia. Krt15 has been 
shown to have a continuous presence in early-gestational, foetal epithelia; whereas, in 
adult skin epithelia, this expression is discontinuous. Krt15 has also been associated 
as a characteristic keratin present in epidermal stem cells (Waseem et al. 1999; 
Bragulla & Homberger 2009; Bose et al. 2013).   
 
There is a difference in the predominant cell type present in adult and foetal wound 
healing. In adult wound healing, macrophages are the predominant cell type present; 
whereas in foetal wound healing, fibroblasts are the predominant cell type (Adzick & 
Lorenz 1994; Cowin et al. 1998; Broker et al. 1999; Larson et al. 2010; Rolfe & 
Grobbelaar 2012). This could account for the rapid healing that is seen in foetal 
healing, due to rapid migration of foetal fibroblasts to the wounded site. This high 
abundance of fibroblasts can increase the synthesis of new ECM components and 
remodel the ECM in a shorter time period, compared to adult dermal healing (Mast et 
al. 1992; Bullard et al. 2003; Lo et al. 2012; Yagi et al. 2016). Despite the high 
presence of fibroblasts in foetal wounds and their early presence, due to their rapid 
migration to the wound site, there is an absence of myofibroblasts in foetal wounds at 
day 14, reducing the contraction of the wound. This often leads to scarring, which may 
be related to the low levels of TGF-β1 present in foetal wounds (Adzick & Lorenz 
1994; Lee & Eun 1999; Leung et al. 2012; Lo et al. 2012; Yagi et al. 2016). In addition, 
bFGF has been shown to be expressed at a higher level in scarless foetal wounds, 
compared to adult scarring wounds. This growth factor exerts a number of important 
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functions, including fibroblast proliferation, ECM synthesis, angiogenesis and 
keratinocyte mobility (Sogabe et al. 2006; Barrientos et al. 2008; Xie et al. 2008; Akita 
et al. 2012; Rolfe & Grobbelaar 2012). Another growth factor difference observed is 
the increased presence of VEGF in foetal wounds, contributing to angiogenesis, 
through increased permeability of the vasculature. Despite this increase in VEGF 
expression, studies indicated that development of new vessels is not significantly 
increased, compared to a control capable of scarring (Bullard et al. 2003; Colwell et 
al. 2005; Yagi et al. 2016). However, there are conflicting reports on VEGF expression 
in foetal wounds, with other studies suggesting that VEGF levels were reduced in 
scarless healing wounds and addition of VEGF induces a fibrotic response (Wilgus et 
al. 2008; Satish & Kathju 2010; Johnson & Wilgus 2014).  
 
In addition to the rapid speed in which the new ECM is laid down in the wounded site 
of foetal injuries, there is also a difference in the composition of the healed foetal 
wounds, compared to adult dermal wounds. There is a much higher proportion of type 
III collagen to type I collagen present in the newly synthesised foetal ECM, compared 
to the ratio in adult dermal wounds (Adzick & Lorenz 1994; Bullard et al. 2003; Larson 
et al. 2010; Leung et al. 2012; Lo et al. 2012; Rolfe & Grobbelaar 2012; Yagi et al. 
2016). The organisation of the collagen fibres is notably different between the two 
wound healing types. In adult wounds, fibres are present in thick bundles of type III 
collagen fibres, with cross-linking evident between fibres, leaving the appearance of a 
disorganised pattern of laid down collagen (Mast et al. 1992; Adzick & Lorenz 1994; 
Larson et al. 2010; Leung et al. 2012; Lo et al. 2012). In contrast, in foetal wounds, it 
is often difficult to distinguish between the unwounded site and the newly repaired 
site; this is thought to be a result of thinner type I collagen fibres being deposited in a 
reticular pattern (Mast et al. 1992; Broker et al. 1999; Bullard et al. 2003; Larson et al. 
2010; Leung et al. 2012; Lo et al. 2012; Yagi et al. 2016). There is also a reduced 
presence of lysyl oxidase in foetal wounds, resulting in less collagen cross-linking 
occurring. In contrast, a much increased activity of prolyl hydroxylase is seen in foetal 
wounds. This enzyme functions as a rate-limiting step in collagen synthesis (Lorenz 
& Adzick 1993; Bullard et al. 2003; Rolfe & Grobbelaar 2012). The presence of type 
III collagen and reduced collagen cross-linking may be responsible for an increased 
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elasticity of the wound and therefore, preventing the rigid structure often reported with 
fibrotic tissue in scarring (Bullard et al. 2003; Larson et al. 2010; Leung et al. 2012).  
 
Another important compositional difference between adult and foetal wounds is the 
high levels of hyaluronan and hyaluronan receptor present in foetal wounds (Longaker 
et al. 1991; Laurent et al. 1995; Fraser et al. 1997; Chen & Abatangelo 1999; Bullard 
et al. 2003; Larson et al. 2010; Leung et al. 2012; Rolfe & Grobbelaar 2012). 
Hyaluronan has been shown to increase the migration of foetal fibroblasts to the wound 
site, enhancing their presence. Once at the site, hyaluronan is deposited rapidly. 
Hyaluronan has been shown to remain at the wound site for a prolonged period in 
early-gestational foetal healing, indicating that hyaluronan is required for synthesising 
a new ECM with an organised structure. This is in comparison to adult wounds where 
lower amounts of hyaluronan are present earlier and more briefly (Longaker et al. 
1991; Mast et al. 1992; Alaish et al. 1994; Huang et al. 2008; Larson et al. 2010; Leung 
et al. 2012; Lo et al. 2012; Rolfe & Grobbelaar 2012; Yagi et al. 2016). Increased 
presence of hyaluronan has also been thought to result in reduced deposition of 
collagen in the granulation tissue, reducing the subsequent scar formation. This was 
demonstrated through fibrosis occurring in the absence of hyaluronan (Chen & 
Abatangelo 1999; Yagi et al. 2016).  Due to the ability of hyaluronan to increase type 
III collagen and TGF-β3 levels, both of which have been associated with a scarless 
healing outcome; increased presence of native hyaluronan may contribute to the 
scarless healing phenotype associated with early-gestational foetal wound healing 
(David-Raoudi et al. 2008; Kishi et al. 2012; Lee et al. 2012; Leung et al. 2012; Lo et 
al. 2012).  
 
The synthesis and remodelling of new ECM is a tightly regulated process, with a 
careful balance between MMPs and their inhibitors, TIMPs. The combination of both 
play a vital part in the remodelling process of the ECM. In foetal wounds, a higher 
MMP presence and a decreased TIMP presence is observed, resulting in an increase in 
ECM turnover, allowing scarless healing to occur (Bullard et al. 2003; Dang et al. 
2003; Satish & Kathju 2010; Rolfe & Grobbelaar 2012; Yagi et al. 2016). In scarring 
wounds, there is an increased expression of both TIMP-1 and -2, along with a 
decreased MMP-2 expression. This decreases the rate of ECM turnover leading to the 
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formation of fibrotic tissue (Lafuma et al. 1994; Lee et al. 2015; Rohani & Parks 2015). 
In foetal scarless healing, there is a quicker and upregulated expression of MMP-1, -
2, -9 and -14. MMP-1 is associated with a preference for the breakdown of type III 
collagen, which has an increased presence in foetal wounds, compared to adult dermal 
wounds (Welgus et al. 1981; Nwomeh et al. 1998; Dang et al. 2003; Dasu et al. 2003; 
Lu et al. 2011; Rolfe & Grobbelaar 2012). Additionally, the presence of either TGF-
β1 or -β3 in foetal scarless wounds is associated with an increased expression of MMP-
13 increasing the ECM turnover; whereas MMP-13 expression is undetectable in adult 
dermal wounds (Ravanti et al. 1999, 2001; Toriseva & Kähäri 2009).  
 
All of these variations in MMP and TIMP expression between adult and foetal wound 
healing results in an increased ECM turnover occurring in foetal wounds, potentially 
leading to a more organised composition of the new ECM. This is due to an increased 
ECM turnover preventing an excessive deposition of newly-synthesised ECM and the 
resultant formation of fibrotic tissue in the dermis (Bullard et al. 2003; Larson et al. 
2010; Lo et al. 2012; Rolfe & Grobbelaar 2012; Yagi et al. 2016). The discovery that 
the newly synthesised ECM in foetal wounds is present in an organised manner was a 
surprising find. It was originally thought that the rapid laying down of collagen fibres 
would result in a disorganised structure (Mast et al. 1992; Larson et al. 2010; Lo et al. 
2012; Malik et al. 2015; Yagi et al. 2016). It is the composition and structure of the 
underlying dermis that determines the presence and appearance of a scar, with an 
unorganised ECM being a major contributor to scarring. Therefore, there is the 
potential that synthesising a new ECM in an organised fashion can aid in the 
prevention of scar development (Mast et al. 1992; Shah et al. 1995; Larson et al. 2010).  
 
1.4.2     Oral Mucosal Wound Healing 
During oral mucosal wound healing, there is a dramatically reduced scar formation, 
but it is not thought to be completely scarless, as seen with early-gestational foetal 
wound healing (Whitby & Ferguson 1991; Szpaderska et al. 2003; Enoch et al. 2008; 
Nauta et al. 2011; Turabelidze & DiPietro 2012; Glim et al. 2013). Oral mucosal 
wounds undergo the same wound healing stages as adult dermal wounds. However, 
the length of time that each stage lasts for varies and there are intrinsic differences 
between the dermal and oral fibroblasts (Szpaderska et al. 2003; Mak et al. 2009; Nauta 
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et al. 2011). In addition, despite similarities between the compositions of the skin and 
the oral mucosal epithelium, there are intrinsic differences between these two types of 
epithelium, as shown in Figure 1.6 (Stephens & Genever 2007). The oral mucosal 
epithelium has been show to produce a reduced angiogenic response, compared to the 
response in skin wounds. This could contribute to the differences in scarring seen 
between the two tissue types (Szpaderska et al. 2005; Novak et al. 2008; Mak et al. 
2009; Chen et al. 2010). As seen with early-gestational foetal wound healing, there are 
differences in the keratins present in the oral mucosal epithelia, compared to adult skin 
epithelia. Krt13 has been shown to be present at a much higher level in oral mucosal 
epithelia, compared to adult skin epithelia (Waseem et al. 1999; Presland & Dale 2000; 
Bragulla & Homberger 2009; Turabelidze et al. 2014).  
 
As with foetal wound healing, there is evidence of a reduced inflammatory response 
during oral mucosal wound healing, along with rapid re-epithelialisation; both of 
which contribute to the minimal scar formation of oral mucosal wounds (Szpaderska 
et al. 2003; Enoch et al. 2008; Mak et al. 2009; Nauta et al. 2011; Turabelidze et al. 
2014). The reduced inflammatory stage is consistent with the decreased levels of 
neutrophils, macrophages and T cells present in oral mucosal wounds. In addition, 
similar to the response seen in early-gestational foetal healing, there is a reduced 
presence of pro-inflammatory cytokines, such as IL-6 and IL-8, along with reduced 
presence of growth factors, such as TGF-β1 (Szpaderska et al. 2003; Mak et al. 2009; 
Chen et al. 2010; Nauta et al. 2011; Glim et al. 2015). Another contributing factor for 
reduced scarring is the decreased presence of pro-inflammatory cytokines, such as IL-
1 and TNF-α. This coincides with the absence of the JAK-STAT signalling pathway, 
which has been associated with the activation of immune and inflammatory responses 
(Chen et al. 2010; Turabelidze & DiPietro 2012). 
 
As previously mentioned, intrinsic differences between dermal fibroblasts and oral 
mucosal fibroblasts have been shown, resulting in this population being genotypically 
and phenotypically distinct from dermal fibroblasts (Enoch et al. 2008; Glim et al. 
2013). The oral mucosal fibroblasts have been shown to possess a ‘younger’ 
phenotype, compared to patient-matched dermal fibroblasts. This ‘young’ phenotype 
is similar to the foetal fibroblast phenotype; and may be responsible for rapid and  
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Figure 1.6: A schematic diagram showing the composition of the oral mucosa with 
the cells present in each section, compared to the composition of skin (Stephens 
& Genever 2007). 
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minimally scarred healing observed in oral mucosal wounds (Enoch et al. 2009, 2010). 
Oral mucosal fibroblasts have also been shown to senesce at much later time points 
than dermal fibroblasts, after undergoing a longer proliferative lifespan and a greater 
number of population doublings. Proliferation has also been reported to occur at a 
faster rate, compared to dermal fibroblasts. The delayed senescence that occurs in oral 
mucosal fibroblasts is due to their ability to retain their telomere length for a longer 
period of time, compared to population doubling level-matched, dermal fibroblasts 
(Lee & Eun 1999; Shannon et al. 2006; Enoch et al. 2009, 2010; Glim et al. 2013, 
2014; Peake et al. 2014). Analysis was performed on the level of telomerase activity, 
the enzyme involved in reducing the breakdown of telomeres. However, neither oral 
mucosal or dermal fibroblasts expressed any active telomerase. Therefore, the oral 
mucosal fibroblasts are telomerase-independent, yet still able to maintain a longer 
proliferative lifespan. This may be an intrinsic function of this population that allows 
the preservation of the telomere length (Enoch et al. 2009; Marynka-Kalmani et al. 
2010).  
 
Oral mucosal fibroblasts are capable of migrating to the wound site much quicker than 
their dermal counterparts, resulting in a quicker re-population of the damaged area and 
synthesis of the new ECM (al-Khateeb et al. 1997; Shannon et al. 2006; Meran et al. 
2007; Enoch et al. 2008, 2010). There are also differences in the composition of the 
ECM synthesised by oral fibroblasts, compared to dermal ECM. Increased presence of 
fibronectin and chondroitin sulphate has been observed in oral wounds. However, 
another study has demonstrated a less prolonged expression of fibronectin splice 
variant ED-A in oral wounds, compared to dermal wounds. Decreased presence of 
elastin has been observed in oral wounds despite a more elastic phenotype. This is 
potentially due to increased presence of other elastic fibres, including oxytalan and 
elaunin (Wong et al. 2009; Glim et al. 2013, 2014). Oral fibroblasts also impact on the 
organisation of the ECM, with increased organisation evident compared to dermal 
fibroblasts (Stephens et al. 2001a; Shannon et al. 2006; Enoch et al. 2010). Fibroblasts 
are associated with the synthesis of MMPs, which are vital for the remodelling of the 
ECM. It has been shown that there is an increased expression and production of MMP-
2 by oral mucosal fibroblasts. This increased expression of MMP-2 may be a result of 
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a decreased expression of both TIMP-1 and TIMP-2, reducing the inhibitory action on 
the metalloproteinases (Stephens et al. 2001a; Chen et al. 2010; Enoch et al. 2010; 
Glim et al. 2013, 2014). However, a number of other MMPs were shown to have 
reduced presence, compared to in skin wounds; these include MMP-1, MMP-8, MMP-
9, MMP-10 and MMP-13 (Chen et al. 2010). Another growth factor potentially 
involved in the remodelling of the ECM is hepatocyte growth factor/scatter factor 
(HGF/SF), which has mitogenic, motogenic and morphogenic actions. HGF increases 
the migratory action towards fibronectin. Oral mucosal fibroblasts have been shown 
to have a significantly increased expression and activity compared to dermal 
fibroblasts (Stephens et al. 2001b; Poomsawat et al. 2003; Shannon et al. 2006; Enoch 
et al. 2008).  
 
Despite playing a vital role in blood vessel growth and subsequent delivery of oxygen 
and nutrients required at the wound site, it has been proposed that a high angiogenic 
response may contribute to the scarring phenotype. Therefore, the reduced 
angiogenesis observed in oral mucosal wounds may reduce scarring (Mak et al. 2009; 
Chen et al. 2010; Tonnesen et al. 2000; Nauta et al. 2011; Johnson & Wilgus 2014). 
There was also a decreased expression of certain pro-angiogenic factors in oral 
mucosal wounds, compared to adult dermal wounds; these include VEGF and TGF-β1 
(Szpaderska et al. 2005; Mak et al. 2009; Turabelidze et al. 2014). Resulting from the 
decreased TGF-β1 expression, there is a lower ratio of TGF-β1 to TGF-β3 in oral 
mucosal wounds. This is similar to the effect seen in foetal wounds, where there is a 
higher TGF-β3 to TGF-β1 ratio, leading to the proposal that decreased TGF-β1 or 
increased TGF-β3 contributes to scarless or minimally scarred healing (Bullard et al. 
2003; Shannon et al. 2006; Nauta et al. 2011; Yagi et al. 2016). Oral mucosal 
fibroblasts were shown to be resistant to the differentiation to myofibroblasts via TGF-
β1 stimulation. This was shown through the lack of α-SMA expression and stress fibre 
formation (Shannon et al. 2006; Meran et al. 2007; Enoch et al. 2008). This is 
compared to dermal fibroblasts, which upon activation by TGF-β1, differentiate into 
the contractile phenotype myofibroblasts. This resistance to differentiating into 
myofibroblasts by the oral mucosal fibroblasts may contribute to the minimal scarring 
observed in oral mucosal wounds (Meran et al. 2007; Enoch et al. 2008). In addition, 
resistance to differentiation in oral fibroblasts was associated with failure of induction 
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of HAS1 and HAS2 transcription and failure of pericellular coat assembly. 
Furthermore, inhibition of HA synthesis in dermal fibroblasts significantly attenuated 
TGF1-mediated differentiation (Yamada et al. 2004; Meran et al. 2007; Glim et al. 
2013).  
 
Although oral mucosal wounds healed in a similar manner to dermal wounds, they 
exhibit a scarless healing phenotype similar to early-gestational foetal wound healing. 
There are a number of similarities between these two scarless healing mechanisms, 
including reduced inflammatory responses, reduced fibroblast differentiation to 
myofibroblasts, rapid fibroblast migration to the wound site; and rapid re-
epithelialisation (Meran et al. 2007; Mak et al. 2009; Wong et al. 2009; Enoch et al. 
2010; Glim et al. 2013; Turabelidze et al. 2014).  
 
1.5     Dysfunctional Wound Healing Situations 
 
As previously mentioned, the wound healing process is tightly regulated. This is 
required in order for successful wound closure and repair to occur (Li et al. 2007; 
Velnar et al. 2009; Reinke & Sorg 2012). Variations in this response can lead to 
detrimental wound healing responses. There are two main categories of dysfunctional 
wound healing, pathological scarring and chronic wounds (Menke et al. 2007; Bran et 
al. 2009; Shih et al. 2010; Frykberg & Banks 2015). Due to the importance of fibroblast 
and keratinocyte functions during wound repair, it is changes in the normal functions 
of these cells that have a vital impact on normal acute, dermal wound healing (Li et al. 
2007; Menke et al. 2007; Bran et al. 2009).  
 
1.5.1     Pathological Scarring 
Scar formation is a normal hallmark of acute skin wound healing and is a result of 
wound contraction and altered collagen composition of the wound (Velnar et al. 2009; 
Olczyk et al. 2014). However, in some instances, pathological scarring can occur. The 
two main examples of this are keloids and hypertrophic scarring (English & Shenefelt 
1999; Szulgit et al. 2002; Bran et al. 2009; Gauglitz et al. 2011; Huang et al. 2013). 
Keloids are scars that have grown past the margin of the wound site, into the 
surrounding healthy tissue. They also typically do not resolve over time and can cause 
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pain to the patient (Bran et al. 2009; Gauglitz et al. 2011; Viera et al. 2012). In addition, 
as some keloids can extend quite far beyond the margin, it can impact the patient’s 
life, through both the resultant impaired functionality and the psychological impact it 
can have (Bran et al. 2009; Shih et al. 2010; Viera et al. 2012). This form of 
pathological scarring is quite rare, although there is a higher incidence in dark-
pigmented populations, with approximately 6-16% incidence in African populations. 
There also seems to be a strong familial inheritance, with over half of keloid patients 
having a family history of keloid scarring (Bran et al. 2009; Russell et al. 2010; 
Gauglitz et al. 2011; Viera et al. 2012; Jumper et al. 2015).  
 
There are a number of histological differences between a normal scar that occurs 
following wound healing and a keloid scar. Some of the main differences include no 
myofibroblasts, higher type I to type III collagen ratio and thick, disorganised collagen 
fibres, along with an increased production of ECM components (Uitto et al. 1985; Lim 
et al. 2002; Bran et al. 2009; Gauglitz et al. 2011; Jumper et al. 2015). The 
inflammatory phase appears to last longer, with a higher presence of mast cells, 
macrophages and lymphocytes, further promoting inflammation (Boyce et al. 2001; 
Shih et al. 2010; Gauglitz et al. 2011; Jumper et al. 2015). There is also an increased 
presence of pro-inflammatory cytokines and growth factors during inflammation, 
compared to normal wound healing. An up-regulation of TNF-α, IL-6, interferon 
(IFN)-β, TGF-β1 and TGF-β2 was observed in keloids, along with an increased 
response to PDGF and TGF-β1 by higher levels of receptors present on fibroblasts 
(Mccauley et al. 1992; Tuan & Nichter 1998; Xue et al. 2000; Chen et al. 2003; Bran 
et al. 2009; Shih et al. 2010; Gauglitz et al. 2011). The prolonged inflammatory phase 
and subsequent increased release of cytokines and growth factors recruits a greater 
number of cells to the wound site during the proliferative phase, resulting in excessive 
proliferation. The increased fibroblast proliferation contributes to the fibrotic response 
seen in keloids (Shih et al. 2010; Gauglitz et al. 2011). 
 
Keloid fibroblast behaviour is intrinsically different to normal dermal fibroblasts. They 
undergo more rapid migration and proliferation than normal dermal fibroblasts, 
increasing their presence at the wound site (Bettinger et al. 1996; Calderon et al. 1996; 
Funayama et al. 2003; Shih et al. 2010). Due to the strong paracrine feedback system 
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between keratinocytes and fibroblasts, it is thought that the increased activities of 
fibroblasts are a result of increased release of cytokines, such as IL-1 from 
keratinocytes (Maas-Szabowski et al. 1999; Maas-Szabowski et al. 2000; Bader & Kao 
2009; Gauglitz et al. 2011; Dong et al. 2013). There are also alteration in the expression 
of keratins, with an increased expression of keratin 16. This keratin is typically 
upregulated after wounding, but is also an associated hyperproliferation marker 
(Mazzalupo et al. 2003; Ong et al. 2010; Jumper et al. 2015). Keloids appear to have 
a thickened epidermis, which may be a result of excessive keratinocyte proliferation. 
The increased keratinocyte presence will also feedback into the paracrine system with 
the fibroblasts, enhancing their activity (Lim et al. 2001; Chua et al. 2011; Gauglitz et 
al. 2011; Jumper et al. 2015).  
 
Keloid fibroblasts are also capable of producing more collagen than dermal fibroblasts, 
approximately 2-3 times more (Uitto et al. 1985; English & Shenefelt 1999; Satish et 
al. 2004; Huang et al. 2013). Additionally, in some keloids, there is a decreased 
breakdown of the ECM, as a result of down-regulated MMP-9, although MMP-2 has 
been shown to be up-regulated (Satish et al. 2004; Imaizumi et al. 2009; Ulrich et al. 
2010; Gauglitz et al. 2011). There is also an altered expression of hyaluronan. It is 
typically present in the papillary dermis in normal dermal wounds, but is present 
between the epidermal layers in keloids. Despite the increased presence of hyaluronan, 
especially smaller molecular weight fragments (<400 kDa) associated with fibrosis, 
keloids possess a decreased presence of hyaluronan compared to normal scar tissue 
and unscarred tissue, leading to the potential treatment option of high molecular weight 
hyaluronan addition to keloid tissue (David-Raoudi et al. 2008; Meyer et al. 2000; Tan 
et al. 2011; Hoffmann et al. 2012; Jumper et al. 2015; Tracy et al. 2016). Hyaluronan 
is an important ECM component and has shown to be increased in scarless healing 
responses. It has important functions in regulating inflammation and is involved in 
fibroblast proliferation and migration (Longaker et al. 1991; Mast et al. 1992; Meyer 
et al. 2000; Ghatak et al. 2015; Jumper et al. 2015; Tracy et al. 2016). This increased 
collagen production may also be due to reduced IFN-α and IFN-γ in keloids, which 
normally reduce the synthesis of collagen type I mRNA, by increasing the expression 
of p53, a pro-apoptotic gene (Satish et al. 2004; Bran et al. 2009; De Felice et al. 2009; 
Berman 2010; Viera et al. 2012). It appears that keloid fibroblasts undergo reduced 
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apoptosis, potentially due to a mutation in tumour suppressor gene, p53. This increases 
the presence of fibroblasts, which results in greater ECM production. The reduced 
apoptosis of keloid fibroblasts retains the wound healing process in a proliferative 
state, as opposed to continuing into the maturation phase, where proliferation and ECM 
synthesis decrease steadily (Ladin et al. 1998; Saed et al. 1998; Funayama et al. 2003; 
Broughton et al. 2006b; Bran et al. 2009; De Felice et al. 2009; Shih et al. 2010; Jumper 
et al. 2015).  
 
Although keloid and hypertrophic scars are both examples of pathological scarring, 
they are characteristically different from each other. The most notable example is that 
although hypertrophic scars are also raised due to excessive scarring, the scarring does 
not extend past the wound margins (English & Shenefelt 1999; Broughton et al. 2006b; 
Bran et al. 2009; Gauglitz et al. 2011; Ding & Tredget 2015; Trace et al. 2016). There 
is a high incidence of hypertrophic scarring following surgery (40-70%) and even 
higher following burn injuries (<90%). However, unlike keloids, hypertrophic scars 
can regress within a few years. This scarring is more prevalent than keloids and doesn’t 
have a higher incidence in any population. It appears within several weeks of injury, 
grows over a period of months, before regressing (Stadelmann et al. 1998; Bran et al. 
2009; Gauglitz et al. 2011; Penn et al. 2012; Xue & Jackson 2015). 
 
The histology of hypertrophic scars is quite different to keloids, with a higher 
proportion of type III collagen in hypertrophic scars, which is organised in fine, 
parallel bundles to the epidermal surface (Bran et al. 2009; Oliveira et al. 2009; 
Verhaegen et al. 2009; Gauglitz et al. 2011; Rabello et al. 2014). There are also 
myofibroblast containing nodules within the scar tissue, which stains positively for α-
SMA. Apoptosis of these cells occurred much later than in normal acute wound 
healing, after a few years instead of a few weeks. This excess myofibroblast activity 
results in excessive contraction of the wound site (Moulin et al. 2004; Broughton et al. 
2006b; Slemp & Kirschner 2006; Bran et al. 2009; Gauglitz et al. 2011; Sarrazy et al. 
2011; Rabello et al. 2014). Some other characteristic features of hypertrophic scars 
include increased cell presence, increased vasculature, increased chondroitin sulphate 
and increased collagen synthesis. The increased collagen deposition is not due to 
abnormal responses to growth factors, as seen with keloids; the synthesis of ECM 
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occurs over an extended period of time, resulting in excess deposition (Kischer et al. 
1975; Scott et al. 1995; Bran et al. 2009; Rabello et al. 2014; Zhu et al. 2016). 
Fibroblast presence is increased in hypertrophic scars, compared to normal wounds, 
but proliferative ability is not affected. The increased number of fibroblasts, together 
with an overexpression of TGF-β1 increases the presence of contractile myofibroblasts 
(Nedelec et al. 2001; Wang et al. 2008; Gauglitz et al. 2011; Sarrazy et al. 2011; 
Rabello et al. 2014).  
 
1.5.1.1     Existing Therapies for Pathological Scarring 
Both of these pathological scarring phenotypes have an impact on patients quality of 
life, with some causing considerable disability and psychological implications. It has 
a huge clinical burden, as approximately 100 million patients per year in the developed 
world, develop a scar following surgery (English & Shenefelt 1999; Al-Attar et al. 
2006; Gurtner et al. 2008; Gauglitz et al. 2011; Ding & Tredget 2015; Andrews et al. 
2016). There are a number of treatment options available for keloids and hypertrophic 
scars, often one of the first options is surgery to remove the excess scar tissue. 
Hypertrophic scars do not recur following surgical removal of the scar tissue and may 
resolve themselves if left for a longer period (English & Shenefelt 1999; Niessen et al. 
1999; Broughton et al. 2006b; Bran et al. 2009; Gauglitz et al. 2011; Rabello et al. 
2014). In nearly 100% of the cases, keloid scar tissue will reoccur and despite this 
probability, it is often still the first treatment strategy. However, as surgical excision 
creates another wound site, many cases have shown the formation of a larger keloid at 
the original site  (Berman & Bieley 1996; English & Shenefelt 1999; Al-Attar et al. 
2006; Broughton et al. 2006b; Slemp & Kirschner 2006; Bran et al. 2009; Gauglitz et 
al. 2011; Rabello et al. 2014) .  
 
In patients known to form keloids or hypertrophic scar, there are a variety of 
preventative treatment options; these include pressure therapy, silicone gel sheeting, 
silicone gel and flavonoids (English & Shenefelt 1999; Al-Attar et al. 2006; Slemp & 
Kirschner 2006; Gauglitz et al. 2011; Gold et al. 2014; Andrews et al. 2016; Trace et 
al. 2016). These treatment options are prophylactic, so are not suitable on formed 
keloids or hypertrophic scars, they can only be used in a preventative manner. These 
treatments often need to be performed for several months, in order to prevent scar 
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formation (Kischer et al. 1975; English & Shenefelt 1999; Gauglitz et al. 2011; Gold 
et al. 2014). Pressure therapy has been shown to be successful, but requires pressure 
to be exerted onto the site for 18-24 hours, for several months. It is thought that this 
pressure impacts on ECM synthesis and degradation, increasing degradation and 
resulting in decreased presence of chrondroitin sulphate. Additionally, compression 
therapy has been shown to increase prostaglandin E2 (PGE2) levels, reducing collagen 
synthesis. This process resolves the scar, however, due to the discomfort with this 
therapy, there is a reduced patient compliance (Kischer et al. 1975; Reno et al. 2001; 
Al-Attar et al. 2006; Broughton et al. 2006b; Gauglitz et al. 2011; Trace et al. 2016). 
Silicone gel sheeting, or silicone gel in areas of continuous movement, is another 
recognised therapy. It is thought that the beneficial response is a result of maintained 
hydration of the wound site (Lyle 2001; Broughton et al. 2006b; Zurada et al. 2006; 
Atiyeh 2007; Ogawa 2010; Gauglitz et al. 2011; Gold et al. 2014; Rabello et al. 2014). 
This hydration may have a positive effect on the keratinocytes and result in beneficial 
fibroblast function and response to growth factors and the subsequent reduced 
deposition of collagen (Niessen et al. 1998; Lyle 2001; Broughton et al. 2006b; Zurada 
et al. 2006; Atiyeh 2007; Mustoe 2008; Rabello et al. 2014). Flavonoids are a topical 
cream, which are thought to possess anti-fibrotic properties, through the inhibition of 
fibroblast proliferation, synthesis of collagen and wound contracture (Atiyeh 2007; 
Cho et al. 2010; Gauglitz et al. 2011; Kandasamy et al. 2011).  
 
The current therapies available for treating developed scars, include corticosteroids, 
cryotherapy, scar revision, radiotherapy and laser therapy (Al-Attar et al. 2006; 
Broughton et al. 2006b; Slemp & Kirschner 2006; Atiyeh 2007; Ogawa 2010; Gauglitz 
et al. 2011; Gold et al. 2014; Rabello et al. 2014; Trace et al. 2016). Corticosteroids 
are often one of the main initial treatment options, especially for keloids. This dampens 
the inflammatory response, which reduces the downstream responses, resulting in 
reduced fibroblast proliferation and collagen deposition. Several applications are 
typically required and successful scar resolution can occur in 50-100% cases. 
However, recurrence can occur in up to 50% of cases (Maguire Jr. 1965; Chowdri et 
al. 1999; Niessen et al. 1999; Roques & Téot 2008; Gauglitz et al. 2011; Gold et al. 
2014; Rabello et al. 2014). Cryotherapy is of use in small scars and induces damage to 
the vasculature through spray application of liquid nitrogen. Application has been 
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delivered through intralesional-needle cryoprobe, which reduces scar volume by 
approximately 50% (Zouboulis et al. 1993; Zouboulis et al. 2002; Har-Shai et al. 2003; 
Broughton et al. 2006b; Gauglitz et al. 2011; Trace et al. 2016). Radiotherapy has been 
a therapeutic option towards keloids for many years and successful treatment 
probabilities have increased over the years, with approximately 64-98% successful 
scar resolution. It is thought to inhibit the proliferation of fibroblasts in the keloid, 
increase the rate of keloid fibroblast apoptosis, decreasing collagen deposition. 
However, the treatment dose is restricted due to potential side effects, including 
atrophy and erythema (Levy et al. 1976; Niessen et al. 1999; Ogawa et al. 2003; Al-
Attar et al. 2006; Broughton et al. 2006b; Gauglitz et al. 2011; Lee & Park 2015). Laser 
therapy has been used on keloids, using a pulsed-dye laser. This is also beneficial to 
early hypertrophic scars. It is also thought to impact on fibroblast proliferation and the 
downstream functions of the cell, whilst causing minimal contraction of the scar 
(Alster & Williams 1995; Alster & Nanni 1998; Broughton et al. 2006b; Bouzari et al. 
2007; Parrett & Donelan 2010; Gauglitz et al. 2011; Jin et al. 2013). Despite the wide 
range of treatment options, often requiring multiple applications, there are few studies 
showing their effectiveness. Additionally, there is a wide range in the chance of a 
successful outcome, with a high incidence of recurrence for keloid scars; a number of 
side effects have also been associated with these treatments (Al-Attar et al. 2006; 
Broughton et al. 2006b; Slemp & Kirschner 2006; Gauglitz et al. 2011; Gold et al. 
2014; Rabello et al. 2014; Trace et al. 2016).    
 
More recently introduced therapies include interferon (IFN-α-2b) and 5-fluorouracil 
(5-FU); both of which are injected into the scar tissue site (Al-Attar et al. 2006; 
Broughton et al. 2006b; Atiyeh 2007; Ogawa 2010; Gauglitz et al. 2011; Gold et al. 
2014; Rabello et al. 2014; Trace et al. 2016). IFN-α was shown to be decreased in 
keloids and injection of IFN-α-2b may impair fibroblast function, in particular the 
deposition of collagen. This is also due to increased collagenase activity. It has also 
been shown to reduce the proliferative action of fibroblasts, reducing their overall 
presence at the scar site; although some studies have reported this treatment to be 
ineffective (Wong et al. 1994; Berman & Flores 1997; Al-Attar et al. 2006; Broughton 
et al. 2006b; Davison et al. 2006; Slemp & Kirschner 2006; Gauglitz et al. 2011; Gold 
et al. 2014; Rabello et al. 2014). However, there are side effects with application of 
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IFN-α-2b. These are typically flu-like symptoms, including fever, along with pain on 
injection, in addition it is an expensive therapy (Al-Attar et al. 2006; Broughton et al. 
2006b; Slemp & Kirschner 2006; Gauglitz et al. 2011; Rabello et al. 2014). 5-FU 
increases fibroblast apoptosis in keloids and inflamed hypertrophic scars. This along 
with an inhibited fibroblast proliferation reduces their presence and the subsequent 
amount of collagen synthesised (Uppal et al. 2001; Kontochristopoulos et al. 2005; 
Broughton et al. 2006b; Gauglitz et al. 2011; Wilson 2013; Gold et al. 2014; Rabello 
et al. 2014; Jones et al. 2015; Shah et al. 2016). It has been shown to more effective 
when given alongside corticosteroid treatment, with a reduction in scar size by 
approximately 50% appears to occur in most patients (Asilian et al. 2006; Broughton 
et al. 2006b; Davison et al. 2009; Gauglitz et al. 2011; Gold et al. 2014; Rabello et al. 
2014). Despite the beneficial responses seen, there are a few side effects observed in 
this treatment, including pain on injection, burning sensation and formation of ulcers 
(Apikian & Goodman 2004; Kontochristopoulos et al. 2005; Al-Attar et al. 2006; 
Gauglitz et al. 2011; Trace et al. 2016). More successful treatment options are essential 
for the resolution of these debilitating pathological scars. Consequently, further 
understanding of the aetiology and pathogenesis of keloids and hypertrophic scars may 
elucidate target mechanisms for successful outcomes (Al-Attar et al. 2006; Slemp & 
Kirschner 2006; Atiyeh 2007; Gauglitz et al. 2011; Rabello et al. 2014; Trace et al. 
2016).  
 
1.5.2     Chronic Wounds 
Chronic wounds are one of the predominate examples of impaired healing, where the 
integrity of the skin is not restored following injury. This increases the risk of 
contamination and a potential loss of function at the site. There are a range of wounds 
that fall under this category, including venous leg ulcers, diabetic ulcers and pressure 
ulcers. Incidence of these chronic wounds increases with age and prevalence of 
diabetes (Gosain & DiPietro 2004; Menke et al. 2007; Posnett & Franks 2008; Gorecki 
et al. 2009; Dreifke et al. 2015; Demidova-Rice et al. 2012a; Frykberg & Banks 2015). 
These non-healing wounds can last for a considerable length of time, typically a 
minimum of 3 months, but a large proportion last over a year. This has a significant 
impact on the patient, through pain, lack of mobility, psychological impact and 
increased morbidity (Posnett & Franks 2008; Sen et al. 2010; Agale 2013; Trøstrup et 
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al. 2013; Dreifke et al. 2015; Frykberg & Banks 2015). In addition to the impact on 
patients, there is also an extensive clinical burden on the NHS caused by treating these 
chronic wounds. It is estimated to cost approximately £5 billion per year, equating to 
about 3% of the UK healthcare expenditure. This cost has almost doubled in less than 
a decade. This is broken down to approximately £2 billion per year, spent on long-
lasting wounds, which healed within a year; and £3 billion per year, on wounds which 
did not heal during the study duration (Posnett & Franks 2008; Trøstrup et al. 2013; 
Guest et al. 2015; Guest et al. 2016).  
 
A common feature of chronic wounds and burn injuries is the lack of re-
epithelialisation. Without re-establishing the protective barrier, the wound site is 
vulnerable to infection and further morbidity. There are a number of intrinsic 
differences in chronic wounds, compared to acute wounds, which contribute to this 
non-healing phenotype and lack of re-epithelialisation (Stojadinovic et al. 2005; 
Menke et al. 2007; Agren & Werthén 2007; Usui et al. 2008; Wikramanayake et al. 
2014; Dreifke et al. 2015; Frykberg & Banks 2015). Keratinocyte function is often 
directly impaired in diabetic patients, in particular migratory ability. This is partly due 
to dysfunctional ECM and a reduced response to EGF and other growth factors 
involved in promoting keratinocyte migration (Stojadinovic et al. 2005; Agren & 
Werthén 2007; Brem et al. 2007; Usui et al. 2008; Schultz & Wysocki 2009; Dreifke 
et al. 2015). It is thought that an impaired response to EGF is a result of over-activation 
of β-catenin, preventing keratinocytes from responding to the growth factor signals 
promoting migration. One theory regarding this reduced response to EGF signalling is 
that the EGF receptor typically present on the keratinocyte membrane is found in the 
cytoplasm of keratinocytes in chronic wounds, preventing the induction of migratory 
signals (Nanney et al. 1984; Stojadinovic et al. 2005; Brem et al. 2007; Barrientos et 
al. 2008). EGF is also thought to be proteolytically degraded due to the high presence 
of metalloproteinases in the chronic wound exudate (Robson 1997; Yager et al. 1997; 
Trengrove et al. 1999; Barrientos et al. 2008). Additionally, β-catenin over-activation 
also has a downstream response, over-activating oncogene c-myc. This results in 
excessive cycling of epidermal stem cells, reducing their ability to respond effectively 
to wounding (Arnold & Watt 2001; Stojadinovic et al. 2005; Agren & Werthén 2007). 
Some studies have also indicated a senescent phenotype of the keratinocytes present 
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at chronic wounds, which could account for the reduced re-epithelialisation response 
(Telgenhoff & Shroot 2005; Frykberg & Banks 2015). High levels of IL-8 has been 
detected in chronic wounds, expression of this inflammatory cytokine has been shown 
to further stimulate the chemotaxis of immune cells, including neutrophils contributing 
to the excessive inflammation. However, it has also been shown to induce a 
proliferative and migratory effect on keratinocytes (Rennekampff et al. 2000; Scapini 
et al. 2000; Barrientos et al. 2008; Wiegand et al. 2010; Jiang et al. 2012; Singh et al. 
2016).  
 
Levels of bFGF have been shown to be reduced in chronic wounds. This growth factor 
is involved in re-epithelialisation, through increasing keratinocyte motility by Rac 
activation. Fibroblast migration is also reduced with lowered expression of bFGF, 
along with a reduced synthesis of ECM components and MMPs (Sogabe et al. 2006; 
Barrientos et al. 2008; Xie et al. 2008; Akita et al. 2012). TGF-β1 and its receptor are 
also reduced in chronic wounds, again potentially degraded by the proteolytic 
environment. Potentially contributing to the reduced TGF-β1 expression, levels of 
PDGF are also lowered in chronic wounds. This growth factor indirectly stimulates 
the release of TGF-β1, in addition to stimulating angiogenesis, re-epithelialisation, 
fibroblast proliferation and subsequent ECM synthesis (Cooper et al. 1994; Robson 
1997; Yager et al. 1997; Barrientos et al. 2008; Demidova-Rice et al. 2012b). Chronic 
wound fibroblasts have often been described as being senescent, or exhibiting 
decreased proliferation, potentially due to the high levels of oxidative stress in the 
wound environment (Mendez et al. 1998; Cook et al. 2000; Telgenhoff & Shroot 2005; 
Menke et al. 2007; Wall et al. 2008; Frykberg & Banks 2015). It is thought that the 
chronic wound fibroblasts still synthesise similar quantities of ECM, although it may 
be defective. This may be partly a result of variations in MMP and TIMP expression 
levels. Decreased MMP-1 and MMP-2 expression occurs with increased TIMP-1 and 
TIMP-2 expression (Cook et al. 2000). Other studies have shown that the wound fluid 
contains higher level of MMPs, due to the excessive inflammation. These MMPs are 
thought to degrade a number of vital growth factors required to successful ECM 
deposition (Yager et al. 1996; Yager et al. 1997; Trengrove et al. 1999; Yager & 
Nwomeh 1999; Telgenhoff & Shroot 2005; Menke et al. 2007; Frykberg & Banks 
2015). The inflammatory response in chronic wounds has been reported to last longer 
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than in acute wounds. This is reported to be a result of a detrimental feedback system, 
where neutrophils are continually recruited to the wound site and release factors, which 
stimulates further chemotactic signals to neutrophils (Fivenson et al. 1997; Moseley et 
al. 2004; Eming et al. 2007; Menke et al. 2007; Wiegand et al. 2010; Wilgus et al. 
2013). The wound environment appears to be causing this feedback system, by 
hypoxia or bacterial presence (Stephens et al. 2003; Jones et al. 2004; Menke et al. 
2007; Schultz & Wysocki 2009). Diabetic wounds are thought to possess high levels 
of MMPs, due to the hyperglycaemic increased expression of TNF-α and IL-1β. This 
contributes to the impaired ECM synthesis (Lobmann et al. 2002; Muller et al. 2008; 
Lev-Tov et al. 2013; Xu & Graves 2013; Dreifke et al. 2015). The dysfunctional ECM 
is thought to impede keratinocyte migration, as a result of a lack of basement 
membrane components required for lamellipodial cell movement across the matrix 
(Agren & Werthén 2007; Usui et al. 2008; Krishnaswamy & Korrapati 2014; Thamm 
et al. 2015). All of these factors contribute to the phenotype observed in chronic non-
healing wounds, impacting across the wound healing phases, including excessive 
inflammation, impaired re-epithelialisation, dysfunctional ECM synthesis (Menke et 
al. 2007; Demidova-Rice et al. 2012a; Trøstrup et al. 2013; Dreifke et al. 2015).  
 
1.5.2.1     Existing Therapies for Chronic Wounds  
Despite the huge clinical burden and a need for therapies, there are no wound healing 
strategies that are adequate enough to resolve these wounds. Consequently, this burden 
is only going to increase with an increased prevalence of diabetes and an ageing 
population (Posnett & Franks 2008; Werdin et al. 2009; Sen et al. 2010; Trøstrup et al. 
2013; Dreifke et al. 2015). There are a number of treatment options available, but these 
typically involve debriding the wound of any contaminants and applying topical 
dressings (Bradley 1999; O’Donnell & Lau 2006; Agren & Werthén 2007; Menke et 
al. 2007; Dreifke et al. 2015).  
 
There a number of topical ECM therapies, which categorised into 4 main families, 
collagen-based, non-collagen, biosynthetic composite scaffolds and processed native 
skin; these are all acellular therapies (O’Donnell & Lau 2006; Agren & Werthén 2007; 
Demidova-Rice et al. 2012b; Dreifke et al. 2015; Frykberg & Banks 2015). There are 
a variety of collagen-based ECM topical products, including: Oasis®, Promogran® and 
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Matrix Collagen™. These are decellularised human or animal tissue, that can provide 
a stable scaffold for the influx of cells required to establish a more permanent ECM 
and aid wound repair. Some improvements in wound healing rates have been observed 
with these dressings, although with some collagen-based topical dressings, this is not 
a significant improvement compared to good wound care (Veves et al. 2002; Niezgoda 
et al. 2005; O’Donnell & Lau 2006; Agren & Werthén 2007; Holmes et al. 2013; Lev-
Tov et al. 2013; Dreifke et al. 2015; Frykberg & Banks 2015). One of the main non-
collagen based ECM therapies is hyaluronan, due to its important role in promoting 
wound healing process. The most notable example of this dressing is Hyalofill®, an 
esterified hyaluronic acid. This treatment appeared to be more beneficial to wound 
closure and repair than standard wound care practice (Edmonds et al. 2000; Lobmann 
et al. 2003; Vazquez et al. 2003; Agren & Werthén 2007; Voigt & Driver 2012; 
Longinotti 2014; Boateng & Catanzano 2015; Dreifke et al. 2015). The two main 
biosynthetic composite scaffolds are Biobrane and Integra, made from porcine and 
bovine collagen with a silicone layer, respectively. Both were typically used in the 
treatment of burns, but Integra has also more recently been used to treat chronic 
wounds (Ruszczak 2003; Agren & Werthén 2007; Mcheik et al. 2014; Dreifke et al. 
2015; Frykberg & Banks 2015; Rowan et al. 2015). Biobrane has been shown to result 
in increased infection rates, through an increase in bacterial presence at the site. This 
is not optimal for chronic wounds where increased risk of infection already occurs 
(Agren & Werthén 2007; Schultz & Wysocki 2009; Dreifke et al. 2015; Tan et al. 
2015; Schulz et al. 2016). Processed native skin dressings can be human or animal-
derived, this includes human cadaver graft, Alloderm® and porcine graft, E-Z Derm™. 
Alloderm® is considered for use on full-thickness diabetic ulcers, whereas E-Z Derm™ 
is considered for use on pressure ulcers; both are acellular biologic dressings 
(Wainwright 1995; Callcut et al. 2006; Agren & Werthén 2007; Broussard & Powers 
2013; Rowan et al. 2015). Despite the wide range of dressing options, there are few 
studies on their effectiveness, whilst some have considered that repeated dressing 
changes may be detrimental to the wound healing response, due to the disruption of 
the wound surface (O’Donnell & Lau 2006; Agren & Werthén 2007; Boateng & 
Catanzano 2015; Dumville et al. 2015; Harding 2015).  
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Another popular wound healing therapy is negative pressure wound therapy (NPWT), 
which uses a suction method on the chronic wound site to remove any contaminants 
and wound exudate (Kasuya & Tokura 2014; Boateng & Catanzano 2015; Dumville 
et al. 2015; Frykberg & Banks 2015; Harding 2015). The suction pressure on the 
wound is also thought to aid wound contraction, drawing the wound edges together. 
Antimicrobials can also be delivered to the site, aiding the clearance of infection from 
the wound (Saxena et al. 2004; Armstrong et al. 2005; Kirby 2007; Vikatmaa et al. 
2008; Frykberg & Banks 2015). This treatment modality can be used in combination 
with another option, such as topical dressings, to further increase the chance of wound 
resolution (Scherer et al. 2008; Isaac et al. 2014; Frykberg & Banks 2015). It is a more 
expensive treatment option, compared to the relatively low cost topical dressings. 
However, studies have indicated positive effects on wound healing following its 
application (Kirby 2007; de Leon et al. 2009; Frykberg & Banks 2015; Harding 2015). 
Conversely, other studies have suggested a bias in these positive outcomes and 
questioned the efficacy of the treatment. However, as it can benefit the wound site, 
through the clearance of infection, it is widely used on chronic wounds (Armstrong et 
al. 2005; Kirby 2007; Vikatmaa et al. 2008; Frykberg & Banks 2015; Harding 2015).  
 
Split-thickness autografts are considered one of the best treatment options for chronic 
wounds, through application of donor or cultured skin grafts over the chronic wound 
site (Sheridan & Tompkins 1999; Loss et al. 2000; Atiyeh & Costagliola 2007; Dreifke 
et al. 2015; Frykberg & Banks 2015). There are a number of limitations with this 
treatment option, including a high risk of scar tissue formation at the wound site and 
limited sites available for harvesting of donor skin (Weber et al. 1995; Hallock 1999; 
Atiyeh & Costagliola 2007; Dreifke et al. 2015). In addition, the use of donor 
epidermal keratinocytes carries the risk of donor-site complications and donor 
keratinocytes from younger adults have an increased response to growth factors, in 
particular KGF (Harris 1998; Koller et al. 2002; Dreifke et al. 2015). However, 
cultured epithelial autografts requires an additional wound site on the patient for 
extraction of the cell required. This delays treatment while the cultured cells expand 
to form a graft, but also carries no risk of graft rejection. Additionally, there is a high 
cost associated with this treatment option (Loss et al. 2000; Atiyeh & Costagliola 2007; 
Dreifke et al. 2015). 
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As often, vital growth factors are degraded by the high level of proteases in chronic 
wounds, direct topical application of growth factors has been evaluated as a therapy, 
including recombinant EGF and PDGF (Robson 1997; Niezgoda et al. 2005; 
Barrientos et al. 2008; Hardwicke et al. 2010; Ching et al. 2011). A masking technique 
was used with dextrin, to shield the growth factor from degradation, until at the wound 
site, where enzymatic degradation of the biodegradable dextrin polymer. The 
conjugate of dextrin-recombinant human EGF was analysed and determined a 
potential beneficial wound healing response on keratinocytes proliferation and 
migration (Hardwicke et al. 2008, 2010). This indicates a potential use in chronic 
wounds, although replacement of one growth factor only targets one aspect of the 
impaired wound healing observed in chronic wounds (Robson 1997; Menke et al. 
2007; Hardwicke et al. 2010; Ching et al. 2011; Frykberg & Banks 2015).  
 
Another growth factor therapy available is becaplermin gel, marketed as Regranex®, 
which is a recombinant form of isoform PDGF-BB. This is applied as a topical gel to 
the wound site and is the only pharmaceutical currently approved by the Food and 
Drug Administration (FDA) for chronic wounds (Edmonds et al. 2000; Goldman 2004; 
Barrientos et al. 2008; Fang & Galiano 2008; Dreifke et al. 2015; Frykberg & Banks 
2015). As mentioned previously, PDGF has a number of beneficial functions during 
wound healing, including chemoattraction of immune cells, fibroblast proliferation 
and involvement in stimulation of ECM synthesis. It has also been shown to have 
reduced presence in chronic wounds, potentially due to its degradation by the high 
expression of wound proteases (Pierce et al. 1989a; Greenhalgh et al. 1990; Robson 
1997; Uchi et al. 2000; Barrientos et al. 2008; Fang & Galiano 2008). Application of 
this topical gel has shown an increased wound closure ability, although there have been 
conflicting results, resulting in a wide percentage of successful wound closure. This is 
partially dependent on the type of chronic wound (Rees et al. 1999; Smiell et al. 1999; 
Goldman 2004; Niezgoda et al. 2005; Fang & Galiano 2008). However, in 
approximately a third of cases, there was evidence of recurrence of diabetic ulcers. In 
addition, concerns have been raised about the risk of tumour formation after use of 3 
or more tubes of Regranex®. This warning, issued by the FDA, was aimed at patients 
with a previous history of malignancies, but questions whether the benefit is sufficient 
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to outweigh these risks (Lacci & Dardik 2010; Papanas & Maltezos 2010; Ziyadeh et 
al. 2011; Dreifke et al. 2015).  
 
Despite all the treatment options described, chronic wounds are still highly prevalent, 
causing reduced quality of life for a number of patients and a major clinical burden on 
healthcare systems. The therapies available are not adequate enough to tackle rising 
burden, requiring alternative, cost-effective treatment options to be developed, with 
the aim of resolving chronic wounds in a shorter time frame, successful re-
epithelialisation of the wound and remodelling of the underlying dermal matrix 
(Posnett & Franks 2008; Werdin et al. 2009; Sen et al. 2010; Trøstrup et al. 2013; 
Boateng & Catanzano 2015; Dreifke et al. 2015; Frykberg & Banks 2015).    
 
1.6     EBC-46 and EBC-211 
 
An Australian drug discovery company, EcoBiotics Ltd. (Queensland, Australia) have 
developed the technology, EcoLogic. Through an understanding of how the rainforest 
ecosystem is maintained, specific knowledge was collected on a number of plant 
species allowing those with the potential to produce chemicals with highly desirable 
properties to be selected for further development, with the aim of novel drug 
development (EcoBiotics Ltd). A subsidiary company of EcoBiotics Ltd; QBiotics 
Ltd. was demerged from EcoBiotics Ltd. due to the different expertise required in each 
company. Through EcoLogic, the naturally derived epoxy-tigliane, EBC-46 (12-
tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliane-3-
one), was discovered in the Queensland tropical rainforest and found to possess potent 
bioactivity. 
 
EBC-46 was found in the seeds of the Fountain’s Blushwood Tree (Fontainea 
picrosperma), indigenous to the Queensland Tropical Rainforest, and developed by 
QBiotics Ltd. (Queensland, Australia). EBC-46 was shown to act as a chemical 
deterrent to predation, in particular to the native marsupials in the surrounding area 
due to the high presence of an inflammatory chemical (QBiotics Ltd.). EBC-211 (12-
tigloyl-13-(2-methylbutanoyl)-5,6-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliane-3-
one) is a ‘lesser activity’ analogue of EBC-46, with approximately a 100-fold reduced 
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activity (QBiotics Ltd.). The chemical structure of EBC-46 (Figure 1.7A), was 
determined through a series of experiments to allow for large scale production to occur 
and it has been shown to be relatively easy to harvest. The chemical structure of EBC-
211 is also shown (Figure 1.7B). 
 
EBC-46 had been shown to possess a potent anti-cancer response, through rapid 
ablation of solid tumours and sarcoids, both cutaneous and non-cutaneous. The 
compound was administered through intra-lesional injection. This anti-tumour 
response has been successfully shown on melanomas, sarcomas, carcinomas, mast cell 
tumours and sarcoids during veterinary studies on tumours that were previously 
deemed inoperable. These veterinary trials have been performed on domesticated 
animals as a palliative treatment. Examples of these responses are shown in Figures 
1.8 and 1.9 (QBiotics Ltd.). The veterinary case studies showed a significant reduction 
in volume of the solid tumours and sarcoids. In light of these obvious beneficial anti-
tumour effects, QBiotics Ltd. has developed and registered EBC-46 as a veterinary 
pharmaceutical for the treatment of solid tumours in these animals.  In addition, as 
QBiotics Ltd. has compelling proof-of-concept data of the drug's efficacy and safety 
both in cancer models in mice and in other domesticated animals, EBC-46 is currently 
undergoing development during human Phase I/II clinical trials.  
 
These novel epoxy-tiglianes have been shown to act through the activation of classical 
PKC isoforms (PKC-βI, -βII, -α, and -γ), although predominantly through PKC-β 
(Boyle et al. 2014). Through a number of studies, it has been hypothesised that EBC-
46 remains at the tumour site, due to low detection in the plasma. It is also thought to 
play a role in the disruption of blood supply to the tumour, through increased 
permeability of the cells at the tumour site causing damage to the vasculature at the 
specific tumour site (Boyle et al. 2014). This disruption results in sloughing of the 
entire tumour, with minimal impact on healthy surrounding tissue (Boyle et al. 2014; 
QBiotics Ltd.). Tumour ablation appears to be long-acting, due to the lack of tumour 
recurrence within 12 month post-treatment in the majority of cases (Boyle et al. 2014). 
It is thought that neutrophils also play a small part in the tumour reduction. However, 
the full mechanism of action has not yet been determined and further is work is being 
undertaken to elucidate this pathway (Boyle et al. 2014). An unexpected exceptional  
83 
 
Figure 1.7: Chemical structure of (A) EBC-46 and (B) EBC-211, found in seeds 
of Blushwood Tree (Fontainea picrosperma) and several species of the Fontainea, 
sourced in Queensland, Australia.   
 
A 
 
 
B 
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Figure 1.8: Intra-lesional injection of a large equine sarcoid with EBC-46. Left-
hand image: prior to treatment. Right-hand image: 22h post-treatment, with 
ablation of tumour mass evident (Reddell et al. 2014; QBiotics Ltd.).  
 
 
 
 
Figure 1.9: Intra-lesional injection of equine sarcoid with EBC-46. Left-hand 
image: Day 6 following injection of 0.75mg EBC-46. Right-hand image: Day 10 
following final injection of 1.5mg EBC-46, with almost complete sarcoid loss and 
wound resolution (Reddell et al. 2014; QBiotics Ltd.).  
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wound healing response was observed following tumour ablation in these cancer 
studies, manifested as rapid re-epithelialisation, wound closure, reduced scarring and 
the reformation of skin appendages (Reddell et al. 2014). 
 
Following the beneficial responses observed during the in vivo anti-tumour studies and 
in vitro studies, wound healing veterinary trials were initiated. Many of the cases 
included in these trials were on wounds that were previously unresponsive to months 
of treatment under current wound care strategies. These veterinary trials has 
demonstrated similarly significant enhancements in wound healing outcomes (Reddell 
et al. 2014). The case study presented in Figure 1.10 shows a deep necrosing facial 
wound that was previously unresponsive to 3 months treatment using current routine 
wound care strategies. Following application of EBC-46, rapid re-epithelialisation 
occurred, resolving the wound and producing an exceptional cosmetic effect. 
Throughout these preliminary veterinary trials and safety studies, there has been no 
evidence of any significant adverse effects following treatment with EBC-46 
(QBiotics Ltd.). 
 
TGF-β1-mediated dermal fibroblast-myofibroblast differentiation is essential to 
wound closure, contraction and scarring, with persistence of myofibroblasts observed 
in fibrosis. Therefore, fibroblasts and myofibroblasts are a viable pharmaceutical 
target to explain the minimal scarring observed with epoxy-tigliane treatment. 
Additionally, due to the huge clinical burden associated with chronic wounds and burn 
injuries, where wounds fail to re-epithelialise, keratinocytes would be a 
pharmaceutical target of great interest as a result of their role in re-epithelialisation.  
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Figure 1.10: Effect of topical EBC-46 gel applications on a non-healing deep 
necrosing facial wound at 28 days. A single dose was injected into multiple sites 
around wound area (0.5mg/ml EBC-46). (A) Prior to treatment; (B) 3 days after 
commencement of treatment; (C) 28 days after topical treatment protocol, prior 
to injection into wound site; (D) 104 days following commencement of treatment, 
and 76 days following injectable treatment (QBiotics Ltd.).  
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1.7     Aims of the Study 
Despite the significant beneficial effects on wound healing previously observed, little 
is known about how the novel epoxy-tiglianes exert these responses (Reddell et al. 
2014; QBiotics Ltd.). The aim of this PhD was to determine how this exceptional 
wound healing response is produced, through analysing the effects of EBC-46 and the 
‘lesser active’ EBC-211 on dermal fibroblasts, myofibroblasts and keratinocytes in 
vitro; the major cell types involved in the acute skin wound healing process. In 
addition, the study aims to identify and elucidate the mechanisms of action responsible 
for these exceptional in vivo wound healing responses. 
 
The specific aims of this PhD are: 
 Determine whether EBC-46 and the ‘lesser active’ EBC-211 modulate 
fibroblast and keratinocyte viability, proliferation, cell cycle progression, 
migration and cellular morphology. 
 Determine whether EBC-46 and the ‘lesser active’ EBC-211 modulate TGF-
β1-driven, fibroblast-myofibroblast differentiation. 
 Determine the effect of EBC-46 and the ‘lesser active’ EBC-211 on gene 
expression in keratinocytes.  
 Validate any key differentially expressed genes detected during global gene 
analysis, following treatment with EBC-46 and the ‘lesser active’ EBC-211.  
 
The hypothesis of this project is that these novel epoxy-tiglianes, EBC-46 and EBC-
211, may induce a more regenerative healing response, as opposed to the typical 
reparative healing process, which results in scar formation. By undertaking these 
studies, it is envisaged that a more comprehensive understanding of epoxy-tigliane 
responses and mechanisms of action will be gained. This could provide justification 
for the development of these pharmaceuticals as wound treatments for impaired and/or 
excessive scarring situations in skin.  
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Chapter 2 - Materials and Methods 
 
 
2.1     Preparation of EBC-46 and EBC-211 
 
EBC-46 and the ‘lesser activity’ form, EBC-211, were both supplied by QBiotics 
Ltd. (Queensland, Australia) and solubilised in dimethyl sulfoxide (DMSO, >99.9%, 
Sigma-Aldrich Company Ltd., Dorset, U.K). EBC-46 and EBC-211 were solubilised 
in DMSO at concentrations of 100mg/ml, and 10mg/ml respectively. Aliquots of 
20µl and 25µl EBC-46 and EBC-211 were prepared respectively, so that only the 
required volumes were thawed when required. The solubilised compounds were 
stored at -20°C, where stable for several months.  
 
Prior to use, EBC-46 and EBC-211 were warmed to room temperature. As numerous 
concentrations were required for analysis, stock solutions of both were diluted as 
appropriate to produce the required concentrations (0.001µg/ml, 0.01µg/ml, 
0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml). Each concentration was diluted in 
Fibroblast-Serum Containing Media (F-SCM; Section 2.2.1) or Keratinocyte-Serum 
Containing Media (K-SCM; Section 2.2.2). Fresh EBC-46 and EBC-211 culture 
medium solutions were prepared on a weekly basis, as these were stable at 4°C for a 
period of 1 week. Untreated controls were also prepared containing 1% DMSO, to 
account for the DMSO in compound containing media, due to EBC-46 and EBC-211 
solubilisation in DMSO.  
 
2.2     General Cell Culture Methods 
 
To ensure sterility of the working environment, safety cabinets and equipment were 
sprayed with 70% ethanol prior to carrying out any cell culture. In addition, the 
incubators, safety cabinets and water baths were cleaned on a weekly basis. All 
consumables, glassware, some plastics, phosphate buffered saline (PBS) and double-
distilled water, were sterilised through autoclaving (123°C, 15lb/m2, 15 minutes); 
and any equipment required remained in the tissue culture laboratory.  
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2.2.1     Dermal Fibroblast Culture 
Normal dermal fibroblast (NF) cultures were obtained from previously collected 
biopsies carried out on healthy, adult patients (n=4), undergoing routine oral surgery 
at the School of Dentistry, Cardiff University, Cardiff, UK Biopsies (6mm) were 
previously obtained from uninjured skin with informed consent from patients and 
Local Research Ethical Committee approval (09/WSE03/18) was obtained prior to 
the sample collection by Professor Phil Stephens, as previously described (Enoch et 
al. 2009, 2010). NF cultures were used in all experiments from these biopsies 
between passages 7-17.  
 
NF were seeded at a cell density of 1.5x105/75cm2 tissue culture flask (Sarstedt, 
Leicester, UK), cultured in F-SCM (10ml), containing Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with 1% antibiotics (100U/ml penicillin G sodium, 
100µg/ml streptomycin sulphate and 0.25µg/ml amphotericin B), 1% L-glutamine 
(2mM) and 10% foetal calf serum (all purchased from Thermo Fisher Scientific, 
Leicestershire, UK). NF were maintained in 37°C, in 5% CO2/95% air, with F-SCM 
changed every 48-72h. When NF reached 80-90% confluence, cells were sub-
cultured, re-suspended in F-SCM and counted to determine cell density. 
 
2.2.2     Epidermal Keratinocyte Culture 
Human adult, spontaneously immortalized, epidermal keratinocytes (HaCaT cells) 
were provided by Dr X.Q. Wei (School of Dentistry, Cardiff University, Cardiff, 
UK); and seeded at a cell density of 1.5x105/75cm2 tissue culture flask, cultured in 
K-SCM (10ml), containing Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with 1% antibiotics (100U/ml penicillin G sodium, 100µg/ml 
streptomycin sulphate and 0.25µg/ml amphotericin B), 1% L-glutamine (2mM) and 
10% foetal calf serum (all purchased from Thermo Fisher Scientific). HaCaTs were 
maintained in 37°C, in 5% CO2/95% air, with K-SCM changed every 24-48h. When 
HaCaTs reached 70-80% confluence, cells were sub-cultured and re-suspended in K-
SCM and counted to determine cell density.  
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2.2.3     Cell Subculture and Counting 
When NF and HaCaTs reach desired confluence, cells were passaged to maintain 
appropriate cell density levels. NF and HaCaTs were washed in PBS, incubated with 
trypsin (3ml/75cm2 tissue culture flask, Thermo Fisher Scientific) for approximately 
5min at 37°C, in 5% CO2/95% air. Trypsin was neutralised by the addition of F-SCM 
or K-SCM (7ml/75cm2 tissue culture flask) for both NF and HaCaTs. The cell 
suspensions containing trypsin and culture media were centrifuged at 1500xg for 
5min and the resulting supernatants removed. The remaining pellets consisting of NF 
or HaCaTs were re-suspended in fresh F-SCM or K-SCM (10ml), respectively. Cell 
densities were then determined through counting viable cells. Cell suspensions 
(10µl) were taken and mixed well with Trypan Blue (10µl, Sigma-Aldrich Company 
Ltd.); 10µl of this mixture was transferred to the Neubauer Improved 
Haemocytometer (Thermo Fisher Scientific). As viable cells with an intact cell 
membrane do not allow the trypan blue stain to pass through, viable cell counts were 
determined through counting the non-stained cells. This was performed using a light 
microscope at x100 magnification (CK2 Inverted Microscope, Olympus UK Ltd., 
Middlesex, UK). Following cell counting, NF and HaCaTs were sub-cultured in their 
respective media (10ml/75cm2), as described above.   
 
2.2.4     Cryopreservation and Cell Retrieval 
To maintain stores of cells with low passages, excess cells produced through sub-
culturing were cryopreserved. The cell pellets produced through sub-culturing 
(Section 2.2.3), were re-suspended in a freezing solution, consisting of 10% DMSO 
and 90% foetal calf serum. The cell/freezing solution mixtures were placed in 
cryovials (Greiner Bio-One Ltd., Gloucestershire, UK) and frozen gradually over a 
24h period to -80°C, through the use of an isopropanol freezing container (Sigma-
Aldrich Company Ltd.); which cools cells at 1°C/minute. After the slow freezing 
process in the -80°C freezer, cryovials were transferred to liquid nitrogen for long 
term storage at -196°C. 
 
For cell retrieval, NF and HaCaTs were removed from their storage in liquid nitrogen 
and the cryovials rapidly thawed at 37°C. The cells were washed in either F-SCM or 
K-SCM respectively, through the addition of 9ml of culture medium to 1ml of 
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cells/cryovial and centrifugation at 1500xg for 5min. The cell pellets obtained were 
re-suspended in fresh culture medium (10ml, F-SCM or K-SCM) through agitation 
of the pellet, before seeding the cells in fresh 75cm2 tissue flasks. 
 
2.2.5     Screening for Mycoplasma Contamination 
Routine checks were performed on cells to determine whether mycoplasma 
contamination was present. This process was performed by Dr Rachael Jordan and 
Dr Maria Stack (School of Dentistry, Cardiff University, UK). Samples of culture 
media were obtained when cells reached 90-100% confluence. Samples were stored 
at -20°C until required for assessment, then thawed on ice before incubated at 95°C 
for 5min. Cellular debris was removed by centrifugation and polymerase chain 
reaction (PCR) Master Mix was established containing; nuclease-free water, GoTaq 
Green buffer, magnesium chloride, primer/nucleotide mix, internal control, GoTaq 
polymerase (all from Promega Ltd., Hampshire, UK). A negative control of 
nuclease-free water only and a positive control DNA, were used to determine 
whether mycoplasma contamination was present. To achieve this, a PCR reaction 
was prepared as follows: 2min at 94°C, followed by 39 cycles of: 30s at 94°C, 30s at 
55°C, 30s at 72°C. The samples were maintained at 4°C and run on 2% agarose gels 
at 100V for 20min using a Mini-Horizontal Electrophoresis Unit (Jencons-PLS, 
Bedfordshire, UK). A positive mycoplasma contamination was shown by the 
presence of a strong band present at 267bp. An internal control always produces a 
band at 191bp to show the reaction had worked. However, if there was a strong 
mycoplasma contamination, this internal control band at 191bp was not visible. Any 
mycoplasma positive cells were either discarded or treated, as detailed below. 
 
If samples were found to be mycoplasma positive, they were subsequently treated 
with BM Cyclin (Roche, Sussex, UK) for 3 weeks, consisting of 3 cycles of 
treatment. Contaminated culture medium was removed, with fresh medium 
containing BM Cyclin 1 (4µl of stock solution/ml, final concentration 10µg/ml) 
added. Cells were cultured as previously described for three days; and passaged 
when necessary. Culture medium containing BM Cyclin 1 was subsequently 
removed and replaced with fresh medium containing BM Cyclin 2 (4µl of stock 
solution/ml, final concentration 5µg/ml). Cells were cultured as previously described 
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for 4 days; and passaged when necessary. This 7 day treatment cycle was performed 
3 times, before a fresh sample of culture medium was reassessed to confirm 
eradication of mycoplasma contamination.  
 
2.3     General in Vitro Wound Healing Methods 
 
2.3.1     Cell Viability and Proliferation 
Cellular viability and proliferation was determined through use of an MTT [3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] Dye-Reduction assay, 
assessing cells at 24h, 72h, 120h and 168h. Confluent NF and HaCaTs were 
trypsinized, counted and seeded in F-SCM and K-SCM respectively, into 96-well 
microtitre plates (Sarstedt Ltd., Leicestershire, UK), at cell densities of 2.5x103 
cells/well and 5x103 cells/well, respectively for 24h. Culture media was then 
removed and replaced with serum-free F-SCM or K-SCM (DMEM, 1% antibiotics 
and 1% L-glutamine), respectively for a further 24h; in order to growth arrest the 
cells. Serum-free media was subsequently removed and replaced with the respective 
1% serum containing culture medium (F-SCM or K-SCM; DMEM, 1% antibiotics, 
1% L-glutamine and 1% foetal calf serum), as described in Section 2.1, with 
different concentrations of EBC-46 and EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 
1µg/ml, 10µg/ml or 100µg/ml). Untreated controls were also established, 0µg/ml, 
containing 1% DMSO as described in Section 2.1. A blank control containing no 
cells, but the respective culture medium only, was included to show no absorbance in 
cell-free wells. These concentrations were used for both EBC-46 and EBC-211, with 
6 wells/concentration (Figure 2.1), for each time point. Cultures were maintained at 
37°C, in a 5% CO2/95% air environment, with culture medium changed every 48h.  
 
At 24h, 72h, 120h and 168h, sterile MTT (25µl of a 5mg/ml MTT solution in PBS, 
Sigma-Aldrich Company Ltd.) was added to culture medium in each well and 
incubated at 37°C, in a 5% CO2/95% air environment, for 4h. The culture 
medium/MTT mixture was removed after 4h and 100µl MTT Extraction Buffer was 
added to each well. MTT extraction buffer consists of sodium dodecyl sulphate (20g; 
SDS, Sigma-Aldrich Company Ltd.), N,N-dimethylformamide (50ml, Sigma-Aldrich 
Company Ltd.) and double-distilled water (50ml). Following solubilisation, the pH  
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Figure 2.1: Representation of the culture plate set up for the MTT assay. 
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was adjusted to 4.7 by the addition of 3ml ‘acid mix’, which consists of glacial acid 
(80ml; Thermo Fisher Scientific), 1M hydrochloric acid (HCl, 2.5ml, Thermo Fisher 
Scientific) and double-distilled water (17.5ml). 
 
Following the addition of Extraction Buffer, the 96-well plates at each time-point 
were wrapped in cling film and maintained at 37°C, in a 5% CO2/95% air 
environment, for a further 4h. At 4h, the absorbance values were read at 540nm using 
Bio-Tek Instruments Microplate Autoreader EL311 (Thermo Fisher Scientific). 
These experiments were performed on 3 separate occasions, the data was expressed 
as percentage data compared to the untreated control, with averages and standard 
error values for each concentration assessed. Statistical analysis was performed using 
one-way ANOVA with post-test Tukey analysis; and statistical significance 
considered at p<0.05.    
 
2.3.2     Cell Cycle Analysis 
Flow cytometry was performed to analyse the effects of EBC-46 and EBC-211 
(0.001-10µg/ml) on dermal fibroblast and HaCaT cell cycle progression, compared 
to untreated controls (0µg/ml). The percentages of cells present in each phase of the 
cell cycle following EBC-46 or EBC-211 treatment were analysed at a number of 
time-points; and compared to the respective untreated controls.  
 
2.3.2.1     Dermal Fibroblast Culture 
Following trypsinisation, dermal fibroblasts were seeded into 6-well, microtitre 
plates (Sarstedt Ltd.) at a cell density of 7.5x104cells/well in F-SCM (Section 2.2.1). 
Fibroblasts were maintained at 37°C in a 5% CO2/95% air atmosphere for 24h and 
subsequently cell cycle synchronized through culturing in serum-free F-SCM for 
24h. Serum-free DMEM was removed and replaced with F-SCM containing 10% 
foetal calf serum, in addition to EBC-46 or EBC-211 (0µg/ml, 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml 1µg/ml or 10µg/ml; 2ml/well). An untreated control (0µg/ml) 
was also included, containing 1% DMSO.  Fibroblasts were maintained at 37°C in 
5% CO2/95% air, for 22h, 29h and 36h; with T0 (0h) analysed at time of treatment. 
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2.3.2.2     Epidermal Keratinocyte Culture 
Following trypsinisation, HaCaTs were seeded into 6-well, microtitre plates (Sarstedt 
Ltd.) at a cell density of 7.5x104cells/well in K-SCM (Section 2.2.2). HaCaTs were 
maintained at 37°C in a 5% CO2/95% air atmosphere for 24h and subsequently 
synchronized through culturing in serum-free K-SCM for 24h. Serum-free DMEM 
was removed and replaced with K-SCM containing 1% foetal calf serum, in addition 
to EBC-46 or EBC-211 (0µg/ml, 0.001µg/ml, 0.01µg/ml, 0.1µg/ml 1µg/ml or 
10µg/ml; 2ml/well). An untreated control (0µg/ml) was also included, containing 1% 
DMSO. HaCaTs were maintained at 37°C in 5% CO2/95% air, for 9h, 17h, 26h, 32h, 
40h and 48h; with T0 (0h) analysed at time of treatment. 
 
2.3.2.3     Cell Fixation 
At each time-point, treated media was removed, wells washed with PBS (x1) before 
the addition of trypsin (500µl/well). After cell detachment, trypsin was neutralised 
with F-SCM or K-SCM (1ml). Cells were centrifuged at 1500xg for 5min, the 
supernatants were carefully removed and the pellets re-suspended in PBS (1ml). 
Samples were centrifuged at 1500xg for 5min and the supernatant discarded. Pellets 
were re-suspended in 4% paraformaldehyde solution in PBS (1ml; Santa Cruz 
Biotechnology Inc., Middlesex, UK); and incubated on ice for 30min before 
centrifugation at 1500xg for 5min and the supernatants discarded. Pellets were re-
suspended in PBS (volume calculated to give ≤4x105 cells/ml). Aliquots (250µl) of 
each cell/PBS mix were transferred to Falcon Round bottom, 5ml polystyrene tubes 
(Scientific Laboratory Supplies Ltd., Nottinghamshire, UK), with Draq5 (1µl; 
BioStatus Ltd., Leicestershire, UK) added and mixed. Cells were incubated in Draq5 
at 37°C for 5min, before being run through the Flow Cytometer System.  
 
2.3.2.4     Flow Cytometry  
Cells were run through the Flow Cytometer System (FACScalibur, Becton 
Dickinson, Oxfordshire, UK), at an approximate speed of 150 events/second. These 
datasets were analysed using a number of software packages. Cell cycle analysis was 
performed using FlowJo Software LLC, Version 7.6 (Ashland, Oregon, U.S.A.), with 
a fixed mean for G1 and G2 peaks to determine the percentage of cells in each phase 
of the cell cycle. This experiment was performed on 3 separate occasions, with the 
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data obtained expressed as percentage data, detailing the percentage of cells in each 
phase of the cell cycle (G1, S and G2), compared to the untreated control. Averages 
and standard error values for each concentration were assessed at each time-point 
studied. Statistical analysis was performed using one-way ANOVA with Dunnett 
Multiple Comparisons Test analysis, using the untreated control as the control for 
comparison. Statistical significance considered at p<0.05.    
 
2.3.3     Cell Morphology 
Confluent NF and HaCaTs were trypsinized, counted, and seeded into 24-well BD 
Falcon microtitre plates (BD Biosciences, Oxfordshire, UK) at a cell density of 
1.56x104 cells/well and 3.12x104 cells/well, respectively. NF and HaCaTs were 
seeded in F-SCM and K-SCM respectively (Sections 2.2.1 and 2.2.2) for 24h. 
Culture media was then removed and replaced with serum-free culture media, as 
Section 2.3.1, for 24h. Serum-free medium was subsequently removed and replaced 
with each respective 1% serum culture medium, containing EBC-46 or EBC-211 
(0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml or 100µg/ml) as detailed in 
Section 2.1, with 3 wells/concentration. An untreated control (0µg/ml) was also 
included, which further contained 1% DMSO. Cultures were maintained at 37°C, in 
a 5% CO2/95% air environment, with culture medium changed every 48h. This 
experiment was performed on 3 separate occasions. Cellular morphology images 
were taken at x100 magnification for each concentration of EBC-46 and EBC-211, 
along with the untreated control, at 24h, 72h, 120h and 168h to correlate with the 
MTT data. Images were obtained using Nikon Eclipse TS100 Inverted Microscope 
(Nikon UK Ltd., Surrey, UK).  
 
2.3.4     Scratch Wound Assay 
Confluent NF and HaCaTs were trypsinized, counted and seeded into 24-well BD 
Falcon microtitre plates (BD Biosciences), at cell densities of 2.5x104 cells/well and 
7.5x104 cells/well, respectively. NF and HaCaTs were seeded in F-SCM and K-SCM 
respectively (Sections 2.2.1 and 2.2.2) for 48h. Culture media was removed and 
replaced with serum-free F-SCM or K-SCM for 24h. At 24h, a scratch was made 
across each cell layer using a sterile pipette and washed (x2) with PBS to remove cell 
debris. Following this, each respective 1% serum culture medium containing 
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different concentrations of EBC-46 and EBC-211 (0-100µg/ml; as in Section 2.1) 
was added to the respective wells, with 3wells/concentration. An untreated control 
(0µg/ml) was also included, containing 1% DMSO. Cultures were maintained at 
37°C, in a 5% CO2/95% air environment, with the migration of cells into the 
denuded area monitored through use of Time Lapse Microscopy, using the Leica 
TCS SP5 Confocal Microscope (Leica Microsystems (UK) Ltd., Buckinghamshire, 
UK).  Digital images were taken every 20min over the 48h period; and converted to a 
video using LAS AF Lite (Leica Software, Version 4.0.11706, Leica Microsystems 
(UK) Ltd). Each experiment was performed on 3 separate occasions.  
 
Wound repopulation was analysed using ImageJ Software (NIH Software, Version 
1.49). Fibroblast cell movement was tracked using Image J tracking plugin, with 
distance travelled, cell displacement, speed and velocity calculated for 6 cells/video 
over 3 separate experiments, resulting in 18 data points/culture condition. Averages 
and standard error values for each condition were calculated. HaCaT migration was 
also analysed through ImageJ, by calculating the percentage closure of the wound 
site at 24h and 48h time-points, with averages and standard error values calculated 
for each culture condition analysed. Statistical analysis of both fibroblast and HaCaT 
wound repopulation was performed using one-way ANOVA with post-test Tukey 
analysis; and statistical significance considered at p<0.05.    
 
2.3.4.1     Optimisation of Mitomycin C Treatment 
Based on the findings of the effects of EBC-46 and EBC-211 on HaCaT proliferation 
and migration (Chapter 4), the scratch wound repopulation was performed in the 
presence of anti-proliferative agent, Mitomycin C (Santhiago et al. 2012; Wang et al. 
2012; Lü et al. 2013). Migration was analysed to determine the effect of EBC-46 and 
EBC-211 on wound repopulation, independent of proliferation. The optimal 
concentration of Mitomycin C for HaCaT culture conditions was determined through 
use of an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] Dye-
Reduction assay. The aim of this MTT assay was determine the concentration 
required to inhibit the proliferative response, without having a cytotoxic effect on the 
HaCaTs.  
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Confluent HaCaTs were trypsinized, counted and seeded into 96-well microtitre 
plates, at a cell density of 5x103 cells/well. HaCaTs were seeded in K-SCM (Section 
2.2.2) for 24h; then replaced with serum free K-SCM for 24h. Serum free medium 
was removed from cell cultures and replaced with respective 1% serum culture 
medium (K-SCM) containing different concentrations of Mitomycin C: 0.5µg/ml, 
1µg/ml, 2.5µg/ml, 5µg/ml or 10µg/ml, and a negative control containing no 
Mitomycin C. There were 6 wells/concentration (similar to Figure 2.1) at 24h, 72h 
and 120h. Cell cultures were maintained at 37°C, in a 5% CO2/95% air environment, 
with culture medium changed every 48h. At 24h, 72h and 120h, the MTT process 
was carried out as described in Section 2.3.1. Absorbance was read at 540nm using 
Bio-Tek Instruments Microplate Autoreader EL311. This experiment was carried out 
on 3 separate occasions, with averages and standard error values calculated for each 
concentration. 
 
2.3.4.2     Scratch Wound Repopulation in Presence of Mitomycin C 
Confluent HaCaTs were trypsinized, counted and seeded into 24-well BD Falcon 
microtitre plates (BD Biosciences) at a cell density of 5x104 cells/well respectively. 
HaCaTs were seeded in K-SCM (Section 2.2.2) for 48h, then replaced with serum 
free K-SCM for 24h. As described in Section 2.3.4, a scratch was made across the 
cell layer using a sterile pipette, then washed twice with PBS. Following this, each 
respective 1% serum culture medium containing different concentrations of EBC-46 
and EBC-211 (0-100µg/ml; as in Section 2.3.1) was added to the respective wells. 
The calculated optimal concentration of Mitomycin C (1µg/ml) was also added to 
each epoxy-tigliane containing media. Two epoxy-tigliane untreated controls were 
also included, one in the presence and one in the absence of Mitomycin C (1µg/ml). 
Cell cultures were maintained at 37°C, in a 5% CO2/95% air environment. Migration 
of cells into denuded area was monitored through use of Time Lapse Microscopy 
using the Leica TCS SP5 Confocal Microscope, as described previously (Section 
2.3.3). Digital images were taken every 20min for 48h, with each experiment 
performed on 3 separate occasions. Migration was analysed by calculating 
percentage wound closure at 24h and 48h using ImageJ. Averages and standard error 
values for each condition were calculated. Statistical analysis of HaCaT wound 
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repopulation was performed using one-way ANOVA with post-test Tukey analysis; 
and statistical significance considered at p<0.05.    
 
2.3.5     Dermal Fibroblast-Myofibroblast Differentiation 
 
2.3.5.1     Immunocytochemistry 
Confluent NFs were trypsinized, counted and seeded into 8-well, Permanox chamber 
slides (VWR International Ltd., Leicestershire, UK). NFs were seeded in F-SCM 
(250l) at a cell density of 2.5x104 cells/ml; and maintained at 37°C, in a 5% 
CO2/95% air environment for duration of the experiment. When cells reached 
approximately 50-60% confluence levels, cells were growth arrested through 
culturing in serum-free, F-SCM (250l) for 48h. Serum-free media was replaced 
with serum-free F-SCM containing EBC-46 or EBC-211 (0µg/ml, 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml or 10µg/ml; 3 wells/concentration) in the presence or 
absence of Transforming Growth Factor β1, (TGF-β1, 10ng/ml; PeproTech Ltd., 
London, UK). Cells were maintained in treated serum-free F-SCM (250l) for 72h.  
 
At 72h, media was removed from cells, the wells washed with PBS (x1) and the cells 
fixed in 4% paraformaldehyde solution in PBS (100µl) for 10min, before being re-
washed in PBS (x1). Cells were permeabilised in 0.1% Triton X-100 (200µl; Sigma-
Aldrich Company Ltd.) for 5min and washed in PBS (x1). Cells were then blocked in 
1% bovine serum albumin (BSA)-PBS for 30min at room temperature and washed in 
0.1% BSA-PBS (x3). Cells were incubated in primary antibody, monoclonal mouse 
anti-actin, α-smooth muscle antibody (1:100 in 0.1% BSA-PBS; Sigma-Aldrich 
Company Ltd.), overnight at 4°C. Cells were washed in 0.1% BSA-PBS (x3), then 
re-washed in 0.1% BSA-PBS for 5min (x3). Cells were subsequently incubated in 
secondary antibody, Alexa Fluor 488 goat anti-mouse IgG antibody (1:1000 in 0.1% 
BSA-PBS; Thermo Fisher Scientific), for 1h at room temperature, under darkness. 
Cells were washed in 0.1% BSA-PBS (x3) and re-washed in 0.1% BSA-PBS for 
5min (x3). Cells were then incubated in Hoechst Solution (1:2000 in 0.1% BSA-
PBS; Sigma-Aldrich Company Ltd.) for 30min at room temperature, under darkness. 
Cells were washed in 0.1% BSA-PBS (x3) and re-washed in 0.1% BSA-PBS for 
5min (x3). The chambers were removed and wells sealed with Fluor Save Reagent 
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(Merck Millipore, Darmstadt, Germany) and Gerhard Menzel Coverslips (Thermo 
Fisher Scientific). Slides were viewed using a Leica Dialux 20 Fluorescent 
Microscope (Leica Microsystems UK Ltd., Buckinghamshire, UK). Images were 
taken at a magnification of x400, with each experiment performed on 3 separate 
occasions.  
 
2.3.5.2     Quantitative Polymerase Chain Reaction (qPCR) 
 
2.3.5.2.1     Cell Culture 
Confirmation of differentiation from dermal fibroblasts to myofibroblasts was 
performed through analysis of α-Smooth Muscle Actin (α-SMA) expression by 
quantitative Polymerase Chain Reaction (qPCR), at 72h. This was analysed for both 
EBC-46 and EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml; 
3wells/concentration) in the presence or absence of TGF-β1 (10ng/ml). Two 
untreated controls were also included, one in the presence and one in the absence of 
TGF-β1 for each experiment to establish control expression levels for both TGF-β1 
positive (0µg/ml + TGF-β1) and TGF-β1 negative (0µg/ml - TGF-β1) conditions, to 
allow comparison to epoxy-tigliane treated cells. Cells were maintained in treated 
serum-free F-SCM (2ml) for 72h.  
 
Confluent NFs were trypsinized, counted and seeded into 6-well, microtitre plates. 
NFs were seeded in F-SCM at a cell density of 5x104 cells/ml and maintained at 
37°C, in a 5% CO2/95% air environment for the duration of the experiment. As 
previously described in Section 2.3.5.1, cells were growth arrested through culturing 
in serum-free F-SCM for a further 48h. Serum-free media was replaced with serum-
free F-SCM containing EBC-46 or EBC-211 (0µg/ml, 0.001µg/ml, 0.01µg/ml, 
0.1µg/ml, 1µg/ml or 10µg/ml; 3 wells/concentration) in the presence or absence of 
Transforming Growth Factor β1, (TGF-β1, 10ng/ml; PeproTech Ltd., London, UK). 
Cells were maintained in treated serum-free F-SCM (2ml) for 72h.  
 
2.3.5.2.2     Extraction of High Quality RNA  
At 72h, samples were harvested and RNA was extracted using Qiagen RNeasy Mini 
Kit (Qiagen Ltd., Lancashire, UK), according to manufacturer’s instructions. This 
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Kit is designed to extract up to 100µg of purified, high-quality RNA from cells; and 
is suitable for sensitive applications. An additional on-column DNase digestion was 
performed to remove any DNA contamination from the samples, using a RNase-Free 
DNase Set Qiagen (Qiagen Ltd.). Digestion of any residual DNA is necessary due to 
the sensitive nature of TaqMan RT-PCR analysis, as the presence of even small 
amounts of DNA may affect the results obtained.   
 
Cells were harvested from wells by the addition of Buffer RLT (350l) to each well. 
Cell/Buffer RLT samples were transferred to an RNase free tube and vortexed for 
1min to disrupt and homogenise cells, in order to release all RNA from the cells and 
allow efficient binding of RNA to the spin columns.  
 
One volume of 70% ethanol (350l) was added to each sample and mixed well by 
pipetting, before immediate transfer to RNeasy Spin Column placed in collection 
tubes (in Kit). Spin Columns were centrifuged at ≥8000xg for 15s; and flow-through 
eluate discarded. Buffer RW1 (350µl) was used to wash the columns. Columns were 
centrifuged at 10,000xg for 15s and subsequent flow-through eluate discarded, as 
above. From additional on-column DNase digestion, 10l DNase I Stock solution 
was added to 70l Buffer RDD (in Kit). This was mixed gently and centrifuged at 
10,000xg for 5s. DNase I incubation mix (80l) was added directly to the Spin 
Columns and incubated at room temperature for 15min. Buffer RW1 (350µl) was 
added to the Spin Columns containing DNase I incubation mix, centrifuged at 
10,000xg for 15s and flow-through eluate discarded.  
 
Buffer RPE (500µl) containing 4 volumes of 96-100% ethanol was added to the Spin 
Columns as a further wash step, centrifuged at 10,000xg for 15s and flow-through 
eluate discarded. A second volume of Buffer RPE (500l) was added to the Spin 
Columns and centrifuged at 10,000xg for 2min. Spin Columns were transferred to 
new 2ml collection tubes and centrifuged at 10,000xg for 1min, to ensure complete 
elimination of Buffer RPE from the spin columns. RNeasy Spin Columns were 
transferred to new 1.5ml collection tubes (in Kit). RNase-free water (30µl) was 
added to each Spin Column, incubated for 1min at room temperature and centrifuged 
at 10,000xg for 1min, to elute RNA from the columns.   
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RNA concentrations were determined using a NanoDrop® ND-8000 
Spectrophotometer (Thermo Fisher Scientific). RNA purity was determined using the 
ratio between absorbance values at 260 and 280nm (260/280 ratio), with purities over 
1.7 considered sufficient for downstream applications. 
 
2.3.5.2.3     Reverse Transcription and Synthesis of Copy DNA (cDNA) 
RNA was converted to cDNA through the use of High Capacity cDNA Reverse 
Transcription Kits (Thermo Fisher Scientific), according to manufacturer’s 
instructions. 2X Reverse Transcription Master Mix was prepared on ice (10X RT 
Buffer, 2µl; 25X dNTP Mix (100mM), 0.8µl; 10X RT Primers, 2µl; Multiscribe 
Reverse Transcriptase, 1µl; RNase Inhibitor, 0.5µl; Nuclease-free H2O, 3.7µl; in 
Kit); and mixed gently. 10µl 2X RT Master Mix was pipetted into each tube, along 
with RNA sample (volume calculated according to RNA concentration) and 
nuclease-free water to a final volume of 10µl and mixed gently. Tubes were briefly 
centrifuged and loaded into the PTC-225 Peltier Thermal Cycler (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK) and programmed accordingly (25°C for 
10min, 37°C for 120min, 85°C for 5min and held at 4°C).  
 
2.3.5.2.4     Quantitative Polymerase Chain Reaction (qPCR) Amplification and 
       Detection 
Target cDNA was amplified and probes hybridised to target sequence through the 
use of TaqMan® Fast Universal PCR Master Mix (2X), No AmpErase® UNG 
(Thermo Fisher Scientific), according to manufacturer’s instructions. Reaction mix 
was prepared (Master Mix, 10µl; H2O, 4µl; α-SMA Gene Expression Assay Mix 
(containing forward PCR Primer, reverse PCR primer and TaqMan probe), 1µl; 
Eukaryotic 18S rRNA Endogenous Control, 1µl); and mixed gently. Reaction 
mixtures (16µl) were added to each well of 96-well plates, with cDNA sample (4µl) 
added to respective wells. Plates were sealed and centrifuged at 10,000xg for 2min, 
then transferred to 7900HT Fast Real Time PCR System (Thermo Fisher Scientific). 
The Thermal Cycler was set for an initial cycle at 95°C for 1s, followed by 40 cycles 
of 95°C for 1s, then 60°C for 20s. Comparative CT (ΔΔCT) method was used for 
relative quantification of α-SMA gene expression. Each experiment was performed 
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on 3 separate occasions, with averages and standard error values calculated for each 
experimental condition. Statistical analysis was performed using one-way ANOVA 
with post-test Tukey analysis; and statistical significance considered at p<0.05.  
 
2.4     Microarray Analysis of Global Gene Expression 
 
Microarray analysis was undertaken to obtain data on gene expression changes that 
occurred following HaCaT treatment with a range of EBC-46 and EBC-211 
concentrations (0.001µg/ml, 0.1µg/ml or 10µg/ml), at 24h and 48h. Differential gene 
expression was then compared versus untreated control HaCaTs. 
 
2.4.1     Epidermal Keratinocyte Culture 
Following trypsinisation, HaCaTs were seeded into separate T-75 tissue culture 
flasks (VWR International, UK); at a cell density of 2x106 cells/flask in K-SCM. 
HaCaTs were maintained at 37°C in a 5% CO2/95% air atmosphere for 24h and 
subsequently growth arrested for 24h in serum-free K-SCM. Serum-free DMEM was 
removed and replaced with 1% serum containing K-SCM; in addition to 0µg/ml, 
0.001µg/ml, 0.1µg/ml or 10µg/ml EBC-46 or EBC-211 (10ml/flask). Untreated 
controls (0µg/ml) also included 1% DMSO (as described in Section 2.1); HaCaTs 
were maintained at 37°C in 5% CO2/95% air atmosphere, for 24h and 48h.  
Therefore, 12 x T-75 tissue culture flasks/experiment were established for a total of 4 
separate experiments (Table 2.1), with 0.1µg/ml EBC-46 and EBC-211 being 
analysed at 48h only.  At 24h and 48h, all culture medium (10ml) was removed, then 
immediately replaced along with RNAprotect Cell Reagent : media (4.5ml/flask, 
Qiagen Ltd.), to maintain the 5:1 ratio and transferred to 15ml Falcon tubes (VWR 
International, UK). HaCaTs were maintained at 4°C, until subsequent shipping to the 
Berghofer Queensland Institute of Medical Research (QIMR), Queensland, 
Australia; where further experimental work and analysis of these samples was 
performed. 
 
2.4.2     Extraction and Purification of High Quality RNA  
RNA was extracted from each HaCaT sample, using Qiagen RNeasy Plus Mini Kits 
(Qiagen Pty Ltd., Victoria, Australia), according to manufacturer’s instructions. This  
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Table 2.1: Summary of the 12 HaCaT conditions analysed through Microarray 
analysis of global gene expression following EBC-46 and EBC-211 treatment; 4 
separate samples were obtained for each condition, resulting in 48 samples 
analysed through Microarray analysis. 
 
 
 
  
Treatment 
Number 
[EBC-46] or [EBC-211] 
(µg/ml) 
Time-point 
(h) 
1 0 (1% DMSO) 24 
2 0 (1% DMSO) 48 
3 0.001 (EBC-46) 24 
4 0.001 (EBC-46) 48 
5 0.001 (EBC-211) 24 
6 0.001 (EBC-211) 48 
7 0.1 (EBC-46) 48 
8 0.1 (EBC-211) 48 
9 10 (EBC-46) 24 
10 10 (EBC-46) 48 
11 10 (EBC-211) 24 
12 10 (EBC-211) 48 
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 Kit is designed to extract up to 100µg of purified, high-quality RNA from cells, 
suitable for sensitive applications. Cell/RNAprotect samples (500µl) were transferred 
to an RNase-free tube and centrifuged at 10,000xg for 1min. Supernatants were 
carefully removed and pellets resuspended in Buffer RLT Plus (350µl; in Kit), (10µl 
β-mercaptoethanol (β-ME)/10ml Buffer RLT Plus). The lysates were homogenised 
through vortexing and pipetting, before transfer to gDNA Eliminator Spin Columns, 
placed in collection tubes (in Kit). Spin Columns were centrifuged at 10,000xg for 
1min, discarding Spin Columns with captured genomic DNA, whilst resultant flow-
through was retained. One volume of 70% ethanol (350µl) was added to each 
collected flow-through, mixed by pipetting and transferred to RNeasy Spin Columns 
placed in collection tubes (in Kit). Spin columns were centrifuged at 10,000xg for 
15s, and flow-through eluates were discarded. Buffer RW1 (700µl, in Kit) was added 
to retained RNeasy Spin Columns to wash the columns; being centrifuged at 
10,000xg for 15s, with subsequent flow-through eluates discarded. Buffer RPE 
(500µl, in Kit) containing 4 volumes of 96-100% ethanol was added to Spin 
Columns as an additional Spin Column wash step, and centrifuged at 10,000xg for 
15s. Subsequent flow-through was discarded and Spin Columns centrifuged at 
≥8000xg for 1min, to ensure all Buffer RPE had been eliminated from the Spin 
Columns. The RNeasy Spin Columns were transferred to fresh 1.5ml collection tubes 
(in Kit). RNase-free water (50µl) was added to each Spin Column and centrifuged at 
10,000xg for 1min, to elute collected RNA from the Spin Column.   
 
2.4.3     Quantifying RNA and Confirmation of Purity and Integrity  
RNA concentrations were determined using a NanoDrop® Lite (Thermo Fisher 
Scientific, Australia Pty Ltd., Victoria, Australia), which also provided the purity of 
each RNA sample through ratio between the absorbance values at 260 and 280nm 
(260/280 ratio). Purities over 1.7 were considered sufficient for downstream 
applications. RNA integrity was confirmed by 1% agarose gel electrophoresis with 
ethidium bromide staining. A 2:1 ratio of 28S rRNA to 18S rRNA confirmed the 
integrity of the RNA samples. Agarose (1%) gels were produced by agarose 
(Seakem® LE Agarose, Lonza Pty Ltd., New South Wales, Australia) and 1x Tris-
acetate-EDTA (TAE) buffer (Tris, Thermo Fisher Scientific, Australia; acetic acid, 
Merck Millipore, Victoria, Australia; and EDTA, Univar Australia Pty Ltd., New 
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South Wales, Australia). Agarose was dissolved through heating and mixed well to 
ensure equal concentrations throughout. Once cooled, 10mg/ml ethidium bromide 
(8µl; Sigma-Aldrich Pty. Ltd., New South Wales, Australia) was added to the 
agarose/TAE and mixed well. Agarose/TAE was poured into prepared RNase-free 
moulds and allowed to set at room temperature, for approximately 30min. RNA 
samples were loaded into wells (10µl), together with a 1kb DNA marker (10µl; 
Thermo Fisher Scientific, Australia). Electrophoresis was applied to the loaded gels, 
at 90V for 30min, in 1xTAE running buffer. Gel images were captured under UV 
light (312nm); and viewed using a UV Imager (Vilber Lourmat, Fisher Biotec, 
Western Australia, Australia), using the DNA marker as a guide for molecular size.  
 
2.4.4     Generation of Biotinylated, Amplified Antisense RNA (cRNA) and 
  Quantification 
RNA was amplified and labelled through the use of Illumina® TotalPrep RNA 
Amplification Kits (Thermo Fisher Scientific, Australia), to provide antisense RNA 
ready for hybridisation with Illumina Sentrix® Arrays. Approximately 500ng of total 
RNA was transferred to RNase-free microcentrifuge tubes and adjusted to a final 
volume of 11µl with nuclease-free water. To synthesise first strand cDNA, Reverse 
Transcription Master Mix was prepared, according to manufacturer’s instructions 
(T7 Oligo(dT) Primer, 1µl; 10X First Strand Buffer, 2µl; dNTP Mix, 4µl; RNase 
Inhibitor, 1µl; ArrayScript, 1µl), mixed by vortexing and centrifuged at 10,000xg for 
15s. Reverse Transcription Master Mix (9µl) was transferred to each sample, mixed 
thoroughly and centrifuged at 10,000xg for 15s, before incubation at 42°C for 2h in 
GeneAmp PCR System 2400 (Perkin Elmer, Victoria, Australia).  
 
Second Strand Master Mix was prepared on ice, according to manufacturer’s 
instructions (nuclease-free water, 63µl; 10X Second Strand Buffer, 10µl; dNTP Mix, 
4µl; DNA Polymerase, 2µl; RNase H, 1µl), mixed by vortexing and centrifuged at 
10,000xg for 15s. Second Strand Master Mix (80µl) was added to each sample, 
mixed thoroughly and centrifuged at 10,000xg for 15s, before incubation at 16°C for 
2h in a a GeneAmp PCR System 2400 (Perkin Elmer), to synthesise second strand 
cDNA.  
 
108 
 
cDNA Binding Buffer (250µl, in Kit) was added to each sample of second strand 
cDNA, mixed thoroughly and centrifuged at 10,000xg for 15s. cDNA samples were 
transferred to cDNA Filter Cartridges placed in collection tubes and centrifuged at 
10,000xg for 1min discarding each flow-through. Wash Buffer containing 100% 
ethanol (500µl, in Kit), was added to the cDNA Filter Cartridges and centrifuged at 
10,000xg for 1min; subsequent flow through eluate was discarded. Filter Cartridges 
were re-spun to ensure all Wash Buffer had been removed, before being transferred 
to cDNA Elution Tubes. Nuclease-free water (20µl), preheated to 55°C, was added 
to cDNA Filter Cartridge, left at room temperature for 2min; and then centrifuged at 
10,000xg for 1.5min to elute purified cDNA.  
 
IVT Master Mix was prepared according to manufacturer’s instructions (T7 10X 
Reaction Buffer, 2.5µl; T7 Enzyme Mix, 2.5µl; Biotin-NTP Mix, 2.5µl), mixed well 
through vortexing and centrifuged at 10,000xg for 15s. IVT Master Mix (7.5µl) was 
added to each cDNA sample, mixed thoroughly and centrifuged at 10,000xg for 15s. 
Samples were incubated at 37°C for 16h in a Thermal Cycler, to synthesise cRNA. 
After 16h, reactions were stopped through the addition of nuclease-free water (75µl) 
to each cRNA sample; and mixed by gentle vortexing.  
 
cRNA Binding Buffer (350µl, in Kit) was added to each sample, followed by 
addition of ACS reagent grade 100% ethanol (250µl). Samples were mixed through 
pipetting and transferred immediately to cRNA Filter Cartridges (in Kit). Wash 
Buffer (650µl, in Kit) was added to each cRNA Filter Cartridge, centrifuged at 
10,000xg for 1min discarding resultant flow-through, and centrifuged again at 
10,000xg for 1min to ensure all Wash Buffer had been removed. cRNA Filter 
Cartridges were transferred to new cRNA collection tubes. Nuclease-free water 
(100µl), preheated to 50-60°C, was added to the cRNA Filter Cartridges and the 
cartridge left at room temperature for 2min, prior to centrifugation at 10,000xg for 
2min to obtain purified cRNA.  
 
As previously described (Section 2.4.3), RNA concentrations were determined using 
a NanoDrop® Lite. RNA purity was also obtained through 260/280 ratio; purities 
over 1.7 were considered sufficient for downstream applications.  
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2.4.5     Illumina Hybridisation of Antisense RNA (cRNA) 
Hybridization of cRNA samples to complementary gene-specific sequence 
BeadChips was performed using the Illumina® Whole-Genome Gene Expression 
Direct Hybridization Assay System (Illumina®, Victoria, Australia), according to 
manufacturer’s instructions. HYB and HCB tubes (in Kit) were incubated at 58°C 
and mixed thoroughly for 10min, prior to use. BeadChips were warmed to room 
temperature, prior to use. Each cRNA sample (750ng) was aliquoted into separate 
hybridization tubes and volumes made up to 5µl with RNase-free water. Samples 
were heated at 65°C for 5min, briefly centrifuged at 250xg and cooled to room 
temperature; before HYB Mix (10µl; in Kit) was added to each sample.  
 
Hyb Chambers were assembled with all four Hyb Chamber inserts. HCB (200µl) was 
added to the eight humidifying buffer reservoirs, for hybridisation of four 
BeadChips. Prepared cRNA mix (15µl) was loaded onto Illumina® Expression 
BeadChips. All BeadChips were loaded into the Hyb Chambers, securely sealed and 
incubated on a rocker at 58°C for 16h.  
 
After incubation, a series of hybridisation and wash steps were performed, according 
to the Whole-Genome Gene Expression Direct Hybridization Assay Guide 
(Illumina®), as detailed below. BeadChips were removed from Hyb Chamber and 
submerged face up in Wash E1BC solution (6ml E1BC buffer in 2L RNase-free 
water) and the cover-seals removed. BeadChips were transferred to slide racks 
submerged in Wash E1BC solution (250ml), the slide racks were transferred to a 
Hybex Waterbath containing High Temperature Wash buffer (250ml; Illumina®); and 
incubated for 10min. Slide racks were transferred to fresh Wash E1BC buffer 
(250ml), plunged in and out of solution (x10); and transferred to an orbital shaker, 
set on medium-low for 5min at room temperature. Slide racks were transferred to 
fresh 100% ethanol (250ml), plunged in and out of solution (x10), before being 
transferred to an orbital shaker, set on medium-low for 10min at room temperature. 
Slides were then transferred back to Wash E1BC buffer (250ml), plunged in and out 
of solution (x10), before transferred to orbital shaker, set on medium-low for 2min at 
room temperature.  
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BeadChips were placed face up in wash trays on a rocker. Block E1 buffer (4ml; 
Illumina®) was added to each wash tray and rocked at a medium speed for 10min at 
room temperature. BeadChips were transferred to wash trays, containing Cy3-
Streptavidin (1:1000 dilution of Cy3-Streptavidin in Block E1 buffer; 2ml), with the 
wash tray lids used to protect the Cy3-Streptavidin from light. Wash trays were 
subsequently placed on a rocker set at medium speed for 10min at room temperature. 
BeadChips were transferred to slide racks in Wash E1BC buffer (250ml), plunged in 
and out of solution (x5), before being transferred to a orbital shaker, set on medium-
low for 5min at room temperature. Slide racks containing BeadChips were placed in 
a centrifuge and spun at 1,000xg for 4min at room temperature.  
 
2.4.6     Microarray Data Acquisition and Data Analysis   
BeadChips were scanned using the iScan System on an Agilent GS2565 Microarray 
Scanner (Agilent Technologies Australia, Victoria, Australia). This system uses a 
laser to excite the fluor of the single-base extension product on the beads, with 
subsequent light emissions recorded and analysed. BeadChips were scanned 
according to the Whole-Genome Gene Expression Direct Hybridization Assay Guide 
(Illumina®), with decoded data input into the iScan System to correspond to specific 
BeadChips.  
 
The Human HT-12 v4 Expression BeadChips cover more than 47,000 transcripts and 
known splice variants across the human transcriptome, providing genome-wide 
transcriptional coverage of >25,000 characterised genes, gene candidates and splice 
variants.  Raw data files were filtered and normalised using BeadScan Software and 
data extracted using BeadStudio Gene Expression Module (Illumina®). Data was 
subsequently imported into GeneSpring GX v12.5 Expression Analysis Software 
(Agilent Technologies), for normalisation, filtering based on detection score, 
statistical analysis and heatmap visualization/clustering. The expression values were 
normalized using quantile normalization with default settings. The entities were 
filtered based on detection score calculated by Genome Studio, where p≤0.05 was 
considered significant. Data from each treatment group (n=4 separate experiments) 
was grouped for combined analysis using Ingenuity Pathway Analysis (IPA®) 
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Software. Further analysis of Microarray data using IPA® Software, used Ingenuity 
Knowledge Base to visualise gene pathways, to aid interpretation of the Microarray 
dataset.  
 
Various databases were further used to identify characteristics and functions of genes 
of interest, in addition to the information gained from GeneSpring GX v12.5 
Expression Analysis Software and Ingenuity Pathway Analysis (IPA®) Software. 
Databases used included PubMed (http://www.ncbi.nlm.nih.gov/gene/), GeneCards 
(http://www.genecards.org/) and OMIM (http://www.omim.org). 
 
2.5     Microarray Validation 
 
2.5.1     Quantitative Polymerase Chain Reaction (qPCR) 
Following on from Microarray studies, qPCR experiments were performed on a 
number of key genes (Krt13, Krt15, Krt16, Krt17, MMP-1 and Cyclin B2), identified 
to be differentially expressed by EBC-46 and EBC-211, in order to validate the 
Microarray data obtained and to further quantify the expression of these genes.  All 
experiments were performed in triplicate.  
 
To prepare samples for qPCR, the samples initially underwent reverse transcription 
of the total RNA. Firstly, a Master Mix containing RNasin (1µl; Promega, New 
South Wales, Australia), Oligo d(T15) at 0.5µg/µl (1µl; Thermo Fisher Scientific, 
Australia), 10mM dNTP Mix (1µl; Promega, Australia) and Ultra-Pure Distilled 
Water (1µl; Thermo Fisher Scientific, Australia), was prepared, mixed and 
centrifuged at ≥8000xg for 15s, before the addition of 4µg/ml total RNA (24µl) to 
each PCR tube. Reverse transcription Master Mix and RNA were mixed well and 
centrifuged at ≥8000xg for 15s, before heating at 70°C for 10min in a Thermal 
Cycler (GeneAmp PCR System 9700, Thermo Fisher Scientific, Australia). The 
Thermal Cycler program was paused and samples transferred to ice for 2min to break 
the secondary structure of RNA, before being re-centrifuged at ≥8000xg for 15s and 
heated in the Thermal Cycler, at 50°C for 10min.  
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Another Master Mix was prepared on ice containing 5x First Strand Buffer (8µl), 
100mM DTT (2µl) and SuperScript III (200units/µl; 2µl; all from Thermo Fisher 
Scientific, Australia). Aliquots (12µl) were added to each RNA sample, gently mixed 
and centrifuged at ≥8000xg for 15s, before incubation in a Thermal Cycler at 50°C 
for 1h. This was followed by heating to 70°C for 15min for inactivation of the 
enzyme to occur. Samples were diluted 1:10 using Elution Buffer (Qiagen, 
Australia); and stored at -20°C for future use.  
 
Master Mix for qPCR was prepared, comprising of 2x SYBR® Green PCR Master 
Mix (10µl; Thermo Fisher Scientific, Australia), Ultra-Pure Distilled Water (3µl; 
Thermo Fisher Scientific, Australia), 10mM Forward Primer (1µl) and 10mM 
Reverse Primer (1µl). Primers were designed using qPrimerDepot and provided by 
Sigma-Aldrich Pty Ltd. Primers were diluted to 1:10 ratio using Elution Buffer, to 
obtain the correct concentration for qPCR. Master Mix (15µl) was vortexed, 
centrifuged and added to each 100µl tube. cDNA samples (5µl) were added to each 
respective tube. Tubes were transferred to Corbett Rotor Gene 6000 machine 
(Corbett Research Pty Ltd., New South Wales, Australia) and heated at 95°C for 
15min, run through 40 cycles of 95°C for 30s, 60°C for 30s and 72°C for 30s, before 
a final melt step which heated samples from 72°C - 95°C at 1°C increments.  
 
2.5.2     Western Blot Analysis 
Following trypsinisation, HaCaTs were seeded into separate T-75 tissue culture 
flasks, at a density of 2x106 cells/flask in K-SCM (10ml; Section 2.2.2). HaCaTs 
were maintained at 37°C in a 5% CO2/95% air atmosphere for 24h, then growth 
arrested for 24h in serum-free K-SCM. Serum-free K-SCM was removed and 
replaced with 1% serum-containing K-SCM, containing a range of EBC-46 and 
EBC-211 concentrations (0.001-10µg/ml, 10ml/flask). Untreated controls (0µg/ml), 
were also used for comparison at each time-point, which included 1% DMSO. 
HaCaTs were maintained at 37°C in 5% CO2/95% air, for 24 and 48h. Each 
experiment was performed on 3 separate occasions.   
 
At 24 and 48h, treated K-SCM was collected and centrifuged at 1,200xg to pellet cell 
debris. HaCaTs were washed in ice-cold PBS (x2) and cell/extracellular matrix 
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(ECM) extracts obtained by scraping the flask contents into ice-cold RIPA buffer 
(1000µl, Thermo Fisher Scientific), containing protease inhibitors (Complete 
Protease Inhibitor Cocktail Tablets, Roche, West Sussex, UK) and sonicated (Digital 
SLPe Cell Disruptor, Branson Ultrasonics Corp., Connecticut, USA). Cell/ECM 
suspensions were centrifuged (15,000xg/4°C, 5min) and each supernatant protein 
concentration quantified using Pierce® BCA Protein Assay Kit (Thermo Fisher 
Scientific), according to manufacturer’s instructions. Western Blot analysis was 
carried out for Krt13, Krt15, Krt16, Krt17, Krt6B, Cyclin B1, Cyclin B2, Cyclin A2, 
UBE2C, CDKN3 and CDKN1A.  
 
Protein samples (15μg) were separated under reducing conditions by mixing with 4x 
Laemmli buffer (Bio-Rad Laboratories), heated to 95°C for 5min, centrifuged and 
stored on ice. Samples underwent SDS-PAGE separation (100V, 75min), using pre-
formed 4–15% gradient TGX™ gels (Bio-Rad Laboratories) and Mini-Protean® Tetra 
Cell System (Bio-Rad Laboratories). A Kaleidoscope Protein Ladder was also loaded 
onto each gel (Bio-Rad Laboratories). Proteins were transferred onto polyvinylidene 
difluoride membranes (Hybond™-P; Thermo Fisher Scientific), using Mini Trans-
Blot® Electrophoretic Transfer Cell (100V, 1h; Bio-Rad Laboratories).  
 
Membranes were blocked with 5% semi-skimmed milk/1% Tween 20 (Thermo 
Fisher Scientific) in Tris-buffered saline (TBS), for 1h at room temperature. 
Membranes were incubated with primary antibody for 1h at room temperature or 4°C 
overnight in 5% semi-skimmed milk/1% Tween 20. Primary antibodies used and 
incubation conditions are shown in Table 2.2 (all supplied by Abcam, 
Cambridgeshire, UK). Protein loading levels were confirmed for each blot using a β-
actin Loading Control (1:4000; Abcam). After primary antibody incubation, 
membranes were washed in 1% Tween 20/TBS (x3); and incubated for 1h at room 
temperature in secondary antibody (HRP-conjugated polyclonal swine anti-rabbit 
Ig’s; 1:3000, Dako UK Ltd., Cambridgeshire, UK), in 5% semi-skimmed milk/1% 
Tween 20/TBS.  Membranes were washed (x3), followed by an additional wash in 
TBS for 5min. Membranes were incubated in Amersham ECL™ Prime Detection 
Reagent (1:1 ratio; (VWR International, UK), for 5min in the dark at room 
temperature and autoradiographic films (Hyperfilm™-ECL, Thermo Fisher  
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Table 2.2: Summary of primary antibodies and conditions used for Western 
blot analysis.  
 
 
 
  
Antibody Concentration 
(mg/ml) 
Expected Molecular 
Weight 
Incubation 
Conditions 
Krt13 0.022 50kDa 4°C o/n 
Krt15 0.029 45kDa 1h at RT 
Krt16 0.163 51kDa 4°C o/n 
Krt17 0.060 48kDa 4°C o/n 
Krt6B 1.000 60kDa 1h at RT 
Cyclin B1 0.316 58kDa 1h at RT 
Cyclin B2 1.369 45kDa 1h at RT 
Cyclin A2 1.000 49kDa 4°C o/n 
UBE2C 0.218 20kDa 4°C o/n 
CDKN3 1.260 24kDa 1h at RT 
CDKN1A 0.681 21kDa 1h at RT 
Beta-actin 0.400 42kDa 1h at RT 
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Scientific) developed, according to manufacturer’s instructions.  Immunoblot images 
were quantified by densitometry (Gel Doc™ EZ System and Image Lab™ Software, 
Bio-Rad Laboratories). Each experiment was performed on 3 separate occasions. 
Statistical analysis was performed using one-way ANOVA, with Dunnett Multiple 
Comparisons Test analysis, using the untreated control as the control for comparison. 
Statistical significance considered at p<0.05.    
 
2.5.3     Matrix Metalloproteinase (MMP) Activity Assays 
Supernatants collected in Section 2.5.2 were centrifuged for 10min at 1000xg/4°C 
and stored at -70°C, until required for further experiments. Matrix metalloproteinase 
(MMP) analysis was undertaken to observe changes in activity following HaCaT  
treatment with a range of EBC-46 and EBC-211 concentrations (0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml or 10µg/ml), at 24h and 48h. Activity levels were 
compared versus an untreated HaCaT control at each time-point. MMP-1/-7/-10 
activities in the samples were quantified using SensoLyte® 520 MMP-1/-7/-10 
Activity Assay Kits, respectively (Fluorimetric; AnaSpec Inc., Cambridge, UK), and 
performed according to manufacturer’s instructions.  
 
Pro-MMPs were activated through the incubation of culture media samples with 
APMA (1mM; in Kits) immediately before each experiment. Samples were 
maintained on ice once activated. MMP-1 containing samples were activated at 37°C 
for 3h, MMP-7 containing samples activated at 37°C for 1h; and MMP-10 containing 
samples activated at 37°C for 24h. Once activated, samples were incubated with 
respective MMP-1/-7/-10 substrates. MMP substrates were diluted 1:100 in Assay 
Buffer (in Kits). MMP-1/-7-/10 containing samples (50µl/well) were added to black, 
flat-bottomed, 96 well microplates (Thermo Fisher Scientific). Assay buffer (50µl) 
was added to three wells as a substrate control. MMP-1/-7/-10 Substrate Mix 
(50µl/well, in Kits) was added to the sample and control wells; and mixed well by 
gentle shaking the plate for 30s. Fluorescence signals were measured at end-point by 
incubating the plate at 37°C for 1h, avoiding direct light. Fluorescence intensity was 
measured every 10min at an excitation of 490nm and emission of 520nm. The 
average values obtained for the substrate control wells were used to blank correct the 
fluorescent readings for each sample. This experiment was performed on 3 separate 
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sample sets for each MMP analysed. The corrected values obtained were used to 
calculate average values and standard errors determined. Statistical analysis was 
performed using one-way ANOVA with post-test Tukey analysis; and statistical 
significance considered at p<0.05. 
 
2.5.4     Enzyme-Linked Immunosorbent Assays (ELISAs) 
Supernatants collected in Section 2.5.2 were centrifuged for 10min at 1000xg/4°C 
and stored at -70°C, until required for further experiments. Enzyme-linked 
immunosorbent assays (ELISAs) were undertaken to observe changes on expression 
levels following HaCaT treatment with a range of EBC-46 and EBC-211 
concentrations (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml or 10µg/ml), at 24h and 
48h. Expression levels were compared versus an untreated HaCaT control at each 
time-point. Interleukin (IL)-6, IL-8, CCL5 and CXCL10 expression levels were 
quantified using Human IL-6 Immunoassay, Human CXCL8/IL-8 Immunoassay, 
Human CCL5/RANTES Immunoassay and Human CXCL10/IP-10 Immunoassay, 
respectively (Quantikine® ELISA; R&D Systems Ltd., Oxfordshire, UK), and 
performed according to manufacturer’s instructions.  
 
Assay Diluent RD1W (100µl) was added to microplate wells (in Kit), followed by 
either the standards, samples or controls (100µl); and incubated for 2h at room 
temperature. Each well was aspirated and washed (x4) using Wash Buffer (400µl; in 
Kit), with complete removal of liquid after each wash step, especially after final 
wash step. Human IL-6 Conjugate (200µl; in Kit) was added to each well and 
incubated for 2h at room temperature. Wash steps were repeated as before (x4), with 
complete removal of liquid after each wash. Substrate Solution (200µl; in Kit) was 
added to each well and incubated for 20min at room temperature, under darkness. 
Stop Solution (50µl; in Kit) was added to each well to stop the reaction and tapped 
gently to ensure thorough mixing. The optical density of each well was determined 
through taking readings of each well at 450nm. Readings were also taken at 540nm 
and subtracted from the 450nm readings, as an additional internal control. This 
ELISA was performed on 3 separate sample sets. The corrected values were used to 
calculate average values and standard errors. Statistical analysis was performed using 
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one-way ANOVA with post-test Tukey analysis; and statistical significance 
considered at p<0.05. 
 
ELISA protocol was repeated for IL-8. Assay Diluent RD1-85 (100µl) was added to 
microplate wells (in Kit), followed by either the standards, samples or controls 
(50µl); and incubated for 2h at room temperature. Each well was aspirated and 
washed (x4) using Wash Buffer (400µl; in Kit), with complete removal of liquid 
after each wash step, especially after final wash step. Human IL-8 Conjugate (100µl; 
in Kit) was added to each well and incubated for 1h at room temperature. Wash steps 
were repeated as before (x4), with complete removal of liquid after each wash. 
Substrate Solution (200µl; in Kit) was added to each well, and incubated for 30min 
at room temperature, under darkness. Stop Solution (50µl; in Kit) was added to each 
well to stop the reaction and tapped gently to ensure thorough mixing. The optical 
density of each well was determined through taking readings of each well, as 
described for IL-6 above; and IL-8 expression levels calculated. Statistical analysis 
was performed using one-way ANOVA with post-test Tukey analysis; and statistical 
significance considered at p<0.05. 
 
ELISA protocol was repeated for CCL5 (also known as RANTES). Assay Diluent 
RD1W (100µl) was added to microplate wells (in Kit), followed by either the 
standards, samples or controls (100µl); and incubated for 2h at room temperature. 
Each well was aspirated and washed (x3) using Wash Buffer (400µl; in Kit); with 
complete removal of liquid after each wash step, especially after final wash step. 
Human RANTES Conjugate (200µl; in Kit) was added to each well and incubated 
for 1h at room temperature. Wash steps were repeated as before (x3), with complete 
removal of liquid after each wash. Substrate Solution (200µl; in Kit) was added to 
each well and incubated for 20min at room temperature, under darkness. Stop 
Solution (50µl; in Kit) was added to each well to stop the reaction and tapped gently 
to ensure thorough mixing. The optical density of each well was determined through 
taking readings of each well, as described for IL-6 above; and CCL5 expression 
levels calculated. Statistical analysis was performed using one-way ANOVA with 
post-test Tukey analysis; and statistical significance considered at p<0.05. 
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ELISA protocol was repeated for CXCL10 (also known as IP-10). Assay Diluent 
RD1-56 (150µl) was added to microplate wells (in Kit), followed by either the 
standards, samples or controls (100µl); and incubated for 2h at room temperature. 
Each well was aspirated and washed (x4) using Wash Buffer (400µl; in Kit); with 
complete removal of liquid after each wash step, especially after final wash step. 
Human IP-10 Conjugate (200µl; in Kit) was added to each well and incubated for 2h 
at room temperature. Wash steps were repeated as before (x4), with complete 
removal of liquid after each wash. Substrate Solution (200µl; in Kit) was added to 
each well and incubated for 30min at room temperature, under darkness. Stop 
Solution (50µl; in Kit) was added to each well to stop the reaction and tapped gently 
to ensure thorough mixing. The optical density of each well was determined through 
taking readings of each well, as described for IL-6 above; and CXCL10 expression 
levels calculated. Statistical analysis was performed using one-way ANOVA with 
post-test Tukey analysis; and statistical significance considered at p<0.05. 
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Chapter 3 - Effects of EBC-46 and EBC-211 on Dermal 
Fibroblast Wound Healing Responses 
 
 
3.1 Introduction 
 
EBC-46 is a naturally-derived, epoxy-tigliane compound, sourced and developed from 
within seeds of the Fountain’s Blushwood Tree in Queensland’s Tropical Rainforest 
by Australian biotechnology company, QBiotics Ltd. (described in Section 1.7; 
Reddell & Gordon 2007). EBC-46 has been demonstrated to possess potent anti-cancer 
effects on solid tumours and sarcoids; this led to the hypothesis that an anti-fibrotic 
response may be involved in tumour ablation, in particular as sarcoids are primarily 
composed of fibroblasts (Reddell & Gordon 2007; Boyle et al. 2014). An unexpected 
beneficial response following tumour sloughing was the rapid wound closure, with 
reduced scarring evident and the reformation of skin appendages (Reddell & Gordon 
2007).  
 
Fibroblasts are a key cell involved in the acute skin wound healing response and 
perform a number of essential wound healing functions, such as extracellular matrix 
(ECM) production (Martin 1997; Reinke & Sorg 2012; Bainbridge 2013). The 
differentiation of fibroblasts to myofibroblasts is a vital function due to the contractile 
force exerted by the myofibroblasts to aid closure of the wound site (Li & Wang 2011). 
Fibroblasts express a number of vital growth factors required during wound healing, 
with some acting in an autocrine response on fibroblasts and others in a paracrine effect 
on keratinocytes. There is a positive feedback system between these key wound 
healing cells, contributing to wound repair (Barrientos et al. 2008; Schultz & Wysocki 
2009). Acute skin wound healing responses are tightly regulated processes and 
alterations in these can produce detrimental healing responses, as seen with chronic 
non-healing wounds where re-epithelialisation is impaired (Chapter 4), or during 
dermal fibrosis, such as with keloid and hypertrophic scars (Section 1.5; Bran et al. 
2009; Shih et al. 2010).  
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Keloid and hypertrophic scars are a result of excessive scarring at the wound site, with 
hypertrophic scars possessing an increased presence of myofibroblasts, resulting in 
excessive wound contraction (Gauglitz et al. 2011; Jumper et al. 2015; Kelsh et al. 
2015). This increased production of matrix components may be a result of an increased 
presence of fibroblasts at the wound site, following enhanced chemoattraction by 
immune cells, in addition to the increased fibroblast proliferation observed in keloid 
fibroblasts (Shih et al. 2010; Gauglitz et al. 2011; Ding & Tredget 2015; Jumper et al. 
2015; Kelsh et al. 2015). Burn injuries have a high incidence of hypertrophic scar 
formation, higher than the incidence following surgery (Gauglitz et al. 2011). This is 
thought to be a result of increased activation of the fibroblasts following increased 
immune and inflammatory responses after thermal injury, leading to increased matrix 
deposition and differentiation to contractile myofibroblasts (Gauglitz et al. 2011; Ding 
& Tredget 2015). Burn injuries result in damaged and necrotic tissue, impacting the 
normal acute wound healing response, by impacting the infiltration of numerous 
growth factors to the wound site as a result of impaired angiogenesis (Rose & Chan 
2016).  
 
Chronic wounds have common features impacting their healing mechanisms, despite 
the variety of wounds and ulcers; including excessive inflammatory response, 
impaired ECM remodelling, increased metalloproteinase activity, bacterial 
colonisation and biofilm formation (Stephens et al. 2003; Wall et al. 2008; Guo & 
DiPietro 2010; Demidova-Rice et al. 2012; Percival et al. 2012; Eming et al. 2014; 
McInnes et al. 2014). Alterations in the phenotype of fibroblasts present in chronic 
wounds have been observed, with reduced proliferation, migration, response to growth 
factors and ECM turnover (Agren & Werthén 2007; Menke et al. 2007; Wall et al. 
2008). One theory was that dermal fibroblasts were becoming senescent, which would 
reduce fibroblast proliferative ability and matrix synthesis (Telgenhoff & Shroot 2005; 
Wall et al. 2008; Eming et al. 2014). Other theories on impaired fibroblast functions 
in chronic wounds include a reduced ability to respond to signals from growth factors 
due to faulty signalling pathways, or faulty adhesion receptor activation, resulting in 
dysfunctional formation of the matrix (Agren & Werthén 2007; Menke et al. 2007; 
Frykberg & Banks 2015). Fibroblast migration is also impaired in chronic wounds, 
with reduced mitogenic function to stimuli, including a number of growth factors. This 
122 
 
has been partly attributed to the wound exudate present in chronic wounds and a 
reduced presence of the receptors required to propagate these migratory responses 
(Raffetto et al. 2001; Menke et al. 2007). Additionally, the high presence of bacteria 
and biofilm formation contributes to this dysfunctional healing response. It has been 
proposed that the excessive inflammation present in chronic wounds induces an aged 
phenotype of the tissue, resulting in reduced functionality and vasculature formation 
(Wall et al. 2008; Guo & DiPietro 2010; Eming et al. 2014).   
 
There are subtle differences between adult dermal wound healing and the preferential 
responses of oral mucosal and early-gestational foetal healing, including attenuated 
inflammatory response, altered cytokine/growth factor profiles; and contrasting 
collagen synthesis (Nauta et al. 2011; Leung et al. 2012; Rolfe & Grobbelaar 2012). 
Fibroblast responses are enhanced in early-gestational foetal healing, with increased 
proliferative and migratory abilities; more organised ECM synthesis occurs by foetal 
fibroblasts (Yates et al. 2012; Helmo et al. 2013). Presence of myofibroblasts in foetal 
wounds has been disputed, with some claiming that they are not present and others that 
they are present earlier in the wound healing process than in adult wound responses. 
Other claims are that they are completely absent from early non-scarring foetal wounds 
but are present during later-gestational foetal wounds, which result in scar formation 
(Larson et al. 2010; Rolfe & Grobbelaar 2012; Yates et al. 2012). Myofibroblasts 
undergo apoptosis once the tissue has been remodelled and is of sufficient tensile 
strength; scarless healing wounds have shown increased caspase 7 levels, the active 
form, which potentially increases apoptosis of a number of cells, including 
myofibroblasts (Satish & Kathju 2010; Rolfe & Grobbelaar 2012; Mcilwain et al. 
2013; Darby et al. 2014; Balaji et al. 2015).  
 
Oral fibroblasts appear to respond earlier to TGF-β isoforms, resulting in earlier but 
less sustained contraction compared to dermal fibroblasts, with also a resistance of oral 
fibroblasts differentiation to contractile myofibroblasts (Lee & Eun 1999; Meran et al. 
2008; Enoch et al. 2010; Nauta et al. 2011). A study has shown that the level of 
hyaluronan may play an important role in fibroblast response to TGF-β signalling, with 
increased hyaluronan resulting in stimulated fibroblast proliferation; reduced levels of 
hyaluronan are evident in oral mucosal wounds, leading to a reduced proliferative 
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response (Meran et al. 2008). Production of certain MMPs, in particular MMP-2 and 
MMP-3, is up-regulated in oral fibroblasts compared to dermal fibroblasts. This 
increased presence may impact on the ECM remodelling ability through a quicker 
remodelling ability and wound contraction, as rapid, scarless healing is a known 
response of oral mucosal healing (Stephens et al. 2001; McKeown et al. 2007; Enoch 
et al. 2010). 
 
Similar beneficial wound healing responses, characterised by rapid re-epithelialisation 
and minimal scarring, were observed in veterinary case studies with EBC-46 treatment 
on wounds that were previously unresponsive to current wound care strategies 
(Reddell et al. 2014). However, despite the significant beneficial effects on wound 
healing previously observed, little was known about how the novel epoxy-tiglianes 
exert these responses (Reddell et al. 2014). The healed wound site is more 
representative of a preferential healing process, such as early-gestational foetal and 
oral mucosal wounds (Mak et al. 2009; Nauta et al. 2011; Rolfe & Grobbelaar 2012). 
Nonetheless, given the prominent role that fibroblasts play in acute skin wound 
healing, a greater understanding of the effects on the fibroblast wound healing 
responses was required; this is vital in order to progress with these novel epoxy-
tiglianes as a novel wound healing agent.  
 
3.2 Aims 
 
Due to the importance of the fibroblasts in acute skin wound healing, any alterations 
in the genotypic or phenotypic responses could alter the healing mechanisms. This 
alteration could produce a favourable scarless response, as discussed previously. 
Therefore, the aims of this Chapter were to assess the effects of EBC-46 or EBC-211 
on key fibroblastic wound healing responses, such as viability, proliferation, cell cycle 
progression, morphology; and cellular migration. In addition, the effects of EBC-46 
and EBC-211 on the differentiation of fibroblasts to myofibroblasts were evaluated, 
due to their importance to wound contraction, closure and scarring outcome in vivo.  
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3.3 Materials and Methods 
 
3.3.1 Preparation of EBC-46 and EBC-211 
EBC-46 and the lesser active analogue, EBC-211, were both supplied by QBiotics 
Ltd., Queensland, Australia. EBC-46 and EBC-211 were solubilised in DMSO 
(Section 2.1). For both compounds, concentrations of 0.001g/ml, 0.01g/ml, 
0.1g/ml, 1g/ml, 10g/ml and 100g/ml were prepared in 1% F-SCM for the 
assessment of dermal fibroblast wound healing responses (Section 2.2.1).  
 
3.3.2 Dermal Fibroblast Culture 
Dermal fibroblasts were sourced, cultured, sub-cultured, counted, cryopreserved and 
mycoplasma screened, as previously described (Sections 2.2.1, 2.2.3, 2.2.4 and 2.2.5 
respectively). 
 
3.3.3 Assessment of Dermal Fibroblast Viability and Proliferation 
The viability and proliferation of dermal fibroblasts was assessed through the use of 
an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] Dye-
Reduction assay at 24h, 72h, 120h and 168h, as previously described (Section 2.3.1).  
 
3.3.4 Assessment of Dermal Fibroblast Cell Cycling 
Dermal fibroblasts were seeded and cultured for cell cycle analysis, with samples 
obtained at T0, T22, T29 and T36 after treatment with EBC-46 or EBC-211 (0g/ml, 
0.001g/ml, 0.01g/ml, 0.1g/ml, 1g/ml and 10g/ml). Samples were prepared, 
Draq5 DNA dye added and analysed by Flow Cytometry (FACScalibur, Becton 
Dickinson, Oxfordshire, U.K.), as previously discussed (Sections 2.3.2.1, 2.3.2.3 and 
2.3.2.4).  
 
3.3.5 Assessment of Dermal Fibroblast Morphology 
Morphology of dermal fibroblasts was assessed by light microscopy, as previously 
described (Section 2.3.3). 
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3.3.6 Assessment of Dermal Fibroblast Repopulation 
Dermal fibroblast repopulation was assessed through the use of an in vitro ‘scratch 
wound’ assay, with images captured every 20min over 48h using Time-Lapse 
Microscopy, as previously described (Section 2.3.4). 
 
3.3.7 Assessment of Dermal Fibroblast-Myofibroblast Differentiation 
The assessment and confirmation of dermal fibroblast to myofibroblast differentiation 
in the presence and absence of TGF-β1 was performed through immunocytochemistry 
and quantitative polymerase chain reaction (qPCR) analysis, as previously described 
(Sections 2.3.5.1 and 2.3.5.2, respectively).  
 
3.4 Results 
 
3.4.1 Effects of EBC-46 and EBC-211 on Dermal Fibroblast Viability and 
Proliferation 
The viability and proliferation study was performed on fibroblasts cultured in EBC-46 
or EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), with 
untreated controls included for comparison purposes (0µg/ml) for both compounds. 
Average absorbance values were obtained at each EBC-46 and EBC-211 concentration 
at 24h, 72h, 120h and 168h. Values were used to calculate the variation from the 
untreated control for each concentration and time-point; and percentage calculations 
produced versus each untreated control (Figures 3.1A and 3.2A).  
 
Both EBC-46 and EBC-211 were shown to be cytotoxic at 100µg/ml. This was evident 
by the significantly decreased percentage data obtained; this was observed for both 
EBC-46 and EBC-211, from 24h onwards (p<0.001; Figures 3.1A and 3.2A, 
respectively), compared to the untreated controls (0µg/ml). However, there was a 
delayed cytotoxic effect of EBC-211, compared to EBC-46, which confirmed the 
reduced activity of EBC-211. This was evident by the longer time period required for 
a complete cytotoxic effect to occur.  
 
EBC-46 also appeared to have an anti-proliferative effect on the fibroblasts across the 
majority of concentrations. At 24h and 120h, this was only significant at a few 
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Figure 3.1: (A) Dermal fibroblast viability and proliferation percentage 
differences, following culture in the presence of EBC-46 (0µg/ml, 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), at 24h, 72h, 120h and 168h; 
(N=3, average±SE). (B) Cross-statistical analysis of significant changes in dermal 
fibroblast proliferation, following treatment with EBC-46 (0.001-100µg/ml) over 
168h, versus untreated controls (*p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 3.2: (A) Dermal fibroblast viability and proliferation percentage 
differences, following culture in the presence of EBC-211 (0µg/ml, 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), at 24h, 72h, 120h and 168h; 
(N=3, average±SE). (B) Cross-statistical analysis of significant changes in dermal 
fibroblast proliferation, following treatment with EBC-211 (0.001-100µg/ml) over 
168h, versus untreated controls (*p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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concentrations (0.001µg/ml, 1µg/ml and 10µg/ml), compared to untreated controls 
(p<0.01-0.05); there was no significant anti-proliferative effect evident at 72h 
(p>0.05). In contrast, at 168h, there was a highly significant anti-proliferative effect 
across all the concentrations, in comparison to untreated controls (p<0.001; Figure 
3.1A). As seen with EBC-46, an anti-proliferative effect was also observed with EBC-
211 (Figure 3.2A). This reduction in proliferation was significant for 0.1-10µg/ml at 
72h, 120h and 168h, in addition to 10µg/ml at 24h, when compared to untreated control 
responses (p<0.001-0.05; Figure 3.2A). A positive proliferative effect on dermal 
fibroblasts was evident upon culture with 0.001µg/ml EBC-211, significant in 
comparison to untreated controls at 168h (p<0.05; Figure 3.2A). Cross-statistical 
analysis was performed for both EBC-46 and EBC-211 (0.001-100µg/ml), comparing 
epoxy-tigliane treated cells between concentrations for both EBC-46 and EBC-211. 
This comparison only showed a few significant differences between concentrations of 
EBC-46. At 24h, there were significant differences between 0.001µg/ml and 
0.01µg/ml compared to 1µg/ml; and 0.1µg/ml compared to 10µg/ml (p<0.001-0.05; 
Figure 3.1B). In addition, at 168h, there was a significant difference between 1µg/ml 
and 10µg/ml EBC-46 (p<0.01; Figure 3.1B). The cross-statistical analysis between 
concentrations for EBC-211 showed response differences between high and low 
concentrations. Significant differences were observed between all comparisons, the 
only exception being between 0.1µg/ml and 10µg/ml EBC-211 (p<0.001-0.05; Figure 
3.2B). 
 
3.4.2 Effects of EBC-46 and EBC-211 on Dermal Fibroblast Cell Cycling 
In light of the potential anti-proliferative effects identified in Section 3.4.1, Flow 
Cytometry was further performed to determine whether treatment with EBC-46 or 
EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml) had an effect on 
the cell cycle progression of dermal fibroblasts, compared to untreated controls 
(0µg/ml); and whether this contributed to the anti-proliferative effects observed. A 
growth curve was initially performed to calculate the cycling time for an untreated 
control fibroblasts (Supplement 3.1). This determined the time-points required to 
observe the different phases of the cell cycle for the untreated fibroblast controls. The 
time-points identified were T0 (at the point of treatment), T22 (22h after treatment), 
T29 (29h after treatment) and T36 (36h after treatment). The T0 time-point was 
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analysed at point of treatment to ensure all cells were at the same synchronised state 
after serum starvation, with any differences that subsequently followed at later time-
points being a consequence of epoxy-tigliane treatment. Data obtained at T0 for both 
EBC-46 and EBC-211 showed no significant differences, compared to untreated 
control. This confirmed that the cells were all synchronised to the same cell cycle 
phase before analysis of the later time-points to determine significant changes in cell 
cycle progression (p>0.05; Figures 3.3A and 3.7A). 
 
Treatment with EBC-46 (0.001-10µg/ml) showed the significantly delayed 
progression of dermal fibroblasts through the cell cycle phases at T22 and T29. This 
was evident at 0.01-10µg/ml EBC-46 at T22 and 0.001-10µg/ml EBC-46 at T29 
(p<0.01-0.05; Figures 3.4A and 3.5A, respectively). This was shown to have a greater 
impact at T29 across the full range of EBC-46 concentrations. The untreated cells had 
progressed back into G1 phase, whereas the EBC-46 treated cells remained in S and 
G2 phases, demonstrating the delayed progression (p<0.01-0.05; Figure 3.5A). There 
was no significant difference evident at T36, between the EBC-46 treated cells and the 
untreated controls (p>0.05; Figure 3.6A). It is thought that this may be a result of 
different lengths of the dermal fibroblast cell cycle phases, with G1 being the longest 
and G2/M the shortest. This gives the appearance that the cells have caught up to the 
same cell cycle phase by T36. The accompanying cell cycle histogram shows a 
proportion of cells treated with EBC-46 remaining in G2 phase (Figure 3.6B). The cell 
cycle histograms show all conditions synchronised at T0, with the normal progression 
through the cell cycle phases for the untreated controls (Figures 3.3B, 3.4B, 3.5B and 
3.6B). However, the EBC-46 treated cells progressed through at a slower rate; this 
delayed progression through the cell cycle could contribute to the anti-proliferative 
responses previously observed.  
 
Treatment with EBC-211 showed a similar effect (Figures 3.7-3.10A), with a 
significantly delayed progression through the cell cycle at 1-10µg/ml EBC-211 at T22 
and 0.001-10µg/ml EBC-211 at T29 (p<0.01-0.05; Figures 3.8A and 3.9A, 
respectively). Due to the lesser activity of EBC-211, the lower concentrations (0.001-
0.01µg/ml) appeared to progress at a similar rate to the untreated control at T22 
(p>0.05; Figure 3.8A). This was evident in the corresponding histograms (Figures 
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Figure 3.3: (A) Dermal fibroblast cell cycle analysis at T0, following culture in the 
presence of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (all p>0.05). (B) Corresponding cell cycle histogram at T0, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 3.4: (A) Dermal fibroblast cell cycle analysis at T22, following culture in 
the presence of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T22, following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 3.5: (A) Dermal fibroblast cell cycle analysis at T29, following culture in 
the presence of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T29, following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 3.6: (A) Dermal fibroblast cell cycle analysis at T36, following culture in 
the presence of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE).  
Statistical analysis (all p>0.05). (B) Corresponding cell cycle histogram at T36, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 3.7: (A) Dermal fibroblast cell cycle analysis at T0, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (all p>0.05). (B) Corresponding cell cycle histogram at T0, 
following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 3.8: (A) Dermal fibroblast cell cycle analysis at T22, following culture in 
the presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T22, following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 3.9: (A) Dermal fibroblast cell cycle analysis at T29, following culture in 
the presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T29, following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 3.10: (A) Dermal fibroblast cell cycle analysis at T36, following culture in 
the presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml; N=3, average % in each phase±SE). 
Statistical analysis (all p>0.05). (B) Corresponding cell cycle histogram at T36, 
following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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3.7B, 3.8B, 3.9B and 3.10B). However, by T29, the delayed cell cycle progression was 
also significant at these concentrations (p<0.01-0.05; Figure 3.9A). For both 
compounds, the delayed cell cycle progression appeared to be a result of progression 
of the cells into S phase, due to delayed progression of the cells treated with epoxy-
tiglianes from G1 to S phase, compared to untreated controls. The untreated controls 
appear to have progressed into S phase by T22, whereas the epoxy-tigliane treated 
cells progression into S phase only occurs by T29. This appeared to be a dose-
dependent reaction, with the lower concentrations behaving in a similar manner to the 
untreated controls, progressing through the cell cycle phases at a similar rate. This was 
particularly evident with EBC-211, due to the lesser activity of this epoxy-tigliane 
(Figure 3.8B). 
 
3.4.3 Effects of EBC-46 and EBC-211 on Dermal Fibroblast Morphology 
EBC-46 and EBC-211 were shown to be highly cytotoxic to dermal fibroblasts at 
100µg/ml, corroborating previous proliferation data. Cellular morphology studies 
confirmed this, with the rounding and subsequent potential apoptosis or necrosis of 
fibroblasts. There was also a noticeable reduction in the number of fibroblasts present 
with the progressing time-points, along with an increased production of cell debris. 
Following 24h treatment with 100µg/ml EBC-46, some viable cells remained; whereas 
at 72h, 120h and 168h after treatment, only a few cells were present along with the 
resultant cell debris (Figures 3.11G, 3.12G, 3.13G and 3.14G). In comparison, viable 
cells were present in decreasing quantities at 24h, 72h and 120h, after treatment with 
100µg/ml EBC-211; whilst 168h was the only time-point where no viable cells 
remained (Figures 3.15G, 3.16G, 3.17G and 3.18G).  
 
Culturing fibroblasts in EBC-46 (0.01-10µg/ml) showed a dramatically altered 
morphology at 24h, producing much larger, more stellate-shaped fibroblasts, as 
opposed to the spindle-shaped cells that are characteristic of dermal fibroblasts. There 
also appeared to be an increased presence of stress fibres, showing a significant 
alteration on the cytoskeleton of the fibroblasts. In contrast, 0.001µg/ml EBC-46 
appeared to not affect the fibroblasts in the same way as the higher concentrations, 
with these cells retaining the normal morphological appearance of dermal fibroblasts 
(Figure 3.11B). Additionally, by 72h, it also appeared that the altered morphological 
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Figure 3.11: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-46 for 24h (N=3). Scale bar = 100µm. 
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Figure 3.12: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-46 for 72h (N=3). Scale bar = 100µm. 
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Figure 3.13: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-46 for 120h (N=3). Scale bar = 100µm. 
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Figure 3.14: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-46 for 168h (N=3). Scale bar = 100µm. 
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Figure 3.15: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-211 for 24h (N=3). Scale bar = 100µm. 
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Figure 3.16: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-211 for 72h (N=3). Scale bar = 100µm. 
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Figure 3.17: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-211 for 120h (N=3). Scale bar = 100µm. 
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Figure 3.18: Dermal fibroblast morphology, cultured in the presence of (A) 
0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and 
(G) 100µg/ml EBC-211 for 168h (N=3). Scale bar = 100µm. 
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changes induced by 24h, revert back to a more normal spindle-shaped morphology, 
which remained this way through 120h and 168h. There also appeared to be reduced 
cell numbers across the EBC-46 concentrations, compared to untreated controls 
(0µg/ml); in line with the data obtained from the viability and proliferation studies.  
 
Fibroblasts at the higher concentrations of EBC-211 (1-10µg/ml) also showed the 
same altered morphology as EBC-46, with a more stellate-structure and presence of 
stress fibres (Figures 3.15E-F). As with EBC-46, there was a reversion back to a more 
typical fibroblast morphology by 72h, which remained at 120h and 168h. In contrast, 
at the lower concentrations of EBC-211 (0.001-0.1µg/ml), there was little effect on 
fibroblast morphology at any time-point, with morphologies retaining the normal 
spindle-shape similar to untreated controls. Confirming the anti-proliferative effect of 
EBC-211, there again appeared to be reductions in cell number at the higher 
concentrations, compared to untreated controls (0µg/ml) at the later time-points, in 
line with the previous viability and proliferation data.   
 
3.4.4 Effects of EBC-46 and EBC-211 on Dermal Fibroblast Repopulation 
Digital images obtained over 48h showed the repopulation of the denuded sites by 
dermal fibroblasts. Cells were cultured in EBC-46 or EBC-211 (0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), with untreated controls 
(0µg/ml) included for comparison purposes (Figures 3.19 and 3.20, respectively). The 
digital images were converted into time-lapse movies (Supplement 3.2), using LAS 
AF lite (Leica Software, Version 4.0.11706, Leica Microsystems (UK) Ltd), to show 
the repopulation of dermal fibroblasts over the 48h time-period. 
 
As expected, untreated controls showed complete re-population of the denuded site 
within 48h, with normal migration and proliferation of dermal fibroblasts occurring. 
Confirming previous proliferation data, the cytotoxic nature of both EBC-46 and EBC-
211 was observed at 100µg/ml for both epoxy-tiglianes. At 100µg/ml, EBC-46 and 
EBC-211, the fibroblasts did not migrate into the denuded space and were seen to 
round up and undergo cell death, releasing cell debris as a result, over the 48h period 
(Figures 3.19G and 3.20G, respectively). 
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Figure 3.19: Dermal fibroblast scratch wound repopulation, in the presence of 
(A) 0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; 
and (G) 100µg/ml EBC-46, over 48h (N=3). Red dashed lines show original 
scratch wound distance at 0h. Scale bar = 100µm. 
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Figure 3.20: Dermal fibroblast scratch wound repopulation, in the presence of 
(A) 0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; 
and (G) 100µg/ml EBC-211, over 48h (N=3). Red dashed lines show original 
scratch wound distance at 0h. Scale bar = 100µm. 
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Repopulation data for the other concentrations of EBC-46 (0.001-10µg/ml) assessed, 
confirmed previous viability and proliferation findings, showing a reduced cell number 
present compared to untreated controls; although the fibroblasts were seen to increase 
in size and produce long processes from their cytoskeleton (Figure 3.19A-F). At 0.01-
10µg/ml EBC-46, there was a perceived reduced number of fibroblasts observed in the 
denuded sites, compared to untreated controls; and therefore, reduced closure of the 
wound space. However, the large stellate morphology of the fibroblasts may give the 
appearance of successful wound closure (Figure 3.19).  
 
The lower concentrations of EBC-211 (0.001-0.01µg/ml) appeared to achieve wound 
closure within 48h, in a comparable manner to untreated controls (0µg/ml; Figure 
3.20B-C). In contrast, 0.1-10µg/ml EBC-211 showed an apparently reduced 
repopulation, through a reduced number of fibroblasts evident in the denuded sites. At 
these concentrations, the fibroblasts appeared to be larger, more stellate-shaped and 
produce long processes (Figure 3.20D-F). 
 
The fibroblast repopulation data was further analysed using ImageJ to identify any 
significant differences in various parameters associated with the fibroblast migratory 
responses, in the presence of EBC-46 and EBC-211 (0.001-100µg/ml), compared to 
untreated controls. These included distance travelled (Figures 3.21A and 3.22A, 
respectively), cell displacement (Figures 3.21B and 3.22B, respectively), speed 
(Figures 3.21C and 3.22C, respectively); and overall cell velocity (Figures 3.21D and 
3.22D, respectively).  
 
Due to the high variability in the movements of fibroblasts treated with EBC-46 (0.01-
10µg/ml), no significant differences were observed, when compared to untreated 
controls for the distance travelled, cell displacement, speed or overall velocity 
(p>0.05). For these EBC-46 concentrations, there was a large variability in the motility 
responses of the fibroblasts, ranging from rapid migration across the well to inhibited 
or greatly reduced migration. Further evidence of this can be viewed in the time-lapse 
movies (Supplement 3.2). This large variability in cell behaviour accounts for the high 
error bars, which prevented any significant differences being observed across the 
concentrations. 
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Figure 3.21: Dermal fibroblast migration analysis, in the presence of EBC-46 
(0µg/ml, 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), (A) distance 
travelled (Tt), (B) cell displacement (Td), (C) speed (Tt/min) and (D) overall 
velocity (Td/min) at 48h (N=3, average±SE, p>0.05). 
 
A 
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Figure 3.22: Dermal fibroblast migration analysis, in the presence of EBC-211 
(0µg/ml, 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), (A) distance 
travelled (Tt), (B) cell displacement (Td), (C) speed (Tt/min) and (D) overall 
velocity (Td/min) at 48h (N=3, average±SE, p<0.01). 
 
A 
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Similar observations were apparent with EBC-211 (0.001-0.01µg/ml and 10µg/ml), 
with no significant differences observed in distance travelled, cell displacement, speed 
or overall velocity, when compared to untreated controls (p>0.05). However, 
significant differences in fibroblast distance travelled and speed were observed at 0.1-
1µg/ml EBC-211 (Figures 3.22A and 3.22C, respectively; p<0.01), with a reduction 
in both parameters compared to untreated controls; which could account for the 
reduced repopulation observed in the time-lapse movies (Supplement 3.2).  
 
3.4.5 Effects of EBC-46 and EBC-211 on Dermal Fibroblast-Myofibroblast 
Differentiation by Immunocytochemistry 
Immunocytochemical analysis was performed on dermal fibroblasts cultured in either 
EBC-46 or EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), with 
an untreated control included for comparison purposes (0µg/ml) for both compounds. 
These experiments were performed in the presence and absence of TGF-β1 (10ng/ml). 
Confirmation of dermal fibroblast differentiation to a contractile myofibroblast was 
through positive staining of α-smooth muscle actin (α-SMA) and the presence of stress 
fibres at 72h, especially evident in cultures supplemented with TGF-β1 (Gabbiani 
2003; Li & Wang 2011). An additional control was included without the incubation of 
the primary α-SMA antibody, this confirmed that non-specific binding of the 
secondary antibody was not occurring as no α-SMA staining was evident (Figures 
3.23H, 3.24H, 3.25H and 3.26H; Burry 2011). 
 
Fibroblasts cultured with EBC-46 (0.001-10µg/ml) and in the presence of TGF-β1 
(10ng/ml), showed varying results when compared to untreated controls (Figure 
3.23A-F). The lower concentrations of EBC-46 (0.001-0.01µg/ml) displayed no 
obvious differences compared to the controls, with a comparable presence of α-SMA 
and stress fibres. However, there were noticeable morphological differences observed 
at 0.1µg/ml EBC-46, as despite α-SMA staining, this was localised to the perinuclear 
region of the cells only. Consequently, there was a distinct lack of stress fibres present 
in 0.1µg/ml EBC-46-treated cells. The α-SMA staining and lack of stress fibres 
appeared more representative of the untreated control in the absence of TGF-β1 (Figure 
3.23G); although the α-SMA staining for 0.1µg/ml EBC-46 appeared to extend along  
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Figure 3.23: Immunocytochemical analysis of dermal fibroblast differentiation to 
myofibroblasts in the presence of TGF-β1 and (A) 0µg/ml, (B) 0.001µg/ml, (C) 
0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml EBC-46, (G) 0µg/ml in the 
absence of TGF-β1 and (H) primary antibody-free control, for 72h (N=3). Scale 
bar = 100µm.  
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Figure 3.24: Immunocytochemical analysis of dermal fibroblast differentiation to 
myofibroblasts in the presence of TGF-β1 and (A) 0µg/ml, (B) 0.001µg/ml, (C) 
0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml EBC-211, (G) 0µg/ml in the 
absence of TGF-β1 and (H) primary antibody-free control, for 72h (N=3). Scale 
bar = 100µm.  
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Figure 3.25: Immunocytochemical analysis of dermal fibroblast differentiation to 
myofibroblasts in the absence of TGF-β1 and (A) 0µg/ml, (B) 0.001µg/ml, (C) 
0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml EBC-46; (G) 0µg/ml in the 
presence of TGF-β1 and (H) primary antibody free-control, for 72h (N=3). Scale 
bar = 100µm. 
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Figure 3.26: Immunocytochemical analysis of dermal fibroblast differentiation to 
myofibroblasts in the absence of TGF-β1 and (A) 0µg/ml, (B) 0.001µg/ml, (C) 
0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml EBC-211, (G) 0µg/ml in the 
presence of TGF-β1 and (H) primary antibody-free control, for 72h (N=3). Scale 
bar = 100µm.  
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the length of the cell, as opposed to being localised around the nuclear region in the 
untreated control. At higher concentrations of EBC-46 (1-10µg/ml), α-SMA staining 
were again present along with the stress fibres, although there were some alterations 
from the typical myofibroblast morphology, as the stress fibres appeared less uniform 
and were not organised as tightly around the nuclear region.  
 
Similar results were seen when fibroblasts were cultured with EBC-211 (0.001-
10µg/ml) in the presence of TGF-β1 (Figure 3.24A-F). The lower concentrations of 
EBC-211 (0.001-0.01µg/ml) showed no major differences in α-SMA staining or in the 
organisation of the stress fibres, when compared to untreated controls (Figure 3.24B-
C). However, at 10µg/ml EBC-211, there was again a distinct lack of stress fibres, 
despite the presence of α-SMA staining localised around the perinuclear region, 
showing similarities to the morphology and α-SMA staining seen in the untreated 
control in the absence of TGF-β1 (Figure 3.24G); as seen previously with 0.1µg/ml 
EBC-46. At 0.1-1µg/ml EBC-211, cells exhibited a slightly altered morphology 
compared to untreated controls, as the stress fibres were present and uniform in their 
organisation (Figures 3.24D-E). However, they appeared to demonstrate a narrower 
cell shape, with the stress fibres remaining quite close to the nuclear region.   
 
These studies were repeated for EBC-46 (0.001-10µg/ml), but in the absence of TGF-
β1 (Figure 3.25A-F). There were no major differences observed in either the α-SMA 
content or in cell morphology at 0.001µg/ml EBC-46, compared to controls. However, 
at higher EBC-46 concentrations (0.01-10µg/ml), cells had altered morphologies with 
the production of α-SMA stress fibres, despite cultures containing no TGF-β1. This 
was similar to the altered morphologies evident in the light microscopy studies 
(Section 3.4.3). In addition, cells at 0.1-10µg/ml EBC-46 also showed altered 
morphologies, with more stellate-shaped cells and the production of actin protrusions, 
as seen previously with the fibroblast repopulation studies (Section 3.4.4), with the 
increased fibroblast size and production of long processes from their cytoskeleton. 
These morphologies, with the presence of TGF-β1 and stress fibres, appear more 
representative of the untreated control in the presence of TGF-β1 (Figure 3.25G). 
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When repeated with EBC-211 (0.001-10µg/ml) in the absence of TGF-β1 (Figure 
3.26A-F), there were no major differences observed in the morphology of the cells or 
the α-SMA content between the lower concentrations of EBC-211 (0.001-0.01µg/ml) 
and the untreated controls (Figures 3.26B-C). At the higher concentrations of EBC-
211 (0.1-10µg/ml), there was evidence of stress fibre formation and altered 
morphologies, similar to those seen previously with the morphology and repopulation 
studies (Figures 3.26D-F). Similar to the response seen with EBC-46, these 
morphologies, with the presence of TGF-β1 and stress fibres, appear more 
representative of the untreated control in the presence of TGF-β1 (Figure 3.26G). 
 
3.4.6 Confirmation of EBC-46 and EBC-211 Effects on Dermal Fibroblast-
Myofibroblast Differentiation by Quantitative Polymerase Chain 
Reaction (qPCR) 
Following on from the immunocytochemistry studies, qPCR analysis was performed 
to determine the gene expression levels of α-SMA upon culture in EBC-46 or EBC-
211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), with an untreated 
control also included for comparison purposes (0µg/ml) for both compounds. These 
experiments were performed in the presence and absence of TGF-β1 (10ng/ml), for 
72h.  
 
Fibroblasts cultured with EBC-46 (0.001-10µg/ml) and in the presence of TGF-β1 
(10ng/ml) were compared to two untreated controls (Figure 3.27A), one in the 
presence of TGF-β1 (positive control) and the other in the absence of TGF-β1 (negative 
control). Some EBC-46 concentrations (0.01µg/ml and 1-10µg/ml) showed no 
significant difference in α-SMA expression, compared to the TGF-β1 positive control 
(p>0.05; Figure 3.27A). This confirmed the immunocytochemistry data (Figure 3.23C, 
E and F), where no major differences were observed. However, there was a significant 
increase in α-SMA expression at 0.001µg/ml EBC-46, compared to the positive 
controls (p<0.05; Figure 3.27A), suggesting the presence of more α-SMA stained 
stress fibres (Figure 3.23B). However, at 0.1µg/ml EBC-46, there was a significant 
reduction in the expression of α-SMA, compared to positive controls, with 
approximately 2.5-fold lower expression (p<0.001; Figure 3.27A). This corroborated 
the lack of stress fibres observed by immunocytochemistry and the unique and specific   
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Figure 3.27: α-SMA expression during dermal fibroblast-myofibroblast 
differentiation in the presence of TGF-β1 and (A) EBC-46 and (B) EBC-211, at 
(0µg/ml, 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml) for 72h; (N=3, 
average±SE; *p<0.05, **p<0.01, ***p<0.001, compared to untreated controls).  
A 
 
B 
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Figure 3.28: α-SMA expression during dermal fibroblast-myofibroblast 
differentiation in the absence of TGF-β1 and in the presence of (A) EBC-46 and 
(B) EBC-211, at (0µg/ml, 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml) 
for 72h; (N=3, average±SE; *p<0.05, ***p<0.001, compared to untreated controls).  
A 
 
B 
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response at this concentration (Figure 3.23D). Interestingly, the α-SMA expression at 
this concentration was approximately 13-fold higher than the negative controls (Figure 
3.27A). This showed that expression of α-SMA is still induced in fibroblasts at 
0.1µg/ml EBC-46, but not to the same extent as in stimulated fibroblasts.   
 
α-SMA expression after treatment with EBC-211 (0.001-1µg/ml) was not significantly 
different to the positive controls (p>0.05; Figure 3.27B), corroborating the previous 
immunocytochemistry data (Figure 3.24B-E). However, at 10µg/ml EBC-211, there 
was a significant reduction in α-SMA expression, also approximately 2.5-fold lower, 
compared to stimulated fibroblasts (p<0.01; Figure 3.27B). As evident with 0.1µg/ml 
EBC-46; this result also showed a higher expression of α-SMA than the negative 
control, approximately 9-fold higher.  
 
The fibroblasts that were treated with 0.001-1µg/ml EBC-46 and in the absence of 
TGF-β1 showed a significant increase in α-SMA expression, compared to untreated 
negative controls (p<0.001; Figure 3.28A), whereas there was no significant increase 
in expression with the highest concentration of EBC-46 (10µg/ml; p>0.05; Figure 
3.28A). Despite there being a significant increase in α-SMA expression 
(approximately 1.5-3.5-fold), compared to the negative controls, the levels of α-SMA 
expression were still much lower than the positive controls (approximately 10-fold 
lower), than in the presence of TGF-β1 (Figure 3.28A). The increased α-SMA 
expression corroborated the immunocytochemistry studies, where an increased 
presence of stress fibres was observed following 0.001-1µg/ml EBC-46 treatment, in 
the absence of TGF-β1 (Figure 3.25B-E).  
 
Treatment with EBC-211 in the absence of TGF-β1 (Figure 3.28B) showed a similar 
response to previously seen with EBC-46. However, due to the approximately 100-
fold reduced activity of EBC-211, compared to EBC-46 (Boyle et al. 2014; Reddell et 
al. 2014), this increase was significant at 0.1-10µg/ml EBC-211, compared to the 
negative control (p<0.001-0.05; Figure 3.28B). As before, the increased α-SMA 
expression (approximately 1.5-2.5-fold) compared to the negative control, 
corroborated the immunocytochemistry studies, where there was an increased 
presence of stress fibres after EBC-211 treatment at these concentrations (Figure 
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3.26D-F). However, the α-SMA expression levels were still much lower 
(approximately 13-fold lower), than the stimulated fibroblasts following treatment 
with TGF-β1 (Figure 3.28B).   
 
3.5 Discussion 
 
This Chapter focused on assessing the effect of the novel epoxy-tiglianes, EBC-46 and 
EBC-211, on key fibroblast wound healing responses, due to their necessary roles in 
acute skin wound healing processes. The palliative animal studies performed by 
QBiotics Ltd. have previously demonstrated the profound effects of these compounds 
in vivo (Reddell & Gordon 2007; Reddell et al. 2014). However, in order to progress 
towards human clinical trials, it was necessary to fully understand these events at a 
cellular level. It is already known that there is a fine balance between the successful 
and impaired healing of wounds, as slight changes in gene expression or the function 
of fibroblasts may have a detrimental effect on wound healing outcomes. This is shown 
through multiple forms of impaired healing, such as chronic wounds or the excessive 
scar tissue formation observed with keloid and hypertrophic scars (Bran et al. 2009; 
Shih et al. 2010). However, it may be possible to induce a regenerative response and 
allow adult wounds to heal preferentially, as opposed to the remodelling process that 
normally occurs. This regenerative healing process would potentially result in the 
rapid, scarless healing typically only seen in early-gestational foetal wounds and in the 
oral mucosa (Nauta et al. 2011; Rolfe & Grobbelaar 2012). The palliative animal 
studies undertaken by QBiotics Ltd. appeared to show this beneficial response by the 
exceptional healing response and a distinct lack of visible scarring, following EBC-46 
treatment, implying that EBC-46 and other epoxy-tiglianes may exert these effects, at 
least in part, via the mediators of preferential healing. 
 
The initial proliferation and viability studies observed through use of an MTT assay 
determined the cytotoxic level of both epoxy-tiglianes as 100µg/ml. This is evident 
within 24h of treatment and resulted in no viable cells remaining by 168h for both 
EBC-46 and EBC-211. This was found to be highly significant (p<0.001), evident by 
a dramatic reduction in the cell viability readings, in comparison to the respective 
untreated controls. However, EBC-46 showed a more profound cytotoxic effect than 
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EBC-211, due to the 100-fold lesser activity of EBC-211 (Boyle et al. 2014; Reddell 
et al. 2014). This was evident by a cytotoxic response at 24h for EBC-46 treatment 
and at 72h for EBC-211 treatment. The cytotoxic effect was also visualised during the 
morphology and repopulation studies, where cells initially rounded up and eventually 
burst, with blebbing occurring. A resultant loss of integrity to the cell membrane 
resulted in the cells releasing their contents. This observation suggested that necrosis 
was responsible for the cytotoxic effect observed, rather than apoptosis (Ogbourne et 
al. 2004; Elmore 2007). Despite it appearing to be a necrotic process, it is still possible 
that apoptosis was occurring, as the cells were cultured in vitro and therefore any 
apoptotic bodies would not be phagocytosed. This lack of clearance of apoptotic 
bodies leads to secondary necrosis, also termed apoptotic necrosis, which may be what 
was being observed in this study (Saraste & Pulkki 2000; Ziegler & Groscurth 2004; 
Fink & Cookson 2005; Elmore 2007; Elliott & Ravichandran 2010). Apoptosis and 
necrosis used to be described as opposite responses. However, it has been shown that 
there may be intermediate forms, especially in terms of in vitro studies. There are 
numerous other cell death mechanisms known, such as oncosis, autophagy and 
pyroptosis, so further studies would be required to determine which cell death 
mechanism is occurring (Ziegler & Groscurth 2004; Fink & Cookson 2005; Elmore 
2007).  
 
At the other concentrations of EBC-46 (0.001-10µg/ml), there appeared to be an 
overall anti-proliferative response in fibroblasts after EBC-46 or EBC-211 treatment, 
particularly at the later time-point (168h) for 0.001-10µg/ml EBC-46 and at 72h, 120h 
and 168h for 0.1-10µg/ml EBC-46. This decrease in fibroblast proliferation is believed 
to be a result of a direct anti-proliferative action, as opposed to the cytotoxic effect 
observed at 100µg/ml. This conclusion is based on the visualisation of viable cells for 
the full 168h duration of the study. Despite this anti-proliferative response being 
statistically significant, the decrease in proliferative ability compared to untreated 
controls appears to be marginal, especially following treatment with EBC-46; 
therefore, there is a possibility that this anti-proliferative response will not be 
biologically significant. It is possible that the anti-proliferative responses observed are 
a result of a phenotypic change in the fibroblasts to resemble those present at a wound 
site, which have a decreased proliferative ability, but are involved in collagen 
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production to fill the denuded site (Beldon 2010). Indeed, as described previously, 
there were dramatic morphological changes in the fibroblasts at 24h, to form a more 
stellate-shaped structure. This morphology is similar to that of senescent cells or those 
undergoing differentiation, with the formation of stress fibres (Gabbiani 2003; 
Campisi & d’Adda di Fagagna 2007).  
 
However, this dramatic morphological alteration of the fibroblasts was found to be 
reversible, with normal stellate-shaped fibroblasts returning by 72h and remaining for 
the duration of the experiment. Although, it is currently unknown what is occurring to 
induce this response, the potential benefits could be significant, if treatment with the 
novel epoxy-tiglianes are capable of stimulating a reversible fibrosis response. This 
would have profound implications on the wide array of fibrotic diseases, including the 
excessive scarring observed in keloid and hypertrophic scars (Darby et al. 2014). A 
number of studies have been performed to reduce the incidence of excessive scarring, 
through reduction of myofibroblast activity. This included inducing myofibroblast 
apoptosis, reducing myofibroblast function, activation of inhibitory myofibroblast 
differentiation factors; and the reduction of stimulatory myofibroblast differentiation 
factors (Chitturi et al. 2015). Further studies would be required to determine whether 
any of these mechanisms are induced following epoxy-tigliane treatment, in particular 
the stimulation or inhibition of crucial factors, resulting in inhibition of myofibroblast 
differentiation; differentially expressed factors could be elucidated through global 
gene analysis on myofibroblast treated with epoxy-tiglianes.  
 
An initial theory was that the cells were becoming senescent, due to the anti-
proliferative response and increased morphology of the cell, features seen in senescent 
fibroblasts (Hayflick 1965; Campisi & d’Adda di Fagagna 2007). Senescent cells 
prevent cell growth by halting progression through the cell cycle; this could explain 
why the fibroblasts did not proliferate at a normal rate, despite the medium being 
replenished every 48 hours, but also remain viable as senescent cells resist apoptosis 
(Campisi & d’Adda di Fagagna 2007). As senescent cells have an altered gene 
expression from those that continue normally through the cell cycle, gene analysis 
could be performed to determine whether these cells are indeed senescent. By 
assessing for specific markers that are associated with senescence, such as senescence-
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associated β-galactosidase, p53, p21WAFI, p16INK4A, senescence-associated DNA-
damage foci and senescence-associated heterochromatin foci (Campisi & d’Adda di 
Fagagna 2007; Rodier & Campisi 2011). However, despite the anti-proliferative 
response following treatment with EBC-46 or EBC-211, the fibroblasts were observed 
to continue proliferating across the 168h time period of the viability/proliferation 
study. Therefore, it is thought that treatment with EBC-46 or EBC-211 results in a 
delayed cell cycle progression, not an induction of senescence.  
 
This response was confirmed with the flow cytometry studies, assessing the 
progression and proportion of cells in the cell cycle phases at 0h, 22h, 29h and 36h; an 
overall anti-proliferative response was observed. This delayed progression of the cell 
cycle after EBC-46 or EBC-211 treatment appeared to be a result of a delayed 
progression of the cells into S phase, which could be a result of S phase checkpoints 
promoting the delayed progression of the cell cycle. This would reduce the replicative 
activity of the cell and contribute to the anti-proliferative effect (Bartek et al. 2004). 
Such responses may have an impact on the ablation of solid tumours and sarcoids, 
through decreasing the volume of fibroblasts present at the tumour site and fibroblast-
rich sarcoids; and the reduced activation to contractile myofibroblasts (Knottenbelt 
2005; Darby et al. 2014). Chronic wound fibroblasts are typically associated with a 
decreased proliferative capabilities and premature senescence. In contrast, an 
increased presence and activation of fibroblast proliferation occurs in keloid and 
hypertrophic scars, reiterating the delicate balance between successful and impaired 
healing (Wall et al. 2008; Bran et al. 2009; Peake et al. 2014; Jumper et al. 2015; Roper 
et al. 2015). 
 
In addition to the anti-proliferative responses evident following EBC-46 or EBC-211 
treatment, a potentially reduced migratory and wound closure ability in these 
fibroblasts was also observed through the incomplete closure of in vitro scratch 
wounds. This was shown through a decreased number of cells appearing to repopulate 
denuded sites, compared to untreated controls. This response along with the anti-
proliferative action potentially results in a reduction of fibroblasts at the wound site, 
decreasing the potential for subsequent myofibroblast formation. Additionally, the 
time-lapse movies showed atypical motility of the fibroblasts following epoxy-tigliane 
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treatment (Supplement 3.2). The higher concentrations of EBC-46 (0.01-10µg/ml) and 
EBC-211 (0.1-10µg/ml), in particular, showed abnormal fibroblast motility. The 
dramatically altered behaviour of fibroblasts was demonstrated in the time-lapse 
movies, with rapid mobility observed in some fibroblasts and a perceived impaired 
mobility in others following EBC-46 or EBC-211 treatment. However, potentially due 
to this wide variability in cellular behaviour, there were no significant differences in 
migration observed following EBC-46 treatment, despite the noticeable effect on 
wound repopulation. Following EBC-211 treatment, there was no significant effect on 
cell displacement or overall velocity. However, there was a significant decrease in 
distance travelled and speed of the fibroblasts at 0.1-1µg/ml EBC-211, resulting in a 
decreased migratory action at these conditions. Impaired fibroblast migratory 
responses are observed in chronic wounds, due to reduced growth factor presence, 
resulting from increased proteolytic degradation (Menke et al. 2007; Barrientos et al. 
2008). Migration of fibroblasts into the wound site is crucial for successful synthesis 
of ECM components; in addition to wound contraction, aiding wound closure (Reinke 
& Sorg 2012; Bainbridge 2013).  
 
Profound changes in the cell structure were also evident during this time-lapse 
procedure, with some cells exhibiting a much larger morphology, which could give the 
appearance of wound repopulation and closure, due to individual cells covering a 
larger area. In addition to the larger, stellate-shaped fibroblasts, cells with very long 
processes were also observed in epoxy-tigliane treated fibroblasts, prior to migration. 
It is possible that these processes are part of the actin cytoskeleton in fibroblasts, 
responsible for forming projections during cell crawling, in order to migrate 
(Ananthakrishnan & Ehrlicher 2007). However, it appears that the actin cytoskeleton 
is significantly affected by treatment with EBC-46 or EBC-211, due to the production 
of numerous projections instead of one uniform projection towards a chemotactic 
signal, along with failure to retract the projection after movement (Van Haastert & 
Devreotes 2004; Ananthakrishnan & Ehrlicher 2007). It is not yet known what is 
causing such changes to the atypical fibroblast morphology and cytoskeletal structure. 
It is possible that the cytoskeletal changes are a result of alterations in Rho family 
GTPases, within the Ras superfamily. These proteins, Rho, Rac and CDC42, are 
involved in actin cytoskeleton regulation, cell migration, stress fibre and focal 
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adhesion formation (Kaibuchi et al. 1999; Wozniak et al. 2004; Parri & Chiarugi 2010; 
Parsons et al. 2010; Petrie & Yamada 2012). Downstream from Rho, the Rho-
associated kinase (ROCK) is involved in stress fibre formation, contraction and focal 
adhesion formation. This effector is capable of maintaining tension, through ROCK-
mediated contraction, with ROCK1 appearing to be the form involved in stress fibre 
formation (Schwartz 2004; Wozniak et al. 2004; Amano et al. 2010; Parsons et al. 
2010). Rac is primarily involved in the motility of fibroblasts, through activation at the 
leading edge and needed for lamellipodia extension; in addition to a vital role in focal 
adhesion formation, activating when cells adhere to the ECM (Schwartz 2004; Parri & 
Chiarugi 2010; Parsons et al. 2010; Petrie & Yamada 2012). Changes in the gene 
expression for these could be elucidated through global gene analysis, following 
epoxy-tigliane treatment, indicating whether changes in stress fibre and focal adhesion 
formation are present. The fibroblasts were cultured in 1% foetal calf serum (FCS), so 
a low expression of growth factors were present which stimulate growth and viability 
of cells. Therefore, there is a possibility that treatment with the novel epoxy-tiglianes, 
along with 1% FCS may result in a fibroblast-myofibroblast differentiation response, 
producing the altered morphology observed (Gabbiani 2003; Zheng et al. 2006).  
 
As mentioned, myofibroblasts have a different morphology to fibroblasts, with 
myofibroblasts expressing higher α-SMA levels and possessing stress fibres. A 
combination of these two factors positively confirm the presence of true 
myofibroblasts. α-Actin is the form present in myofibroblasts, while β- and γ-actin are 
present in fibroblasts. Therefore, α-SMA is the isoform used as a marker to detect that 
myofibroblast differentiation has occurred (Gabbiani 2003).  Proto-myofibroblasts are 
an intermediate point between fibroblasts and smooth muscle cells, possessing some 
stress fibres, but these do not express high levels of the α-actin isoform that 
characterise myofibroblasts. The differentiation of fibroblasts to myofibroblasts is 
activated by the presence of TGF-β1 (Evans et al. 2003; Gabbiani 2003). Actin fibres 
also produce cell to cell connections, which are necessary for the contractile function 
of myofibroblasts. This contraction is essential in wound healing for closing the wound 
edges together; however, increased contraction does lead to increased scar tissue 
formation (Evans et al. 2003; Li & Wang 2011).  
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At 0.1µg/ml EBC-46 and 10µg/ml EBC-211 in the presence of TGF-β1, despite α-
SMA being expressed, it was not present along stress fibres as typically observed 
following TGF-β1 stimulation, but remained localised to the perinuclear regions of the 
cells. Due to the definition that a true myofibroblast must possess both α-SMA staining 
and have the contractile stress fibres present, these cells are not true myofibroblasts 
(Gabbiani 2003). This was confirmed with qPCR studies, where there was a significant 
reduction in α-SMA expression, although this was still markedly higher than the TGF-
β1-free control. Nonetheless, such findings imply that at these specific EBC-46 and 
EBC-211 concentrations, there is an inhibition of myofibroblast formation. As 
mentioned previously, mechanisms of myofibroblast inhibition have been studied and 
a number of compounds have been shown to reduce or inhibit this fibrotic response. 
One agent capable of inhibiting TGF-β1-induced, myofibroblast differentiation is 
endogenous aryl hydrocarbon (AhR) ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-
carboxylic acid methyl ester (ITE), which has potential as an anti-fibrotic therapy 
(Lehmann et al. 2011). Another agent able to inhibit fibrosis is the synthetic PPAR-γ 
agonist, triterpenoid, through blocking TGF-β/Smad and Akt signalling pathway; the 
synthetic triterpenoid is oleanane 2-cyano-3,12-dioxoolean-1,9-dien-28-oic (CDDO), 
which has been shown to a possess good safety profile, resulting in a promising 
potential as an anti-scarring therapy (Wei et al. 2014). There are a number of other 
biologically-derived and synthetic pharmaceuticals that possess TGF-β-mediated anti-
fibrotic responses on a variety of tissues, including ginsan, trichostatin A, relaxin, 
resveratrol and curcumin (Heeg et al. 2005; Olson et al. 2005; Masamune et al. 2006; 
Glenisson et al. 2007; Guo et al. 2009; Ahn et al. 2011). As mentioned in Chapter 1, 
TGF-β-mediated responses act through SMAD signalling pathway to induce the 
fibroblast-myofibroblast differentiation. Therefore, EBC-46 and EBC-211 may exert 
their responses through inhibition of SMADs; previous studies have shown SMAD3 
inhibition reduces myofibroblast formation, resulting in an anti-fibrotic therapy (Evans 
et al. 2003; Javelaud & Mauviel 2004; Schiller et al. 2004; Darby et al. 2016). 
Additionally, hyaluronan is also involved in TGF-β-mediated fibroblast to 
myofibroblast differentiation, with inhibition of hyaluronan synthesis inhibiting this 
response; therefore, the epoxy-tigliane-mediated responses may occur due to 
hyaluronan synthesis inhibition (Jenkins et al. 2004; Meran et al. 2007; Webber et al. 
2009). Further studies would be required to determine which mechanism is impacted 
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by epoxy-tigliane treatment to inhibit fibroblast-myofibroblast differentiation at 
0.1µg/ml EBC-46 and 10µg/ml EBC-211; comparisons to the other epoxy-tigliane 
concentrations would also be of interest to determine why this response only occurs at 
these specific concentrations.  
 
As activation of protein kinase C (PKC) isoforms and subsequent downstream 
signalling pathways have previously been associated with these novel epoxy-tiglianes, 
in particular EBC-46; this could be the mechanism by which EBC-46 and EBC-211 
mediate these responses during myofibroblast formation (Boyle et al. 2014). Further 
work will be necessary to look at the impact of epoxy-tigliane treatment on TGF-β1-
mediated, fibroblast-myofibroblast differentiation, using pan- and specific-PKC 
inhibitors, to determine what roles PKCs have in stress fibre formation.  Alternatively, 
due to the lack of stress fibre formation, but the expression of α-SMA, albeit reduced, 
it is possible that the cells present are not either a differentiated myofibroblast or an 
undifferentiated fibroblast. Therefore, further studies are required to understand this 
situation fully. An initial theory was that the cells were forming an intermediate proto-
myofibroblast form. However, as mentioned previously, proto-myofibroblasts also 
possess stress fibres, which are noticeably absent at 0.1µg/ml EBC-46 and 10µg/ml 
EBC-211 (Gabbiani 2003; Micallef et al. 2012). In addition α-actin is present, albeit 
at a lower expression than seen in true myofibroblasts, whereas β- and γ-actin are the 
forms known to be present in proto-myofibroblasts, with no expression of α-SMA 
(Gabbiani 2003; Micallef et al. 2012; Darby et al. 2014). Consequently, the presence 
of the α-actin isoform seems to indicate that this theory is unlikely. Another probability 
is that they could be transforming into fibrocytes, a circulating cell type involved in 
wound repair and fibrotic tissue development; capable of expressing α-SMA albeit at 
lower levels (Reilkoff et al. 2011; Calderhead & Goo 2014). In a similar scenario, the 
studies performed in the absence of TGF-β1 show an increase of α-SMA expression, 
albeit reduced compared to positive controls, with some stress fibre formation. This 
could be another example of the differentiation to a myofibroblast phenotype not being 
complete.  
 
This dramatic effect on the myofibroblast differentiation process at these specific 
concentrations of EBC-46 and EBC-211 may indicate the potential action these novel 
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epoxy-tiglianes have on myofibroblast differentiation by inhibiting or reducing the 
contractile myofibroblast formation. If this is the case, EBC-46 or EBC-211 may have 
a use as an anti-scarring treatment and be of particular use in excessive scarring 
situations, such as keloid and hypertrophic scarring (Gauglitz et al. 2011). Foetal 
wound healing is an example of successful wound healing with a reduced presence of 
α-SMA expressing myofibroblasts, with actin ‘purse-string’ closure observed in early-
gestational foetal wounds. Of interest, myofibroblast presence increases with 
gestational age, with late-gestational wounds displaying myofibroblast presence and 
scarring (Redd et al. 2004; Satish & Kathju 2010; Otranto et al. 2012; Yates et al. 
2012). Oral mucosal wounds have also been associated with a minimal scarring 
response following injury, this is despite an enhanced collagen contraction, potentially 
due to the increased motility of oral fibroblasts resulting in an increased migration into 
the wound site to re-establish the ECM (Shannon et al. 2006; Meran et al. 2008). The 
reduced scarring response may be a result of a significantly lowered presence of TGF-
β1 expression in oral wounds, when compared to dermal wounds; as TGF-β1 is strongly 
involved in the induction of fibroblast to myofibroblast differentiation, this decreased 
expression also results in a reduced α-SMA expression in oral mucosa and the 
potentially subsequent reduction in myofibroblast presence (Szpaderska et al. 2003; 
Shannon et al. 2006). Low levels of TGF-β1 have been observed in both early-
gestational foetal and oral mucosal wounds, leading to the theory that it is a reduced 
presence of myofibroblasts that allows scarless or minimal scarred healing to occur; 
and not an overall reduction in contraction of the wound (Bullard et al. 2003; 
Szpaderska et al. 2003; Shannon et al. 2006; Meran et al. 2008; Yates et al. 2012). 
Therefore, the implication of the reduced α-SMA expression following treatment of 
certain concentrations of EBC-46 (0.1µg/ml) and EBC-211 (10µg/ml); and subsequent 
reduced myofibroblast formation, may lead to a minimal scarring response following 
injury. This theory fits in with the previous in vivo animal studies performed by 
QBiotics Ltd., demonstrating a reduced scarring healing response following treatment 
with novel epoxy-tiglianes (Reddell et al. 2014). However, it is not yet understood why 
these inhibitory myofibroblast responses only occur at 0.1µg/ml EBC-46 and 10µg/ml 
EBC-211, but not at the other concentrations of both epoxy-tiglianes. In addition, it is 
not yet known the comparable concentration used during in vivo studies and whether 
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these optimal concentrations were used, resulting in the observed reduced scarring 
response.  
 
EBC-46 has been shown to act primarily through the activation of classical PKC-β 
isoforms, along with other classical and novel isoforms, albeit to a much lower level 
(Boyle et al. 2014). This is a calcium-activated, phospholipid and diacylglycerol 
(DAG) dependent serine/threonine protein kinase, which requires DAG and calcium 
for activation (Breitkreutz et al. 2007; Roffey et al. 2009; Sumagin et al. 2013). PKC-
β is involved in regulating mitochondrial function and subsequent apoptosis, cell 
survival and mitosis. This apoptosis regulation may confirm the cell death mechanism 
occurring during the cytotoxicity studies (Breitkreutz et al. 2007; Ali et al. 2009; Saba 
& Levy 2012; Mehta 2014). This PKC isoform also plays a role in vascular endothelial 
growth factor (VEGF) induced cell proliferation, impacting on the permeability of the 
blood vessel (Boyle et al. 2014). Treatment with EBC-46 subsequently resulted in 
leaky vasculature (Graff et al. 2005; Ali et al. 2009). PKC-β is also thought to be 
activated in a high glucose environment, therefore is shown to be upregulated in 
experimental diabetes and contributes to renal fibrosis. Inhibition of this isoform is 
thought to reduce the progression of diabetic nephropathy (Kelly et al. 2003; Meier et 
al. 2007; Geraldes & King 2010). PKC-β is also involved in actin polymerisation, 
allowing the migration of smooth muscle cells (Larsson 2006; Mochly-Rosen et al. 
2012). Other functions of PKC signalling include cell transformation, cell growth and 
apoptosis, acting down the mitogen-activated protein kinases (MAPK) pathway 
affecting cell growth through an effect on cyclins. Due to these important roles, 
dysfunctional MAPK pathway signalling has been implicated in cancer development 
(Larsson 2006; Ali et al. 2009; Hampson et al. 2010; Mason et al. 2010; Mochly-Rosen 
et al. 2012). MAPK signalling is activated by epidermal growth factor (EGF) family 
binding to EGF receptor. This pathway has been shown to regulate cell proliferation 
and differentiation, in particular the downstream signalling pathways, c-Jun N-
terminal kinase (JNK), extracellular signal-regulated kinase (ERK)1/2 and p38, with 
an apparent opposing roles from the different downstream pathways (Zhang & Liu 
2002; Mccubrey et al. 2007; Hampson et al. 2010). These MAPK downstream 
signalling pathways have also been shown to play an important role in cell migration, 
in particular JNKs, with inhibitors shown to impair fibroblast migratory responses 
175 
 
(Huang et al. 2004; Kajanne et al. 2007).  Upregulated activity of JNKs has been shown 
to affect stress fibres in fibroblasts, resulting in morphological changes in the cells. 
Gene analysis following epoxy-tigliane treatment may determine whether any of these 
downstream signalling pathways are altered, resulting in the in vitro and in vivo 
responses previously observed (Rennefahrt et al. 2002; Huang et al. 2004).  
 
The role of PKC-βII has been well-studied and has shown to impact angiogenesis, B 
cell survival and the AKT pathway, involved in cell survival mechanisms and shown 
to exert an anti-apoptotic effect. However, less is known about PKC-βI function 
(Martiny-Baron & Fabbro 2007; Reyland 2007; Serova et al. 2008; Saba & Levy 
2012). PKC-βI appears to function in opposing manners, in some cases it also 
promotes cell survival and stimulates proliferation mediated through VEGF (Ali et al. 
2009). In contrast, it also seems to have a pro-apoptotic role, again potentially 
confirming the cell death mechanism discussed previously, along with an inhibitory 
effect on cell cycle progression (Poole et al. 2004; Ali et al. 2009; Saba & Levy 2012). 
An important PKC-β-dependent process is plasminogen activator inhibitor (PAI) 
synthesis, which impacts a number of key features of wound healing, such as 
migration, cell attachment to extracellular matrix and angiogenesis. Therefore, 
stimulation of PKC-β will enhance these functions (Berg et al. 2005).  
 
Novel PKC isoform, epsilon (ε), has also been shown to have an involvement in wound 
closure and myofibroblast formation, along with a decreased α-SMA expression and 
subsequent stress fibre formation; targeting this isoform may be of use for excessive 
scarring situations, such as hypertrophic scarring, by reducing the presence of the 
contractile myofibroblasts (Leask et al. 2008). This decreased α-SMA expression and 
myofibroblast formation is similar to the response seen at EBC-46 (0.1µg/ml) and 
EBC-211 (10µg/ml), indicating a potential reduction in activity of this novel isoform 
(Leask et al. 2008). In addition to the inhibitory effect on myofibroblast formation 
when PKC-ε is knocked out, there is also a reduction in migration response. Although 
no significant difference was observed following epoxy-tigliane treatment, there was 
a perceived reduction in wound closure ability observed by a lack of repopulation of 
the denuded site (Leask et al. 2008). PKC-δ has also been associated with the 
migratory response of dermal fibroblasts, through the activation of Stat3, a factor 
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involved in wound healing. This isoform has also been shown following activation by 
EGF to increase fibronectin expression, an essential component of the wound healing 
process, involved in re-epithelialisation, ECM formation and clot production (Mimura 
et al. 2004; Fan et al. 2006). PKC-δ has also been shown to have an important role in 
the impaired wound healing response observed in diabetic wounds, focusing on 
fibroblast responses, with enhanced diabetic wound repair following inhibition of 
PKC-δ. This response was also demonstrated by inducing impaired wound healing in 
healthy situations through an excessive expression of PKC-δ (Khamaisi et al. 2016). 
Determining the specific PKC isoforms involved in inducing the potential anti-fibrotic 
response observed during the veterinary trials will help elucidate the mechanism of 
action of the novel epoxy-tiglianes and understand what changes to the normal acute 
skin wound healing response are occurring.  
 
Overall, there is a profound effect following treatment with EBC-46 or EBC-211 on 
dermal fibroblasts, including delayed cell cycle progression and an overall anti-
proliferative effect; and a modulatory effect on the actin cytoskeleton resulting in the 
inhibition of myofibroblast formation. However, there was no overall effect on the 
migratory responses of dermal fibroblasts following epoxy-tigliane treatment, 
potentially due to the large variability in fibroblast motility; the only exceptions being 
the reduced fibroblast distance travelled and speed at 0.1-1µg/ml EBC-211. Many of 
these responses can be attributed to PKC-β stimulation. The veterinary trials 
previously performed with EBC-46 have already demonstrated wound healing 
responses similar to those in preferential healing tissues, with the lack of visible 
scarring. However, no studies have yet been performed to observe the histology of the 
dermis to determine the composition of the wound site and if there is a presence of 
granulation tissue, myofibroblasts or the ratio of type I collagen to type III collagen. 
These are all factors of the wound healing response that differ in early-gestational 
foetal and oral mucosal wound healing, compared to normal acute skin wound healing 
responses (Rolfe & Grobbelaar 2012; Yates et al. 2012). Further studies are, therefore, 
required to understand how these modulatory effects on the dermal fibroblasts are 
achieved and whether myofibroblast inhibition is occurring, resulting in a potentially 
scarless healing outcome.  
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Chapter 4 - Effects of EBC-46 and EBC-211 on Keratinocyte 
Wound Healing Responses 
 
 
4.1 Introduction 
 
As described in Chapter 3, the epoxy-tiglianes, EBC-46 and EBC-211, were 
demonstrated to possess significant anti-proliferative effects in dermal fibroblasts, in 
addition to the ability to inhibit transforming growth factor-β1 (TGF-β1)-driven, dermal 
fibroblast-myofibroblast differentiation at certain concentrations. Previous veterinary 
studies undertaken by QBiotics Ltd. have demonstrated that EBC-46 induces enhanced 
wound healing responses, such as rapid wound closure and reduced scarring (Section 
1.7). Such in vitro findings may shed light on the mechanisms responsible for these 
preferential wound healing outcomes in vivo. In addition to the fibroblast-mediated 
wound healing responses, rapid wound re-epithelialisation is also a common feature 
of enhanced healing in EBC-46 treated skin (Reddell et al. 2014). These responses 
were evident during wound healing studies undertaken by QBiotics Ltd., comprising 
veterinary cases that were previously unresponsive to months of treatment under 
current wound healing strategies (Reddell et al. 2014).  
 
Re-epithelialisation is a vital process during acute skin wound healing, as it restores 
the protective barrier of the skin; there are numerous cells involved in this function, 
although as approximately 95% of the epidermis consists of keratinocytes, these 
contribute the largest role to re-epithelialisation (Martin 1997; Menon 2002). Terminal 
differentiation of keratinocytes is halted in wound healing, as the keratinocytes 
undergo proliferation and migration to re-establish the protective barrier, with 
differentiation only resumed once the epidermal barrier has been restored (Candi et al. 
2005; Bader & Kao 2009; Portou et al. 2015). The basement membrane is also re-
established before normal keratinocyte differentiation can resume, through the re-
formation of anchors between keratinocytes and the basal layer; the hemidesmosome 
complex provides stability to the differentiating keratinocytes (Martin 1997; Menon 
2002; Li et al. 2007). It has been reported that when epidermal keratinocytes are 
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stimulated by certain signals, such as basic fibroblast growth factor (bFGF) or 
epidermal growth factor (EGF), they are capable of undergoing dedifferentiation to a 
less differentiated state (Fu et al. 2001; Li et al. 2007; Sun et al. 2011). It has been 
hypothesised that the extracellular signal-regulated kinase (ERK), mitogen-activated 
protein kinases (MAPK)-dependent signalling pathway is strongly involved in this 
dedifferentiation process and re-establishing a profound proliferative potential of the 
keratinocytes (Sa et al. 2009). This dedifferentiated state enables keratinocytes to 
possess a higher proliferative capacity and obtain characteristics of stem cells or 
become a precursor cell to the differentiated epidermal keratinocyte. This is confirmed 
through the presence of specific markers, such as cytokeratin 19 and β1 integrin, which 
have been associated as positive epidermal stem cell markers (Sa et al. 2009; Zhang et 
al. 2010; Sun et al. 2011). This dedifferentiation may result in a regenerative healing 
process, as opposed to remodelling, which typically occurs after injury (Zhang et al. 
2010; Sun et al. 2011). 
 
Some components necessary for the remodelling of the extracellular matrix (ECM) are 
synthesised by keratinocytes in the epithelia, such as metalloproteinases, laminin 
proteins and tenascin C glycoprotein. These components play a role in aiding 
keratinocyte migration at the wound edge (Schultz & Wysocki 2009). Keratinocytes 
at the wound healing edge can sense the ECM, allowing for migration across the 
dermal layer (Martin 1997; Li et al. 2007). As mentioned in Section 1.2.1.1, there is a 
‘double paracrine’ process between keratinocytes and fibroblasts, stimulating wound 
healing responses in the other cell type (Werner et al. 2007; Bader & Kao 2009).  
 
As with fibroblasts, keratinocyte function is tightly regulated as variation in normal 
phenotype can have detrimental effects on overall wound healing outcomes, such as 
with chronic wounds and burn injuries, where there is a loss of skin integrity, 
increasing the risk of contamination or infection of the wound site; and a resultant loss 
in functionality (Singer & Clark 1999; Menke et al. 2007; Dreifke et al. 2015). An 
example of this loss in function is the potential lack of response to migratory signals 
(Tomic-Canic et al. 2004; Agren & Werthén 2007; Li et al. 2007). Additional causes 
of impaired re-epithelialisation are the inability of keratinocytes to migrate over 
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chronic wound sites, either due to presence of infection or a dysfunctional ECM 
(Agren & Werthén 2007; Li et al. 2007).  
 
Unfortunately, current wound healing strategies are not sufficient to tackle this major 
clinical burden, a burden that is only going to increase with the ageing population and 
prevalence of diabetes. Chronic wounds associated with diabetes include foot ulcers, 
can lead to amputation if not diagnosed early and treatment is not successful (Menke 
et al. 2007; Posnett & Franks 2008; Dreifke et al. 2015). As mentioned previously, 
there is another pharmaceutical agent currently available, Regranex® with isoform 
PDGF-BB as the main active component; decreased levels of PDGF are present in 
chronic wounds, indicating their essential role in the wound healing response (Beer et 
al. 1997; Barrientos et al. 2008; Fang & Galiano 2008). This treatment was approved 
by the Food and Drug Administration (FDA) for treatment of chronic wounds, in 
particular diabetic ulcers (Goldman 2004; Barrientos et al. 2008; Howard et al. 2014). 
However, the findings on the effectiveness of this agent are not encouraging, with 
recurrence of ulcers observed in approximately 30% of patients (Niezgoda et al. 2005; 
Fang & Galiano 2008). A theory for this lack of effectiveness is that there are 
numerous changes to the wound environment in chronic wounds and the addition of 
one growth factor is not sufficient to resolve this. One of the main issues is the high 
levels of inflammatory cytokines and proteases at the chronic wound site, degrading 
PDGF, along with other vital growth factors, such as FGF and transforming growth 
factor-β (TGF-β) (Fang & Galiano 2008). In addition, there has since been a warning 
issued from the FDA of an increased mortality after use of 3 or more tubes of 
Regranex® gel. This warning was aimed at patients with a history of malignancy and 
questions whether the potential beneficial response outweighs the risk (Lacci & Dardik 
2010; FDA). Despite the wide array of treatment options for chronic wounds described 
in Section 1.5.2.1, these are not adequate enough to ease the rising burden of chronic 
wounds (Fang & Galiano 2008; Dumville et al. 2015; Harding 2015). Therefore, 
alternative options are required to ease this clinical burden and resolve wounds quicker 
with successful re-epithelialisation and dermal remodelling (Niezgoda et al. 2005; 
Dumville et al. 2015; Harding 2015).   
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Due to the previous palliative veterinary studies performed by QBiotics Ltd., we are 
aware that the treatment of previously unresponsive veterinary chronic wounds with 
EBC-46 results in rapid wound closure with exceptional cosmesis (Reddell et al. 
2014). Rapid re-epithelialisation responses are a recognised feature of preferential 
healing in tissues, such as early-gestational foetal healing and oral mucosal healing 
(Coolen et al. 2010; Turabelidze et al. 2014). The rapid re-epithelialisation seen in oral 
mucosal wounds appears to be partly a result of increased keratinocyte proliferation 
(Chen et al. 2010; Turabelidze et al. 2014). Studies have shown that there are a number 
of differentially regulated genes between dermal keratinocytes and oral keratinocytes. 
In addition, there is a different presence of keratins, with keratins 8 and 19 present in 
the foetal epidermal layer, but absent in adult epidermal layers (Coolen et al. 2010; 
Turabelidze et al. 2014). Some of these gene changes may result in this exceptional 
healing response, with genes upregulated leading to enhanced keratinocyte 
proliferation and migration in oral mucosal wounds (Colwell et al. 2008; Turabelidze 
et al. 2014). This shows that despite similarities in the wound healing processes of 
these tissues, the preferential benefits are a result of core changes in gene expression 
on crucial functions of the cells, such as keratinocyte migration (Turabelidze et al. 
2014).  
 
4.2 Aims 
 
Keratinocytes are another key cell type involved in acute skin wound healing, where 
they perform the essential role of re-forming the epidermal barrier to close the wound 
site, thereby protecting against infection. As with dermal fibroblasts (Chapter 3), any 
alterations in the genotypic or phenotypic responses of the keratinocytes could alter 
their mechanisms of action and healing outcomes. Therefore, the aims of this chapter 
were to assess the effects of EBC-46 or EBC-211 on key keratinocyte wound healing 
responses, such as viability, proliferation, cell cycle progression, morphology and 
migration. HaCaTs were used instead of primary keratinocytes, as this immortalised 
cell line has been widely used to assess epidermal responses, due to their close 
similarity of functional response to normal adult epidermal keratinocytes (Boukamp 
et al. 1988; Pessina et al. 2001; Wilson 2014).   
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4.3 Materials and Methods 
 
4.3.1 Preparation of EBC-46 and EBC-211 
EBC-46 and the lesser active analogue, EBC-211, were both supplied by QBiotics 
Ltd., Queensland, Australia. EBC-46 and EBC-211 were solubilised in DMSO 
(Section 2.1). For both compounds, concentrations of 0.001g/ml, 0.01g/ml, 
0.1g/ml, 1g/ml, 10g/ml and 100g/ml were prepared in 1% K-SCM for the 
assessment of epidermal keratinocyte wound healing responses (Section 2.2.2).  
 
4.3.2 HaCaT Culture 
Epidermal keratinocyte cell line (HaCaTs) were sourced, cultured, sub-cultured, 
counted, cryopreserved and screened for mycoplasma, as previously described 
(Sections 2.2.2, 2.2.3, 2.2.4 and 2.2.5, respectively). 
 
4.3.3 Assessment of HaCaT Viability and Proliferation 
The viability and proliferation of keratinocyte cell line (HaCaTs) was assessed through 
the use of an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] 
Dye-Reduction assay at 24h, 72h, 120h and 168h, as previously described (Section 
2.3.1).  
 
4.3.4 Assessment of HaCaT Cell Cycling 
Keratinocyte cell line (HaCaTs) were seeded and cultured for cell cycle analysis, with 
samples obtained at T0, T9, T17, T26, T32, T40 and T48 after treatment with EBC-46 
or EBC-211 (0g/ml, 0.001g/ml, 0.01g/ml, 0.1g/ml, 1g/ml and 10g/ml). 
Samples were prepared, Draq5 DNA dye added and analysed by Flow Cytometry 
(FACScalibur, Becton Dickinson, Oxfordshire, U.K.), as previously discussed 
(Sections 2.3.2.2, 2.3.2.3 and 2.3.2.4).  
 
4.3.5 Assessment of HaCaT Morphology 
Morphology of keratinocyte cell line (HaCaTs) was assessed by light microscopy, as 
previously described (Section 2.3.3). 
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4.3.6 Assessment of HaCaT Repopulation 
Keratinocyte cell line (HaCaTs) migration was assessed through the use of an in vitro 
‘scratch wound’ assay, with images captured every 20min over 48h using Time-Lapse 
Microscopy, as previously described (Section 2.3.4). 
 
4.3.7 Assessment of HaCaT Migration in Presence of Mitomycin C 
HaCaTs were cultured in the presence of mitomycin C (1g/ml) and migration 
assessed by in vitro ‘scratch wound’ assay, with images captured every 20min over 
48h using Time-Lapse Microscopy, as previously described (Sections 2.3.4.1 and 
2.3.4.2).  
 
4.4 Results 
 
4.4.1 Effects of EBC-46 and EBC-211 on HaCaT Viability and Proliferation  
The viability and proliferation study was performed on HaCaTs cultured in EBC-46 
or EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), with 
untreated controls included for comparison purposes (0µg/ml) for both compounds. 
Average absorbance values were obtained at each EBC-46 and EBC-211 concentration 
at 24h, 72h, 120h and 168h. Values were used to calculate the variation from the 
untreated control for each concentration and time-point; and percentage calculations 
produced versus each untreated control (Figures 4.1A and 4.2A). 
 
As with the fibroblast studies (Chapter 3), it was shown that EBC-46 and the lesser 
active analogue, EBC-211, were both cytotoxic at 100µg/ml from 24h onwards 
(Figures 4.1 and 4.2, respectively). This was evident by the significantly decreased 
percentage data obtained (p<0.001; Figures 4.1A and 4.2A, respectively), compared 
to the untreated controls (0µg/ml). However, the delayed cytotoxic effect of EBC-211, 
compared to EBC-46, confirmed the reduced activity of EBC-211. This was evident 
by the longer time period required for a complete cytotoxic effect to occur.  
 
There was a stimulated proliferative response evident across the remaining 
concentrations of both EBC-46 and EBC-211 (0.001-10μg/ml). However, at 24h, any 
increases were deemed to be non-significant, compared to untreated controls (p>0.05). 
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Figure 4.1: (A) HaCaT viability and proliferation percentage differences 
following culture in the presence of EBC-46 (0µg/ml, 0.001µg/ml, 0.01µg/ml, 
0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), at 24h, 72h, 120h and 168h (N=3, 
average±SE). (B) Cross-statistical analysis of significant changes in HaCaT 
proliferation following treatment with EBC-46 (0.001-100µg/ml) over 168h, 
versus untreated controls (*p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 4.2: (A) HaCaT viability and proliferation percentage differences, 
following culture in the presence of EBC-211 (0µg/ml, 0.001µg/ml, 0.01µg/ml, 
0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), at 24h, 72h, 120h and 168h (N=3, 
average±SE). (B) Cross-statistical analysis of significant changes in HaCaT 
proliferation following treatment with EBC-211 (0.001-100µg/ml) over 168h, 
versus untreated controls (*p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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The only exception was 0.001µg/ml EBC-46, where a significant increase in 
proliferation was observed (p<0.01; Figure 4.1A). At 72h, the most profound 
proliferative responses were observed across all EBC-46 and EBC-211 concentrations 
(0.001-10μg/ml; p<0.001; Figures 4.1A and 4.2A, respectively). Increased 
proliferation was also observed at 120h and 168h for EBC-46, although this was not 
considered to be as significant as the responses seen at 72h (p<0.001-0.05; Figure 
4.1A). EBC-211 also showed an increase in proliferation across the concentrations 
(0.001-10μg/ml) at 120h and 168h. This was deemed significant for 0.001-0.1µg/ml 
EBC-211 at 120h and 0.001-10µg/ml at 168h (Figure 4.2A; p<0.001). The continual 
increase in the absorbance values for EBC-211 at each subsequent time-point, showed 
a consistent increase in proliferation.  
 
As the greatest increase in cell proliferation for EBC-46 treated cells occurred at 72h, 
there was a possibility that the cells were fully confluent by this time-point and 
therefore, unable to proliferate to the same extent beyond this time-point. The 
proliferation study was repeated with a lower cell density to account for this 
observation; however, the greatest increase in cell proliferation occurred again at 72h 
(Supplement 4.1). This leads to the theory that there may be a profound proliferative 
burst occurring between 24h and 72h, to produce the significant increase in HaCaT 
proliferative response at 72h. Cross statistical analysis was performed for both EBC-
46 and EBC-211 (0.001-100µg/ml), comparing epoxy-tigliane treated cells to 
untreated controls. In addition, comparisons were made between concentrations for 
both EBC-46 and EBC-211. Cross-statistical analysis between EBC-46 concentrations 
only showed a few conditions that were considered significant, including between 
0.001µg/ml and 10µg/ml at 24h and 120h; also between 0.01-0.1µg/ml and 10µg/ml, 
along with 0.01µg/ml and 1µg/ml at 120h (p<0.001-0.05; Figure 4.1B). EBC-211 
cross-statistical analysis showed significant between 0.001-0.1µg/ml and 10µg/ml at 
120h and 168h; in addition, to between 0.001-0.01µg/ml and 1µg/ml at 120h, and 
0.001µg/ml and 1µg/ml at 168h (p<0.001-0.05; Figure 4.2B). 
 
4.4.2 Effects of EBC-46 and EBC-211 on HaCaT Cell Cycling 
In light of the potential pro-proliferative effects identified in Section 4.4.1, flow 
cytometry was further performed to determine whether treatment with EBC-46 or 
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EBC-211 (0.001-10µg/ml) had an effect on HaCaT cell cycle progression and whether 
this contributed to the profound stimulatory effects observed. A growth curve was 
initially performed to calculate the cycling time for an untreated control (Supplement 
4.2). This determined the time-points required to observe the different phases of the 
cell cycle for the untreated HaCaT controls. The time-points identified were T0 (at 
point of treatment), T9 (9h after treatment), T17 (17h after treatment), T26 (26h after 
treatment), T32 (32h after treatment), T40 (40h after treatment) and T48 (48h after 
treatment). The T0 time-point was analysed at point of treatment to ensure cells across 
all conditions were at the same synchronised state after serum starvation; and any 
differences that follow at the later time-points are a result of the epoxy-tigliane 
treatment. Data obtained at T0 for both EBC-46 and EBC-211 showed no significant 
differences, compared to untreated control. This confirmed that the cells were all 
synchronised to the same cell cycle phase before analysis of the later time-points to 
determine significant changes in cell cycle progression (p>0.05; Figures 4.3A and 
4.10A). 
 
There was no significant difference between EBC-46-treated cells and the untreated 
controls at T0 and T9 (p>0.05; Figures 4.3A and 4.4A, respectively), although there 
were indications that the cells were progressing through the cycle at a quicker rate. 
This was observed by following the progression of the cell populations through the 
cell cycle phases at each time-point. The rapid transition from G1 at T17 to G2 phase 
at T26, through S phase, was evident (p<0.01-0.05; Figures 4.5A and 4.6A). This led 
to the possibility that either the G1 to S or S to G2 transitions, or both, were stimulated 
by epoxy-tigliane treatments. At T17, T26, T32 and T40, an increase in cell cycle 
progression, compared to untreated controls, was evident across all EBC-46 
concentrations (0.001-10µg/ml). These were deemed significant at each of these time-
points (p<0.01-0.05; Figures 4.5A, 4.6A, 4.7A and 4.8A). The most profound 
differences were observed at T40, where the acceleration through the cell cycle caused 
significant differences across all phases (p<0.01-0.05; Figure 4.8A). At this time-point, 
untreated controls predominantly remained in G1 phase, compared to EBC-46-treated 
cells, which had progressed through S phase and into the G2 phase. This corroborated 
the previous proliferation data (Section 4.4.1), where the burst of proliferation 
appeared to occur between 24h and 72h, to produce the dramatic increase in cell   
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Figure 4.3: (A) HaCaT cell cycle analysis at T0, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (all p>0.05). (B) Corresponding cell cycle histogram at T0, following 
culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.4: (A) HaCaT cell cycle analysis at T9, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (all p>0.05). (B) Corresponding cell cycle histogram at T9, following 
culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.5: (A) HaCaT cell cycle analysis at T17, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram at T17, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.6: (A) HaCaT cell cycle analysis at T26, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram at T26, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.7: (A) HaCaT cell cycle analysis at T32, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram at T32, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.8: (A) HaCaT cell cycle analysis at T40, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram at T40, 
following culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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Figure 4.9: (A) HaCaT cell cycle analysis at T48, following culture in the presence 
of EBC-46 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (*p<0.05). (B) Corresponding cell cycle histogram at T48, following 
culture in the presence of EBC-46 (0-10µg/ml).  
A 
 
B 
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number at 72h (Figure 4.1A). The accompanying cell cycle histograms (Figures 4.3B, 
4.4B, 4.5B, 4.6B, 4.7B, 4.8B and 4.9B) further show these dramatic and significant 
differences in cell distribution throughout the phases of the cell cycle, particularly at 
T26 and T40 (Figures 4.6B and 4.8B, respectively). There was also only a marginal 
increase in cell cycle progression at T48, although this was deemed to be significant, 
with 0.001µg/ml EBC-46 in G1 phase (p<0.05; Figure 4.9A). It is thought that due to 
the different lengths of cell cycle phases, with G1 being the longest and G2/M the 
shortest, the cells appear to catch up to the same cell cycle phase, G1, by T48; although 
the accompanying cell cycle histogram shows a proportion of cells treated with EBC-
46 remaining in G2 phase, with the untreated controls present in G1 phase (Figure 
4.9B). 
 
EBC-211-treated cells showed similar effects to EBC-46, with increased cell cycle 
progression, compared to untreated controls (Figures 4.10A, 4.11A, 4.12A, 4.13A, 
4.14A, 4.15A and 4.16A). There were no significant differences observed at T0, T9 or 
T17, although as before, there was evidence that the cells were moving from G1 to S 
phase at a more rapid rate. However, this was not statistically significant (p>0.05; 
Figures 4.10A, 4.11A and 4.12A, respectively). By T26, this acceleration through the 
cell cycle was significant across all concentrations of EBC-211 (0.001-10µg/ml; 
p<0.01-0.05; Figure 4.13A). This acceleration continued at T32, T40 and T48 (p<0.01-
0.05; Figures 4.14A, 4.15A and 4.16A, respectively), potentially due to the lesser 
activity of EBC-211. There was a greater degree of significant differences obtained to 
the untreated controls with EBC-211, than EBC-46 at T48, as a result of a slightly less 
dramatic acceleration through the cell cycle. The corresponding cell cycle histograms 
(Figures 4.10B, 4.11B, 4.12B, 4.13B, 4.14B, 4.15B and 4.16B) again confirmed the 
rapid and significant cell cycle progression, compared to untreated controls; which 
particularly showed the clear differences in cell distribution within the cell cycle 
phases at T26 and T40 (Figures 4.13B and 4.15B).  
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Figure 4.10: (A) HaCaT cell cycle analysis at T0, following culture in the presence 
of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (all p>0.05). (B) Corresponding cell cycle histogram at T0, following 
culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 4.11: (A) HaCaT cell cycle analysis at T9, following culture in the presence 
of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), compared to 
untreated controls (0µg/ml) (N=3, average % in each phase±SE). Statistical 
analysis (all p>0.05). (B) Corresponding cell cycle histogram at T9, following 
culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 4.12: (A) HaCaT cell cycle analysis at T17, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml) (N=3, average % in each phase±SE). 
Statistical analysis (all p>0.05). (B) Corresponding cell cycle histogram at T17, 
following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 4.13: (A) HaCaT cell cycle analysis at T26, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml) (N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T26, following culture in the presence of EBC-211 (0-10µg/ml).  
A 
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Figure 4.14: (A) HaCaT cell cycle analysis at T32, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml) (N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T32, following culture in the presence of EBC-211 (0-10µg/ml).  
A 
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Figure 4.15: (A) HaCaT cell cycle analysis at T40, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml) (N=3, average % in each phase±SE). 
Statistical analysis (*p<0.05, **p<0.01). (B) Corresponding cell cycle histogram 
at T40, following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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Figure 4.16: (A) HaCaT cell cycle analysis at T48, following culture in the 
presence of EBC-211 (0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml), 
compared to untreated controls (0µg/ml) (N=3, average % in each phase±SE). 
Statistical analysis (**p<0.01). (B) Corresponding cell cycle histogram at T48, 
following culture in the presence of EBC-211 (0-10µg/ml).  
A 
 
B 
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4.4.3 Effects of EBC-46 and EBC-211 on HaCaT Morphology 
EBC-46 was shown to be highly cytotoxic to the HaCaTs at 100µg/ml, as shown 
initially with the proliferation data. This was confirmed through the cellular 
morphology studies with the potential apoptosis of the HaCaTs. There was a large 
reduction in the number of HaCaTs present, along with a high content of cell debris at 
the earlier time-points (Figures 4.17G, 4.18G, 4.19G and 4.20G). The cytotoxicity of 
EBC-211 at 100µg/ml was also confirmed through the HaCaT morphology studies. 
However, it also showed a slightly reduced cytotoxic effect than seen with EBC-46, 
again confirming the lesser activity of EBC-211. At 24h, there was evidence of a few 
viable cells remaining; whereas at 72h, 120h and 168h, there were no viable cells 
remaining (Figures 4.21G, 4.22G, 4.23G and 4.24G).  
 
At the other EBC-46 concentrations (0.001-10µg/ml), there were no major differences 
in morphology or cell number visible at 24h, compared to untreated controls (0µg/ml; 
Figure 4.17A-F). In contrast, at 72h, 120h and 168h, the profound proliferative effect 
initially observed from the viability and proliferation studies was confirmed through 
the cellular morphology studies, by increased presence of cells evident (Figures 4.18, 
4.19 and 4.20A-F). However, there did not appear to be any noticeable differences 
between the EBC-46 concentrations. Unlike the fibroblast studies, no obvious 
morphological changes in the HaCaTs were evident, with the cells retaining the typical 
cobble-stone morphology at all concentrations and throughout the entire culture 
period.  
 
The other concentrations of EBC-211 (0.001-10µg/ml) also showed no obvious 
differences in morphology or cell number, when compared to untreated controls 
(0µg/ml) at 24h (Figures 4.21A-F). At 72h, 120h and 168h, the profound proliferation 
that occurs across the range of EBC-211 concentrations (0.001-10µg/ml) was evident, 
in comparison to untreated controls (Figures 4.22, 4.23 and 4.24A-F). However, as 
with EBC-46, there was no noticeable difference in cell numbers between EBC-211 
concentrations. Again, there were no obvious morphological changes in the HaCaTs 
when cultured with EBC-211, as the cells retained their typical cobble-stone structure 
at all concentrations throughout the culture period.  
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Figure 4.17: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-46 for 24h (N=3). Scale bar = 100µm. 
  
205 
 
Figure 4.18: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-46 for 72h (N=3). Scale bar = 100µm. 
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Figure 4.19: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-46 for 120h (N=3). Scale bar = 100µm. 
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Figure 4.20: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-46 for 168h (N=3). Scale bar = 100µm. 
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Figure 4.21: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-211 for 24h (N=3). Scale bar = 100µm. 
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Figure 4.22: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-211 for 72h (N=3). Scale bar = 100µm. 
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Figure 4.23: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-211 for 120h (N=3). Scale bar = 100µm. 
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Figure 4.24: HaCaT morphology, cultured in the presence of (A) 0µg/ml, (B) 
0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-211 for 168h (N=3). Scale bar = 100µm. 
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4.4.4 Effects of EBC-46 and EBC-211 on HaCaT Repopulation 
Digital images obtained over 48h showed the repopulation of the denuded sites by 
HaCaTs. Cells were cultured in EBC-46 or EBC-211 (0.001µg/ml, 0.01µg/ml, 
0.1µg/ml, 1µg/ml, 10µg/ml and 100µg/ml), with untreated controls (0µg/ml) included 
for comparison purposes (Figures 4.25 and 4.26, respectively). The digital images 
were converted into movies (Supplement 4.3), using LAS AF lite (Leica Software, 
Version 4.0.11706, Leica Microsystems (UK) Ltd), to show the repopulation of 
HaCaTs over the 48h time-period. HaCaTs in the untreated control migrated across 
the wound space, moving in a ‘wave-like’ action to repopulate the denuded area. The 
untreated control closed the wound over 48h, leaving approximately 50% of wound 
site remaining. The cytotoxic action of both EBC-46 and EBC-211 (at 100µg/ml) was 
again demonstrated through the apparent death of HaCaTs over the 48h time-period 
(Figure 4.25G and 4.26G, respectively).   
 
Repopulation data for the other concentrations of EBC-46 (0.001-10µg/ml) was 
assessed, which demonstrated a greatly enhanced migratory response, when compared 
to untreated controls (Figure 4.25A-F). This was particularly evident at 0.001-
0.01µg/ml EBC-46, with full wound closure observed in some cases at 48h (Figure 
4.25B-C). A similar effect was observed upon culture with EBC-211 (Figure 4.26B-
D). However, due to the lesser activity of EBC-211, this enhanced migratory response 
was observed across a larger range of EBC-211 concentrations, than previously seen 
with EBC-46 (Figure 4.25A-F). Enhanced repopulation was evident at 0.001-10µg/ml 
EBC-211 (Figure 4.26A-F), in comparison to untreated controls, with full wound 
closure observed at 0.001-0.1µg/ml EBC-211 after 48h (Figure 4.26B-D).  
 
The HaCaT repopulation data was further analysed using ImageJ to identify any 
significant differences in wound repopulation and closure ability at both 24h and 48h, 
in the presence of EBC-46 and EBC-211 (0.001-100µg/ml); compared to the untreated 
controls (Figures 4.27A and 4.27B, respectively). At 24h, wound closure ability was 
not significantly different across the majority of EBC-46 concentrations (0.01-
10µg/ml), compared with untreated controls (p>0.05; Figure 4.27A). However, at 
0.001µg/ml EBC-46, the wound closure rate was significantly enhanced at 24h, 
compared to untreated controls (p<0.01; Figure 4.27A). At 48h, enhanced and  
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Figure 4.25: HaCaT scratch wound repopulation, in the presence of (A) 0µg/ml, 
(B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-46, over 48h (N=3). Red dashed lines show original scratch wound 
distance at 0h. Scale bar = 100µm.  
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Figure 4.26: HaCaT scratch wound repopulation, in the presence of (A) 0µg/ml, 
(B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, (E) 1µg/ml, (F) 10µg/ml; and (G) 
100µg/ml EBC-211, over 48h (N=3). Red dashed lines show original scratch 
wound distance at 0h. Scale bar = 100µm.  
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Figure 4.27: HaCaT scratch wound repopulation and closure analysis, in the 
presence of (A) EBC-46 or (B) EBC-211 (0.001-10µg/ml), versus untreated 
controls (0µg/ml) at 24h and 48h (N=3, average±SE, with statistical analysis 
*p<0.05, **p<0.01, ***p<0.001).  
A 
 
B 
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significant wound closure was evident at 0.001-0.1µg/ml EBC-46, compared to 
untreated controls (p<0.001-0.01; Figure 4.27A). However, in contrast, the higher 
concentrations of EBC-46 (1-10µg/ml) did not show enhanced or significant wound 
closure rates, compared to untreated controls, at either 24h or 48h (p>0.05; Figure 
4.27A).
 
Wound closure rates were also significantly enhanced at 24h, following treatment with 
0.001-0.1µg/ml EBC-211, compared to untreated controls (p<0.001-0.05; Figure 
4.27B). At 24h, 0.01µg/ml EBC-211 exhibited the most significant wound closure rate, 
compared to these controls (p<0.001; Figure 4.27B). At 48h, the wound closure rates 
were significantly enhanced across the range of EBC-211 concentrations (0.001-
10µg/ml), compared to untreated controls (p<0.001-0.05; Figure 4.27B). Treatment 
with 0.001-1µg/ml EBC-211 resulted in a highly significant enhancement of wound 
closure ability (p<0.001; Figure 4.27B); with 0.001-0.1µg/ml EBC-211 showing 
almost complete wound closure, corroborating the images previous observed (Figure 
4.26B-D).   
 
4.4.5 Effects of EBC-46 and EBC-211 on HaCaT Migration in Presence of 
Mitomycin C 
Based on previous findings of the significantly enhanced HaCaT proliferative response 
following treatment with EBC-46 and EBC-211 (Figures 4.1A and 4.2A, respectively); 
the scratch wound repopulation was repeated in the presence of anti-proliferative 
agent, mitomycin C (Santhiago et al. 2012; Wang et al. 2012; Lü et al. 2013). This 
experiment aimed to determine the extent of which the significant proliferation 
responses in HaCaTs following treatment by EBC-46 and EBC-211, contribute to the 
enhanced in vitro scratch wound closure. As previously discussed, the optimal 
concentration of mitomycin C was initially determined, to produce a non-cytotoxic 
response to the HaCaTs, whilst also inducing an inhibition of proliferation (Section 
2.3.4.1). This concentration was determined to be 1µg/ml mitomycin C (Supplement 
4.4).  
 
As before, digital images were obtained over 48h and converted into movies 
(Supplement 4.5), using LAS AF lite (Leica Software, Version 4.0.11706, Leica 
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Microsystems (UK) Ltd), to record the migration of HaCaTs cultured in either EBC-
46 or EBC-211 across a range of concentrations (0.001-10µg/ml; Figures 4.28 and 
4.29, respectively). These were compared to untreated controls, controls untreated 
with EBC-46 or EBC-211 or mitomycin C; and a control untreated with EBC-46 or 
EBC-211, but treated with 1µg/ml mitomycin C. This allowed the repopulation of 
denuded sites to be observed through the in vitro scratch wound assay and for wound 
closure rate to be determined, without the stimulatory proliferative effect on HaCaTs 
biasing the results. There was an enhanced migration rate for the lower concentrations 
of EBC-46-treated HaCaTs (0.001-1µg/ml), compared to controls with mitomycin C 
(Figure 4.28). However, this migration appeared to be enhanced even when compared 
to the control without mitomycin C, where the control HaCaTs without mitomycin C 
were capable of proliferation. However, there did not appear to be an enhanced 
migratory effect at 10µg/ml EBC-46, when compared to either untreated control at 
48h.  
 
As seen with EBC-46, there was a stimulated migratory response evident for the 
HaCaTs into denuded sites following treatment with 0.001-1µg/ml EBC-211, when 
compared to both untreated controls (Figures 4.29B-F). At certain concentrations of 
EBC-211 (0.01-0.1µg/ml), there appeared to be full wound closure at 48h, despite the 
lack of proliferation (Figures 4.29C-D). As before, the HaCaT migration data was 
further analysed using ImageJ to identify any significant differences in wound closure 
at both 24h and 48h. This was performed by analysing percentage wound closure, in 
the presence of EBC-46 and EBC-211 (0.001-100µg/ml) compared to the two 
untreated controls, in the absence and presence of mitomycin C (Figures 4.30A and 
4.30B, respectively).  
 
At 24h, wound closure ability was not significantly different across the majority of 
EBC-46 concentrations (0.01-10µg/ml), when compared with the untreated controls 
(p>0.05; Figure 4.30A). However, at 0.001µg/ml EBC-46, wound closure rates were 
significantly enhanced at 24h, compared to both untreated controls in the absence and 
presence of mitomycin C (p<0.001; Figure 4.30A). At 48h, significantly enhanced 
wound closure was evident at 0.001-1µg/ml EBC-46, compared to the untreated 
control treated with mitomycin C (p<0.001-0.05; Figure 4.30A). In addition, 
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Figure 4.28: HaCaT scratch wound repopulation, in the presence of mitomycin C 
(1µg/ml) and EBC-46 (A) 0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, 
(E) 1µg/ml, (F) 10µg/ml; and (G) an untreated control in the absence of EBC-46 
or mitomycin C, at 48h (N=3). Red dashed lines show original scratch wound 
distance at 0h. Scale bar = 100µm.  
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Figure 4.29: HaCaT scratch wound repopulation, in the presence of mitomycin C 
(1µg/ml) and EBC-211 (A) 0µg/ml, (B) 0.001µg/ml, (C) 0.01µg/ml, (D) 0.1µg/ml, 
(E) 1µg/ml, (F) 10µg/ml; and (G) an untreated control in the absence of EBC-211 
or mitomycin C, at 48h (N=3). Red dashed lines show original scratch wound 
distance at 0h. Scale bar = 100µm.  
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Figure 4.30: HaCaT scratch wound repopulation, in the presence mitomycin C 
(1µg/ml) and (A) EBC-46 or (B) EBC-211 (0.001-10µg/ml), with mitomycin-
containing (1µg/ml) and mitomycin-free controls (0µg/ml) at 24h and 48h (N=3, 
average±SE, with statistical analysis *p<0.05, **p<0.01, ***p<0.001).  
A 
 
 
B 
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0.001µg/ml EBC-46 showed significantly enhanced wound closure ability, compared 
to the untreated control in the absence of mitomycin C (p<0.001; Figure 4.30A). The 
level of wound closure at 0.001µg/ml EBC-46 was dramatically enhanced compared 
to the other EBC-46 concentrations (0.01-10µg/ml), in addition to the two untreated 
controls. This was evident by the highly significant levels of wound closure at this 
concentration (p<0.001; Figure 4.30A). In contrast, the higher concentration of EBC-
46 (10µg/ml) did not show enhanced or significant wound closure rates, compared to 
either untreated control at both 24h and 48h (p>0.05; Figure 4.30A). 
 
Similar to previous findings, wound closure rates were significantly enhanced at 24h, 
following treatment with 0.001-0.1µg/ml EBC-211, compared to both untreated 
controls (p<0.001-0.01; Figure 4.30B). At 24h, treatment with 0.001-0.01µg/ml EBC-
211 showed the most significant wound closure rates, compared to the untreated 
controls in the absence and presence of mitomycin C (p<0.001; Figure 4.30B). At 48h, 
wound closure rates were significantly enhanced across a range of EBC-211 
concentrations (0.001-1µg/ml), compared to the untreated control treated with 
mitomycin C (p<0.001; Figure 4.30B). In addition, at 48h, wound closure rates were 
also significantly enhanced across the range of EBC-211 concentrations (0.001-
0.1µg/ml), when compared to the control untreated with mitomycin C (p<0.001; 
Figure 4.30B).
 
4.5 Discussion 
 
This Chapter examined the effects of the novel epoxy-tiglianes, EBC-46 and EBC-
211, on HaCaTs, focusing on some of the vital functions carried out by keratinocytes 
during wound healing, such as proliferation and migration (Haase et al. 2003; Bader 
& Kao 2009; Portou et al. 2015). Veterinary case studies previously performed by 
QBiotics Ltd. have already demonstrated a remarkable wound closure ability in vivo 
with rapid re-epithelialisation, which would re-establish the protective barrier of the 
skin (Candi et al. 2005). As previously discussed, wound healing is a tightly regulated 
process and deviations from these normal mechanisms could result in a detrimental 
healing response, as seen with chronic wounds and complications from burn injuries 
(Schwacha et al. 2008; Dreifke et al. 2015). There are numerous genotypic and 
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phenotypic changes in preferential wound healing responses, such as early-gestational 
foetal and oral mucosal wounds; including reduced inflammatory response and rapid 
re-epithelialisation (Colwell et al. 2008; Turabelidze et al. 2014). A number of in vitro 
experiments were performed to determine the effect of treatment with the novel epoxy-
tiglianes on HaCaT wound healing responses. HaCaTs were used instead of primary 
keratinocytes, as this immortalised cell line has been widely used to assess epidermal 
responses, due to their close similarity of functional response to normal adult 
epidermal keratinocytes (Boukamp et al. 1988; Pessina et al. 2001; Wilson 2014). 
HaCaTs have been shown to maintain key behavioural functions, similar to primary 
keratinocytes, such as retaining differentiation capacity. Little change to cell cycle 
related genes has also been observed, compared to primary keratinocytes (Sprenger et 
al. 2013). As a result of these beneficial properties, HaCaTs are considered suitable 
for use instead of primary keratinocytes and be representative of keratinocyte 
responses (Sprenger et al. 2013). In addition, use of primary keratinocytes can 
potentially result in a range of responses, due to variations in donor age, gender and 
localisation of biopsy (Sprenger et al. 2013).  
 
The viability and proliferation assay was performed on HaCaTs for both EBC-46 and 
EBC-211. Likewise with the effects seen with fibroblasts, EBC-46 and EBC-211 were 
both cytotoxic to HaCaTs at 100µg/ml. This was extremely significant for both epoxy-
tiglianes from 24h onwards, with no viable cells remaining (p<0.001). The effects were 
slightly reduced for EBC-211, again confirming the lesser activity of this epoxy-
tigaline compared to EBC-46 (Reddell et al. 2014). As with the fibroblasts, it was 
possible that the HaCaTs were undergoing apoptosis at this concentration for both 
epoxy-tiglianes, followed by secondary necrosis, also referred to as apoptotic necrosis. 
This was visualised during the morphology and repopulation studies; as the cells were 
cultured in vitro, there was a lack of viable cells to phagocytose the apoptotic bodies, 
potentially resulting in this apoptotic necrosis process. This was visualised during the 
repopulation studies, where no viable cells remained by 24h and the cells were 
observed to shrink and condense (Saraste & Pulkki 2000; Ziegler & Groscurth 2004; 
Fink & Cookson 2005; Elmore 2007; Elliott & Ravichandran 2010).  
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Keratinocyte proliferation was studied due to its vital role in re-epithelialisation, 
through increasing the presence of keratinocytes at the wound site, in order to migrate 
across the wound and re-establish the protective barrier (Li et al. 2007; Bader & Kao 
2009; Turabelidze et al. 2014; Portou et al. 2015). There was a significantly profound 
stimulation of proliferation observed at EBC-46 and EBC-211 concentrations of 
0.001-10µg/ml, with a marked increase in proliferation evident throughout the 168h 
culture period. This was particularly apparent with respect to the untreated controls at 
72h, 120h and 168h, with only 0.001µg/ml EBC-46 showing a significant proliferative 
effect at 24h. The largest proliferative response was observed at 72h, with all 
concentrations shown to be significant. Despite the continued increase in proliferation 
at each subsequent time-point, it was only at 72h that all concentrations of EBC-46 
(0.001-10µg/ml) were considered to be significant, compared to untreated controls. In 
contrast, EBC-211 was considered to induce significant increases in proliferation 
across all concentrations (0.001-10µg/ml) at 72h and 168h. At the other time-points, 
increases in proliferation were still observed. However, this was not apparent across 
all epoxy-tigliane concentrations and not to the same significance in some cases, 
compared to the results seen at 72h. The results obtained at 120h and 168h for EBC-
46 appear to show a biphasic response with significant proliferative responses 
observed at both the low and high concentrations, in particular at 0.001µg/ml and 1-
10µg/ml, whereas 0.01µg/ml EBC-46 was not significantly increased at either of these 
time-points. In contrast, EBC-211 appeared to show a dose-dependent response. The 
lowest concentration of EBC-211 (0.001µg/ml) exhibited the greatest proliferative 
response, compared to untreated controls. Although the other concentrations were 
mostly significant compared to untreated controls, the proliferative ability was reduced 
with increasing concentration of EBC-211. At 120h, this reduced ability resulted in no 
significant difference being shown at 1-10µg/ml EBC-211, compared to untreated 
controls.  
 
Due to the rapid increase in cell number, it was a consideration that the proliferative 
effect was partly dampened after 72h due to the wells becoming fully confluent and 
restricting the proliferative ability. Therefore, this study was repeated with a lower 
starting cell density to account for this potential issue. However, this study showed 
that the greatest proliferative response for both EBC-46 and EBC-211 was also at 72h, 
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despite the wells not being confluent at this point (Supplement 4.1). This potentially 
indicates that a proliferative burst on the HaCaTs occurs between 24h and 72h to 
produce this response. Visualisation of the cells during this study showed that no 
morphological changes were observed, indicating that the epoxy-tiglianes were not 
impacting the cytoskeletal structure of the HaCaTs.  
 
Cell cycle progression after treatment with EBC-46 or EBC-211 was studied to further 
determine whether the significant proliferative response observed was related to the 
cell cycle. A number of time points were analysed to observe the progression through 
the phases, with epoxy-tigliane treated cells compared to untreated controls at each 
time-point. As expected, there was an increased progression through the cell cycle 
after treatment with EBC-46 and EBC-211. T0 was also analysed to confirm that all 
cells started in the same phase across the conditions. There was no significant 
difference or minimal significance compared to the untreated controls at the earlier 
time-points. However, at T26 and T40 in particular for both epoxy-tiglianes, there was 
a significant acceleration through the cell cycle phases. This was evident with the 
corresponding cell cycle histograms showing that the cells had progressed out of G1 
phase into S phase, with some progressing into G2 phase; while a significant 
proportion of the control cells remain in G1 phase. As the cells cycled at a faster rate 
after 24h treatments, this was likely to contribute to the stimulated proliferative ability 
observed at 72h during proliferation studies.  
 
Another key function of keratinocytes during wound healing is migration, where 
wound edge keratinocytes migrate across the ECM and re-epithelialise the denuded 
site. Repopulation studies were performed to analysis the effect of EBC-46 and EBC-
211 on migratory ability, with time-lapse movies obtained over 48h and percentage 
wound closure rates analysed. The data clearly showed an enhanced wound 
repopulation into the denuded site after treatment with EBC-46 or EBC-211, compared 
to untreated controls. The enhanced repopulation following epoxy-tigliane treatment 
appeared to be dose-dependent, with the lower concentrations exhibiting greater 
wound closure ability. Due to the lesser activity of EBC-211, the beneficial response 
was present over a wider range of concentrations (0.001-10µg/ml), compared to EBC-
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46 (0.001-0.1µg/ml), with all EBC-211 concentrations producing a significantly 
enhanced wound closure rate.  
 
Although, the proliferative rates were significantly enhanced after epoxy-tigliane 
treatment, it is possible that this stimulated proliferation is biasing the repopulation 
results due to the increased cell number present in the EBC-46 and EBC-211 
conditions, closing the wound site in a shorter time period. Therefore, these studies 
were repeated with the addition of anti-proliferative agent, mitomycin C, which 
prevents DNA synthesis through alkylating and cross-linking DNA and inhibiting 
subsequent mitosis (Santhiago et al. 2012; Jones et al. 2015). The mitomycin C 
concentration was optimised to inhibit proliferative ability, without having a cytotoxic 
effect on the cells (Santhiago et al. 2012). The migration studies performed with the 
addition of mitomycin C (1µg/ml) displayed a similar pattern to the previous 
repopulation studies. Low concentrations of both epoxy-tiglianes produced an 
accelerated wound closure by 24h, compared to untreated controls with mitomycin C. 
EBC-211 again showed a greater range of concentrations (0.001-0.1µg/ml) to produce 
the beneficial wound repopulation, whereas as before, only 0.001µg/ml EBC-46 
showed a highly significant migratory response by 24h, compared to untreated controls 
with mitomycin C. By 48h, this significantly enhanced wound repopulation was 
observed across a greater range of both EBC-46 and EBC-211 (0.001-1µg/ml), 
compared to the untreated control with mitomycin C. An untreated control, without 
the addition of mitomycin C, was also included. These cells were able to proliferate as 
normal. Interestingly, the lower concentrations of both epoxy-tiglianes showed an 
enhanced wound closure ability, even against this control; with EBC-211 again 
showing this enhanced wound repopulation across a greater range of concentrations 
(0.001-0.1µg/ml), whereas this response is only observed at 0.001µg/ml EBC-46. This 
indicated that EBC-46 and EBC-211 are effecting the migratory ability of HaCaTs 
independent of proliferation at these low concentrations, producing a dual effect on 
the cells ability to repopulate wound sites.  
 
This dual beneficial response on keratinocyte proliferation and migration observed 
during the in vitro studies may contribute to the exceptional wound healing response 
observed, during the in vivo animal wound healing studies, with rapid re-
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epithelialisation evident (Reddell et al. 2014). Foetal keratinocytes have been observed 
to possess an increased proliferative potential, compared to adult keratinocytes, in 
addition to possessing longer telomeres and maintaining the ability to differentiate 
successfully into a stratified epidermal layer (Tan et al. 2014). As mentioned 
previously, oral keratinocytes also possess a dramatically increased proliferative 
capacity, compared to adult dermal keratinocytes. This enhanced proliferation, 
together with a stimulated migratory ability, may also contribute to the rapid re-
epithelialisation process observed in scarless oral mucosal wound healing (Turabelidze 
et al. 2014). 
 
As previously discussed, the migratory action of foetal keratinocytes is through a 
different mechanism, than in adult acute wound healing; via the use of the ‘purse string 
closure’ method, as opposed to lamellipodia formation and cell crawling (Martin 1997; 
Chen et al. 2010; Rolfe & Grobbelaar 2012). However, the rapid re-epithelialisation 
observed during oral mucosal wound healing undergoes migration in the same manner 
as adult acute wound healing (Turabelidze et al. 2014). In vitro studies performed by 
Turabelidze et al. (2014) have analysed wound closure rates in the oral mucosa. 
Migration studies were performed, independent of proliferative ability, which showed 
a higher rate of migration of oral keratinocytes, compared to adult skin keratinocytes. 
V-AKT murine thymoma viral oncogene homolog 3 (AKT3), is a serine/threonine-
protein kinase involved in cell migration regulation, along with a number of other 
cellular functions. AKT3 was found to have a significantly higher expression in oral 
keratinocytes than epidermal skin keratinocytes (Turabelidze et al. 2014). This 
increased expression could be partly responsible for the enhanced proliferative and 
migratory ability, leading to the rapid re-epithelialisation observed in oral mucosal 
wounds (Turabelidze et al. 2014).  
 
There are a number of stimulatory growth factors, EGF, TGF-α and KGF, involved in 
inducing re-epithelialisation, through stimulation of keratinocyte proliferation and 
migration. A number of integrins are also crucially involved, α5β1, αvβ6, αvβ5 and 
α2β1, which are responsible for lamellipodia movement, providing temporary 
adhesion for the keratinocytes migrating across the ECM (Martin 1997; Werner & 
Grose 2003; Ching et al. 2011; Seeger & Paller 2015). Therefore, such knowledge on 
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how to stimulate re-epithelialisation responses and the how the preferential responses 
are induced, will have major beneficial actions on chronic wounds and burn injuries; 
where these responses are impaired and will aid the re-establishment of the protective 
barrier (Candi et al. 2005; Seeger & Paller 2015). 
 
In chronic wounds and burns, there is often a decreased migratory action, preventing 
this subsequent re-epithelialisation. For instance, the presence of β-catenin in chronic 
wounds has been associated with inhibition of keratinocyte migration, reducing the re-
epithelialisation ability (Haase et al. 2003; Stojadinovic et al. 2005; Seeger & Paller 
2015; Hameedaldeen et al. 2014; Pastar et al. 2014). Both chronic wounds and burn 
injuries have a stimulated presence of pro-inflammatory cytokines, causing sustained 
inflammation, which can result in impaired re-epithelialisation. This is potentially due 
to the increased and sustained presence of neutrophils, as it has been shown that an 
absence or reduction of neutrophils at a wound site can accelerate re-epithelialisation 
(Schwacha 2003; Dovi et al. 2004; Barrientos et al. 2008; Schwacha et al. 2008; 
Rowan et al. 2015; Rose & Chan 2016). Additionally, depending on the thickness of 
the burn, this may disrupt blood supply to the site and together with the presence of 
oedema at the site, may reduce access to immune cells and essential growth factors 
needed in normal acute wound healing (Edgar et al. 2011; Ching et al. 2011; Rose & 
Chan 2016). High presence of anaerobic bacteria in chronic wounds has been shown 
to impair keratinocyte proliferative and migratory responses, resulting in impaired re-
epithelialisation (Stephens et al. 2003). This impaired response in chronic wounds is 
often a result of biofilm formation, composed primarily of Staphylococcus, 
Pseudomonas, Corynobacterium and a number of obligate anaerobic species. This has 
an inhibitory effect of keratinocyte ability to migrate across the wound site and 
undergo successful re-epithelialisation (Pastar et al. 2014).   
 
These stimulatory effects on proliferation and migration could be especially beneficial 
in diabetic wounds, where both responses are impaired; inducing a rapid re-
epithelialisation of the wound site would re-establish this barrier and reduce the 
clinical and economic burden of these long lasting chronic wounds (Hameedaldeen et 
al. 2014; Portou et al. 2015). Such reduced proliferative and migratory abilities have 
been observed in impaired healing, chronic wounds result from a loss of signalling 
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from growth factors, required to stimulate migration (Seeger & Paller 2015). There are 
contrasting opinions on keratinocyte proliferative ability in chronic wounds, with some 
studies indicating that keratinocytes become senescent; whereas other studies 
demonstrate an enhanced proliferative ability of keratinocytes at chronic wound edges 
and diabetic ulcer margins (Usui et al. 2008; Hameedaldeen et al. 2014; Pastar et al. 
2014; Frykberg & Banks 2015).  
 
However, despite this potentially hyperproliferative response, keratinocyte migration 
abilities at these wound edges are dramatically reduced (Usui et al. 2008; 
Hameedaldeen et al. 2014; Pastar et al. 2014; Portou et al. 2015). One pathway 
involved in this delayed migratory response is a result of excessive levels of the 
transcription factor, forkhead box O1 (FOXO1), seen in diabetic wounds. FOXO1 is 
essential for normal acute wound healing and keratinocyte migration, but elevated 
expression induces synthesis of pro-inflammatory molecules and subsequently reduces 
migration of keratinocytes (Hameedaldeen et al. 2014). Another potential contributor 
towards impaired keratinocyte migration in diabetic ulcers, is the reduced presence of 
a precursor form of laminin (LM-3A32). This precursor is involved in the activation 
of keratinocyte migration, through regulating the stable attachment of keratinocytes to 
the basement membrane (Usui et al. 2008). A greater understanding of the genotypic 
changes involved in epoxy-tigliane-mediated responses may elucidate which 
mechanisms are impacted to induce the beneficial wound healing responses and 
potentially stimulate successful repair of chronic wounds.  
 
Studies performed by Boyle et al. (2014) show that EBC-46 predominantly acts 
through PKC-βI and -βII, and by PKC-α and -γ to a lesser degree, also marginally by 
PKC-δ and -θ. EBC-211 also acts through PKC-βI and -βII, although to a much 
reduced level and also very slightly through PKC-α and -γ isoforms (QBiotics Ltd.). 
There are a number of PKC isoforms present in keratinocytes, PKC-α, -β, -γ, -δ, -ε, -
ζ, -η and -θ. PKC-β is present in HaCaTs, but not primary human keratinocytes (Mitev 
& Miteva 1999; Papp et al. 2003). Therefore, different PKC isoforms play important 
roles in regulating proliferation, differentiation and apoptosis (Mitev & Miteva 1999; 
Papp et al. 2003; Denning 2004; Breitkreutz et al. 2007). PKC-α and -β appear to have 
opposing roles, PKC-α is present in the actin cytoskeleton and involved in the 
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regulation of differentiation, with an inhibition of proliferation. In contrast, PKC-β is 
associated with an increase in proliferative ability and a reduction in differentiation 
(Papp et al. 2004; Breitkreutz et al. 2007; Zhang et al. 2015). Despite the opposing 
behaviours of PKC-α and -β and that they are both stimulated by EBC-46 and EBC-
211, it is likely that the effect on proliferation is affected to a greater degree due to a 
higher activation of PKC-βI and -βII (QBiotics Ltd.). PKC-βII has also been shown to 
have an impact on epithelial migration, through enhanced formation of lamellipodia, 
aiding the wound closure process by cell crawling (Sumagin et al. 2013). Increased 
activation of PKC-β after treatment with novel epoxy-tiglianes may be the major 
pathway involved in the increased proliferative and migratory effect observed, both of 
which result in an enhanced re-epithelialisation (Papp et al. 2004; Sumagin et al. 2013). 
As an abnormal and sustained proliferation is often associated with tumour formation, 
studies have shown that overexpression of PKC-β producing an enhanced proliferative 
response does not result in tumour development through malignant cell transformation 
(Papp et al. 2004; Hanahan & Weinberg 2011).  
 
The different isoforms of PKC exert different responses on HaCaTs, with PKC-α and 
PKC-δ associated with an inhibition of proliferation in favour of stimulating 
differentiation; whereas increased activation of PKC-δ has been shown to upregulate 
migration responses on collagen (Li et al. 2002; Papp et al. 2004). Despite the inhibited 
proliferative response associated with PKC-α, this isoform is also shown to play an 
important role in stimulating wound re-epithelialisation. Diminished PKC-α 
expression has been shown to delay this response, whereas an enhanced response 
occurs following excessive expression (Thomason et al. 2012). It is thought that this 
is related to the desmosomal adhesions, due to its presence at this site following 
wounding, rather than stimulated proliferation or migration. However, it is a necessary 
feature required for wound edge keratinocytes to migrate and has been noted that PKC-
α is not present with the desmosomes in chronic wounds, which have been shown to 
have impaired re-epithelialisation responses (Thomason et al. 2012). However, 
increased expression of PKC-β and PKC-ε isoforms have been shown to increase 
HaCaT proliferation; whilst a reduction in PKC-βII expression has been observed in 
psoriatic skin, showing the vital importance of a careful balance in PKC expression in 
regulating cellular functions (Fisher et al. 1993; Papp et al. 2003, 2004). Downstream 
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signalling pathways from PKC activation also impact on wound healing responses, 
with a careful regulation required for successful healing to occur; 
phosphatidylinositide 3-kinase (PI3K) has been shown in some studies to increase 
proliferation of some cells (Fitsialos et al. 2007). However, other studies have shown 
an inhibitory effect of PI3K on proliferation and migration of keratinocytes, impairing 
re-epithelialisation (Fitsialos et al. 2007). In contrast, ERK1/2 and p38MAPK have a 
stimulatory effect on keratinocyte re-epithelialisation responses (Fitsialos et al. 2007). 
An inhibitor of ERK signalling pathway, U0126, has shown the importance of the ERK 
pathway on keratinocyte wound closure ability, with inhibited wound repopulation 
evident following treatment with U0126 (Fitsialos et al. 2007). It has also shown a 
connection to the EGF family of growth factors, with U0126 also inhibiting many of 
these growth factors. EGF family growth factors are strongly involved in the 
proliferative and migratory roles of keratinocytes (Fitsialos et al. 2007; Pastore et al. 
2008; Mascia et al. 2012). Another beneficial response exerted through the ERK 
pathway is the reduced inflammatory response, through a decreased presence of pro-
inflammatory cytokines. This is especially important as excessive inflammation has 
been observed in a number of non-healing wounds (Pastore et al. 2005). MAPK 
signalling pathway has also been shown to regulate keratinocyte migration, through an 
impact on motility (Haase et al. 2003). Wnt signalling pathway has been proposed to 
stimulate keratinocyte proliferation and reduce apoptosis, with an overexpression 
present in psoriasis, the hyperproliferative skin disorder. The inhibited keratinocyte 
apoptosis exacerbates the increased keratinocyte presence, following enhanced 
proliferation, as this alters the careful balance required for normal wound healing 
function (Zhang et al. 2015).  
 
This Chapter has shown a significant stimulatory effect on keratinocyte proliferation, 
cell cycle progression and wound repopulation following treatment with EBC-46 or 
EBC-211. A greater range of EBC-211 concentrations appeared to induce these 
beneficial responses, especially regarding the wound repopulation studies. In addition, 
the lower concentrations of both EBC-46 and EBC-211, surprisingly, showed the 
greatest stimulatory responses. The proliferation studies showed an apparent dose-
dependent response with the lower concentrations of EBC-211 inducing a greater 
proliferative response than the higher concentrations. A similar trend was observed in 
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the scratch wound repopulation studies, as EBC-211 possesses approximately 100-fold 
lesser activity than EBC-46, this stimulated wound repopulation response was 
observed over a wider therapeutic range. It appears that such stimulatory responses are 
likely a result of the activation of PKC-β isoforms (Papp et al. 2004; Boyle et al. 2014). 
The veterinary palliative trials have already demonstrated the in vivo response after 
treatment with EBC-46, displaying rapid wound closure with exceptional re-
epithelialisation responses. However, before human clinical trials can commence, a 
greater understanding of the effect on the cells involved in the wound healing response 
is required.  
 
Keratinocytes have a major involvement in acute skin wound healing process and there 
are cellular differences between the keratinocytes present in dermal wounds and the 
oral keratinocytes involved in the beneficial healing response. One of the main 
characteristics of preferential healing in regards to keratinocyte function is rapid re-
epithelialisation, which is observed in both oral mucosal and early-gestational foetal 
wounds (Coolen et al. 2010; Rolfe & Grobbelaar 2012; Turabelidze et al. 2014). The 
veterinary studies performed by QBiotics Ltd. appear to be representative of these 
preferential responses. Although, further studies are required to determine whether 
there are important genotypic differences in keratinocytes following treatment with 
these novel epoxy-tiglianes, similar to those observed in early-gestational foetal skin 
and oral mucosal keratinocytes; and which pathways these genes and wound healing 
responses impact upon (Colwell et al. 2008; Turabelidze et al. 2014). For instance, 
gene analysis can be performed to determine the mechanisms involved in the increased 
proliferation and accelerated migratory responses, leading to the enhanced wound 
repopulation and closure responses observed. This could ultimately lead to the 
potential to treat impaired dermal healing conditions associated with altered or 
impaired keratinocyte wound healing responses (Colwell et al. 2008; Turabelidze et 
al. 2014). 
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Chapter 5 - Effects of EBC-46 and EBC-211 on Global Gene 
Expression in HaCaTs 
 
5.1 Introduction 
 
As discussed previously, acute skin wound healing is a tightly regulated process and 
changes in gene expression and resultant protein can have profound effects on this 
response. In some instances, this effect can result in a detrimental healing effect, as 
seen with keloid and hypertrophic scarring where excessive scarring occurs (Chen et 
al. 2003; Hahn et al. 2013; Jumper et al. 2015; Huang et al. 2015; Ma et al. 2015; 
Tan et al. 2015). Another detrimental response is observed in chronic wounds, where 
re-epithelialisation does not occur successfully and healing is impaired (Tomic-Canic 
& Brem 2004; Agren & Werthén 2007; Brem et al. 2007; Shih et al. 2012; Caley et 
al. 2015; Jumper et al. 2015). Alternatively, it has been documented that there are a 
number of differentially expressed genes associated with preferential healing 
responses, such as during early-gestational, foetal wound healing and oral mucosal 
healing (Colwell et al. 2008; Chen et al. 2010; Hu et al. 2014; Turabelidze et al. 
2014). Some of the gene changes observed in these preferential processes are 
involved in cellular proliferation, cell cycle progression, DNA synthesis, repair and 
gene transcription; and in protein synthesis and degradation processes (Colwell et al. 
2008; Helmo et al. 2013). Furthermore, it has been shown that the inflammatory 
phase is reduced in early-gestational foetal and oral mucosal wound healing, with a 
decreased presence of pro-inflammatory cytokines (Mak et al. 2009; Chen et al. 
2010; Rolfe & Grobbelaar 2012; Yates et al. 2012; Helmo et al. 2013). There is also 
an increased expression of metalloproteinases in foetal and oral wounds, resulting in 
increased matrix degradation and subsequent extracellular matrix (ECM) turnover 
(Stephens et al. 2001; Rolfe & Grobbelaar 2012; Yates et al. 2012; Helmo et al. 
2013). The objective of this study was to determine what genes were differentially 
expressed by the novel epoxy-tiglianes and whether any of these were associated 
with preferential healing responses, as observed with the healing processes, 
previously mentioned. This might elucidate whether the exceptional healing 
responses previously observed with epoxy-tiglianes during in vivo veterinary case 
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studies are a result of similar alterations in keratinocyte function, as seen in early-
gestational foetal and oral mucosal wound healing (Colwell et al. 2008; Turabelidze 
et al. 2014).  
 
From the previous studies, it had been shown that both EBC-46 and EBC-211 induce 
a beneficial wound healing response on epidermal keratinocytes, shown by the 
stimulation of both proliferation and migration in the keratinocyte cell line, HaCaTs. 
However, little is known about how these compounds exert these beneficial wound 
healing effects. In order to elucidate the mechanistic actions of both EBC-46 and 
EBC-211, global gene expression analysis was performed through the use of 
Microarray studies.   
 
Due to the high-throughput of Microarray studies with thousands of genes analysed 
per sample and compared across conditions, a number of techniques were performed 
to narrow down the results produced with the aim of illuminating which genes were 
involved in producing the preferential wound healing response observed in the 
palliative veterinary studies. The process used in this global gene analysis was direct 
hybridisation, using the Eberwine protocol assay and Illumina’s proprietary 
BeadArray technology, which has high sensitivity and reproducibility. Gene-specific 
probes are able to detect previously labelled cRNA in samples and detect 
transcriptional changes between samples through detecting mRNA transcripts and 
quantifying the expression (Schulze & Downward 2000; Miller & Tang 2009; Lovén 
et al. 2012).   
 
5.2 Aims 
 
The data obtained in Chapter 4 demonstrated the profound effects of EBC-46 and 
EBC-211 on HaCaT wound healing responses in vitro, altering genes and pathways 
to give rise to such preferential healing responses, such as with enhanced 
proliferation and migration, along with an accelerated cell cycle progression. 
Stimulation of proliferation and migration following epoxy-tigliane treatment would 
be immensely beneficial for the treatment of impaired healing situations, such as 
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chronic wounds and burn injuries, where rapid re-epithelialisation is necessary to re-
establish the protective skin barrier (Candi et al. 2005).  
 
5.3 Materials and Methods 
 
5.3.1 Preparation of EBC-46 and EBC-211 
EBC-46 and the lesser active analogue, EBC-211, were both supplied by QBiotics 
Ltd., Queensland, Australia. EBC-46 and EBC-211 were solubilised in DMSO 
(Section 2.1). For both compounds, concentrations of 0.001g/ml, 0.01g/ml, 
0.1g/ml, 1g/ml and 10g/ml were prepared in 1% K-SCM for the assessment of 
HaCaT wound healing responses (Section 2.2.2). The 100µg/ml was not included as 
it was previously shown to be cytotoxic to HaCaTs. 
 
5.3.2 HaCaT Culture 
The epidermal keratinocyte cell line (HaCaTs) were sourced, cultured, sub-cultured, 
counted, cryopreserved and mycoplasma screened, as previously described (Sections 
2.2.2, 2.2.3, 2.2.4 and 2.2.5 respectively). HaCaTs were seeded and cultured for 
Microarray analysis (n=4), with samples obtained at 24h and 48h after treatment. 
Samples were subsequently shipped to the QIMR Berghofer Medical Research 
Institute in Australia, in order to undertake the Microarray analysis (Section 2.4.1).  
 
5.3.3 Assessment of HaCaT Gene Expression by Microarray Analysis 
RNA was extracted from HaCaT samples, purified and quantified; RNA integrity 
and purity was analysed as previously described (Section 2.4.2 and 2.4.3). 
Biotinylated, amplified antisense RNA (cRNA) was generated and quantified; cRNA 
was hybridised to gene-specific sequence BeadChips, as previously described (2.4.4 
and 2.4.5).   
 
5.3.4 Microarray Data Acquisition and Data Analysis  
BeadChips were scanned using the iScan System on Agilent GS2565 Microarray 
Scanner (Agilent Technologies Australia, Victoria, Australia); raw data files were 
filtered and normalised using BeadScan Software (Illumina®, Victoria, Australia). 
Data was subsequently imported into GeneSpring GX v12.5 expression analysis 
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software (Agilent Technologies), for normalisation, statistical analysis and heatmap 
visualization/clustering. Data from each treatment group (n=4) was grouped for 
combined analysis using Ingenuity Pathway Analysis (IPA®) for further analysis of 
Microarray data, as previously described (Section 2.4.6). 
 
5.3.5 Statistical Analysis of Global Gene Expression Changes 
Statistical analysis was carried out on the differences in gene expression by an 
unpaired T-Test unpaired, with Benjamini-Hochberg, multiple testing correction. 
Statistical significance was considered at p<0.05. Data from each experiment group 
(n=4) was combined for analysis, with hierarchical clustering analysis performed for 
the comparison between treated samples and untreated controls. Hierarchical 
clustering analysis allowed relationships between treatment groups to be observed, 
comparing EBC-46 (0.001µg/ml, 0.1 µg/ml and 10 µg/ml) and EBC-211 
(0.001µg/ml, 0.1 µg/ml and 10 µg/ml) at 24h and 48h. Fold-changes in gene 
expression for each treatment group were identified; and compared to the untreated 
control for each respective time-point.  
 
5.4 Results  
 
5.4.1 Effects of EBC-46 and EBC-211 on Global Gene Expression 
The Microarray analysis identified a number of genes differentially expressed after 
treatment with EBC-46 and EBC-211 (0.001µg/ml, 0.1 µg/ml and 10 µg/ml) at 24h 
and 48h, when compared to untreated controls at the same time-points. Due to the 
large number of genes analysed, only those differentially expressed ≥2 fold were 
focused upon.  
 
Hierarchal clustering was performed in GeneSpring, producing heatmaps and 
organising the gene expression data, based on how similar their expression was and 
showed sections of genes which were differentially up- or down-regulated following 
treatment with EBC-46 or EBC-211 for 24h or 48h. This allowed comparison 
between each dataset condition and compared epoxy-tigliane treated cells to 
untreated controls, in addition to comparisons between the different concentrations of 
epoxy-tiglianes. In an attempt to see which genes were more significantly up-/down-
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regulated, heatmaps were also produced showing the greater than 2-fold 
differentially expressed genes, compared to untreated controls, following 24h and 
48h treatment (Figures 5.1A-B and 5.2A-B for EBC-46 and EBC-211, respectively). 
The heatmaps demonstrated that for the majority of genes analysed, the epoxy-
tigliane treated cells produced similar changes in gene expression, compared to 
untreated controls, irrespective of the concentrations of epoxy-tigliane applied. This 
was observed through apparent similar levels of up- or down-regulation, compared to 
the respective untreated controls, for the majority of genes analysed. Any genes of 
interest were validated at a protein level (Chapter 6), to determine whether the 
genotypic differences observed after epoxy-tigliane treatment were replicated at a 
protein level and likely to result in a phenotypic response.  
 
Tables 5.1 and 5.2 show the number of genes differentially expressed ≥2 fold, ≥3 
fold, ≥5 fold and ≥10 fold, compared to untreated controls at the same time-points 
for EBC-46 and EBC-211, respectively. The fold differences in gene expression were 
determined through the use of GeneSpring GX11, a statistical tool for the analysis of 
Microarray data. Tables 5.1 and 5.2 show that the greatest number of genes 
differentially expressed occurred at the higher concentrations of both EBC-46 and 
EBC-211, especially at 48h post-treatment. This is also when the highest fold-
changes in expression were evident. Due to large number of genes identified to be 
differentially expressed by the Microarray study, the raw data showing all genes 
differentially expressed is included in Supplement 5.1.  
 
Key differentially expressed genes are displayed for keratins, cell cycle-related 
genes, cell proliferation-related genes, cell motility-related genes, proteinases, 
cytokines and chemokines, ECM component genes; and cell signalling-related genes 
(Supplement 5.2; Tables 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7 and 5.8, respectively). All 
genes shown are differentially expressed by more than 2-fold, with some genes 
belonging to multiple categories due their exertion of a number of cellular functions. 
As shown in Supplement 5.2; Tables 5.1-5.8, some genes are present more than once 
on each BeadChip, with separate probe IDs/Entrez Gene ID. This provides additional 
validation of expression changes, compared to untreated controls. This resulted in 
more than one value produced for some differentially expressed genes compared to  
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Figure 5.1: Heatmap visualization through hierarchical clustering of genes 
differentially ≥2 fold expressed by HaCaTs (n=4 biological samples), cultured in 
the presence of 0.001g/ml, 0.1g/ml or 10g/ml EBC-46 at 24h (A) and 48h (B), 
and compared to an untreated control. (A) Lane 1 = Untreated HaCaT control; 
Lane 2 = 0.001g/ml EBC-46; Lane 3 = 10g/ml EBC-46. (B) Lane 1 = 
Untreated HaCaT control; Lane 2 = 0.001g/ml EBC-46; Lane 3 = 0.1g/ml 
EBC-46; Lane 4 = 10g/ml EBC-46. Red = up-regulated genes, Green = down-
regulated genes. 
 
 A       B 
     1            2           3          1        2        3        4 
 
  
  
   
  
  
239 
 
Figure 5.2: Heatmap visualization through hierarchical clustering of genes 
differentially ≥2 fold expressed by HaCaTs (n=4 biological samples), cultured in 
the presence of 0.001g/ml, 0.1g/ml or 10g/ml EBC-211 at 24h (A) and 48h 
(B), and compared to an untreated control. (A) Lane 1 = Untreated HaCaT 
control; Lane 2 = 0.001g/ml EBC-211; Lane 3 = 10g/ml EBC-211. (B) Lane 1 
= Untreated HaCaT control; Lane 2 = 0.001g/ml EBC-211; Lane 3 = 0.1g/ml 
EBC-211; Lane 4 = 10g/ml EBC-211. Red = up-regulated genes, Green = 
down-regulated genes. 
 
 A       B 
     1            2           3          1        2        3        4 
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Table 5.1: Number of genes differentially expressed ≥ 2-fold, ≥ 3-fold, ≥ 5-fold and ≥ 10-fold in HaCaTs cultured with EBC-46 
(0.001µg/ml, 0.1µg/ml or 10µg/ml) for 24h or 48h, in comparison to untreated controls.  
 EBC-46 
 24h 48h 
 0.001g/ml 10g/ml 0.001g/ml 0.1g/ml 10g/ml 
 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
≥ 2-fold 53 55 64 145 161 215 161 215 167 266 
≥ 3-fold 2 9 5 40 34 64 34 64 35 111 
≥ 5-fold 0 0 0 10 2 16 2 16 3 30 
≥ 10-fold 0 0 0 1 0 0 0 0 0 6 
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Table 5.2: Number of genes differentially expressed ≥ 2-fold, ≥ 3-fold, ≥ 5-fold and ≥ 10-fold in HaCaTs cultured with EBC-211 
(0.001µg/ml, 0.1µg/ml or 10µg/ml) for 24h or 48h, in comparison to untreated controls.  
 
 EBC-211 
 24h 48h 
 0.001g/ml 10g/ml 0.001g/ml 0.1g/ml 10g/ml 
 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
Up-
regulated 
Down-
regulated 
≥ 2-f 
old 
37 33 62 126 146 138 159 215 130 220 
≥ 3-fold 2 8 5 25 29 30 35 72 27 76 
≥ 5-fold 0 0 0 6 3 5 1 13 2 22 
≥ 10-fold 0 0 0 0 0 0 0 1 0 2 
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the untreated control, some genes are present on more than one BeadChip, resulting 
in two probe IDs for these genes. This can provide further confirmation of 
differentially expressed genes, if result observed for both BeadChips. 
 
No genes were differentially expressed when the comparisons were made between 
the same concentration of EBC-46 and EBC-211, at each time-point (p>0.05). 
However, there were differentially expressed genes evident between 0.001µg/ml, 
0.1µg/ml and 10µg/ml EBC-46 and EBC-211. This was particularly evident when 
comparing the lower concentrations of EBC-46 and EBC-211 (0.001 and 0.1µg/ml) 
to the higher concentration (10µg/ml); which may explain the superior wound 
repopulation responses evident at lower EBC-46 and EBC-211 concentrations 
(Supplement 5.2; Tables 5.9-16). 
 
Ingenuity Pathway Analysis (IPA®) Software was used to analyse the Microarray 
data, using Ingenuity Knowledge Base to visualise gene pathways. Pathway analysis 
helped determine the resultant downstream effects of gene expression changes 
following novel epoxy-tigliane treatment. The regulator effect networks determined 
using IPA® software, shown in Figures 5.3-5.8, display predicted downstream 
phenotypic responses, according to the increase or decrease in expression of 
particular genes. Regulator effects were shown to predict stimulated proliferation of 
cells following 48h treatment with 0.001µg/ml or 0.1µg/ml EBC-46 (Figure 5.3). 
Significantly enhanced proliferative response was observed during the in vitro 
viability and proliferation studies (Figure 4.1A), although this study showed the 
enhanced proliferative ability for all concentrations of EBC-46. In addition, the 
growth and development of epithelial tissue was predicted to be stimulated following 
treatment with 0.001µg/ml and 0.1µg/ml EBC-46, but again not at 10µg/ml (Figure 
5.4). This response was also observed following 48h treatment with 0.1µg/ml EBC-
211, potentially contributing to the enhanced re-epithelialisation observed during the 
in vivo veterinary studies.  
 
Figures 5.5-5.8 demonstrate that the result of epoxy-tigliane treatment and 
subsequent gene expression changes likely to produce a migratory response on the 
cells, which was previously seen in the observational experiments (Chapter 4). This 
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Figure 5.3: Regulator effects on HaCaTs after 48h treatment with 0.001µg/ml or 
0.1µg/ml EBC-46; resulting in proliferation of cells.  
 
 
Figure 5.4: Regulator effects on HaCaTs after 48h treatment with 0.1µg/ml 
EBC-211; resulting in cell viability, leukocyte migration, growth of epithelial 
tissue, development of cardiovascular and epithelial tissue; and inhibited 
apoptosis of blood cells. 
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Figure 5.5: Regulator effects on HaCaTs after 48h treatment with 0.001µg/ml or 
0.1µg/ml EBC-46; resulting in migration of cells, activation of cells, synthesis of 
nitric oxide and protein kinase cascade.  
 
 
 
Figure 5.6: Regulator effects on HaCaTs after 48h treatment with 0.001µg/ml or 
0.1µg/ml EBC-46, resulting in migration of cells, activation of cells, growth of 
epithelial tissue; and development of cardiovascular and epithelial tissue. 
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Figure 5.7: Regulator effects on HaCaTs after 48h treatment with 0.001µg/ml 
EBC-211; resulting in migration of cells. 
 
Figure 5.8: Regulator effects on HaCaTs after 48h treatment with 0.1µg/ml 
EBC-211; resulting in cell movement.  
 
 
246 
 
is particularly evident for Figures 5.5 and 5.6, where the migration of cells was 
predicted to be stimulated due to the differentially expressed genes shown. This was 
observed for 0.001µg/ml and 0.1µg/ml EBC-46, but not at 10µg/ml. This 
corroborates the in vitro wound repopulation studies, where significantly enhanced 
migration was evident for these two concentrations of EBC-46, but not 10µg/ml 
(Figure 4.27). Other regulator effects were shown to predict stimulated migration of 
cells or movement of cells, evident following 0.001µg/ml or 0.1µg/ml EBC-211 
treatment, respectively (Figures 5.7 and 5.8, respectively). Migration of cells and 
movement of cells are listed as two separate functions, although there are a number 
of genes involved in both functions. Movement of cells may induce a motility 
response, whereas migration of cells may indicate a chemoattractant force 
stimulating a directional movement of cells. Significantly enhanced migration was 
also evident at the lower concentrations of EBC-211, shown through the in vitro 
wound repopulation studies (Figure 4.27).  
 
Despite both EBC-46 and EBC-211 stimulating cell migration, there are different 
genes involved in these regulator effect responses. The regulator effect response for 
EBC-46 appears to involve chemokines, potentially inducing a chemoattractant 
gradient; whereas EBC-211 involved some metalloproteinases, so may induce the 
migratory response through degradation of the provisional matrix required for 
keratinocyte migration to occur (Michel et al. 1992; Pilcher et al. 1997; Engelhardt et 
al. 1998; Nagase et al. 2006; Kroeze et al. 2012; Nuutila et al. 2012). It is not fully 
understood yet why there are differences in these regulator responses, when the 
previous in vitro studies showed some similar responses between the two epoxy-
tiglianes.  
 
5.5 Discussion 
 
The global gene analysis performed in this Chapter aimed to distinguish 
differentially expressed genes following EBC-46 and EBC-211 treatment at 24h and 
48h, compared to untreated controls. The aim of this analysis was to identify which 
genes contribute to the beneficial HaCaT wound healing responses observed, both 
through the in vitro studies performed (Chapters 3 and 4) and the in vivo animal 
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palliative studies performed by QBiotics Ltd. As discussed previously, there are a 
number of genes involved in producing preferential or detrimental wound healing 
responses. Therefore, this study was undertaken to elucidate any potential expression 
changes in genes relevant to these HaCaT responses and the overall healing process. 
The aim was that some of these differentially expressed genes might explain the 
strong proliferative and migratory response in HaCaTs, along with the enhancement 
of cell cycle progression, following epoxy-tigliane treatment. As apparent in Tables 
5.1 and 5.2, there are a large number of genes differentially expressed following 
EBC-46 and EBC-211 treatment, across all concentrations and time-points. IPA® 
software was instrumental in determining the impact these gene expression changes 
have on wound healing functions, narrowing down the genes of interest for further 
protein-based validation (Chapter 6).  
 
There was a greater number of fold-changes in expression after 48h treatment for 
both epoxy-tiglianes, compared to 24h treatment. Similar patterns in differentially 
expressed genes were observed, when comparing the two epoxy-tiglianes at the same 
concentration and time-point; no genes were shown to be differentially expressed in 
this comparison. As previously mentioned, a number of genes were shown to be 
differentially expressed in comparisons between different concentrations of each 
epoxy-tigliane and compared to the other epoxy-tigliane, at the same time-point. 
These were predominantly the same genes, as observed when compared to the 
untreated controls. Due to the large number of genes analysed, the genes were further 
categorised by their function during the wound healing process and analysed 
accordingly. However, certain genes impart multiple cellular functions and therefore, 
fell into several categories. Therefore, these have been allocated into one category 
only for the purpose of displaying the results from this study. Despite the dramatic 
concentration differences evident during the in vitro studies, in particular during the 
wound repopulation and closure analysis, there was not a huge difference in 
expression fold-change across the concentrations for EBC-46 or EBC-211. In 
addition, the fold-changes observed were similar for EBC-46 and EBC-211 
concentrations, compared to the untreated controls.  However, there did appear to be 
a greater number of genes seen to be differentially expressed in each category of ≥ 2-
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fold, ≥ 3-fold, ≥ 5-fold and ≥ 10-fold, with increasing concentration for both epoxy-
tiglianes. 
 
5.5.1 Keratins 
 
Numerous keratins were found to be differentially expressed in this Microarray study 
following epoxy-tigliane treatment, when compared to untreated controls. This study 
showed that keratin (Krt)13, Krt15 and Krt9 were predominantly upregulated 
following 48h treatment with both epoxy-tiglianes, with Krt81 upregulated following 
24h. In all cases, this upregulation was greater than 2-fold change in expression, 
compared to the respective untreated controls, with Krt13 and Krt15 upregulated 
approximately 4-7 fold.  
  
The profound upregulation of Krt13 and Krt15 is of particular interest, as these are 
keratin types not typically found in adult skin epithelia. These keratins are present in 
non-keratinized, oral mucosal and foetal epithelia respectively, which are both 
recognised as preferential healing responses with rapid re-epithelialisation (Waseem 
et al. 1999; Turabelidze et al. 2014). A Microarray study by Turabelidze et al. 
(2014), showed an increased presence of Krt13 in oral mucosal epithelium, in 
contrast to the situation with skin epithelium (Bragulla & Homberger 2009). 
Additionally, Krt13 has also been documented to be present in the suprabasal layer 
of foetal epithelia and has a role in the regeneration of the epidermis (Kallioinen et 
al. 1995). Krt15 is present in basal keratinocytes and plays a major role in 
keratinocyte proliferation; this keratin is found to be upregulated and partner with 
Krt5 in the absence of Krt14 (Bragulla & Homberger 2009; Bose et al. 2013). Krt15 
has been associated with tissue development and providing structural integrity to the 
developing basal layer, due to its’ continuous presence in foetal epithelium compared 
to a discontinuous presence in the skin epithelium (Waseem et al. 1999; Bose et al. 
2013). Krt15 has also been referred to as an epidermal stem cell marker and is 
present in the hair follicle bulge, an area that has been previously thought of as a 
stem cell niche (Liu et al. 2003; Bose et al. 2013). The upregulation of these two 
keratins following epoxy-tigliane treatment may be partly responsible for the 
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exceptional wound healing response observed, where the healing mechanism appears 
to be more representative of a regenerative healing model (Yates et al. 2012).  
 
The Microarray analysis also showed a down-regulation of Krt6B, Krt16 and Krt17 
at 2-4 fold, compared to untreated controls, at 24h and 48h. Krt16, Krt17 and Krt6B 
are typically absent from the epidermis in uninjured skin, but are induced following 
wounding and play a part in the wound healing response (Santos et al. 2002; 
Mazzalupo et al. 2003). These keratins form heterodimers and are associated with a 
hyperproliferative and migratory response, which is beneficial to wound healing 
situations in the repopulation of denuded sites if carefully controlled (Freedberg et al. 
2001; Komine et al. 2001; Trost et al. 2010). Krt17 is typically found in complex 
epithelia, such as hair follicles, but not healthy epidermal skin (Shen et al. 2006; Jin 
& Wang 2014). Despite the roles of Krt6, Krt16 and Krt17 in the wound healing 
response, these keratins are also associated with a detrimental healing process. 
Downregulation of Krt6 has also been associated with increased keratinocyte 
migration and resultant re-epithelialisation (Wong & Coulombe 2003). The 
association between Krt17 expression and psoriasis is so well-established, that Krt17 
expression levels are used diagnostically to determine the presence and severity of 
psoriatic disorders (Zhang et al. 2012). Additionally, an overexpression of Krt16, 
which occurs in aged skin, has been demonstrated to have an inhibitory effect on 
migratory potential of wound edge keratinocytes, although Krt16 has been associated 
with providing mechanical strength to these keratinocytes, instead of inducing 
migration (Trost et al. 2010). It has been hypothesised by Trost et al. (2010) that a 
careful balance between expressions of these keratins is necessary to provide strength 
at the wound edge, whilst also permitting the migration of keratinocytes across the 
wound site. The downregulation of these three keratins was not expected given their 
important role in wound healing. However, given that their expression is induced 
following wounding, this might explain the lack of upregulation observed following 
epoxy-tigliane treatment. Of particular interest was their inhibitory action on 
keratinocyte migration, the decreased expression of these keratins may contribute to 
the enhanced migratory responses observed during the in vitro wound repopulation 
studies and the animal in vivo studies.  
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5.5.2 Cell Cycle-Related Genes 
A number of cell cycle-related genes were shown to be upregulated following epoxy-
tigliane treatment, compared to untreated controls. This upregulation was in the 
range of 2-4 fold. Genes of particular interest that were upregulated included, cyclin 
B2 (CCNB2), cyclin B1 (CCNB1), cyclin A2 (CCNA2), cyclin-dependent kinase 
inhibitor 3 (CDKN3), ubiquitin-conjugating enzyme E2C (UBE2C), cell division 
cycle associated 7 (CDCA7), centrosomal protein 55kDa (CEP55) and E2F 
transcription factor 2 (E2F2). For the majority of these genes, the upregulation was 
only present at 48h. In contrast, cyclin-dependent kinase inhibitor 1A (CDKN1A) 
was downregulated following epoxy-tigliane treatment 2-3 fold across all conditions, 
compared to untreated controls.  
 
Cyclin genes in particular were found to be upregulated, which are associated with 
the progression of cells into mitosis, along with cyclin-dependent protein kinases 
(CDKs), through the formation and dissociation of cyclin-CDK complexes 
(Hochegger et al. 2008; Huang et al. 2013). When cyclins bind to a CDK and 
subsequently activate, this signals to the cell to progress onto the next cell cycle 
phase (Alberts et al. 2002; Vermeulen et al. 2003; Huang et al. 2013). There is a 
specific association between cyclins and CDKs, an example is the complex formed 
between CCNB1 or CCNB2 and CDK1; this complex is involved in the progression 
of cells into M phase, initiating mitosis (Vermeulen et al. 2003; Hochegger et al. 
2008; Huang et al. 2013). CCNB1, CCNB2 and CCNA2 promote G2-M transition, 
while CCNA2 also controls G1-S transition for DNA synthesis (Wu et al. 2010; 
Huang et al. 2013). The combined effect of these upregulated genes would result in 
the stimulated progression of cells into S phase and M phase, subsequently 
enhancing the proliferative effect on cells (Gong & Ferrell 2010). CCNB1 and 
CCNB2 are essential regulators of mitosis-promoting factor (MPF), through the 
formation of complexes with CDK1 or CDC2; although expression of these cyclins 
is also increased in cancers (Tschöp & Engeland 2007).  
 
In addition to the cyclins required for mitosis to occur, cyclin-dependent inhibitors 
are also crucial. CDKN3 has been shown to regulate the G1 to S phase transition by 
arresting G1 phase, along with controlling the normal function of mitosis (Nalepa et 
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al. 2013). The loss or mutation of CDKN3 has been linked to the formation of 
several cancer types. As a result, this inhibitor is referred to as a tumour suppressor 
by preventing abnormal mitosis occurring (Nalepa et al. 2013). Another cyclin-
dependent kinase inhibitor differentially expressed was CDKN1A, a potent inhibitor 
of cell cycle progression. CDKN1A acts through inhibiting the action of cyclin/CDK 
complexes, in particular complexes which contain CDK2, such as the complex 
formed with CCNA2. This subsequently prevents the transition of cells from G1 to S 
phase (Gartel & Tyner 2002; Koljonen et al. 2006). In this study, CDKN1A was 
downregulated after epoxy-tigliane treatment, reducing the inhibition of cell cycle 
progression and proliferative ability of the cells. Another essential factor for cell 
cycle progression differentially expressed after epoxy-tigliane treatment is UBE2C, 
which was upregulated greater than 3-fold at 48h with both EBC-46 and EBC-211. 
Cyclin-CDK complexes have to be disrupted to allow progression of cells into 
mitosis. UBE2C is involved in the breakdown of these cyclins, stimulating cell 
proliferation (Hao et al. 2012; Shen et al. 2013; Chou et al. 2014; Xie et al. 2014). 
However, overexpression of UBE2C can have a detrimental effect on the cell cycle 
profile, by the loss of certain crucial mitotic checkpoints. As a result, this gene has 
also been associated with a number of cancer types (Hao et al. 2012; Xie et al. 2014). 
Overall, these differentially expressed cell cycle-related genes result in an increased 
proliferative potential of keratinocytes, through enhanced cell cycle progression, 
maintenance of normal mitosis and a reduced inhibitory effect on cell cycle 
progression. This likely contributes to the enhanced cell cycle progression, following 
epoxy-tigliane treatment, observed during the flow cytometry studies; in addition, to 
the resultant increased proliferative ability observed during the in vitro viability and 
proliferation studies. The veterinary in vivo case studies showed enhanced wound re-
epithelialisation, with increased keratinocyte proliferation potentially contributing to 
this response, this may be aided by the increased cell cycle progression due partly to 
these differentially expressed genes.  
 
5.5.3 Cell Proliferation-Related Genes 
There were a number of cell-proliferation genes differentially expressed following 
epoxy-tigliane treatment, including GINS complex subunit 2 (GINS2), polymerase 
(DNA directed), epsilon 2, accessory subunit (POLE2), KIAA0101 and parathyroid 
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hormone-like hormone (PTHLH). These genes were up-regulated in EBC-46- and 
EBC-211-treated cells between 2-4 fold, compared to untreated controls. GINS2 is a 
known gene involved in DNA replication, through its part in the replicative helicase 
allowing the progression of cells into S phase and subsequent cell division. GINS2 is 
also involved in the DNA damage response and DNA repair (Rantala et al. 2010; 
Gao et al. 2013; Zheng et al. 2014).  
 
As previously discussed, keratinocyte wound healing responses have a paracrine 
feedback system with dermal fibroblasts, along with an autocrine feedback response 
(Bader & Kao 2009). One of the key genes involved in this feedback system is 
PTHLH, which is secreted by keratinocytes and acts on fibroblasts. PTHLH 
stimulates keratinocyte growth factor (KGF) expression in fibroblasts, a growth 
factor involved in keratinocyte wound healing responses (Blomme et al. 1999). 
PTHLH has been shown to have a proliferative effect on keratinocytes, with the 
expression increased throughout the cell cycle until mitosis is reached, where the 
greatest expression is observed (Feuerherm et al. 2013). Epoxy-tigliane induced 
upregulation of this gene may play a part in the increased keratinocyte proliferative 
response observed. These cell proliferation-related genes have been shown to directly 
or indirectly increase keratinocyte proliferative ability. This suggests their 
involvement in the enhanced proliferation observed during the in vitro studies. In 
addition, this upregulation may be involved in the potential increase in keratinocyte 
presence at the wound site during the animal in vivo case studies.  
 
5.5.4 Cell Motility-Related Genes 
The S100 proteins are a family of calcium binding proteins, with a wide array of 
functions through action on a range of cell types (Lee & Eckert 2007; Zibert et al. 
2010). Some of the genes for this protein family were differentially expressed 
following epoxy-tigliane treatment, including S100A4, S100A7, S100A7A, S100A8, 
S100A9 and S100A12 (Mazzucchelli 2002; Lee & Eckert 2007; Zibert et al. 2010; 
Gross et al. 2014).  
 
S100A4 was the only gene from this family that was upregulated at 48h with EBC-
46 and EBC-211, with the up-regulation ranging between 2-3-fold, compared to 
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untreated controls. S100A4 has been shown to have a positive effect on cell 
proliferation, through affecting the cell cycle progression, with increased expression 
resulting in enhanced G1 to S phase transition. However, potentially due to this 
stimulatory effect on cell proliferation, along with a stimulatory effect on cell 
invasion, S100A4 has also been implicated in cancer progression, with a higher 
expression often correlating to a poor clinical outcome (Cajone & Sherbet 2000; 
Mazzucchelli 2002; Klingelhöfer et al. 2009). This enhanced proliferative effect can 
have detrimental outcomes, with an excessive expression of S100A4 also being 
linked to psoriasis (Zibert et al. 2010). This protein has also been shown to enhance a 
number of other cellular functions, such as cell motility, survival, differentiation and 
angiogenesis. The effect on cell motility may be a result of changes to the 
organisation of actin in the cell, increasing cell protrusions (Klingelhöfer et al. 2009; 
Sin et al. 2011).  
 
S100A7, also known as psoriasin, and S100A7A (koebnerisin/S100A15) were down-
regulated following epoxy-tigliane treatment, between 3-19-fold, compared to 
untreated controls. Increased expression of these two proteins has also been 
associated with psoriatic skin (Hattinger et al. 2013). They also have a 
chemoattractant activity, recruiting more immune cells to the site and subsequently 
enhancing the inflammatory reaction. However, due to the strongly similar structure 
of these two proteins, it is difficult to distinguish between them and determine which 
performs certain functions (Büchau et al. 2007; Wolf et al. 2011; Hattinger et al. 
2013). S100A8 and S100A9, down-regulated between 2-11-fold and 4-8-fold 
respectively, are also expressed highly in psoriatic skin, along with S100A7; 
although despite psoriasis being a result of uncontrolled proliferation, a study has 
showed that over-expression of S100A8/A9 in HaCaTs reduces proliferation 
(Martinsson et al. 2005; Zibert et al. 2010; Voss et al. 2011). S100A8/A9 have been 
shown to be up-regulated after wounding, with the chemotaxis of immune cells to the 
site; and also where the epithelium is hyperproliferative (Thorey et al. 2001; Voss et 
al. 2011). S100A12 was down-regulated between 2-3-fold compared to untreated 
controls, along with a number of the other S100 family calcium binding proteins; 
S100A12 also has a chemoattractant effect on immune cells (Thorey et al. 2001; 
Gross et al. 2014). This protein is also found to be over-expressed in psoriatic 
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lesions, with expression correlating to severity of the skin disorder; expression is 
increased following stimulation by pro-inflammatory cytokines (Moroz et al. 2003; 
Wilsmann-Theis et al. 2015). The overall effect of these differentially expressed 
genes results in an enhanced proliferative response in keratinocytes, but would 
potentially inhibit the induction of a hyperproliferative response, as observed in 
psoriasis. In addition, increased cell mobility and decreased differentiation responses 
are potentially induced, as a result of these gene expression changes. This could lead 
to the enhanced proliferation and migration of keratinocytes observed in vitro, 
through proliferation and wound repopulation studies, respectively. As a rapid re-
epithelialisation response was also observed during in vivo studies, these 
differentially expressed genes could contribute to this response, by enhancing 
keratinocyte proliferation and motility.  
 
5.5.5 Proteinase and Proteinase Inhibitor Genes 
In the proteinase and proteinase inhibitor gene category, some key wound healing 
proteases were differentially expressed between 2-6 fold, namely matrix 
metalloproteinase (MMP)-1, MMP-7 and MMP-10, which were upregulated 
following epoxy-tigliane treatment. Keratinocytes are the predominant producer of 
these three MMPs (Xue & Jackson 2015). However, no tissue inhibitors of 
metalloproteinases (TIMPs) were differentially expressed greater than 2-fold 
following epoxy-tigliane treatment.  
 
Peptidase inhibitor 3, skin derived (PI3), also referred to as elafin, is a serine protease 
inhibitor and was shown to be profoundly downregulated following epoxy-tigliane 
treatment, between approximately 6-15-fold, when compared to untreated controls 
(Nakane et al. 2002; Pol et al. 2003). A number of serpin peptidase inhibitors 
(SERPINs) were differentially expressed following epoxy-tigliane treatment. 
SERPINA3, SERPINB3, SERPINB4 were all downregulated between approximately 
2-8-fold, whereas SERPINB2 was upregulated approximately 2.3-fold at the lower 
concentrations of EBC-46 and EBC-211.  
 
MMP-1 is a key proteinase in wound healing, which has a specific proteolysis action 
on type I collagen; this allows the migration of keratinocytes into the wound site and 
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for the subsequent re-epithelialisation process (Pilcher et al. 1997; Vu & Werb 2000; 
Agren et al. 2001; Dasu et al. 2003; Nagase et al. 2006; Muller et al. 2008; Nuutila et 
al. 2012; Rohani et al. 2014). Studies have shown that inhibiting MMP activity 
through use of broad spectrum inhibitors, GM 6001 or BB-94, resulted in a lack of 
keratinocyte migration, indicating the importance of MMP activity; however, re-
epithelialisation did eventually occur despite constant presence of BB-94 (Agren et 
al. 2001; Mirastschijski et al. 2004; Mirastschijski et al. 2010). However, a careful 
balance of expression of MMPs is necessary as an increased expression for a longer 
time period can also be associated with non-healing wounds, such as chronic 
wounds; this excessive disruption of the ECM during chronic wounds has been 
shown to impede keratinocyte migratory ability, due to the fragmented nature of 
degraded ECM (Vaalamo et al. 1996; Pilcher et al. 1997; Trengrove et al. 1999; 
Cook et al. 2000; Saito et al. 2001; Mwaura et al. 2006; Beidler et al. 2008; Brandner 
et al. 2008; Eming et al. 2008; Muller et al. 2008; Alsaigh et al. 2011; Rohani & 
Parks 2015).  
 
Conversely, keloid and hypertrophic scars have been shown to have decreased 
expression of MMP-1; with studies showing that increasing MMP-1 expression aids 
fibrosis through increased degradation of collagen, leading to therapies targeting 
increase of MMP-1 activity (Dasu et al. 2004; Cho et al. 2010; Eto et al. 2012; Aoki 
et al. 2014; Li et al. 2014; Rohani & Parks 2015). However, increased MMP-1 
expression has been shown in some keloid studies, allowing the fibrotic response to 
extend past the wound margin, through a degradative action on collagen (Fujiwara et 
al. 2005; Shih et al. 2010).  
 
MMP-7, also known as matrilysin, is typically found in mucosal epithelium and has 
been shown to be upregulated following bacterial infection and epithelial injury, 
where it plays a role in inflammation and repair (Kassim et al. 2007; Gill & Parks 
2008; Chen et al. 2009; Rohani & Parks 2015). It has also been shown to degrade the 
basement membrane to allow keratinocyte migration and subsequent re-
epithelialisation (Kassim et al. 2007; Chen et al. 2009; Philips et al. 2011). Increased 
levels of MMP-7 have been observed in chronic wounds or following exposure to 
Staphylococcus aureus; and associated with an increased degradative activity at the 
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wound site (Kanangat et al. 2006; Löffek et al. 2011; Puthenedam et al. 2011; Letra 
et al. 2013). MMP-10 (stromelysin-2) is expressed in wound edge keratinocytes and 
has been associated with keratinocyte migration following injury, through 
degradation of basement membrane collagens (Saarialho-Kere et al. 1994; Vaalamo 
et al. 1997; Rohani et al. 2015; Schlage et al. 2015). However, the function of MMP-
10 on wound healing has yet to be fully elucidated. All three MMPs discussed appear 
to induce positive responses on keratinocyte migration, contributing to re-
epithelialisation. Therefore, an increased expression of all in the Microarray studies 
following epoxy-tigliane treatment may account for the greatly enhanced migratory 
responses observed during the in vitro scratch wound repopulation studies; and the 
induction of a rapid re-epithelialisation during in vivo studies. Although, the in vitro 
migration assay was performed on tissue culture plastic and not an ECM, which 
would replicate in vivo settings more accurately (Kramer et al. 2013).  
 
SERPINs are irreversible protease inhibitors involved in a number of wound healing 
functions, including coagulation, inflammation, angiogenesis and apoptosis 
(Janciauskiene 2001; Pike et al. 2002; Nuutila et al. 2012). A number of SERPINs 
are induced by tumour necrosis factor-α (TNF)-α, including SERPINB1, SERPINB2, 
SERPINB3 and SERPINB8; due to their protease inhibitory action, this may be a 
protective mechanism for the keratinocytes against increased inflammatory 
environments (Banno et al. 2004). SERPINA3, also known as α-1-antichymotrypsin 
(ACT), has been shown to be upregulated following injury and topical application 
enhanced wound repair in impaired healing situations, such as in diabetic wounds, 
through induction of granulation tissue formation and re-epithelialisation responses 
(Hoffmann et al. 2011).  
 
SERPINB2, also known as plasminogen activator inhibitor (PAI)-2 is an inhibitor of 
urokinase-type plasminogen activator (uPA) and is upregulated following infection; 
this inhibits the role of uPA on keratinocyte cell cycle progression and subsequent 
proliferation (Reinartz et al. 1996; Hibino et al. 1999; Risse et al. 2000; Jang et al. 
2010). PAI-2 has also been shown to have an increased presence in diabetic wound 
keratinocytes, contributing to impaired keratinocyte migration; although increased 
expression has been shown following wounding, stimulating keratinocyte 
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proliferation (Jensen & Lavker 1996; Zhang et al. 2015). SERPINB3, also known as 
squamous cell carcinoma antigen-1 (SCCA-1) and SERPINB4, also known as 
SCCA-2, are almost identical gene products within the SERPIN family (Katagiri et 
al. 2006; Katagiri et al. 2010). Both SCCA-1 and SCCA-2 have been shown to be 
present in abnormal skin disorders, such as psoriasis, associated with dysfunctional 
differentiation and a hyperproliferative profile (Titapiwatanakun et al. 2005; Katagiri 
et al. 2006; Mee et al. 2007; Yao et al. 2008; Katagiri et al. 2010). They both have 
also been implicated in inflammation, through increasing the expression of S100A8. 
Expression of SCCAs may lead to excessive inflammation and chronic wound 
situations (Sivaprasad et al. 2015). Of interest, protein levels of SCCA-1 were shown 
to be increased in rapidly healing diabetic wounds, as opposed to non-healing 
wounds (Fadini et al. 2014). 
 
Some of the differentially expressed SERPIN functions are at contrast with the in 
vitro and in vivo results, previously observed. SERPINA3 was shown to be 
downregulated; whereas it is typically upregulated following injury and capable of 
stimulating enhanced wound repair in non-healing wounds. However, the samples 
used for this global gene analysis were not wounded. In addition, the upregulation of 
SERPINB2 resulting in inhibited keratinocyte proliferation conflicts with the 
enhanced proliferation observed during the in vitro studies. However, expression has 
been shown to be increased during re-epithelialisation, which may contribute to the 
rapid re-epithelialisation response observed during these in vitro and in vivo studies. 
The downregulation of SERPINB3 and SERPINB4, but enhanced wound repair 
during the in vivo animal studies, is in contrast to the enhanced healing observed in a 
study in diabetic wounds. The in vitro and in vivo studies have shown an increased 
proliferative ability of keratinocytes following epoxy-tigliane treatment, but this 
increased proliferation may be controlled, due to downregulation of a number of 
hyperproliferative-related genes.  
 
5.5.6 Cytokine and Chemokine Genes  
There was a down-regulation of a number of cytokines and chemokines following 
epoxy-tigliane treatment. These included tumour necrosis factor-α (TNF-α), 
interferon β1, fibroblast (IFNB1), chemokine (C-C motif) ligand 2 (CCL2), CCL3, 
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CCL5 (also known as RANTES), CCL8, CCL20, chemokine (C-X-C motif) ligand 1 
(CXCL1), CXCL6; and CXCL10 (also known as IP-10; interferon γ-induced protein 
10).  
 
Expression of TNF-α is decreased approximately 2-4-fold at 48h with both EBC-46 
and EBC-211, along with 10µg/ml EBC-46 and EBC-211, compared to untreated 
controls. A higher expression of TNF-α has been shown in non-healing chronic 
wounds, compared to normal acute skin wounds (Wallace & Stacey 1998; Barrientos 
et al. 2008; Brandner et al. 2008; Ashcroft et al. 2012; Gragnani et al. 2013). TNF-α 
stimulates KGF expression, which indirectly promotes re-epithelialisation through 
stimulating keratinocyte proliferation (Barrientos et al. 2008; Gragnani et al. 2013). 
However, if TNF-α expression is too high, it has been shown to inhibit the re-
epithelialisation process, through increased keratinocyte adhesion and inhibition of 
keratinocyte proliferation, by keeping the cells in G1 phase (Wallace & Stacey 1998; 
Banno et al. 2004; Barrientos et al. 2008; Morhenn et al. 2013). It has also been 
shown to induce a positive response on keratinocyte migration, increasing re-
epithelialisation response; although, this motility appeared to be more erratic, with 
cells migrating in and out of the denuded spaces (Banno et al. 2004; Scott et al. 
2004). IFNB1, an inflammatory cytokine, was down-regulated between 3-5-fold 
following epoxy-tigliane treatment at both 24h and 48h, compared to untreated 
controls. IFNB1 has been shown to have antiviral properties, along with an anti-
proliferative and enhanced differentiation effect on keratinocytes, acting through the 
Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway 
(Yaar et al. 1985; Dai et al. 2008; Ismail & Yusuf 2014; Takiguchi et al. 2014).  
 
CCL5 and CCL2 (also known as MCP-1), are potent chemokines produced by 
keratinocytes involved in the wound healing process, by attracting immune cells to 
the wound site, including macrophages and neutrophils (Wetzler et al. 2000; Pastore 
et al. 2005; Suga et al. 2014; Balaji et al. 2015; Portou et al. 2015). Expression was 
downregulated following epoxy-tigliane treatment by approximately 2-5-fold, 
compared to untreated controls; this may result in a reduced inflammatory phase, 
similar to that seen in foetal wound healing (Larson et al. 2010; Balaji et al. 2015). 
CCL5 has a role in the majority of phases of the wound healing process: haemostasis, 
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inflammation and proliferation; in addition it exerts a mitogenic effect on 
keratinocytes, attracting more to the wound site (Spiekstra et al. 2007; Suga et al. 
2014; Balaji et al. 2015). High expression of CCL2 is present in keratinocytes at the 
wound edge, with a hyperproliferative response. A significantly reduced expression 
of CCL2, following induction by TNF-α or IFN-γ, is observed in oral keratinocytes, 
compared to skin keratinocytes (Li et al. 2000). CXCL10, also known as IP-10, is 
another inflammatory chemokine which was down-regulated between 3-13-fold 
following epoxy-tigliane treatment, compared to untreated controls during all 
conditions. CXCL10 is an angiostatic chemokine and expression is induced 
following wounding; although, increased expression has been associated with 
detrimental wound healing, due to an elevated inflammatory response (Boorsma et 
al. 1998; Luster et al. 1998; Bodnar et al. 2006; Barrientos et al. 2008; Zaja-
Milatovic & Richmond 2008; Yates-Binder et al. 2012; Lee et al. 2013). This 
chemokine has been shown to have a stimulatory response on the migratory response 
of undifferentiated keratinocytes, with delayed re-epithelialisation observed when the 
receptor for this chemokine, CXCR3, is dysfunctional (Satish et al. 2003; Satish et al. 
2005; Behm et al. 2012; Kroeze et al. 2012; Yates-Binder et al. 2012; Zibert et al. 
2013; Rees et al. 2015).  
 
Due to the inflammatory response of these cytokines and chemokines on the wound 
healing process, the downregulation observed following epoxy-tigliane treatment, 
will potentially attenuate inflammation during wound healing. A dampened 
inflammatory phase is a characteristic feature of preferential healing responses, such 
as early-gestational foetal and oral mucosal healing (Liechty et al. 1998; Liechty et 
al. 2000; Turabelidze & DiPietro 2012; Turabelidze et al. 2014). These genes 
collectively exert opposing responses on keratinocytes, with expression of some 
inducing an anti-proliferative or senescent effect on keratinocytes. Reduction of this 
response may account for the greatly enhanced proliferative responses observed both 
during the in vitro proliferation studies. However, some of these genes are shown to 
induce migratory responses on keratinocytes, which is in contrast to the profoundly 
enhanced migration observed during the in vitro wound repopulation studies and the 
rapid re-epithelialisation seen during the in vivo studies.  
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There was a down-regulation of a number of other immune and inflammatory 
cytokines, including IL-1α, IL-6, IL-8, IL-28, IL-29 and IL-32. IL-1α is a key 
cytokine involved in skin homeostasis and is released by keratinocytes. This cytokine 
was down-regulated between 2-3-fold, for most epoxy-tigliane conditions at 48h 
(Mizutani et al. 1991; Corradi et al. 1995; Chen et al. 1995; Mee et al. 2005; 
Magcwebeba et al. 2012). It also plays a role in the paracrine feedback relationship 
between keratinocytes and fibroblasts, acting through c-Jun and JunB in fibroblasts 
to stimulate the release of KGF and granulocyte macrophage colony-stimulating 
factor (GM-CSF). These growth factors are strongly involved in stimulating 
keratinocyte proliferation and subsequent re-epithelialisation (Maas-Szabowski et al. 
1999; Maas-Szabowski et al. 2000; Szabowski et al. 2000; Werner et al. 2007; Bader 
& Kao 2009; Wojtowicz et al. 2014).  
 
There was a profound down-regulation of IL-6 and IL-8, ranging between 2-8-fold 
following epoxy-tigliane treatment. IL-6 has been shown to be involved in a number 
of functions, including inflammation, neovascularisation and re-epithelialisation; this 
was observed through IL-6 knockout mice studies, showing inhibited wound healing 
responses (Gallucci et al. 2004). Studies have indicated that the migratory response 
was not through a mitogenic response, as this was shown to be weak. However, it 
was potentially due to an indirect stimulation through the induction of motogenic 
factors from fibroblasts; this factor is currently unidentified, but potentially through 
the STAT3 pathway or through stromal cell-derived factor-1 (SDF-1), acting through 
extracellular signal-regulated kinases (ERK)/mitogen-activated protein kinases 
(MAPK) pathway (Gallucci et al. 2004; Hernández-Quintero et al. 2006; Quan et al. 
2015). IL-6 and IL-8 appear to stimulate proliferative and migratory responses in 
keratinocytes, beneficial in wound healing if regulated; however, these can also 
contribute to the hyperproliferative aspect of such disorders, in addition to an 
involvement in excessive inflammation (Liechty et al. 1998; Liechty et al. 2000; 
Rennekampff et al. 2000; Sugawara et al. 2001; Gallucci et al. 2004; Hernández-
Quintero et al. 2006; Jiang et al. 2012). There have also been studies showing IL-8 
has a stimulatory effect on keratinocyte migration, by producing a chemokinetic 
gradient response for keratinocytes. This was thought to be mediated through the 
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phosphoinositide phospholipase C (PLC)-γ pathway, shown by the use of inhibitors 
(Rennekampff et al. 2000; Jiang et al. 2012).  
 
IL-28 (α isoform) and IL-29 are part of the type III interferon family and are highly 
similar at an amino acid level (Uzé & Monneron 2007; Witte et al. 2010; Zahn et al. 
2011; Fujie & Numasaki 2012). Both cytokines exert an antiviral activity through 
antiviral proteins and were down-regulated between approximately 2-3-fold 
following epoxy-tigliane treatment (Sheppard et al. 2003; Uzé & Monneron 2007; 
Wolk et al. 2008, 2010; Witte et al. 2010; Fujie & Numasaki 2012). There is a high 
presence of the common receptor for both of these cytokines, IL-28R1, in 
keratinocytes and has been shown to induce activity through STAT1 and STAT2 
activation, as a result of activation of the JAK/STAT pathway (Sheppard et al. 2003; 
Witte et al. 2010; Wolk et al. 2010; Fujie & Numasaki 2012). Another action of these 
cytokines on keratinocytes is thought to be growth inhibition, shown by an anti-
proliferative response on HaCaTs; although it has been shown that stimulation with 
the type III IFNs leads to the apoptosis of HaCaTs (Maher et al. 2008; Wolk et al. 
2010). The cytokines discussed are immune or inflammatory-related genes and were 
all shown to be down-regulated following epoxy-tigliane treatment, which would 
contribute to a reduced inflammatory phase. An attenuated inflammatory response is 
a characteristic response of preferential healing, present in both early-gestational 
foetal and oral mucosal healing (Liechty et al. 1998, 2000; Turabelidze & DiPietro 
2012; Turabelidze et al. 2014). In addition, these cytokines exert essential functions 
on keratinocytes, including neovascularisation, keratinocyte migration,  re-
epithelialisation; and an involvement in the paracrine feedback system between 
keratinocytes and fibroblasts (Maas-Szabowski et al. 2000; Gallucci et al. 2004; 
Bader & Kao 2009; Jiang et al. 2012). Some of these differentially expressed genes 
oppose the previously observed in vitro and in vivo results. In particular, the 
enhanced keratinocyte migration observed, which would be reduced with the down-
regulated cytokines. However, there are a number of factors involved in controlling 
these functions, and the previous studies indicate that such responses are not 
inhibited despite the differentially expressed genes observed.  
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5.5.7     Extracellular Matrix Component Genes 
There were a number of ECM component genes differentially expressed, following 
epoxy-tigliane treatment. Hyaluronan synthase 3 (HAS3), fibulin 1 and hyaluronan 
mediated motility receptor (HMMR) were up-regulated between 2-3-fold, following 
epoxy-tigliane treatment. Collagen type IV α5 (4A5), laminin-α3, laminin-γ2 and 
laminin-β3; and syndecan-4 were down-regulated between 2-3-fold, following 
epoxy-tigliane treatment.  
 
HAS3 was shown to be upregulated 2-fold at 24h following epoxy-tigliane treatment. 
It has been shown to be present in the epidermal layer and upregulated following 
wounding, potentially contributing to re-epithelialisation (Sayo et al. 2002; Tammi et 
al. 2005). Although HAS3 synthesises extracellular hyaluronan in the epidermis, 
knockout studies have shown no effect on keratinocyte proliferation abilities, 
whereas levels of HAS3 are shown to decrease as the differentiation capacity of 
keratinocytes increases (Sayo et al. 2002; Malaisse et al. 2014, 2016). HMMR, also 
known as RHAMM, was up-regulated between 2-3-fold, following epoxy-tigliane 
treatment at 48h. RHAMM is a hyaluronan receptor, was named according to its role 
in mediating cell motility, and along with CD44, it is involved in hyaluronan 
signalling. (Hall et al. 1995; Lovvorn et al. 1998; Cheung et al. 1999; Turley et al. 
2002; Niedworok et al. 2013; Tolg et al. 2014). Increased presence of HMMR has 
been associated with the transition from early-gestational foetal scarless wound 
healing to adult scarring healing, indicating a role in fibrosis (Lovvorn et al. 1998; 
Tolg et al. 2012). However, expression is also upregulated following wounding, this 
along with knockout studies have indicated an important role in wound repair and 
migration (Tolg et al. 2006, 2014). The induction of cell motility is believed to be 
due to serine/threonine kinase activation, through proto-oncogene tyrosine protein 
kinase (c-Src); this induces focal adhesion turnover and subsequent cell motility or 
invasion (Turley et al. 2002; Tolg et al. 2006). It is believed that cancer cells exploit 
this motility effect, which results in the tumour invasion response (Tolg et al. 2014).  
 
Fibulin-1, transcript variant D, was also up-regulated, between approximately 2-3-
fold, following epoxy-tigliane treatment at 48h. Fibulin-1 has been shown to be 
present in basement membranes, connective tissues and the epidermis, especially the 
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basal layer, dermal-epidermal junctional region, hair follicles and sebaceous glands 
(Roark et al. 1995). Fibulin-1 is present alongside elastin in elastic fibres and has 
been shown to bind to tropoelastin, in addition to fibronectin and fibrinogen (Tran et 
al. 1997; Argraves et al. 2003; Timpl et al. 2003). Collagen type IV α5 was down-
regulated 2-fold following treatment with 10µg/ml EBC-46 and EBC-211, at 24h. 
Type IV collagens are typically found in the basement membrane, with α5 chain 
present in the skin basement membrane, at the dermal-epidermal junction. This α-
chain is also present in early-gestational foetal skin, but to a lower level than adult 
skin (Hudson et al. 1993; Peissel et al. 1995; Tanaka et al. 1998; Khoshnoodi et al. 
2008; Abreu-Velez & Howard 2012). Autoantibodies against α5 and α6 chain results 
in subepidermal blisters, indicating its important role in basement membrane 
integrity (Sado et al. 1998; Ghohestani et al. 2000, 2003).  
 
Syndecan-4 is down-regulated 2-3-fold following epoxy-tigliane treatment at all 
conditions, apart from 0.001µg/ml EBC-211 at 24h. It has been shown to be up-
regulated following injury, with excess expression at the wound edge; and knockout 
studies have demonstrated impaired wound healing (Echtermeyer et al. 2001; Araki 
et al. 2009; Bitoux et al. 2009). It has also been shown to play a role in keratinocyte 
migration, by stimulating focal adhesions formation, by binding to β4 integrin, 
inducing EGF-stimulated motility of the keratinocytes (Araki et al. 2009; Wang et al. 
2015). Syndecan-4 acts through direct connection to PKC-α at focal adhesions, 
which is believed to activate the integrin and subsequently stimulating migration and 
wound repair (Morgan et al. 2007; Bass et al. 2011). However, syndecan-4 levels 
have been shown in some studies to be present at a reduced level during keratinocyte 
migration across the wound site, compared to the higher expression present in the 
hyperproliferating keratinocytes at the wound edge (Echtermeyer et al. 2001; Bitoux 
et al. 2009).  
 
Laminin-5, also known as Laminin-332, is composed of α3, β3 and γ2 chains and 
present in the basal layer; these three chains were all down-regulated following 
epoxy-tigliane treatment (Korang et al. 1995; O’Toole et al. 1997; Akutsu et al. 
2005; Baudoin et al. 2005; Schneider et al. 2007; Araki et al. 2009; Carulli et al. 
2012). Laminin-332 was demonstrated to be synthesised at higher levels following 
264 
 
injury and play a role in wound repair, through migration and adhesion of 
keratinocytes (Amano et al. 2004). Some studies have indicated a positive role on 
keratinocyte migration, with increased expression from wound edge keratinocytes 
undergoing migration across the wound site (Amano et al. 2004; Schneider et al. 
2007; Araki et al. 2009). It has been shown that the unprocessed form of laminin-332 
is present at the wound edge and unprocessed laminin-α3 is deposited along a 
migratory path, resulting in increased keratinocyte migration (Schneider et al. 2007; 
Hamill et al. 2010). However, of interest is that oral mucosal keratinocytes do not 
deposit collagen type IV or laminin, during migration across the wound site, yet 
induce rapid re-epithelialisation responses (Larjava et al. 1993).  
 
A number of extracellular matrix components were differentially expressed, 
following epoxy-tigliane treatment. HAS3, HMMR and fibulin-1 were all up-
regulated, with fibulin-1 appearing to have an opposing action on keratinocyte 
migration, compared to HAS3 and HMMR. Increased expression of HMMR 
enhances migration, whereas increased fibulin-1 expression results in a reduced 
fibronectin-promoted migration. The expression for HAS3 and HMMR corroborate 
the previous in vitro studies, where greatly enhanced migration was occurred 
following EBC-46 or EBC-211 treatment; in addition to the enhanced re-
epithelialisation responses during the in vivo studies. However, the fibulin-1 
expression is in contrast to this response, although it appears to mainly impact on 
fibronectin-promoted migration and the in vitro wound repopulation studies occurred 
on tissue culture plastic dishes, as opposed to ECM. Collagen type IV α5, syndecan-4 
and the subunits comprising laminin-332 (α3, β3 and γ2 chains) were all down-
regulated following epoxy-tigliane treatment. Collagen type IV α5 was only down-
regulated at 10µg/ml EBC-46 and EBC-211; and is associated with reduced integrity 
of the basement membrane. However, this concentration of both epoxy-tiglianes 
exhibited the least preferential responses, including lack of or reduced significantly 
enhanced migration and wound repopulation, compared to the lower concentrations. 
Syndecan-4 was shown to be down-regulated, following epoxy-tigliane treatment, 
but has been associated with enhanced keratinocyte migration. Laminin-332 
components, α3, β3 and γ2 chains, were all individually down-regulated following 
epoxy-tigliane treatment. As with syndecan-4, laminin-332 expression is up-
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regulated at wound sites, so may be induced following injury, whereas the cells 
during the Microarray study were not wounded, potentially preventing this increased 
expression. In addition, laminin deposition is not present in oral mucosal 
keratinocytes migrating across the wound site, yet they are still capable of inducing 
rapid re-epithelialisation.  
 
5.5.8     Cell Signalling Genes 
A number of cell signalling genes were shown to be differentially expressed between 
2-4-fold following epoxy-tigliane treatment, compared to untreated controls; those 
downregulated included bone morphogenetic protein and activin membrane-bound 
inhibitor (BAMBI), Jun proto-oncogene (JUN, also referred as c-Jun), STAT1 and 
STAT2. In contrast, follistatin (FST) was upregulated between 2-4-fold following 
24h of EBC-46 or EBC-211 treatment. FST was primarily upregulated at 24h for 
both EBC-46 and EBC-211, along with 0.1µg/ml EBC-211 at 48h, between 2-4-fold. 
FST has been shown to indirectly stimulate keratinocyte proliferation through acting 
as an antagonist to activin, inhibiting its action (Antsiferova & Werner 2012). It has 
been suggested that FST regulates keratinocyte proliferation, preventing 
hyperproliferative responses (Beer et al. 2000; Antsiferova et al. 2009; Antsiferova & 
Werner 2012).  
 
BAMBI was shown to be downregulated between 2-4-fold, following EBC-46 and 
EBC-211 treatment at all conditions, for 24h and 48h, when compared to the 
respective untreated controls. It has been suggested that the inhibitory effect of 
BAMBI may reduce BMP and activin signalling. As mentioned previously, 
overexpression of activins inhibits in vitro keratinocyte proliferative and contributes 
to pathological scarring (Harrison et al. 2005; Antsiferova & Werner 2012). BAMBI 
has been shown, through Wnt signalling, to stimulate cell cycle progression and 
proliferation. However, this has been demonstrated in tumours, with overexpression 
leading to a tumorigenic response (Lin et al. 2008; Xavier et al. 2010; Zhou et al. 
2013). c-Jun was shown to be downregulated between approximately 2-4-fold, 
following EBC-46 and EBC-211 treatment at most conditions, for 24h and 48h, 
when compared to the respective untreated controls. c-Jun is a member of the 
activator protein (AP)-1 family; knockout studies have indicated a negative impact 
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on keratinocyte proliferation in vitro (Zenz et al. 2003; Florin et al. 2004; 
Kappelmann et al. 2014). However, c-Jun has also been implicated in psoriasis and 
malignancies, with increased invasion, proliferation and motility of cells; although a 
lack of c-Jun has also been reported to impair keratinocyte migration (Mehic et al. 
2005; Zenz & Wagner 2006). There are opposing studies regarding the wound 
healing response of c-Jun, with one indicating no difference in keratinocyte 
proliferation or migration observed using c-Jun knockout mice; in contrast, an 
inhibitor to c-Jun has been tested resulting in more rapid re-epithelialisation, 
compared to controls, with increased proliferation of HaCaTs evident (Zenz et al. 
2003; Giles et al. 2008).  
 
STAT1 and STAT2 was downregulated between 2-3-fold across all conditions, 
following 24h and 48h epoxy-tigliane treatment; STAT3 was also downregulated, 
although this was only at approximately 1.5-fold. The STAT protein family mediate 
a number of functions, with STAT1 and STAT3 inducing opposite responses on 
apoptosis and cell proliferation (Adámková et al. 2007). STAT1 is activated through 
IFN-α and IFN-γ signalling and has been shown to be required for the anti-
proliferative effect of IFN-α on keratinocytes, through inhibited progression of cells 
into S phase (Bromberg et al. 1996; Ramana et al. 2000; Clifford et al. 2002; Ismail 
& Yusuf 2014). STAT2 is thought to be primarily located in the granular layer of the 
epidermis and involved in the IFN-α-mediated inhibition of cell growth, 
demonstrated through use of a double negative STAT2 protein expression. This 
inhibition is due to apoptosis, as opposed to an anti-proliferative response (Nishio et 
al. 2001; Clifford et al. 2003; Ismail & Yusuf 2014). STAT3 has been associated 
keratinocyte differentiation, with upregulation evident during conditions required for 
differentiation to occur (Hauser et al. 1998; Nishio et al. 2001). STAT3 has been 
shown to be involved in a number of processes involved in wound healing response 
and tumour formation, including inducing an anti-apoptotic response, cell cycle 
progression, proliferation and keratinocyte migration (Bromberg et al. 1999; Akira 
2000; Grandis et al. 2000; Yu & Jove 2004; Dauer et al. 2005; Gartsbein et al. 2006). 
This enhanced migratory ability is partly due to the upregulation by STAT3 of a 
number of genes involved in inducing cell migration, such as CCL2 and CXCL2;  
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this was demonstrated through impaired epidermal repair in mice with disrupted 
STAT3 (Sano et al. 1999; Kira et al. 2002; Dauer et al. 2005).  
 
BAMBI and c-JUN were both down-regulated, following epoxy-tigliane treatment, 
which appeared to induce opposing responses on re-epithelialisation, with decreased 
BAMBI expression reducing the inhibitory action on activin signalling, resulting in 
inhibited keratinocyte proliferation. Whilst decreased expression of c-Jun has been 
indicated by some studies to enhance re-epithelialisation responses, other studies 
suggest this impairs keratinocyte migration. FST was up-regulated following epoxy-
tigliane treatment, which is believed to result in stimulated keratinocyte proliferation, 
due to reduced activin signalling. As all three STATs discussed were downregulated 
following epoxy-tigliane treatment, there may have been conflicting effects on the 
keratinocytes due to their opposing roles. Downregulation of STAT1 and STAT2 
may contribute to the increased keratinocyte presence through reduced anti-
proliferative and apoptotic responses. This could lead to the enhanced proliferative 
response observed in the in vitro viability and proliferation studies and contribute to 
the rapid re-epithelialisation observed during in vivo studies. Downregulation of 
STAT3 appears to oppose the in vitro and in vivo responses previously seen. 
However, downregulation of STAT3 was lower than STAT1 and lower than the 2-
fold differentially expressed criteria, following epoxy-tigliane treatment, which its 
action typically conflicts with.  
 
The Microarray study elucidated a number of key differentially expressed genes, 
following epoxy-tigliane treatment. Many of these appear to corroborate the previous 
in vitro and in vivo studies, due to their role in stimulating keratinocyte proliferation 
and migration. However, others appeared to oppose the responses previously 
observed. Although, it was necessary to confirm that these alterations in gene 
expression were also evident at the protein level. Genotypic changes are not always 
evident at a phenotypic level, due to post-translational modifications, preventing the 
differential change translated to a protein expression change or activity level. A 
number of key genes determined from this Chapter were subsequently selected for 
further protein level validation in Chapter 6. 
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Chapter 6 – Validation of Differential HaCaT Gene 
Expression Responses Induced by EBC-46 and EBC-211 
 
 
6.1     Introduction 
 
Wound healing is a carefully controlled process, to ensure successful wound closure 
and reformation of the dermal matrix and appendages (Grinnell 1992; Patel et al. 
2006; Braiman-Wiksman et al. 2007; Li et al. 2007; Pastar et al. 2014). Alterations in 
this process can lead to impaired healing situations or pathological scarring, as seen 
in situations such as chronic wounds and keloids, respectively (Falanga 2005; Agren 
& Werthén 2007; Menke et al. 2007; Dreifke et al. 2015; Jumper et al. 2015). 
However, some alterations from the normal acute wound healing response have been 
shown to induce beneficial healing outcomes, through differentially expressed genes 
evident during early-gestational, foetal and oral mucosal wound healing. Both of 
these response are characterised as preferential healing, as a result of the rapid 
wound closure ability and the minimal scarring responses observed (Liechty et al. 
1998; Liechty et al. 2000; Colwell et al. 2008; Lee et al. 2012; Rolfe & Grobbelaar 
2012; Turabelidze et al. 2014).  
 
Following the elucidation of a number of key differentially expressed genes during 
global gene analysis (Microarray) studies (Chapter 5), validation studies were 
performed to determine whether these expression changes occurred at the protein 
level, following epoxy-tigliane treatment. The global gene analysis was performed 
on HaCaTs to identify differentially expressed genes induced by EBC-46 and EBC-
211, involved in keratinocyte wound healing responses (Chapter 4). However, due to 
the paracrine feedback between fibroblasts and keratinocytes, this can also impact on 
fibroblast wound healing responses (Maas-Szabowski et al. 1999; Werner & Smola 
2001; Barrientos et al. 2008; Bader & Kao 2009). The Microarray study was able to 
provide information on more than 25,000 genes. Key genes shown to be 
differentially expressed by more than 2-fold, following treatment with EBC-46 or 
EBC-211 for 24 or 48h, were further analysed to determine protein expression or 
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activity level. The differentially expressed genes validated at a protein level included 
keratin 13 (Krt13), Krt15, Krt16, Krt17, Krt6B, cyclin A2, cyclin B1, cyclin B2, 
cyclin-dependent inhibitor 3 (CDKN3), CDKN1A, ubiquitin-conjugating enzyme 
E2C (UBE2C), matrix metalloproteinase (MMP)-1, MMP-7, MMP-10, interleukin 
(IL)-6, IL-8, chemokine (C-C motif) ligand 5 (CCL5); and chemokine (C-X-C motif) 
ligand 10 (CXCL10). The gene expression fold-changes for these validated proteins 
are shown in Tables 6.1 and 6.2, for EBC-46 and EBC-211, respectively. These 
genes and proteins also play important roles in mediating normal and pathological 
wound healing responses, in particular re-epithelialisation. This is achieved through 
increased keratinocyte proliferation and migration and is discussed in more detail in 
Sections 5.5.1, 5.5.2, 5.5.5 and 5.5.6 (Nagase et al. 2006; Bragulla & Homberger 
2009; Toriseva & Kähäri 2009; Gong & Ferrell 2010; Hao et al. 2012; Koppel et al. 
2014; Turabelidze et al. 2014).  
 
Genotypic changes between normal, acute skin wound healing and preferential 
healing responses have been reported. These include enhanced keratinocyte 
proliferation, increased cell cycle progression; and enhanced protein synthesis and 
degradation (Colwell et al. 2008; Kim et al. 2013; Reddell et al. 2014; Tan et al. 
2014; Turabelidze et al. 2014). In addition, a reduced inflammatory phase has been 
observed during preferential healing, including decreased IL-6 and IL-8 levels 
(Liechty et al. 1998; Liechty et al. 2000; Chen et al. 2010; Rolfe & Grobbelaar 2012; 
Yates et al. 2012). This is in contrast to the more prolonged inflammatory phase 
associated with chronic wounds and keloid scars (Yager & Nwomeh 1999; Menke et 
al. 2007; Shih et al. 2010; Wiegand et al. 2010; Gauglitz et al. 2011; Jumper et al. 
2015). Variations in MMP levels have also been observed between normal adult, 
acute wound healing and early-gestational, foetal wounds, with increased MMP-1 
expression in foetal wounds (Dang et al. 2003; Rolfe & Grobbelaar 2012). Studies 
have shown an increase in MMP activity in chronic wounds, indicating that they 
have a vital role in extracellular matrix (ECM) remodelling, through matrix 
degradation (Vaalamo et al. 1997; Lobmann et al. 2002; Mwaura et al. 2006; Eming 
et al. 2008; Wiegand et al. 2010; Thamm et al. 2015).  
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Table 6.1: Fold changes in key differentially expressed genes, following 
treatment with EBC-46 for 24h or 48h. Red = up-regulated genes, Green = down-
regulated genes. 
 
Table 6.2: Fold changes in key differentially expressed genes, following 
treatment with EBC-211 for 24h or 48h. Red = up-regulated genes, Green = down-
regulated genes. 
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As preferential wound healing responses were observed during the in vivo animal 
wound healing studies performed by QBiotics Ltd., the aim of the global gene 
analysis and subsequent protein validation studies were to elucidate key genes and 
pathways involved in inducing these responses. Validation at the protein level is vital 
to determine whether the changes in genotypic response will result in a phenotypic 
effect, through increased translation of protein expression or activity. Differentially 
expressed genes may not result in any changes at a protein level, due to a number of 
post-transcriptional mechanisms (Hause et al. 2014). Therefore, important 
differentially expressed genes, may have no phenotypic impact following epoxy-
tigliane treatment, compared to untreated controls.  
 
6.2     Aims 
 
The aim of this Chapter was to validate the key differentially expressed genes in 
HaCaTs at a protein level, following treatment with EBC-46 or EBC-211, for 24h or 
48h. This was performed using a variety of techniques to confirm the protein 
expression or activity. Quantitative polymerase chain reaction (qPCR) analysis was 
initially used to validate Krt13, Krt15, Krt16, Krt17, Cyclin B2 and MMP-1 gene 
expression levels; while Western blot analysis was used to validate the protein levels 
of Krt13, Krt15, Krt16, Krt17, Krt6B, Cyclin A2, Cyclin B1, Cyclin B2, CDKN3, 
CDKN1A and UBE2C. MMP activity assays were used to validate MMP-1, MMP-7 
and MMP-10 activities. Enzyme-linked immunosorbent assays (ELISAs) were 
performed to validate IL-6, IL-8, CCL5 and CXCL10 levels.  
 
6.3     Materials and Methods 
 
6.3.1     Preparation of EBC-46 and EBC-211 
EBC-46 and the ‘reduced activity’ isomer, EBC-211, were both supplied by QBiotics 
Ltd., Queensland, Australia and solubilised in DMSO (Section 2.1). For both 
compounds, concentrations of 0.001g/ml, 0.01g/ml, 0.1g/ml, 1g/ml and 
10g/ml were prepared in F-SCM for dermal fibroblast (Section 2.2.1); 100µg/ml 
was not included as this concentration has previously been shown to be cytotoxic.  
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6.3.2     HaCaT Culture 
Epidermal keratinocyte cell line (HaCaTs) were sourced, maintained, subcultured, 
counted, cryopreserved and screened for mycoplasma, as previously described 
(Sections 2.2.2, 2.2.3, 2.2.4 and 2.2.5 respectively).  
 
6.3.3     Validation of Gene Expression Changes by Quantitative PCR 
   (qPCR) 
Keratinocyte cell line (HaCaT) gene expression changes were validation through 
qPCR for Krt13, Krt15, Krt16, Krt17, CCNB2 and MMP-1 at 24h and 48h, as 
previously described (Section 2.5.1). 
 
6.3.4     Validation of Gene Expression Changes by Western Blotting 
Keratinocyte cell line (HaCaT) gene expression changes were validation through 
analysing protein expression changes for Krt13, Krt15, Krt16, Krt17, Krt6B, Cyclin 
A2, Cyclin B1, Cyclin B2, CDKN3, CDKN1A and UBE2C by Western blotting, as 
described in Section 2.5.2.  
 
6.3.5     Validation of Gene Expression Changes by Activity Assays 
Keratinocyte cell line (HaCaT) gene expression changes were validation through 
analysing MMP-1, MMP-7 and MMP-10 activities at 24h and 48h, as previously 
described (Section 2.5.3). 
 
6.3.6     Validation of Gene Expression Changes by ELISA 
Keratinocyte cell line (HaCaT) gene expression changes were validation through 
analysing IL-6, IL-8, CCL5 and CXC10 protein expression at 24h and 48h, as 
previously described (Section 2.5.4).       
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6.4     Results  
 
6.4.1    Validation of Gene Expression Changes by Quantitative PCR 
 (qPCR) 
qPCR was used to validate Krt13, Krt15, Krt16, Krt17, MMP-1 and Cyclin B2 at 24h 
and 48h, following EBC-46 and EBC-211 treatment. This was performed using the 
same epoxy-tigliane concentrations as in the Microarray studies (0.001µg/ml, 
0.1µg/ml and 10µg/ml). Krt13 was previously shown in the Microarray studies to be 
upregulated following epoxy-tigliane treatment at 48h (Tables 6.1 and 6.2). In the 
qPCR studies, it was shown to be upregulated following EBC-46 and EBC-211 
treatment, at both 24h and 48h (Figures 6.1A and 6.1B respectively). This 
upregulation was only considered to be significant for 0.001µg/ml and 10µg/ml 
EBC-46 at 24h (p<0.05); whereas at 48h, the upregulation was significant at all 
EBC-46 concentrations (p<0.001; Figure 6.1A), compared to untreated controls. A 
similar response was seen following EBC-211 treatment, with a significant 
upregulation of Krt13 expression at 0.001µg/ml EBC-211 at 24h (p<0.001; Figure 
6.1B). Corroborating the Microarray studies, a significant upregulation of Krt13 at 
all EBC-211 concentrations (p<0.001) at 48h was seen, compared to untreated 
controls.  
 
Krt15 gene expression was also shown to be upregulated following epoxy-tigliane 
treatment after 48h, during the Microarray studies. However, after 24h treatment 
with EBC-46 at 10µg/ml, there was a downregulation in expression of Krt15, 
compared to untreated controls (Tables 6.1 and 6.2). The qPCR data for EBC-46 
showed this significant downregulation of Krt15 at both 0.001µg/ml and 10µg/ml, 
after 24h treatment (p<0.001); whereas EBC-211 only showed the significant 
downregulation at 24h for 10µg/ml, compared to untreated controls (p<0.001; 
Figures 6.2A and 6.2B, respectively). Following the same pattern as the Microarray 
studies (Tables 6.1 and 6.2), there was a significant upregulation of Krt15 expression 
after 48h treatment for EBC-46. This was significant at 0.1µg/ml and 10µg/ml EBC-
46 (p<0.001) and to a lesser degree at 0.001µg/ml (p<0.05), compared to untreated 
controls. There was also a significant increase in Krt15 expression at 0.001µg/ml and 
10µg/ml (p<0.001) at 48h, compared to untreated controls. It was also significantly  
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Figure 6.1: Krt13 expression in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to untreated 
controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical analysis 
displayed *p<0.05, ***p<0.001).  
A 
 
B 
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Figure 6.2: Krt15 expression in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to untreated 
controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical analysis 
displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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upregulated at 0.1µg/ml (p<0.01), although at a reduced level, in line with the 
Microarray data. 
 
Krt16 was downregulated following epoxy-tigliane treatment at 24h, although this 
was not considered to be significant after EBC-46 treatment. However, there was a 
significant downregulation at 10µg/ml EBC-211 (p<0.05; Figures 6.3A and 6.3B, 
respectively). By 48h, there was a significant downregulation of Krt16 expression at 
0.001µg/ml and 10µg/ml EBC-46 treatment (p<0.001-0.01), in addition to a 
significant downregulation at 0.1µg/ml (p<0.05). This pattern corroborated the fold 
changes in gene expression identified in the Microarray studies (Tables 6.1 and 6.2). 
Following 48h treatment with EBC-211, there was a significant downregulation of 
Krt16 expression at 0.1µg/ml and 10µg/ml, compared to untreated controls (p<0.001-
0.01).  
 
Krt17 was downregulated following EBC-46 and EBC-211 treatment at both 24h and 
48h (Figures 6.4A and 6.4B, respectively), corroborating the Microarray studies 
(Tables 6.1 and 6.2). This downregulation was considered to be significant for EBC-
46, at 24h and 48h, compared to the respective untreated controls (p<0.001). EBC-
211 also showed a downregulation in Krt17 expression at 24h for 10µg/ml EBC-211 
(p<0.001), and to a lesser degree at 0.001µg/ml (p<0.05). Corroborating the 
Microarray studies, there was a significant downregulation in Krt17 expression for 
all EBC-211 concentrations at 48h (p<0.001), compared to untreated controls.  
 
MMP-1 expression was upregulated following epoxy-tigliane treatment, similar 
upregulation was observed during the Microarray studies, as shown in Tables 6.1 and 
6.2. Although there appeared to be an upregulation at 24h following EBC-46 
treatment, this was not considered to be significant (p>0.05; Figure 6.5A). In 
contrast, at 48h, there was a significant upregulation in MMP-1 expression at 
0.1µg/ml (p<0.001), compared to untreated controls. As seen at 24h, although there 
was an appeared upregulation at 0.001µg/ml and 10µg/ml EBC-46, these were 
deemed to be non-significant (p>0.05). There was a significant upregulation of 
MMP-1 expression following 0.001µg/ml EBC-211 treatment at 24h (p<0.05; Figure 
6.5B), compared to untreated controls; and a further significant upregulation with  
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Figure 6.3: Krt16 expression in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to untreated 
controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical analysis 
displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 6.4: Krt17 expression in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to untreated 
controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical analysis 
displayed *p<0.05, ***p<0.001). 
A 
 
B 
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Figure 6.5: MMP-1 expression in HaCaTs, cultured in the presence of 
0.001µg/ml, 0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to 
untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical 
analysis displayed *p<0.05, ***p<0.001).  
A 
 
B 
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0.001µg/ml EBC-211 at 48h (p<0.001). However, the other concentrations were not 
considered to be significant, compared to untreated controls (p>0.05). 
 
Cyclin B2 expression was shown to be upregulated at 48h for both EBC-46 and 
EBC-211 in the Microarray studies (Tables 6.1 and 6.2, respectively). The qPCR 
studies corroborated these results, showing no significant upregulation in Cyclin B2 
expression following 24h treatment of EBC-46 or EBC-211 (p>0.05; Figures 6.6A 
and 6.6B, respectively). In contrast, at 48h, there was a significant increase in 
expression following 10µg/ml EBC-46 treatment, compared to untreated controls 
(p<0.001). The lower EBC-46 concentrations (0.001 and 0.1µg/ml) appeared to show 
an increase in expression, although these were not considered significant (p>0.05). 
Treatment with 0.1µg/ml EBC-211, at 48h, appeared to increase expression, although 
this again was not deemed significant (p>0.05). However, treatment with 0.001µg/ml 
and 10µg/ml EBC-211 significantly upregulated Cyclin B2 expression, compared to 
untreated controls (p<0.01-0.05).  
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Figure 6.6: Cyclin B2 expression in HaCaTs, cultured in the presence of 
0.001µg/ml, 0.1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), compared to 
untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, statistical 
analysis displayed *p<0.05, **p<0.01, ***p<0.001).  
A 
 
B 
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6.4.2     Validation of Gene Expression Changes by Western Blot 
Western blot analysis was also performed to validate a number of differentially 
expressed genes identified during the Microarray studies, shown in Tables 6.1 and 
6.2, for EBC-46 and EBC-211 respectively. These included Krt13, Krt15, Krt16, 
Krt17, Krt6B, Cyclin A2, Cyclin B1, Cyclin B2, CDKN3, CDKN1A and UBE2C. A 
number of keratins were shown to be upregulated or downregulated following epoxy-
tigliane treatment. Krt13 and Krt15 were upregulated at 48h for all conditions 
analysed with both EBC-46 and EBC-211, although a downregulation was observed 
for Krt15 following 10g/ml EBC-46 at 24h. Krt16, Krt17 and Krt6B were all shown 
to be downregulated following epoxy-tigliane treatment, predominantly at 48h.  
 
Krt13 Western blots are shown in Figures 6.7A and 6.8A, for EBC-46 and EBC-211, 
respectively, with β-actin used as a loading control for each blot. The densitometry 
graphs are shown in Figures 6.7B-C and 6.8B-C, for EBC-46 and EBC-211, 
respectively. The Western blot for Krt13 following EBC-46 treatment appeared to 
indicate increased levels, compared to untreated controls, at both 24h and 48h 
(Figure 6.7A). The densitometry was performed on three separate blots, one per 
sample set. No significant change in Krt13 protein detection was observed at 24h 
(p>0.05; Figure 6.7B). However, at 48h, it appeared to show an increase across all 
EBC-46 concentrations, with this deemed significant at 0.1g/ml and 10g/ml EBC-
46 (p<0.01-0.05; Figure 6.7C). Western blot analysis of EBC-211 effects appeared to 
show an increase in Krt13 levels at certain concentrations (0.001g/ml, 0.1g/ml and 
10g/ml), at 48h (Figure 6.8A). Densitometry analysis indicated that Krt13 detection 
following EBC-211 treatment may be increased at 24h for all concentrations (0.001-
10g/ml), although this was not considered to be significant (p>0.05; Figure 6.8B). 
At 48h, increased detection was also indicated; however, this was not considered to 
be significant (p>0.05; Figure 6.8C).  
 
Krt15 Western blots are shown in Figures 6.9A and 6.10A, for EBC-46 and EBC-
211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.9B-C and 6.10B-
C. The Western blot for EBC-46 did not appear to show any change in Krt15 protein 
detection at 24h or 48h (Figure 6.9A). This was corroborated by no significant  
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Figure 6.7: Western blot analysis on (A) Krt13 in HaCaTs, at 24h and 48h; with 
densitometry analysis on Krt13 levels in HaCaTs, cultured in the presence of 
0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE, 
statistical analysis displayed *p<0.05, **p<0.01). 
A 
 
B 
 
C 
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Figure 6.8: Western blot analysis on (A) Krt13 in HaCaTs, at 24h and 48h; with 
densitometry analysis on Krt13 levels in HaCaTs, cultured in the presence of 
0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Figure 6.9: Western blot analysis on (A) Krt15 in HaCaTs, at 24h and 48h; with 
densitometry analysis on Krt15 levels in HaCaTs, cultured in the presence of 
0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Figure 6.10: Western blot analysis on (A) Krt15 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt15 levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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difference in detection, compared to untreated controls, observed in the densitometry 
analysis for 24h and 48h (p>0.05; Figures 6.9B and C). The Western blot for EBC-
211 showed no noticeable difference in protein levels for Krt15 at 24h (Figure 
6.10A). However, it appeared that levels were increased following EBC-211 
treatment, at 48h. These effects were confirmed through the densitometry data, with 
no difference in Krt15 levels at 24h (p>0.05; Figure 6.10B); whereas, a perceived 
increase in Krt15 levels was seen at 48h, although this is deemed to not be significant 
(p>0.05; Figure 6.10C).  
 
Krt16 Western blots are shown in Figures 6.11A and 6.12A, for EBC-46 and EBC-
211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.11B-C and 
6.12B-C. The Western blot for EBC-46 appeared to show a decrease in Krt16 protein 
detection, compared to untreated controls, at 48h, although a potential increase was 
observed at 24h (Figure 6.11A). The densitometry analysis showed a significant 
increase in Krt16 protein levels at 10g/ml EBC-46 at 24h, in contrast to the 
Microarray findings (p<0.05; Figure 11B). In contrast, no significant difference in 
Krt16 levels were observed at 48h (p>0.05; Figures 6.11C). The Western blot for 
EBC-211 showed a potential decrease in Krt16 detection at 24h and 48h (Figure 
6.12A). However, densitometry analysis showed no significant change in Krt16 
levels at 24h or 48h (p>0.05; Figures 6.12B and C, respectively); although there was 
a perceived decrease in expression at 48h for 0.01g/ml and 1g/ml EBC-211, this 
was not considered to be significant (p>0.05).  
 
Krt17 Western blots are shown in Figures 6.13A and 6.14A, for EBC-46 and EBC-
211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.13B-C and 
6.14B-C. The Western blot for EBC-46 did not appear to show any change in Krt17 
protein detection at 24h or 48h (Figure 6.13A). The densitometry analysis 
corroborated this result, with no significant difference in Krt17 level observed 
following EBC-46 treatment, at 24h or 48h (p>0.05; Figures 6.13B and C, 
respectively). There was a perceived increase in Krt17 level at 24h, following 
0.001g/ml EBC-46 treatment; in addition to a decrease in Krt17 expression at   
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Figure 6.11: Western blot analysis on (A) Krt16 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt16 levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE; 
statistical analysis displayed *p<0.05). 
A 
 
B 
 
C 
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Figure 6.12: Western blot analysis on (A) Krt16 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt16 levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Figure 6.13: Western blot analysis on (A) Krt17 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt17 levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Figure 6.14: Western blot analysis on (A) Krt17 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt17 levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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10g/ml. However, both were shown not to be significant (p>0.05). The Western 
blot for EBC-211 showed no noticeable difference in Krt17 protein detection at 24h. 
Although, there was a decrease in Krt17 detection at 48h, compared to untreated 
controls (Figure 6.14A). However, the densitometry analysis showed no significant 
change in Krt17 levels following EBC-211 treatment, at 24h or 48h (p>0.05; Figures 
6.14A and B, respectively). Although there was a perceived decrease in levels at 48h 
for 1g/ml EBC-211, this was also not considered to be significant (p>0.05).  
 
Krt6B Western blots are shown in Figures 6.15A and 6.16A, for EBC-46 and EBC-
211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.15B-C and 
6.16B-C. The Western blot for EBC-46 did not appear to show any change in Krt6B 
protein detection at 24h or 48h (Figure 6.15A). The densitometry analysis showed no 
significant difference in Krt6B levels at 24h or 48h (p>0.05; Figures 6.15B and C, 
respectively). There was a perceived increase in Krt6B levels at 24h and 48h, 
following EBC-46 treatment, although this was shown to not be significant (p>0.05). 
The Western blot for EBC-211 did not appear to show any change in Krt6B detection 
at 24h. However, it did show a potential decrease in Krt6B expression at 48h for 
0.01g/ml EBC-211 (Figure 6.16A). The densitometry analysis corroborated these 
results, showing no significant change in Krt6B levels at 24h (p>0.05; Figures 
6.16B), although the perceived decrease in Krt6B levels for 0.01g/ml and 1g/ml 
EBC-211 was not considered to be significant (p>0.05; Figure 6.16C).  
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Figure 6.15: Western blot analysis on (A) Krt6B in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt6B levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Figure 6.16: Western blot analysis on (A) Krt6B in HaCaTs, at 24h and 48h; 
with densitometry analysis on Krt6B levels in HaCaTs, cultured in the presence 
of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, compared to 
untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, average±SE). 
A 
 
B 
 
C 
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Western blot analysis was also performed on a number of cell cycle-related genes, as 
upregulation of Cyclin A2, Cyclin B1, Cyclin B2, CDKN3 and UBE2C, were 
observed during global gene analysis. The downregulation of CDKN1A was also 
seen (Tables 6.1 and 6.2, for EBC-46 and EBC-211 respectively).  
 
Cyclin A2 Western blots are shown in Figures 6.17A and 6.18A, for EBC-46 and 
EBC-211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.17B-C and 
6.18B-C. The Western blot for Cyclin A2 following EBC-46 treatment appeared to 
indicate reduced protein detection at 0.1-10g/ml at 24h. However, there appeared to 
be a dose-dependent increase in Cyclin A2 levels with EBC-46 treatment at 48h, 
with increased detection particularly evident at higher concentrations (0.1-10g/ml), 
compared to untreated controls (Figure 6.17A). The densitometry was performed on 
three separate blots, one per sample set. There were no significant changes in Cyclin 
A2 levels, following EBC-46 treatment at 24h (p>0.05; Figure 6.17B). At 48h, the 
dose-dependent increase in Cyclin A2 detection was confirmed, with a steady 
increase in levels evident with increasing concentration, from 0.001-10g/ml EBC-
46. However, despite this increase, only 10g/ml was considered to be significant 
compared to untreated controls (p<0.01; Figure 6.17C). The Western blot for Cyclin 
A2 following EBC-211 treatment showed no change in protein level at 24h. 
However, a dose-dependent increase in Cyclin A2 levels was evident with EBC-211 
treatment at 48h, with largest detection evident at higher concentrations (0.1-
10g/ml), compared to untreated controls (Figure 6.18A). Densitometry analysis 
confirmed these findings, with no noticeable or significant change in Cyclin A2 
levels following EBC-211 treatment at 24h (p>0.05; Figure 6.18B). There was a 
perceived increase in Cyclin A2 levels following EBC-211 treatment (0.001-
10g/ml) at 48h. However, this was not considered to be significant (p>0.05; Figure 
6.18C).  
 
Cyclin B1 Western blots are shown in Figures 6.19A and 6.20A, for EBC-46 and 
EBC-211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.19B-C, and 
6.20B-C. The Western blot for Cyclin B1 following EBC-46 treatment showed   
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Figure 6.17: Western blot analysis on (A) Cyclin A2 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin A2 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed **p<0.01). 
A 
 
B 
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Figure 6.18: Western blot analysis on (A) Cyclin A2 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin A2 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE). 
A 
 
B 
 
C 
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Figure 6.19: Western blot analysis on (A) Cyclin B1 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin B1 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed *p<0.05, **p<0.01). 
A 
 
B 
 
C 
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Figure 6.20: Western blot analysis on (A) Cyclin B1 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin B1 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed **p<0.01). 
A 
 
B 
 
C 
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increased detection at 24h and 48h, compared to untreated controls (Figure 6.19A). 
The densitometry confirmed the increase at 24h, following EBC-46 treatment. 
However, despite this perceived increase across the range of concentrations (0.001-
10g/ml), it was only deemed to be significant at 0.1g/ml and 1g/ml EBC-46 
(p<0.01; Figure 6.19B). At 48h, the increases in Cyclin B1 protein levels were also 
confirmed, with increased detection evident across the range of EBC-46 
concentrations (0.001-10g/ml). This was considered to be significant at 0.001g/ml, 
0.01g/ml and 1g/ml EBC-46 (p<0.01-0.05; Figure 6.19C). The Western blot for 
Cyclin B1 following EBC-211 treatment showed an increased detection at 24h and 
48h, compared to untreated controls (Figure 6.20A). However at 48h, there appeared 
to be a greater increase in Cyclin B1 levels at the lower EBC-211 concentrations 
(0.001-0.1g/ml); compared to the higher concentrations (1-10g/ml), and the 
untreated controls. Densitometry analysis confirmed these findings, with a significant 
increase in Cyclin B1 detection at 24h for 0.001-10g/ml EBC-211 (all p<0.01; 
Figure 6.20B).  An increase in Cyclin B1 levels was also perceived at 48h following 
EBC-211 treatment, in an apparent dose-dependent manner, with the lower 
concentrations inducing the largest increases; however, this was deemed to not be 
significant (p>0.05; Figure 6.20C).  
 
Cyclin B2 Western blots are shown in Figures 6.21A and 6.22A, for EBC-46 and 
EBC-211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.21B-C and 
6.22B-C. The Western blot for Cyclin B2 following EBC-46 treatment showed 
increased detection at 24h and 48h, particularly at higher concentrations (0.1-
10g/ml) at 48h, compared to untreated controls (Figure 6.21A). The densitometry 
confirmed the increase at 24h, following EBC-46 treatment, although this increase 
was not considered to be significant (p>0.05; Figure 6.21B). At 48h, this increase in 
Cyclin B2 levels was also confirmed, with increased detection evident across the 
range of EBC-46 concentrations (0.001-10g/ml); however, this was only considered 
to be significant at 10g/ml EBC-46 (p<0.05; Figure 6.21C). The Western blot for 
Cyclin B2 following EBC-211 treatment showed increased detection at 24h and 48h, 
compared to untreated controls (Figure 6.22A). The densitometry analysis showed no  
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Figure 6.21: Western blot analysis on (A) Cyclin B2 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin B2 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed *p<0.05). 
A 
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Figure 6.22: Western blot analysis on (A) Cyclin B2 in HaCaTs, at 24h and 48h; 
with densitometry analysis on Cyclin B2 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE). 
A 
 
B 
 
C 
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significant difference in Cyclin B2 protein levels at 24h, following EBC-211 
treatment (p>0.05; Figure 6.22B). There was a perceived increase in Cyclin B2 levels 
at 48h, following EBC-211 treatment (0.001-10g/ml). However, this was not 
considered to be significant, when compared to untreated controls (p>0.05; Figure 
6.22C).  
 
CDKN3 Western blots are shown in Figures 6.23A and 6.24A, for EBC-46 and 
EBC-211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.23B-C and 
6.24B-C. The Western blot for CDKN3 following EBC-46 treatment showed no 
noticeable differences in detectable protein at 24h or 48h, compared to untreated 
controls (Figure 6.23A). The densitometry analysis showed that there was no 
significant difference in CDKN3 detection (p>0.05), following EBC-46 treatment at 
24h, although a perceived downregulation was observed at 0.001g/ml EBC-46. 
However, this was deemed to not be significant (p>0.05; Figure 6.23B). There was 
also no significant difference in CDKN3 levels following EBC-46 treatment at 48h, 
compared to untreated controls (p>0.05; Figure 6.23C). The Western blot for 
CDKN3 following EBC-211 treatment also showed no noticeable differences in 
detectable protein at 24h or 48h, compared to untreated controls (Figure 6.24A). The 
densitometry analysis showed a perceived upregulation of CDKN3 expression at 
24h, following EBC-211 treatment, which was shown to be significant at 0.1g/ml 
(p<0.05; Figure 6.24B). Confirming the Western blot data, the densitometry analysis 
showed no significant difference in CDKN3 detection at 48h, following EBC-211 
treatment (p>0.05; Figure 6.24C).  
 
CDKN1A Western blots are shown in Figures 6.25A and 6.26A, for EBC-46 and 
EBC-211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.25B-C and 
6.26B-C. The Western blot for CDKN1A following EBC-46 treatment showed a 
profound reduction in detectable CDKN1A at 24h, after treatment with 0.001-
10g/ml EBC-46, compared to untreated controls (Figure 6.25A). Reduced levels 
were also observed at 10g/ml EBC-46 at 48h, with no noticeable difference at the 
lower concentrations of EBC-46 (0.001-1g/ml) at 48h, compared to untreated  
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Figure 6.23: Western blot analysis on (A) CDKN3 in HaCaTs, at 24h and 48h; 
with densitometry analysis on CDKN3 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE). 
A 
 
B 
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Figure 6.24: Western blot analysis on (A) CDKN3 in HaCaTs, at 24h and 48h; 
with densitometry analysis on CDKN3 levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed *p<0.05). 
A 
 
B 
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Figure 6.25: Western blot analysis on (A) CDKN1A in HaCaTs, at 24h and 48h; 
with densitometry analysis on CDKN1A levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed **p<0.01). 
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Figure 6.26: Western blot analysis on (A) CDKN1A in HaCaTs, at 24h and 48h; 
with densitometry analysis on CDKN1A levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed **p<0.01). 
A 
 
B 
 
C 
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controls (Figure 6.25A). The densitometry analysis corroborated the profound 
decrease in CDKN1A, evident by the significant decreases in detectable protein 
levels across all EBC-46 concentrations (0.001-10g/ml) at 24h (p<0.01; Figure 
6.25B). However, at 48h, there was no significant difference in CDKN1A levels 
(p>0.05; Figure 6.25C). The Western blot for CDKN1A following EBC-211 
treatment showed a similar response to EBC-46, with a profound reduction in 
CDKN1A levels at 24h. No obvious differences in CDKN1A levels were apparent at 
48h, compared to untreated controls (Figure 6.26A). The densitometry analysis again 
confirmed this profound decrease in CDKN1A levels at 24h, with these decreases 
shown to be significant at 0.001-10g/ml EBC-211 (p<0.01; Figure 6.26B). 
Confirming the Western blot data, the densitometry analysis showed no significant 
difference in CDKN1A levels at 48h, following EBC-211 treatment (p>0.05; Figure 
6.26C).  
 
UBE2C Western blots are shown in Figures 6.27A and 6.28A, for EBC-46 and EBC-
211, respectively, with β-actin used as a loading control for each blot. The 
densitometry graphs for each epoxy-tigliane are shown in Figures 6.27B-C and 
6.28B-C. The Western blot for UBE2C following EBC-46 treatment showed an 
increase in UBE2C detection following treatment with 0.001-0.1g/ml EBC-46 at 
24h. At 48h, an increase in UBE2C detection was also evident at 0.001g/ml EBC-
46, compared to untreated controls (Figure 6.27A). The densitometry analysis 
showed a perceived upregulation in UBE2C levels following EBC-46 treatment, at 
both 24h and 48h; however, this was not deemed to be significant (p>0.05; Figures 
6.27B and C, respectively). The Western blot for UBE2C following EBC-211 
treatment also showed an increased detection following EBC-211 treatment at both 
24h and 48h. This appeared to be increased quite profoundly at 0.001-10g/ml EBC-
211 at 24h, compared to untreated controls (Figure 6.28A). However, the 
densitometry analysis showed no significant difference in UBE2C levels at 24h, 
following EBC-211 treatment (p>0.05; Figure 6.28B). UBE2C levels were shown to 
be increased at 48h, following EBC-211 treatment, compared to untreated controls; 
this was shown to be significantly increase at  0.1g/ml EBC-211 (p<0.05; Figure 
6.28C).   
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Figure 6.27: Western blot analysis on (A) UBE2C in HaCaTs, at 24h and 48h; 
with densitometry analysis on UBE2C levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE). 
A 
 
B 
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Figure 6.28: Western blot analysis on (A) UBE2C in HaCaTs, at 24h and 48h; 
with densitometry analysis on UBE2C levels in HaCaTs, cultured in the 
presence of 0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-211, 
compared to untreated controls (0µg/ml), at (B) 24h and (C) 48h. (N=3, 
average±SE; statistical analysis displayed *p<0.05). 
A 
 
B 
 
C 
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6.4.3     Validation of Gene Expression Changes by Activity Assays 
MMP activity assays were performed on MMP-1, MMP-7 and MMP-10, as these 
MMPs were shown to be differentially expressed in HaCaTs, following treatment 
with the novel epoxy-tiglianes, compared to untreated controls (Tables 6.1 and 6.2). 
The results of these activity assays are shown in Figures 6.29, 6.30 and 6.31, 
respectively. There was a perceived increase in MMP-1 activity at 24h following 
EBC-46 treatment, although this was not considered to be significant (p>0.05; Figure 
6.29A). However, at 48h, the elevated activity of MMP-1 was significant across all 
concentrations (0.001-10µg/ml; p<0.001-0.05), with the lower concentrations 
displaying a higher level of significance (p<0.001). In contrast, treatment with EBC-
211 significantly increased MMP-1 activity at both 24h and 48h; particularly at 
0.001-1µg/ml at 24h and 0.001-10µg/ml at 48h (p<0.001; Figure 6.29B).  
 
MMP-7 activity was also increased following EBC-46 and EBC-211 treatment, at 
both 24h and 48h (Figures 6.30A and 6.30B, respectively). Following 24h treatment 
with EBC-46, there was a significant increase in MMP-7 activity at 0.001-0.1µg/ml 
EBC-46 (p<0.01-0.05; Figure 3.30A). This significant increase in activity was also 
evident at 0.001-0.01µg/ml, at 48h (p<0.01-0.05). The increased activity of MMP-7 
was particularly observed at the lower concentrations of EBC-46 and potentially due 
to the lesser activity of EBC-211, this enhanced activity level was observed across a 
greater range of concentrations (0.001-1µg/ml; Figure 3.30B). This elevated activity 
following EBC-211 treatment was considered to be significant at 24h (p<0.01-0.05) 
and at 48h (p<0.001), for 0.001-1µg/ml EBC-211.  
 
MMP-10 was only shown to be increased for EBC-211 in the Microarray studies 
(Tables 6.1 and 6.2). Corroborating this data, the perceived increases in MMP-10 
activity following EBC-46 treatment were found to be not significant, compared to 
untreated controls (Figure 6.31A). However, treatment with EBC-211 was shown to 
increase MMP-10 activity at all concentrations (0.001-10µg/ml), at both 24h and 48h 
(Figure 6.31B). These increases were determined to be significant at 24h (all 
p<0.001) and at 48h (p<0.001-0.01).  
  
313 
 
Figure 6.29: MMP-1 activity in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml (A) EBC-46 or (B) EBC-211, 
compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, 
statistical analysis displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
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Figure 6.30: MMP-7 activity expression of HaCaTs, cultured in the presence of 
0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 
(B), compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, 
average±SE, statistical analysis displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 6.31: MMP-10 activity expression of HaCaTs, cultured in the presence of 
0.001µg/ml, 0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 
(B), compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, 
average±SE, statistical analysis displayed **p<0.01, ***p<0.001). 
A 
 
B 
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6.4.4     Validation of Gene Expression Changes by ELISA 
ELISAs were performed on IL-6, IL-8, CCL5 and CXCL10 (Figures 3.32, 3.33, 3.34 
and 3.35, respectively), as these genes were observed to be differentially expressed 
following epoxy-tigliane treatment, during the Microarray studies (Tables 6.1 and 
6.2). IL-6 gene expression were predominantly shown to be downregulated following 
EBC-46 and EBC-211 treatment at 48h; this was corroborated by ELISA (Figures 
6.32A and 6.32B, respectively). There were no significant changes following EBC-
46 treatment at 24h (p>0.05). However, at 48h, there were significant decreases in 
IL-6 levels across all EBC-46 concentrations (0.001-10µg/ml; p<0.001-0.01), 
compared to untreated controls. Treatment with EBC-211 also showed an enhanced 
reduction in levels at 48h, with these decreases considered significant at all 
concentrations (0.001-10µg/ml; p<0.001). There was a slight increase in IL-6 levels 
at 24h for 10µg/ml EBC-211 (p<0.05), with no significant change for the remaining 
concentrations.  
 
Microarray studies showed a profound downregulation in IL-8 gene expression, 
following EBC-46 and EBC-211 treatment. This was predominantly observed at 48h 
(Tables 6.1 and 6.2, respectively). ELISAs showed a dose-dependent increase in IL-8 
levels for both EBC-46 and EBC-211 at 24h. This in contrast to the Microarray 
studies. This increase was significant for 0.01-10µg/ml EBC-46, with the peak 
increase at 0.01µg/ml (p<0.001-0.01). Some increases were shown to be significant 
between 0.1-10µg/ml for EBC-211 (p<0.001-0.05), with the greatest increase at 
10µg/ml (p<0.001). In contract, the decrease in IL-8 levels observed in Microarray 
studies was corroborated at 48h with the ELISAs, for both EBC-46 and EBC-211 
(Figures 6.33A and 6.33B, respectively); although this decrease was only considered 
significant for EBC-46 at 0.001µg/ml and 10µg/ml (p<0.01-0.05). In contrast, 
following EBC-211 treatment, the decrease was significant across all EBC-211 
concentrations (0.001-10µg/ml; p<0.001-0.05), especially at 0.01-1µg/ml (p<0.001).  
 
CCL5 was shown to be profoundly downregulated in the Microarray studies 
following epoxy-tigliane treatment. This was observed for all concentrations studied 
of EBC-46 and EBC-211, at 24h and 48h (Tables 6.1 and 6.2). This downregulation 
was corroborated at the protein level by ELISA, for both EBC-46 and EBC-211  
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Figure 6.32: IL-6 levels in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), 
compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, 
statistical analysis displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
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Figure 6.33: IL-8 levels in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), 
compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, 
statistical analysis displayed *p<0.05, **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 6.34: CCL5 levels in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), 
compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, 
statistical analysis displayed **p<0.01, ***p<0.001). 
A 
 
B 
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Figure 6.35: CXCL10 levels in HaCaTs, cultured in the presence of 0.001µg/ml, 
0.01µg/ml, 0.1µg/ml, 1µg/ml and 10µg/ml EBC-46 (A) or EBC-211 (B), 
compared to untreated controls (0µg/ml), at 24h and 48h. (N=3, average±SE, 
statistical analysis displayed **p<0.01, ***p<0.001). 
A 
 
B 
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(Figures 6.34A and 6.34B, respectively). This reduced protein level was found to be 
significant for all EBC-46 concentrations (0.001-10µg/ml) at 24h (p<0.001-0.01); 
and to a greater significance at 48h (all p<0.001), compared to untreated controls. 
The reduced CCL5 protein levels following EBC-211 treatment was also significant 
at all concentration (0.001-10µg/ml), at both 24h and 48h (all p<0.001), compared to 
untreated controls.  
 
Similarly, CXCL10 was shown to be greatly downregulated in the Microarray 
studies following EBC-46 or EBC-211 treatment, compared to untreated controls 
(Tables 6.1 and 6.2). This profound decrease was corroborated at the protein level by 
ELISA, for both EBC-46 and EBC-211 (Figures 6.35A and 6.35B, respectively). 
This reduction in protein level was found to be significant for all concentrations of 
EBC-46 (0.001-10µg/ml) at 24h (p<0.001-0.01); and again, to a greater significance 
at 48h (all p<0.001). The decrease in CXCL10 protein level following EBC-211 
treatment was significant at all EBC-211 concentrations (0.001-10µg/ml) at both 24h 
and 48h (all p<0.001), compared to untreated controls.  
 
6.5     Discussion 
 
Following on from Chapter 5, which identified a number of key genes differentially 
expressed following treatment with EBC-46 or EBC-211, at 24h and 48h; this 
Chapter aimed to validate these changes in gene expression and at the protein level, 
thereby indicating whether such changes could result in phenotypic responses to 
epoxy-tigliane treatments. The genes chosen for validation were differentially 
expressed by more than 2-fold by epoxy-tigliane treatment, compared to untreated 
controls. These genes have also been shown to be involved in wound healing 
responses, as described in Section 5.5. Elucidation of the protein level changes 
following epoxy-tigliane treatment were required, as these may be responsible for the 
beneficial responses seen during the in vitro HaCaT studies, described in Chapter 4. 
In addition, these protein level changes may also determine how the beneficial 
veterinary in vivo responses following epoxy-tigliane treatment were potentially 
induced.  
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The qPCR studies were performed as further validation of genotypic response 
following epoxy-tigliane treatment (Section 6.4.1). This was analysed for a few key 
differentially expressed genes, identified during the Microarray studies (Chapter 5). 
Western blots were performed with subsequent densitometry analysis to validate the 
genotypic responses observed at the protein level for Krt13, Krt15, Krt16, Krt17, 
Krt6B, Cyclin A2, Cyclin B1, Cyclin B2, CDKN3, CDKN1A and UBE2C (Section 
6.4.2). MMP activity assays were performed on MMP-1, MMP-7 and MMP-10, as 
these were all shown to be differentially expressed during Microarray analysis, 
following epoxy-tigliane treatment (Section 6.4.3). ELISAs were performed to 
validate the protein levels of IL-6, IL-8, CCL5 and CXCL10 (Section 6.4.4). These 
cytokines and chemokines were shown to be greatly downregulated in Microarray 
studies. 
 
Krt13 was shown to be upregulated at 24h and 48h in these qPCR studies, 
corroborating the microarray analysis. The Western blots for Krt13 also showed a 
significant increase in protein detection at 48h following 0.1g/ml and 10g/ml 
EBC-46 treatments. However, for the other conditions for Krt13, no significant 
differences in protein levels were observed following epoxy-tigliane treatment, 
despite an upregulation in gene expression of Krt13. This keratin has been shown to 
be typically present in oral mucosal epithelia and early-gestational foetal epithelia, as 
opposed to adult skin epithelia (Kallioinen et al. 1995; Moll et al. 2008; Bragulla & 
Homberger 2009). The increased presence of this keratin may induce a beneficial 
healing outcome, due to the preferential rapid re-epithelialisation response associated 
with oral mucosal healing and the role that Krt13 plays in epidermal regeneration 
(Moll et al. 2008; Bragulla & Homberger 2009).  
 
Krt15 was shown, through qPCR studies, to be downregulated at 24h following 
EBC-46 and EBC-211 treatment. However, it was significantly upregulated at 48h, 
following epoxy-tigliane treatment. Western blot analysis showed no significant 
differences in Krt15 protein levels for all conditions, following epoxy-tigliane 
treatment; this was despite an upregulation in gene expression for this keratin. 
Similarly to Krt13, Krt15 is typically found in early-gestational, foetal epithelia, 
another preferential wound healing tissue, and has also been considered as an 
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epidermal stem cell marker (Waseem et al. 1999; Liu et al. 2003; Bose et al. 2013). 
In addition, Krt15 has been shown to be strongly involved in keratinocyte 
proliferation, an important feature for re-epithelialisation. Rapid re-epithelialisation 
is a characteristic feature of early-gestational, foetal wound healing (Rolfe & 
Grobbelaar 2012; Bose et al. 2013).  
 
Krt16 was shown in the qPCR studies to be downregulated at 48h for both EBC-46 
and EBC-211; and at 24h for EBC-211. The Western blots for Krt16 showed a 
significant increase in Krt16 protein levels at 24h, following 10g/ml EBC-46 
treatment. However, for the other conditions for Krt16, no significant differences in 
protein levels were observed following epoxy-tigliane treatment, despite an observed 
downregulation in gene expression of Krt16. There was a perceived decrease in 
protein detection, but this was not considered to be significant. This keratin is 
typically associated with wound healing, due to its upregulation following wounding 
(Santos et al. 2002; Mazzalupo et al. 2003). However, it has also been shown to 
inhibit keratinocyte migration. Decreased migratory ability of keratinocytes could 
reduce re-epithelialisation response, due to a lack of keratinocytes migrating to the 
wound site and across the injury (Trost et al. 2010).  
 
Krt17 was shown to be significantly downregulated in qPCR studies at 24h and 48h, 
for both EBC-46 and EBC-211. Western blot analysis showed no significant 
differences in Krt17 protein levels for all conditions, following epoxy-tigliane 
treatment; this was despite a downregulation in gene expression for this keratin. 
However, there was a perceived decrease in protein expression for Krt17, following 
EBC-211 treatment at 48h, but this was not deemed to be significant. This keratin is 
upregulated alongside Krt16 following wounding (Mazzalupo et al. 2003; Morley et 
al. 2003; Zhang et al. 2012). However, an increase in Krt17 has also been shown to 
be strongly implicated in the severity of psoriasis, a hyperproliferative skin disorder 
(Leigh et al. 1995; Zhang et al. 2012). 
 
Krt6B was also shown to downregulated in Microarray studies, following epoxy-
tigliane treatment, although there were no significant difference in protein levels 
identified through Western blot analysis for either EBC-46 or EBC-211. This keratin 
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is also upregulated following wounding and often forms a keratin pair with Krt16 
(Moll et al. 2008; Bragulla & Homberger 2009; Hobbs et al. 2012). Despite its 
upregulation after injury, decreased Krt6B expression has been shown to increase 
keratinocyte migration and subsequent re-epithelialisation (Wong & Coulombe 
2003).  
 
MMP-1 expression was shown, through qPCR studies, to be significantly 
upregulated following epoxy-tigliane at both 24h and 48h for EBC-211; and at 48h 
for EBC-46. This result was corroborated with a significantly increased MMP-1 
activity observed at 48h, following EBC-46 treatment. Significantly increased MMP-
1 activity was also observed following EBC-211 treatment, at both 24h and 48h. This 
metalloproteinase degrades collagen, in particular type I and III collagens, the major 
collagen types present in the dermal matrix. This degradation aids keratinocyte 
migration into the wound site and subsequent re-epithelialisation (Dasu et al. 2003; 
Nagase et al. 2006; Muller et al. 2008). MMP-1 has also been shown to be 
downregulated in pathological scarring, such as keloids and hypertrophic scarring 
(Lee et al. 2015).  
 
MMP-7 activity was also shown to be increased following EBC-46 and EBC-211 
treatments at 24h and 48h. This increase was only significant at the lower 
concentrations of EBC-46 and over a greater range of concentrations of EBC-211, 
presumably due to the ‘lesser activity’ of this epoxy-tigliane. MMP-7 is also 
involved in aiding keratinocyte migration, through degradation of the basement 
membrane matrix components. This MMP has been shown to be upregulated 
following epithelial injury (Philips et al. 2011; Rohani & Parks 2015). MMP-10 
activity was only shown to be significantly increased by EBC-211. This was evident 
at 24h and 48h; and corroborated Microarray studies. MMP-10 is highly expressed 
by wound edge keratinocytes and degrades the basement membrane to allow 
keratinocyte migration to promote re-epithelialisation (Gill & Parks 2008; Philips et 
al. 2011; Rohani & Parks 2015). Increased expression and activity of these three 
MMPs may subsequently lead to enhanced keratinocyte migration and re-
epithelialisation.  
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Gene expression of Cyclin B2 was upregulated following epoxy-tigliane treatment, 
in the Microarray studies. It was also shown, through qPCR studies, to be 
upregulated at 48h, following EBC-46 and EBC-211 treatment. Protein levels were 
also elevated, seen through Western blot analysis; although this was only significant 
for 10µg/ml EBC-46 at 48h. This cyclin has been associated with increasing the 
transition from the G2 phase to mitosis, increasing cell proliferation (Wu et al. 2010; 
Huang et al. 2013). The increased presence of keratinocytes at the wound site would 
be beneficial by increasing the availability of migratory keratinocytes, thereby 
enhancing re-epithelialisation (Shaw & Martin 2009). Cyclin A2 was shown to be 
upregulated during the Microarray studies; although the protein expression was only 
significantly upregulated at 10µg/ml EBC-46 at 48h. Cyclin B1 gene expression was 
also upregulated following epoxy-tigliane treatment and the protein levels were also 
significantly increased at 24h and 48h for EBC-46; and at 24h for EBC-211. These 
cyclins are all involved in the progression of cells from G2 phase to mitosis, with 
Cyclin A2 also involved in the progression from G1 to S phase. Therefore, the 
combination of increased cell progression to S phase and mitosis will lead to 
enhanced keratinocyte proliferation and enhanced re-epithelialisation (Gong & 
Ferrell 2010; Wu et al. 2010; Huang et al. 2013).  
 
CDKN3 was shown to be upregulated during Microarray studies, although the 
protein levels were not found to be significantly increased following EBC-46 
treatment, but a significant increase was observed at 0.1µg/ml EBC-211 at 24h. This 
cyclin inhibitor control mitosis function and prevents abnormal mitosis occurring; 
downregulation of this inhibitor is often observed in tumours (Nalepa et al. 2013). 
Another cyclin inhibitor, CDKN1A, was found to be downregulated during 
Microarray studies. This was corroborated by Western blot analysis, showing 
significantly decreased protein levels at 24h for EBC-46 and EBC-211. CDKN1A 
has an inhibitory ability on cell cycle progression, through inhibiting cyclin/cyclin 
dependent kinase inhibitor (CDK) complexes and preventing cells progressing into S 
phase (Gartel & Tyner 2002; Koljonen et al. 2006). This results in a reduced 
proliferative ability. Therefore, downregulation of this gene and subsequent protein 
expression may increase proliferative ability, through reduction of this inhibitory 
action (Gartel & Tyner 2002). UBE2C was shown to be upregulated during 
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Microarray studies. Although protein expression upregulation observed through 
Western blot analysis was only considered significant at 0.1µg/ml EBC-211 at 48h. 
This is another essential factor for cell cycle progression and acts through the 
breakdown of cyclin/CDK complexes, required to progress cell into mitosis. 
Therefore, increased presence of this protein will enhance cell proliferation (Hao et 
al. 2012).  
 
IL-6 protein levels were shown to be decreased at 48h, following EBC-46 or EBC-
211 treatment. This decrease was shown to be significant, compared to untreated 
controls. IL-6 is a pro-inflammatory cytokine, which increases the presence of 
neutrophils and monocytes at the wound site through a chemoattractive effect 
(Barrientos et al. 2008). It has been shown that IL-6 has beneficial effects towards 
keratinocyte migration in acute skin wounds, increasing re-epithelialisation. 
However, there is a lowered presence observed in early-gestational, foetal and oral 
mucosal wounds, where rapid re-epithelialisation occurs along with reduced 
inflammatory phase (Szpaderska et al. 2003; Gallucci et al. 2004; Barrientos et al. 
2008; Leung et al. 2012; Rolfe & Grobbelaar 2012). IL-8 levels were found to be 
significantly increased at 24h for both EBC-46 and EBC-211; whereas by 48h, it was 
shown to be significantly decreased for both epoxy-tiglianes. This decrease was more 
significant and over a greater range of concentrations with EBC-211, compared to 
untreated controls. IL-8 is another pro-inflammatory cytokine and has a strong 
chemoattractive effect on neutrophils. Levels have been shown to be increased in 
non-healing wounds, potentially due to the excessive inflammation associated with 
increased IL-8 presence (Liechty et al. 1998; Barrientos et al. 2008). In addition, IL-8 
levels are shown to be lowered in early-gestational foetal wounds. Alongside lower 
IL-6 levels, the presence of reduced pro-inflammatory cytokine levels contributes 
greatly to the minimal inflammation that occurs in this preferential healing response 
(Liechty et al. 1998; Liechty et al. 2000; Szpaderska et al. 2003; Barrientos et al. 
2008; Leung et al. 2012; Rolfe & Grobbelaar 2012). Therefore, the reduction of these 
cytokines following epoxy-tigliane treatment may impact on the inflammation phase 
of normal acute skin wound healing, producing an attenuated inflammatory response.  
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CCL5 was shown by Microarrays to be profoundly downregulated following EBC-
46 or EBC-211 treatment at both 24h and 48h, compared to untreated controls. CCL5 
is a potent chemokine for immune cells, including monocytes, macrophages, mast 
cells and leukocytes. Therefore, its increased presence can increase the inflammatory 
phase and higher expression of CCL5 has been detected in chronic wounds (Gillitzer 
& Goebeler 2001; Balaji et al. 2015; Rees et al. 2015). This chemokine can also 
induce a mitogenic response on keratinocytes, in addition to having a role in 
angiogenesis; although its main role appears to be inflammatory with the strong 
chemokine response on immune cells and facilitation of immune responses (Rees et 
al. 2015). Another chemokine validated was CXCL10, which was also shown by 
Microarrays to be profoundly downregulated following both EBC-46 and EBC-211 
treatment, at 24h and 48h. CXCL10 is another chemokine with a potent 
chemoattractant effect on lymphocytes and monocytes, resulting in a pro-
inflammatory effect due to increased immune cells at the wound site; and levels are 
increased in chronic inflammation (Barrientos et al. 2008; Turabelidze & Dipietro 
2012; Balaji et al. 2015; Ding & Tredget 2015; Rees et al. 2015). This chemokine 
has also been shown to delay re-epithelialisation, through inhibition of epidermal 
growth factor (EGF)-mediated cell mobility in fibroblasts, impairing granulation 
tissue formation. Platelet-derived growth factor (PDGF) mediated cell migration is 
also thought to be inhibited and both of these growth factors are associated with 
promoting re-epithelialisation (Shiraha et al. 1999; Barrientos et al. 2008; 
Turabelidze & Dipietro 2012; Rees et al. 2015). This inhibited cell motility is 
thought to be induced through the inhibited de-adhesion of cell to the membrane, 
through m-calpain inhibition, important for retraction of the rear of the cell. In 
addition, activation of CXCR3, the receptor for CXCL10, is thought to convert 
fibroblasts to a contractile phenotype instead of migratory  (Shiraha et al. 1999; 
Behm et al. 2012). CXCL10 has been shown to inhibit angiogenesis, through 
inhibiting vessel growth and neovascularisation. It is also believed to increase 
keratinocytes motility through promoting keratinocyte chemotaxis (Romagnani et al. 
2004; Bodnar et al. 2006; Turabelidze & Dipietro 2012; Yates-Binder et al. 2012; 
Rees et al. 2015).  
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Chapter 5 elucidated a number of key differentially expressed genes during the 
Microarray studies, some of these were validated at a protein level during this 
chapter. An overview of these results are displayed in Tables 6.3 and 6.4, for EBC-
46 and EBC-211, respectively. Some of these results from the validation studies 
corroborates the global gene analysis, although there are a few results which are in 
contrast to the gene analysis. Some of these genotypic and resultant phenotypic 
changes may contribute to the enhanced keratinocyte proliferative and migratory 
responses seen during the in vitro studies, described in Chapter 4. In addition, they 
may give greater understanding to the exceptional wound healing responses observed 
during the in vivo animal wound healing studies (Reddell et al. 2014). A number of 
key gene and protein changes involved with enhanced keratinocyte proliferation and 
migration were confirmed, following epoxy-tigliane treatment. This provides support 
for the rapid re-epithelialisation responses observed in these in vitro and in vivo 
studies; and confirms key mechanisms through which these epoxy-tiglianes exert 
exceptional wound healing responses. A number of the gene and protein changes 
observed were similar to the expression seen in preferential tissues, such as early-
gestational, foetal and oral mucosal epithelia. This leads to the theory that treatment 
with these novel epoxy-tiglianes may induce a regenerative response, as opposed to 
the normal repair mechanism seen in adult dermal wound healing.   
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Table 6.3: Corroboration of global gene analysis by validation studies, following 
treatment with EBC-46. Red = up-regulated, Green = down-regulated, White = no 
significant change. 
 
Gene/ Protein Microarray Result Validation 
Experiment 
Validation Result 
Krt13 Up-regulated qPCR Up-regulated 
Western Blot   Up-regulated 
Krt15 Up-regulated qPCR Up-regulated 
Western Blot No significant 
change 
Krt16 Down-regulated qPCR Down-regulated 
Western Blot Up-regulated 
Krt17 Down-regulated qPCR Down-regulated 
Western Blot No significant 
change 
Krt6B Down-regulated Western Blot No significant 
change 
Cyclin A2 Up-regulated Western Blot Up-regulated 
Cyclin B1 Up-regulated Western Blot Up-regulated 
Cyclin B2 Up-regulated qPCR Up-regulated 
Western Blot Up-regulated 
CDKN3 Up-regulated Western Blot No significant 
change 
CDKN1A Down-regulated Western Blot Down-regulated 
UBE2C Up-regulated Western Blot No significant 
change 
MMP-1 Up-regulated qPCR Up-regulated 
MMP Activity 
Assay 
Up-regulated 
MMP-7 Up-regulated MMP Activity 
Assay 
Up-regulated 
IL-6 Down-regulated ELISA Down-regulated 
IL-8 Down-regulated ELISA Down-regulated 
CCL5 Down-regulated ELISA Down-regulated 
CXCL10 Down-regulated ELISA Down-regulated 
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Table 6.4: Corroboration of global gene analysis by validation studies, following 
treatment with EBC-211. Red = up-regulated, Green = down-regulated, White = no 
significant change. 
 
Gene/ Protein Microarray Result Validation 
Experiment 
Validation Result 
Krt13 Up-regulated qPCR Up-regulated 
Western Blot No significant 
change 
Krt15 Up-regulated qPCR Up-regulated 
Western Blot No significant 
change 
Krt16 Down-regulated qPCR Down-regulated 
Western Blot No significant 
change 
Krt17 Down-regulated qPCR Down-regulated 
Western Blot No significant 
change 
Krt6B Down-regulated Western Blot No significant 
change 
Cyclin A2 Up-regulated Western Blot No significant 
change 
Cyclin B1 Up-regulated Western Blot Up-regulated 
Cyclin B2 Up-regulated qPCR Up-regulated 
Western Blot No significant 
change 
CDKN3 Up-regulated Western Blot Up-regulated 
CDKN1A Down-regulated Western Blot  Down-regulated 
UBE2C Up-regulated Western Blot Up-regulated 
MMP-1 Up-regulated qPCR Up-regulated 
MMP Activity 
Assay 
Up-regulated 
MMP-7 Up-regulated MMP Activity 
Assay 
Up-regulated 
MMP-10 Up-regulated MMP Activity 
Assay 
Up-regulated 
IL-6 Down-regulated ELISA Down-regulated 
IL-8 Down-regulated ELISA Down-regulated 
CCL5 Down-regulated ELISA Down-regulated 
CXCL10 Down-regulated ELISA Down-regulated 
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Chapter 7 – Discussion 
 
 
7.1 Overview 
 
This PhD study aimed to determine the effects of the naturally occurring epoxy-
tiglianes, EBC-46 and EBC-211, on dermal wound healing responses. This was 
performed through culturing dermal fibroblasts and an epidermal keratinocyte cell line 
(HaCaTs) with these novel epoxy-tiglianes and observing the effects on a number of 
key in vitro wound healing responses, including viability, proliferation, cell cycle 
progression, morphology, repopulation; and for fibroblasts, their differentiation to 
contractile myofibroblasts. Previous in vivo animal studies performed by QBiotics Ltd. 
have demonstrated the exceptional wound healing responses induced following epoxy-
tigliane treatment, with treated skin displaying rapid re-epithelialisation, wound 
closure and minimal scarring (Reddell et al. 2014). Such findings justified the 
necessity to determine how EBC-46 and EBC-211 influence fibroblast and 
keratinocyte responses; and how these in vivo responses are induced. EBC-46 has been 
shown to act through classical protein kinase C (PKC) activation, in particular the 
PKC-β isoforms (Boyle et al. 2014).  
 
7.2 Fibroblasts and Myofibroblasts 
 
Fibroblasts cultured with 0.001-10µg/ml EBC-46 or EBC-211 demonstrated 
significant anti-proliferative responses, potentially partly due to the delayed cell cycle 
progression observed. Despite little significance shown, there was also a perceived 
inhibitory response of fibroblast wound repopulation and closure, following epoxy-
tigliane treatment. In addition, apparent inhibition of fibroblast-myofibroblast 
differentiation was evident at certain concentrations of EBC-46 (0.1µg/ml) and EBC-
211 (10µg/ml), demonstrated through lack of stress fibre formation and significantly 
reduced α-smooth muscle actin (SMA) expression (Gabbiani 2003).  
 
Alterations in normal dermal fibroblast function are evident in both detrimental and 
preferential healing processes, such as excessive scarring and chronic wounds or early-
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gestational foetal and oral mucosal healing, respectively (Menke et al. 2007; Bran et 
al. 2009; Shih et al. 2010; Frykberg & Banks 2015). Some aspects of the fibroblast 
responses to epoxy-tigliane treatment can be likened to impaired healing, such as the 
apparent inhibitory fibroblast proliferative and migratory responses and subsequent 
reduced wound repopulation (Menke et al. 2007). This has implications on the 
successful synthesis of new extracellular matrix (ECM), with a reduced presence of 
fibroblasts at the wound site resulting in a decreased replacement of the provisional 
fibrin matrix, reducing the tensile strength of the tissue (Menke et al. 2007; Eming et 
al. 2014; Frykberg & Banks 2015). In addition, chronic wound fibroblasts have also 
been demonstrated to possess reduced proliferative abilities, potentially a result of the 
proteolytic environment of the chronic wound degrading a number of key growth 
factors (Telgenhoff & Shroot 2005; Wall et al. 2008; Eming et al. 2014). In contrast, 
excessive scarring is a result of increased presence of fibroblasts, through enhanced 
migratory responses to the wound site as a result of chemotactic signals released by 
immune cells; along with an upregulated proliferative ability and resultant 
differentiation into the contractile myofibroblast phenotype (Gauglitz et al. 2011; 
Jumper et al. 2015; Kelsh et al. 2015). This indicates the extremely delicate balance 
between normal wound healing and the two opposing impaired healing responses.  
 
The in vivo veterinary studies have elucidated the apparent dermal response following 
epoxy-tigliane treatment, with an exceptional cosmesis and wound closure ability, 
demonstrating an overall lack of scarring at the wound site (Reddell et al. 2014). This 
preferential healing response is evident despite the opposing fibroblast responses 
following epoxy-tigliane treatment to preferential healing, such as early-gestational 
foetal and oral mucosal wound repair, where fibroblast proliferative and migratory 
abilities are seen to be increased (Enoch et al. 2010; Yates et al. 2012; Helmo et al. 
2013). In addition to the apparent impaired wound closure response, following epoxy-
tigliane treatment, fibroblasts demonstrated an altered cytoskeletal structure. This was 
evident by the formation of multiple lamellipodia, as opposed to only one during 
normal cell crawling locomotion. This could be a result of alterations to ENA/VASP 
proteins, known to impact the elongation and branching of actin filaments and 
protrusion of lamellipodia (Kwiatkowski et al. 2003; Krause & Gautreau 2014). 
Additionally, the retraction of these projections does not occur in all instances, 
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especially evident during the time-lapse movies (Supplement 3.2), where trailing 
projections were shown to extend across large distances. Further studies would be 
required to determine whether this is a result of alteration in the actin cytoskeleton or 
other cytoskeletal proteins.  
 
There are phenotypic differences between adult dermal fibroblasts and those present 
in preferential tissues, such as early-gestational, foetal and oral mucosal wounds. Oral 
mucosal fibroblasts have been described as having a ‘younger phenotype’ than dermal 
fibroblasts, resulting in a longer proliferative lifespan (Enoch et al. 2010). This is due 
to the delayed senescence, which is independent of telomerase activity (Enoch et al. 
2009). Foetal fibroblasts have also been shown to possess increased levels of 
hyaluronan and its receptor, which has been associated with inducing fibroblast 
migration and contributing to the scarless healing response (Alaish et al. 1994; Bullard 
et al. 2003; Leung et al. 2012; Yagi et al. 2016).  In addition, there is a variation in 
collagen type produced by foetal fibroblasts, with greater synthesis of type I collagen, 
compared to dermal fibroblast production; type I collagen fibres are finer and are 
difficult to discern from the surrounding uninjured tissue (Bullard et al. 2003; Leung 
et al. 2012; Yagi et al. 2016). Oral fibroblasts, like foetal fibroblasts, also exert a 
quicker migratory ability, compared to dermal fibroblasts. This combined with the 
extended proliferative lifespan, may result in an increased cell number at the wound 
site and contributes to the rapid wound closure seen in this preferential tissue (Bullard 
et al. 2003; Enoch et al. 2010; Yagi et al. 2016). In early-gestational, foetal wounds, 
there is an absence of myofibroblasts at day 14 following injury and subsequent 
reduced collagen contraction; oral fibroblasts have also shown to exert a reduced 
contraction than dermal fibroblasts (Cass et al. 1997; Lee & Eun 1999; Moulin & 
Plamondon 2002; Shannon et al. 2006; Leung et al. 2012; Yagi et al. 2016). This 
reduced contraction through myofibroblasts results in reduced scarring, which may be 
similar to the potentially inhibited myofibroblast formation, following epoxy-tigliane 
treatment, resulting in the production of minimal scarring (Enoch et al. 2008; Leung 
et al. 2012; Yagi et al. 2016). A degree of contraction has been thought to be beneficial 
through closure of the wound space, re-establishing a protective barrier for the 
underlying connective tissue (Li & Wang 2011; Eming et al. 2014). Although this 
mechanism needs to be tightly regulated, as too much or too little contraction can have 
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implications on the healing mechanism (Gabbiani 2003; Eckes et al. 2010; Li & Wang 
2011). As previously mentioned, a lack of contraction may prevent successful closure 
of the wound, whilst excessive contraction can result in a fibrotic response and loss of 
function at the site (Gabbiani 2003; Eckes et al. 2010; Li & Wang 2011; Eming et al. 
2014).  
 
The altered fibroblast morphology and perceived inhibition of fibroblast-
myofibroblast differentiation was of most interest, due to the potential anti-fibrotic 
implications following epoxy-tigliane treatment. The morphological studies showed a 
profound cytoskeletal change at 24h following epoxy-tigliane treatment, where the 
cells appeared to resemble a myofibroblast phenotype, with an increased morphology, 
stellate-structure and potential presence of stress fibres. The reversion of this 
morphology back to a typical spindle-shaped structure by 72h was intriguing and of 
interest; it led to the theory of a potentially reversible fibrosis response (Chitturi et al. 
2015). This theory was developed upon during the differentiation studies and the 
inhibitory responses evident at certain concentrations of both epoxy-tiglianes. In this 
instance, it appeared that there was an inhibition of myofibroblast formation, as 
opposed to a reversion back to the normal fibroblast morphology as seen previously. 
It is still unknown what is inducing these responses and especially with the potential 
myofibroblast inhibition, why this response is only evident at 0.1µg/ml EBC-46 and 
10µg/ml EBC-211. It would be of interest to know the comparable concentration used 
during the animal in vivo studies, which produced these anti-scarring responses, to 
determine whether this response also occurs in vivo. The in vivo studies previously 
performed have indicated that the healing responses are more characteristic of 
preferential healing, as observed in early-gestation foetal and oral mucosal wound 
responses. Therefore, treatment with these novel epoxy-tiglianes may induce 
regeneration at the wound site, instead of the typical repair mechanism, which occurs 
in adult wounds and results in scar formation. Of particular interest was the 
reformation of appendages during in vivo studies, which is typically absent following 
adult dermal repair and noted to occur during early-gestational foetal wound repair 
(Lorenz et al. 1993; Bullard et al. 2003; Werner & Grose 2003; Kishi et al. 2012; 
Leung et al. 2012).  
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Presence or absence of myofibroblasts in wounds has been shown to induce 
dysfunctional or preferential responses, respectively. A greatly increased presence is 
observed in keloid and hypertrophic scarring, resulting in excessive contraction of the 
wound site and resultant scarring (Gauglitz et al. 2011; Jumper et al. 2015; Kelsh et al. 
2015). In contrast, it has been thought that, along with a decreased expression of 
transforming growth factor-β1 (TGF-β1), there is a reduced presence of myofibroblasts 
in early-gestational foetal healing; although their function is not fully known, due to a 
different wound closure method occurring in this healing response, instead of 
myofibroblast contraction (Larson et al. 2010; Rolfe & Grobbelaar 2012; Yates et al. 
2012). The other widely noted preferential healing response, oral mucosal healing also 
possesses a decreased TGF-β1 presence, along with a resistance to differentiation into 
myofibroblasts (Meran et al. 2007). This resistance is thought to be connected to the 
inhibited synthesis of hyaluronan in oral mucosal wounds, due to downregulated 
transcription of the related synthase enzymes, HAS2 (Meran et al. 2007). A global 
gene analysis could elucidate whether these synthase genes are some of the genes 
differentially expressed at those certain concentrations of EBC-46 and EBC-211, 
where differentiation appears to be inhibited. This may indicate whether this is the 
mechanism of myofibroblast inhibition and resultant scarless healing. As previously 
mentioned, it would be interesting to know the comparative concentration used during 
the in vivo studies, to understand which concentration results in the beneficial healing 
response observed in the case studies. This is of particular interest regarding the 
potential inhibition of myofibroblast formation and resultant minimal scarring, due to 
the apparent narrow range of concentrations of EBC-46 and EBC-211 which produce 
this response in vitro.  
 
7.3 Keratinocyte Cell Line (HaCaTs) 
 
In contrast to the dermal fibroblast responses, profound increases in HaCaT 
proliferative and migratory responses were evident, following culture with 0.001-
10µg/ml EBC-46 or EBC-211. The most significant increased proliferation, compared 
to the untreated control, was evident following 72h treatment. This was shown to be a 
result of a proliferative burst occurring between 24h and 72h and a result of accelerated 
cell cycle progression. The cell cycle progression appeared to have a dose-dependent 
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response, with the lower concentrations initially exhibiting a similar progression to the 
untreated controls. In contrast, the enhanced HaCaT migratory responses were shown 
to be most significant at the lower concentrations of both epoxy-tiglianes, with 
complete wound closure evident at these lower concentrations; this was observed at 
0.001-0.01µg/ml EBC-46 and 0.001-0.1µg/ml EBC-211. This enhanced response was 
evident across a wider therapeutic range for EBC-211, due to the lesser activity, 
compared to EBC-46. This increased range of enhanced wound repopulation may be 
of greater benefit from a clinical perspective, increasing the therapeutic range where 
exceptional wound healing responses can occur. The morphology and migration 
studies demonstrated no morphological change in the HaCaTs, indicating that the 
epoxy-tiglianes did not induce any differentiation responses in these cells.  
 
Of interest was the dual response on wound repopulation ability, through independent 
upregulation of proliferative and migratory responses. This was demonstrated through 
analysing wound repopulation of an in vitro scratch wound, in the presence of 
mitomycin C, an inhibitor of proliferation (Santhiago et al. 2012; Wang et al. 2012; 
Lü et al. 2013). This was necessary to rule out whether the enhanced proliferation, 
observed previously, was biasing the wound repopulation outcome, through an overall 
increase in keratinocyte presence at the site. Keratinocyte presence at a wound site has 
extreme importance in the successful wound closure ability, through the re-
epithelialisation process and re-establishment of the protective barrier, as described 
previously (Menon 2002; Candi et al. 2005; Portou et al. 2015).  
 
Impaired wound closure has been shown in a number of chronic wound types and burn 
injuries, both of which result in impaired function and increased morbidity to the 
patient (Gorecki et al. 2009; Dreifke et al. 2015). Both proliferative and migratory 
response are shown to be impaired in chronic wounds, due to lack of response to 
signals, the reduced presence of growth factors stimulating motility, such as basic 
fibroblast growth factor (bFGF); and the proteolytic environment within chronic 
wounds capable of degrading a number of vital growth factors (Menke et al. 2007; 
Barrientos et al. 2008; Shirakata 2010). The inflammatory environment has also been 
thought to have implications on keratinocyte proliferation, with increased IL-8 shown 
to reduce proliferative responses (Barrientos et al. 2008). In addition, chronic wounds 
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possess a dysfunctional ECM. This may prevent the migration of keratinocytes across 
this wound bed, due to the necessity of a stable matrix for keratinocytes to migrate 
across and form focal adhesion complexes (Agren & Werthén 2007; Li et al. 2007).  
 
The in vivo studies performed by QBiotics Ltd. have demonstrated exceptional healing 
of chronic wounds that were previously unresponsive to current wound care strategies. 
This indicates that the novel epoxy-tiglianes are able to induce a preferential wound 
healing response on these previously chronic wounds. This could have profound 
clinical implications, as chronic wounds and burn injuries cost the NHS approximately 
£5 billion to manage and treat (Posnett & Franks 2008; Guest et al. 2015; Harding 
2015). A characteristic feature of preferential wound healing, both early-gestational 
foetal and oral mucosal, is induction of rapid re-epithelialisation, which appeared to 
occur during the in vivo studies (Coolen et al. 2010; Turabelidze et al. 2014). The in 
vitro studies suggest that the combination of the enhanced proliferative and migratory 
abilities, previously observed, will result in enhanced wound repopulation and 
potentially rapid re-epithelialisation. Enhanced keratinocyte proliferation has been 
observed in both early-gestational foetal and oral mucosal healing. In addition, 
enhanced migratory abilities are present in oral mucosal healing, which repopulates 
the wound in a similar manner to adult wound healing (Tan et al. 2014; Turabelidze et 
al. 2014). There are also a number of differentially expressed genes evident in both 
preferential healing responses, compared to adult dermal wound repair. Therefore, 
examination of genotypic expression following epoxy-tigliane was essential to 
determine the mechanisms behind this exceptional wound healing response (Colwell 
et al. 2008; Rolfe & Grobbelaar 2012; Turabelidze et al. 2014).  
 
7.4 Genotypic and Phenotypic Responses  
 
Following the exceptional responses observed in Chapter 4 on key keratinocyte wound 
healing functions, it was crucial to determine the genotypic responses following 
epoxy-tigliane treatment. There were a number of key differentially expressed genes 
identified following EBC-46 or EBC-211 treatment, with similar fold-changes in gene 
expression observed for both epoxy-tiglianes. This was noted despite slight variations 
in the in vitro results, with EBC-211 exhibiting a greatly enhanced migratory response, 
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compared to EBC-46. However, some cell-proliferation related genes, such as GINS 
complex subunit 2 (GINS2) and polymerase (DNA directed), ε2, accessory subunit 
(POLE2), were shown to be upregulated for 0.001µg/ml and 0.1µg/ml EBC-211 at 
48h, but not at 10µg/ml, which may contribute to the reduced proliferative response 
seen in HaCaTs at the higher concentrations, following epoxy-tigliane treatment. In 
addition, matrix metalloproteinase (MMP)-1, MMP-7 and MMP-10 were shown to be 
upregulated at the lower concentrations (0.001µg/ml and 0.1µg/ml) of both epoxy-
tiglianes, but not at the high concentration (10µg/ml). This was particularly evident for 
EBC-211 at 24h and 48h. This upregulation may contribute to the enhanced migratory 
responses observed at the lower concentrations, with some exhibiting full wound 
closure during the in vitro study. This response was further confirmed through pathway 
analysis on the differentially expressed genes predicting a stimulated migration of cells 
for 0.001µg/ml and 0.1µg/ml EBC-46 and EBC-211, but not at 10µg/ml. This 
corroborates the in vitro wound repopulation studies, where significantly enhanced 
migration was evident for the lower concentrations of both epoxy-tiglianes. The main 
areas of interest with differentially expressed genes, include cell cycle-related genes, 
cell-related genes, keratins and immune-related genes. The presence of certain 
keratins, only typically present in early-gestational foetal and oral mucosal epithelia, 
such as Krt13 and Krt15, respectively; were of particular interest, due to their roles in 
keratinocyte proliferation and epithelial regeneration (Kallioinen et al. 1995; Bose et 
al. 2013; Turabelidze et al. 2014). Of note, some crucial keratins that are typically 
induced following injury were shown to be downregulated, such as Krt16, Krt17 and 
Krt6B. This may be due to the lack of wounding to the cells during the in vitro 
experiment and would be interesting to observe the differential expression of these 
following a scratch wound study (Santos et al. 2002; Mazzalupo et al. 2003; Trost et 
al. 2010).  
 
The previous in vitro cell cycle progression responses were shown to result from 
genotypic changes following epoxy-tigliane treatment, with enhancement of a number 
of cyclins and cyclin-dependent kinase inhibitors required for progression through the 
cell cycle (Tschöp & Engeland 2007; Hochegger et al. 2008; Nalepa et al. 2013). These 
differentially expressed genes, Cyclin A2, Cyclin B1 and Cyclin B2, confirmed the 
previous theory in Chapter 4, that G1 to S phase and G2 to mitosis transitions were 
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promoted. This was corroborated with a number of the upregulated cyclins involved 
in promoting this transition, seen at both the gene and protein level, contributing to the 
increased proliferative potential. In addition, proliferation was seen to be promoted 
through upregulation of a number of cell proliferation-related genes. Of interest, was 
the upregulation of factors, such as parathyroid hormone-like hormone (PTHLH), that 
are involved in the paracrine feedback system with fibroblasts, resulting in enhanced 
keratinocyte responses (Blomme et al. 1999; Bader & Kao 2009; Feuerherm et al. 
2013). This leads us to question which genes of interest are differentially expressed in 
fibroblasts following epoxy-tigliane treatment, in particular those shown to be strongly 
linked to keratinocyte proliferation and migration, such as keratinocyte growth factor 
(KGF; Barrientos et al. 2008; Shirakata 2010).  
 
Key MMPs were shown to be upregulated following epoxy-tigliane treatment. This 
can lead to beneficial or detrimental responses, as MMPs are vital for allowing 
migration of both keratinocytes and fibroblasts into the wound site to re-establish an 
epidermal barrier and re-form the underlying ECM (Vu & Werb 2000; Muller et al. 
2008). However, if this upregulation is too excessive or prolonged, this could lead to 
the detrimental responses observed in chronic wounds, where high presence is 
observed (Menke et al. 2007; Frykberg & Banks 2015; Rohani & Parks 2015). As we 
already have confirmation of epoxy-tigliane efficacy from in vivo studies performed 
by QBiotics Ltd., it appears that the MMP levels are optimal for cell migration, without 
creating a chronic wound site. MMP-10 was the only proteinase that was shown to be 
differentially expressed for EBC-211, but not EBC-46. This result was confirmed 
through the MMP activity assays. However, as this MMP has been associated with the 
migration of keratinocytes at the wound edge, this result may contribute to the 
enhanced migratory response of EBC-211, compared to EBC-46 (Gill & Parks 2008; 
Philips et al. 2011; Rohani & Parks 2015). Although, the in vitro migration assay was 
performed on tissue culture plastic and not an ECM, which would replicate in vivo 
settings more accurately (Kramer et al. 2013).  
 
A greatly important observation from the global gene analysis, corroborated at a 
protein level through ELISAs, was the profound downregulation of inflammatory 
cytokines and chemokines, such as IL-6, IL-8, CCL5 and CXCL10. This 
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downregulation and subsequent attenuated inflammatory phase are typically 
associated with preferential healing responses, again indicating that treatment with the 
novel epoxy-tiglianes, especially EBC-211, may induce a preferential response as 
opposed to the normal response associated with acute adult dermal wound healing 
(Barrientos et al. 2008; Leung et al. 2012; Rolfe & Grobbelaar 2012; Turabelidze & 
DiPietro 2012; Balaji et al. 2015). However, these inflammatory cytokines and 
chemokines have also been shown to induce keratinocyte migration to the wound site; 
with IL-8, this is through production of a chemokinetic gradient (Satish et al. 2003; 
Gallucci et al. 2004; Spiekstra et al. 2007; Jiang et al. 2012; Rees et al. 2015). 
However, as chronic wounds often possess an excessive inflammatory phase, 
treatment with these novel epoxy-tiglianes may attenuate this response and induce a 
rapid regenerative healing mechanism, as opposed to the typical repair response 
(Menke et al. 2007; Frykberg & Banks 2015).  
 
7.5 Significance to Wound Healing Response 
 
Of great interest, a number of the differentially expressed genes following epoxy-
tigliane treatment have been associated with preferential healing responses, 
corroborating the enhanced wound repair responses observed through both the in vitro 
and animal in vivo studies (Rolfe & Grobbelaar 2012; Reddell et al. 2014; Turabelidze 
et al. 2014). The benefit of the prior performance of in vivo veterinary studies was the 
indication that treatment with the novel epoxy-tiglianes induced an exceptional wound  
healing response, with minimal scarring (Reddell et al. 2014). However, in order for 
these epoxy-tiglianes to progress as a novel pharmaceutical agent for enhanced wound 
repair, a greater understanding of the mechanism of action for these pharmaceuticals 
was required. EBC-46 has been shown to disrupt blood supply to the site during 
tumour ablation, increasing cell permeability at the wound site (Boyle et al. 2014). 
This is an interesting effect, as increased permeability has also been shown to occur in 
early-gestational foetal wound healing. This is potentially due to increased vascular 
endothelial growth factor (VEGF) expression, although there are conflicting studies 
on VEGF expression levels in foetal wounds (Bullard et al. 2003; Colwell et al. 2005; 
Henderson et al. 2011; Rolfe & Grobbelaar 2012; Johnson & Wilgus 2014; Yagi et al. 
2016). However, the association between increased angiogenesis and scar formation 
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has been documented, with preferential healing responses exhibiting reduced 
angiogenesis (Szpaderska et al. 2005; Van Der Veer et al. 2011; DiPietro 2013). As 
mentioned previously, it is theorised that the epoxy-tiglianes are inducing a more 
regenerative wound healing response, reminiscent of early-gestational foetal wound 
healing (Leung et al. 2012; Rolfe & Grobbelaar 2012; Yates et al. 2012).  
 
This theory that a regenerative healing response is induced is an area of immense 
interest and importance, through the potential as a treatment in impaired healing 
responses, such as chronic wounds and burn injuries, where large tissue sites are often 
impacted, requiring this stimulated wound closure ability (Menke et al. 2007; Dreifke 
et al. 2015; Frykberg & Banks 2015). In addition, the potentially anti-fibrotic response 
resulting from reduced fibroblast presence and perceived inhibition of myofibroblast 
differentiation, would be of great benefit in excessive scarring situations, such as 
keloid and hypertrophic scarring (Bran et al. 2009; Gauglitz et al. 2011; Viera et al. 
2012). Despite the wide array of treatment options for fibrosis, it still presents a huge 
clinical burden and there is no gold standard treatment available yet. It was only in 
recent years that the formation of a larger keloid may occur at the wound site following 
surgical removal of keloids was discovered, which results in a higher disability to the 
patient (Gauglitz et al. 2011; Gold et al. 2014; Rabello et al. 2014). The perceived 
regenerative capability of epoxy-tigliane treatment may induce an anti-fibrotic 
response, through decreasing the proliferative and migratory action of the fibroblasts 
within the keloid and inhibition of myofibroblast formation, resulting in reduced 
wound contraction.  
 
Furthermore, as discussed in detail in Chapter 1, current wound care strategies are not 
sufficient in the treatment of chronic wounds, resulting in persistent, non-healing 
wounds for many months; or for excessive dermal scarring situations, which can 
reduce patient functionality (Gauglitz et al. 2011; Viera et al. 2012; Rabello et al. 2014; 
Dreifke et al. 2015; Frykberg & Banks 2015). There is an urgent need for new 
treatment modalities and the novel epoxy-tiglianes show great promise in resolving 
these wounds and easing the huge impact on healthcare providers (Posnett & Franks 
2008; Guest et al. 2015; Harding 2015). These epoxy-tiglianes have shown to induce 
these responses following topical application to the wound site and even show success 
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on long lasting chronic wounds, as in the veterinary case study with a deep necrosing 
chronic wound (Reddell et al. 2014). The in vivo veterinary trials have only involved 
EBC-46; although from the in vitro studies, it appears that both analogues exert their 
responses by the same mechanism, leading to the theory that EBC-211 would also be 
successful in the veterinary in vivo studies. However, an increased beneficial 
concentration range was observed following EBC-211 treatment, especially for wound 
repopulation, compared to EBC-46 responses; additionally, EBC-211 is considered to 
be of ‘lesser activity’ and has been demonstrated to possess a reduced cytotoxicity 
compared to EBC-46. Therefore, there is the possibility that EBC-211 may be 
considered as more promising therapeutically than EBC-46 for in vivo responses. 
However, despite these exceptional responses observed through the in vitro studies, 
there are numerous other cell types present within the epidermal and dermal layers, 
including a variety of stem cell and immune cell populations, impacting on the overall 
wound healing process; their responses to epoxy-tigliane treatment have not yet been 
investigated (Haake et al. 2001; Walters & Roberts 2002).  
 
7.6 Future Research 
 
EBC-46 and EBC-211 have been shown to induce the anti-cancer response, primarily 
through PKC-β isoforms, but also through PKC-α and -γ, to a lesser degree (Boyle et 
al. 2014; Reddell et al. 2014). It is theorised that the wound healing responses are 
acting through PKC pathways also, in particular the classical pathways (Boyle et al. 
2014; Reddell et al. 2014). However, further studies are required to confirm this theory 
through a number of PKC studies, initially involving performing the proliferation and 
migratory studies in the presence of pan- and specific PKC inhibitors; such as BIM-1 
and Gö6976 (Koivunen et al. 2004; Rotmann et al. 2006; Aaltonen & Peltonen 2010; 
Dang et al. 2011). Such studies will confirm a role for PKCs and specifically, classical 
PKCs in keratinocyte responses in vitro. In addition, PKC inhibition will be used to 
observe the impact of PKC activity, following epoxy-tigliane treatment, on the key 
differentially expressed genes identified during the global gene analysis. Gene and 
protein expression levels will be determined, following PKC inhibition, of key 
keratins, cell cycle-related genes, matrix metalloproteinase; and inflammatory 
cytokines and chemokines.  
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However, it has been indicated that PKC-β is present in HaCaTs only, not primary 
human keratinocytes. This may have implications for the wound healing studies and 
requires future experiments to be performed on primary keratinocytes to determine 
whether the same beneficial responses are observed (Mitev & Miteva 1999; Denning 
2004). Although there are conflicting reports on this, with some stating that PKC-β is 
present in keratinocytes and that there is a reduction in expression of this isoform in 
the epidermal layer of psoriasis, compared to normal adult skin (Fisher et al. 1993; 
Papp et al. 2003). Other isoforms were also shown to be involved, albeit to a lesser 
level than PKC-β. However, these isoforms may predominate in the epoxy-tigliane 
mediated wound healing responses. As the in vitro studies performed in this thesis 
have indicated that the lower concentrations exert the greatest beneficial wound 
healing responses, resulting in the greater therapeutic range with EBC-211 treatment, 
low levels of PKC activation may be sufficient to induce these exceptional wound 
healing responses.  
 
HaCaTs were used initially instead of primary keratinocytes, as this immortalised cell 
line has been widely used to assess epidermal responses, due to their close similarity 
of functional response to normal adult epidermal keratinocytes (Boukamp et al. 1988; 
Pessina et al. 2001; Wilson 2014). HaCaTs have been shown to maintain key 
behavioural functions, similar to primary keratinocytes, such as retaining 
differentiation capacity. Little change to cell cycle related genes have also been 
observed, compared to primary keratinocytes (Sprenger et al. 2013). As a result of 
these beneficial properties, HaCaTs are deemed suitable for use instead of primary 
keratinocytes, whilst being representative of epidermal keratinocyte responses 
(Sprenger et al. 2013). Primary keratinocytes have been reported to potentially induce 
a range of responses, due to variations in donor age, gender and localisation of biopsy 
(Sprenger et al. 2013). However, due to the potentially altered PKC isoform presence 
in HaCaTs, it would be necessary to perform studies on primary keratinocyte as well 
and compare to the previous results obtained from HaCaTs.  
 
Correlating with the lesser activity of EBC-211, compared to EBC-46, the level of 
PKC activation by EBC-211 is thought to be much reduced (QBiotics Ltd.). Therefore, 
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the PKC inhibitors studies will elucidate whether both epoxy-tiglianes mediate their 
responses through the same mechanism of action, or if another pathway is involved in 
the responses observed by EBC-211. Once PKC activity has been determined, a 
number of mechanistic studies could identify the impact of specific PKC isoforms on 
the responses, previously observed. This analysis could focus on downstream 
signalling pathways of PKCs, including MAPK/ERK Kinase (MEK)1/2, extracellular 
signal-regulated kinase (ERK)1/2, mitogen-activated protein kinase (MAPK)1/2, 
phosphatidylinositide 3-kinase (PI3K), Akt, signal transducer and activator of 
transcription (STAT)1-3, janus kinase/signal transducers and activators of 
transcription (JAK-STAT) and SMAD. The impact on these downstream signalling 
pathway genes/proteins will be determined by quantitative polymerase chain reaction 
(qPCR) and Western blot analysis, respectively, through use of specific pathway 
inhibitors. These should also be performed in the absence of inhibition for comparison 
and those of interest will undergo further study through performing the proliferation 
and migratory studies in the HaCaTs in the presence of these certain inhibitors. As 
before, gene and protein expression levels should be determined, following inhibition 
of these downstream signalling pathways, of key keratins, cell cycle-related genes, 
matrix metalloproteinase; and inflammatory cytokines and chemokines. 
 
As discussed, the profound response on fibroblast-myofibroblast differentiation, 
following epoxy-tigliane, requires further investigation, due to its potential as an anti-
fibrotic agent. Following from the success of the keratinocyte Microarray studies, 
where a number of key genes were observed to be differentially expressed and helped 
elucidate the mechanism of action, global gene analysis could be performed during 
TGF-β1-driven, dermal fibroblast-myofibroblast differentiation, following treatment 
with epoxy-tiglianes. This will be of great benefit to determine the pathways involved 
in inducing this unexpected and exceptional response. It may also elucidate key genes 
which result in inhibition of myofibroblast formation, especially at 0.1µg/ml EBC-46 
and 10µg/ml EBC-211, which has been an area of great interest in the fibrosis field. In 
addition, a number of in vitro could be performed on keloid and hypertrophic 
fibroblasts, to determine whether treatment with the novel epoxy-tiglianes can induce 
an anti-fibrotic response on this highly proliferative and contractive cell type. This 
would be undertaken once the anti-fibrotic response has been confirmed for normal 
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dermal fibroblasts to determine whether this response is induced on this excessive 
scarring situation (Bran et al. 2009; Gauglitz et al. 2011).  
 
Greater knowledge in the mechanism of action of these novel epoxy-tiglianes and how 
these apparent preferential wound healing responses are induced is vital for the 
continued development of a novel pharmaceutical. Additional in vitro studies could be 
performed, incorporating the strong paracrine feedback system between dermal 
fibroblasts and epidermal keratinocyte, through use of a 3D organotypic culture 
system. This could give an insight into how the epoxy-tiglianes induce their responses 
on each cell type, along with the basement membrane formation; however, this model 
does not incorporate all cell types involved in wound healing, such as immune cells 
(Maas-Szabowski et al. 1999; Lee & Cho 2005; Bader & Kao 2009; Lee et al. 2009; 
Safferling et al. 2013; Sriram et al. 2015). Another in vitro study which could be 
undertaken is a collagen lattice contraction assay, which measures the contractile 
ability of cells within the collagen matrix (Ngo et al. 2006; Ehrlich & Moyer 2013; Jin 
et al. 2015). This assay could potentially elucidate whether the contractile ability is 
reduced in fibroblasts cultured in the presence of TGF-β1, and 0.1µg/ml EBC-46 and 
10µg/ml EBC-211, compared to untreated controls and other concentrations. This is 
due to the observation that treatment with both of these concentrations appeared to 
induce a resistance in fibroblast to myofibroblast differentiation.  
 
Further in vivo studies could also be performed, through use of animal wound healing 
models, to determine the histology of the tissue following repair and observe the tensile 
strength of the regenerated tissue (Davidson 1998; Birch et al. 2005; Ansell et al. 
2012). Due to the obvious benefit towards chronic non-healing wounds, use of a 
diabetic mouse model would be of great interest, such as the db/db mouse model, due 
to the impaired wound healing response associated with diabetic ulcers (Sullivan et al. 
2004; Michaels et al. 2007; Trousdale et al. 2009). There are a number of other chronic 
wound animal models, including skin flap models inducing ischemic wounds and 
pressure wounds through use of magnets as a model for reperfusion of ischemic 
wounds; these are suitable models for ischemic ulcers and pressure ulcers, respectively 
(Davidson 1998; Ansell et al. 2012; Nunan et al. 2014). There have been limited 
animal models for pathological scarring, delaying the elucidation of full understanding 
347 
 
of the mechanism of action which results in keloid and hypertrophic scars (Morris et 
al. 1997; van den Broek et al. 2014; Alrobaiea et al. 2016). Part of the restriction for 
development of a hypertrophic scarring animal model is that these scars do not form 
in animal skin. An athymic nude mouse model has been developed, where full 
thickness human skin is grafted onto the mouse, which will overcome this problem. 
This model will provide greater understanding of excessive dermal fibrosis, as keloid 
skin or skin known to develop hypertrophic scars, can also be grafted onto the nude 
mouse; expected pathologies were evident for the excessive dermal fibrosis models 
(van den Broek et al. 2014; Alrobaiea et al. 2016). Wound closure ability and rate can 
be calculated following experimental treatment modalities, using these animal models. 
In addition, histological assessment can be performed to determine the composition 
and organisation of the underlying dermis (Sullivan et al. 2004; Trousdale et al. 2009; 
Alrobaiea et al. 2016). Immunohistochemical analysis on the athymic nude mouse 
model for hypertrophic scarring can determine the expression of α-SMA, as these scars 
contain myofibroblast-containing nodules (Rabello et al. 2014; Alrobaiea et al. 2016). 
The aim of undertaking these further studies would be to elucidate the mechanism of 
action of these novel epoxy-tiglianes and determine the resultant underlying dermal 
composition. This knowledge would enable progression into clinical trials for these 
epoxy-tiglianes for treatment of impaired healing situations, such as chronic wounds 
and burn injuries; in addition to treatment for excessive dermal fibrosis, including 
keloid and hypertrophic scarring.  
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